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Summary 
 
Inflammatory bowel diseases (IBD), mainly consisting of Crohn’s disease (CD) and ulcerative colitis 
(UC) are chronic relapsing and remitting diseases resulting in uncontrolled inflammation of the gastrointestinal 
(GI) tract. The etiology of these diseases is unknown, but accumulating evidence suggests that it results from 
an inappropriate inflammatory response to intestinal microbes in a genetically susceptible host. The prevalence 
of IBD has increased during the last decades, overall in newly industrialized countries and is increasingly 
considered an emerging global disease. Unfortunately, IBD remains incurable due to its complex 
etiopathogenesis, and current treatments available only ameliorate symptoms. Current knowledge of these 
disorders are based on a combination of gene association studies, clinical investigations, and laboratory 
experiments in mice. The last ones have been very valuable tools to understand the pathogenesis of IBD.  
In this thesis work, we investigated the role of CD9, a tetraspanin that regulates major biological processes 
such as cell migration and immunological responses, in two mouse models of colitis that have been used to 
study the pathogenesis of IBD. Tetraspanins are a family of proteins with four transmembrane domains that 
associate between themselves and cluster with other partner proteins, conforming a distinct class of membrane 
domains, the tetraspanin-enriched microdomains (TEMs). These TEMs constitute macromolecular signaling 
platforms that regulate key processes in several cellular settings controlling signaling thresholds and avidity 
of receptors. Previous in vitro studies revealed an important role for CD9 in the interaction of leukocytes with 
inflamed endothelium, but in vivo evidence of the involvement of this tetraspanin in inflammatory diseases is 
scarce. Here, we studied the role of CD9 in the pathogenesis of colitis in vivo. Colitis was induced by 
administration of dextran sodium sulfate (DSS), a chemical colitogen that causes epithelial disruption and 
intestinal inflammation. CD9-/- mice showed less severe colitis than wild-type counterparts upon exposure to 
DSS (2% solution) and enhanced survival in response to a lethal DSS dose (4%). Decreased neutrophil and 
macrophage cell infiltration was observed in colonic tissue from CD9-/- animals, in accordance with their lower 
serum levels of TNF-α, IL-6, and other proinflammatory cytokines in the colon. The specific role of CD9 in 
IBD was further dissected by transfer of CD4+ CD45RBhi naive T cells into the Rag1-/- mouse colitis model. 
However, no significant differences were observed in these settings between both groups, ruling out a role for 
CD9 in IBD in the lymphoid compartment. Experiments with bone marrow chimeras revealed that CD9 in the 
non-hematopoietic compartment is involved in colon injury by limiting the proliferation of epithelial cells. 
Future strategies to repress CD9 expression may be of therapeutic benefit in the treatment of IBD. 
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Resumen 
 
La enfermedad inflamatoria intestinal (EII) engloba dos patologías, la colitis ulcerosa (CU) y la 
enfermedad de Crohn (EC), las cuales se caracterizan por una inflamación crónica intermitente de diferentes 
partes del tracto gastrointestinal. La etiología de la EII es desconocida, pero las evidencias obtenidas hasta 
ahora sugieren que son el resultado de una respuesta inflamatoria exacerbada desencadenada contra los 
microbios intestinales en sujetos con susceptibilidad genética. La prevalencia de la EII ha ido incrementando 
durante las últimas décadas, sobre todo en países recientemente industrializados alcanzando un carácter global. 
Desafortunadamente, debido a la compleja etiopatogenia que subyace a la EII, ésta permanece incurable y los 
tratamientos actuales únicamente atenúan los síntomas. Los conocimientos que se tienen hoy en día acerca de 
estas enfermedades se basan en la combinación de estudios de asociación genética, estudios clínicos y 
experimentos con ratones en los laboratorios de investigación.  
En este trabajo de tesis doctoral, hemos investigado el papel de CD9, una tetraspanina que regula importantes 
procesos biológicos tales como la migración celular o la respuesta inmunológica, en dos modelos murinos de 
colitis utilizados para estudiar la patogénesis de la EII. Las tetraspaninas son una familia de proteínas con 
cuatro dominios transmembrana que interaccionan entre sí y se agrupan con otras proteínas asociadas, 
conformando unos dominios de membrana, llamados microdominios enriquecidos en tetraspaninas o TEMs 
(del inglés, tetraspanin-enriched microdomains). Estos TEMs constituyen plataformas macromoleculares de 
señalización que regulan importantes procesos en diversos escenarios celulares controlando umbrales de 
señalización y avidez de receptores. Estudios previos in vitro han revelado un papel importante de CD9 en la 
interacción de los leucocitos con el endotelio inflamado, pero no existen prácticamente estudios in vivo 
relacionados con la implicación de esta tetraspanina en enfermedades inflamatorias. En este trabajo, 
estudiamos el papel de CD9 en la patogénesis de la colitis in vivo. La inducción de la colitis se realizó mediante 
la administración del químico colitogénico dextrano sulfato de sodio (DSS), el cual causa una disrupción de la 
barrera epitelial e inflamación intestinal. Los ratones CD9-/- mostraron menos colitis en comparación con los 
ratones de cepa salvaje tras la administración de una solución de DSS al 2% y una mayor supervivencia en 
respuesta a una dosis letal del químico al 4%. De manera concordante, se detectó una menor infiltración de 
neutrófilos y macrófagos en el colon de los ratones CD9-/-, así como una disminución de los niveles séricos de 
TNF-α, IL-6 y otras citoquinas pro-inflamatorias en el colon. El papel específico de CD9 en EII se investigó 
también en el modelo de transferencia de células T naïve CD4+CD45RBhi en animales Rag1-/-. Sin embargo, 
no se observaron diferencias entre ratones inyectados con linfocitos que expresaban CD9 o no. Los 
experimentos realizados en ratones quiméricos mediante trasplante de médula ósea demostraron que la no 
expresión de CD9 en el compartimento no hematopoyético era la responsable de mediar la protección frente a 
la colitis inducida por DSS. En estos animales se detectó una mayor proliferación del epitelio intestinal. Por 
ello, CD9 podría llegar a ser en un futuro una posible diana terapéutica para el tratamiento de la EII.
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1. INTRODUCTION 
 
1.1. INFLAMMATORY BOWEL DISEASE 
 
1.1.1. Introduction 
 
Inflammatory bowel disease (IBD) defines a group of complex and multifactorial intestinal disorders, 
principally, ulcerative colitis (UC) and Crohn’s disease (CD). Both diseases are characterized by chronic 
inflammation of the gastrointestinal tract interspersed with relapsing phases [429]. UC and CD disorders have 
distinct pathological and clinical characteristics. CD affects any component of the gastrointestinal tract from 
the oral cavity to the annus (although it mostly associates with the terminal ileum and colon) in a non-
continuous fashion, as opposed to a colon-limited disease in the case of UC (Figure 1.1). Transmural 
inflammation leading to a thickened colon wall and a typical “cobblestone” appearance are observed in CD, 
corresponding to longitudinal and circumferential fissures and ulcers that separate islands of mucosa (Figure 
1.2) [298]. 
  
 
 
 
 
 
 
 
 
 
Moreover, CD can be associated with intestinal granulomas, strictures (narrowing of the intestinal lumen due 
to the scar tissue produced by the repair process after inflammation), and fistulas, but these are not typical 
findings in UC. On the other hand, UC involves superficial inflammatory changes, affecting mainly the mucosa 
and a thinner colon wall shows continuous inflammation with no patches of healthy tissue [3,560] (Figure 
1.1), pseudopolyps (non-neoplastic lesions originating from the mucosa) (Figure 1.2), cryptitis and/or crypt 
abscesses. In both diseases, patients could experience diarrhea, fever and fatigue, abdominal pain and 
cramping, blood in stools, reduced appetite and weight loss [135]. The natural course of IBD alternates periods 
of remission and relapse, meaning that often IBD symptoms can be stable (low or absent) but suddenly worsen 
during a flare [429]. IBD diseases remain incurable and existing treatments only pale sympthoms and have a  
Figure 1.1. Basic hallmarks and distribution of IBD disorders found in colon of patients with active 
disease. Left CD, right UC. Taken from MBBS medicine webpage. 
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limited efficiency [554]. Additionally, around 20-30% of UC and 30-40% of CD patients require surgical 
intervention at some point in their lifes to remove the affected region of the bowel [147]. Some of them may 
also require temporary or permanent colostomy or ileostomy. Nevertheless, in many cases, surgical resection 
or stomas do not achieve a permanent cure, and patients suffer relapses later in time [219]. On top of that, IBD 
patients display an elevated risk for colorectal carcinoma (CRC). In both cases, UC and CD, the risk of CRC 
is related to disease duration as well as the length of colon involved [125,126,232]. Thus, IBD constitutes an 
incurable, chronic, lifelong disease which entails detrimental consequences on patient’s quality of life [165] 
and causes a major impact on health care resources [246,579].  
1.1.2. Epidemiology 
 
IBD could be diagnosed at any age, but the majority of new cases turn up in adolescence and early 
adulthood, being its peak onset in persons from 15 to 30 years of age [235]. Pediatric IBD (before 20 years 
old) accounts for approximately 25% of patients, with the peak onset in adolescence [466]. Nowadays, IBD 
affects around 5 million people worldwide, although the highest incidence and prevalence are found in 
westernized countries of Northern Europe and Northern America [9] (Table 1.1. )   
 
 
 
 
 
However, during the last decades, both prevalence and incidence of IBD have increased in newly industrialized 
countries whose societies have become more westernized, evolving into a global disease [386,597]. Besides, 
economic advances inherent to industrialization increased health-care access and case reports. Importantly, 
Asia, South America and Middle East countries have documented the rise of IBD cases 
[388,454,474,528,563,586,638]. These cases report the same complications, morbidity, and mortality as in 
already settled patient populations in high-income countries [387,438]. Intriguingly, if epidemiological 
forecasts are correct, the global prevalence of IBD will affect tens of millions of people worldwide within a 
Figure 1.2. Typical endoscopic features of UC (B and C) and CD (D and E). (A) Normal looking mucosa in the 
descending colon (B) pseudopolyps (C) ulcers (D) cobblestone appearance (E) linear ulceration. Modified from: Lee 
JM. et al, 2016 [298]. 
A B C D E 
Table 1.1. Highest annual incidence rates and reported prevalence 
rates for IBD. Taken from World Gastroenterology Organisation (WGO) 
webpage, data for 2015. 
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few decades [243,244]. Along with industrialization, people from developing countries faced a series of 
changes in lifestyle behaviors that have been reported to correlate with IBD pathogenesis: 1) dietary changes 
from home-grown to processed foods which contain chemical food additives [98], reduction in fiber intake 
and breast-feeding [411]; 2) augmented antibiotic use [509]; 3) pollution exposure [35,404]; and 4) chronic 
stress [340], among others. Moreover, the rise in migratory rates to occidental countries impulsed by natural 
population increase, would also contribute to increase IBD incidence [37,306]. However, the exact causative 
relationships with IBD are yet to be unraveled and further research is needed to precisely elucidate the 
associated molecular alterations.  
1.1.3. Etiology: factors contributing to the development of intestinal inflammation 
 
Although much progress has been made in understanding IBD, the exact etiopathogenesis remains 
unknown. Recent studies have implicated an interaction between genetics, immunology, environment, and 
microbiome [9]. 
Genetic factors 
Accumulating evidence points out that IBD results from an inappropriate and continuing inflammatory 
response to intestinal microbes in a genetically susceptible individual [3], and a heritable component to the 
disease has been recognized [256]. Epidemiological evidence for a genetic contribution support this hypothesis 
[315]. Early epidemiological observations showed clear familial clustering in IBD, translated in higher risk 
ratios among first-degree relatives, especially siblings, and a positive family history [138,313,417]. Indeed, a 
positive family history is reported in around 8 to 12% of IBD patients [486]. Moreover, twin concordance rates 
are significantly greater in monozygotic than dizygotic twins for both CD (50-58% versus 0-12%) and UC (6-
14% versus 0-5%) [44,57,406,569], providing additional evidence for genetic contribution in IBD. Likewise, 
an increased burden of IBD has been observed in certain ethnic groups like Ashkenazi Jews, who present a 
significantly higher risk of developing CD irrespective of their geographical location [467,252].  As a complex 
multifactorial disorder, IBD possess the added difficulty that a susceptibility allele often requires other genetic 
and non-genetic cues to manifest its symptoms [256]. Thus, the genetic predisposition to develop IBD does 
not follow Mendelian inheritance patterns for a single locus, being instead polygenic in nature [86]. Only rare 
early-onset (EO-IBD) (before 5 years) and very-early-onset (VEO-IBD) (before 2 years) forms of IBD or IBD-
like diseases (it is sometimes difficult to clearly ascribe the diseases to CD or UC), rely on monogenic defects 
[43,573]. Therefore, the advent of Genome Wide Association Studies (GWAS) at the beginning of the 21st 
century, constituted a crucial step towards the understanding of complex disorders like IBD. Importantly, the 
recent advances during the past two decades in sequencing techniques and the creation of large consortia 
assembling thousands of patients with IBD, allow for the discovery of many genetic risk loci, experiencing an 
exponential increase since GWAS development from 2005 onwards [110,614]. By now, around 200 genetic 
variants have been specifically found to be associated with CD, UC or both [81,345]. In fact, irrespective of 
their distinct clinical features, nearly 30% of IBD-related genetic loci are shared between CD and UC [256] 
(Figure 1.3. ). Analyses of the genetic risk loci implicated in IBD elucidated numerous pathways that are 
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crucial for intestinal homeostasis. Genetic variations that disturb any stage of immune homeostasis, 
inflammation, or resolution can result in the exaggerated inflammatory response found in IBD [171]. Some of 
these genes are involved in epithelial barrier function, epithelial restitution, microbial defense, innate immune 
regulation, antigen sampling, antigen presentation or T cell differentiation, among others. At the cellular level,  
 
processes like autophagy, endoplasmic reticulum (ER) stress, apoptosis, cell migration or oxidative stress 
could be also affected in IBD [256]. Genetic studies are already used to predict sensitivity to IBD therapies 
[55]. Combining these studies with different aspects of IBD pathophysiology will promote advances in 
translating genetic knowledge into predictive biomarkers and new treatments. 
Environmental factors  
Genetics alone cannot explain IBD. Allele variants found in genetic analyses can only explain about 
20-25% of all IBD cases [315], and a lack of a 100% concordance rate in monozygotic twins is noticed. Thus, 
this is indicating microbiota and other environmental cues might be interacting with genetic susceptibility in 
the pathogenesis of the disease. In order to validate GWAS data, a number of genetically modified mice have 
been developed. However, a direct link of gene targeting to pathogenesis has not always been straight forward 
[77,108] supporting that additional environmental triggers are required for developing of the disease. The 
changing epidemiology of IBD across time and geography further supports environmental factors influence 
[9,245]. The more recent emergence of IBD in developing countries over the last two decades points to 
westernization of lifestyle and industrialization as the responsibles of introducing higher incidence numbers 
through environmental changes [597]. Some of these changes have been revised above, under “Epidemiology” 
section. Mainly, drugs and antibiotics intake, infection, stress, smoking, pollution and changes in diet and 
intestinal microbial milieu (also affected through the use of antibiotics and infections) have all been implicated 
in the development of intestinal inflammation in cohorts of patients [10,291,339,455]. Besides, migratory data 
have been quite valuable and informative in this matter. Many migrant populations from developing low 
incidence countries acquire higher incidence rates than their country of origin and similar to the country they 
migrated to, mainly in the second generation [74,439].  
Figure 1.3. Inflammatory bowel 
disease susceptibility loci. The 
loci are depicted by lead gene 
name, according to pathway. Loci 
attaining genome-wide significance 
(P<5x10-8) are shown for CD (red), 
UC (blue) and IBD (black). This 
last includes the shared loci that 
confer susceptibility to both CD 
and UC (approximately one-third 
of loci). From Lees CW. et al., 
2011[299].  
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Gut microbiota in IBD 
 
The human GI tract harbors a complex microbial community containing over 1014 microorganisms of 
greater than 1000 different species, which occupy a vast mucosal interface (250-400m2) of the human body 
[22]. As a result of many years of co-evolution, the host immune system has been shaped to tolerate 
commensals as a means to maintain a symbiotic relationship within the human body [20,104]. Some of the gut 
microbiota benefits include nutrient metabolism, xenobiotic and drug metabolism, maintenance of structural 
integrity of the gut mucosal barrier, immunomodulation, and protection against colonization of pathogenic 
microorganisms [229]. Tolerance mechanisms exerted by microbial species include inhibition of 
proinflammatory cytokines [325,50] and NF-κB induction [616], compartmentalization of mucosal IgA 
secretion [326], promotion of regulatory T cells (Tregs) generation [158,446,468,367], secretion of anti-
inflammatory cytokines like IL-10 [185,51] and generation of metabolic substrates that stimulate mucosal 
barrier functions, like butyrate [459]. In IBD, microbiota can act as a double edged-sword, as it is important in 
both maintaining health and mediating disease [324]. On one hand, it is indispensable for colitis development 
[174,488,103,536] and, for instance, IL10KO mice housed in germ-free facilities do not develop colitis at all, 
as opposed to their counterparts raised under conventional conditions [284]. The clinical observation that IBD 
can respond to antibiotic treatment substantiate that gut microbiota is an essential factor in driving the 
inflammatory response [593,254,75]. Moreover, the detection of more inflammation associated to certain 
anatomical regions like the terminal ileum and rectum with faecal stasis [270], together with inflammatory 
remission observed in the excluded intestinal segment after faecal diversion (by means of an ileostomy or 
colostomy) [230], and reactivation after reinfusion of intestinal contents [105], support this notion. On the 
other hand, certain immunoregulatory bacterial subpopulations help to maintain intestinal homeostasis [240]. 
On top of this, we have to take into account that several aspects may complex the study of the relationship 
between microbiota and IBD. First, there is a huge interindividual variability (even among monozygotic twins 
only the 40% of faecal phylotypes are shared) [567], secondly, the vast majority of studies are performed in 
mice whose microbiota composition can be finely tuned and not always a correlation with humans occurs 
[389], and lastly, it is sometimes difficult to ascribe whether the changes detected on microbial populations are 
cause or consequence of enterocolitis [390].  
1.1.4. Mediators of intestinal inflammation 
 
The intestinal mucosa is constantly exposed to commensal bacteria and dietary antigens. The first line 
of defense is constituted by the intestinal epithelial cell line, which provides a physical barrier to pathogens 
but also acts as a frontline sensor that translates information to underneath mucosal immune cells. Thus, 
epithelial barrier disruption accounts for IBD pathogenesis, and alterations in these cells functions have been 
found in IBD patients [420]. In a normal situation, after pathogen clearance, resolution of the inflammatory 
process is required to fully achieve the restoration of tissue integrity and function [407]. Unfortunately, may 
the host have a genetic susceptibility trait and/or failure to accurately trigger tolerance mechanisms, an acute 
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inflammatory response that should be dampened could derive in chronic inflammation, leading to IBD 
[464,487]. 
Disruption of the epithelial cell barrier  
 
Intestinal epithelial cells (IECs) have a dual role, regulating water and nutrients uptake while at the 
same time acting as a barrier to the permeation of luminal pathogens and potentially harmful substances. The 
GI columnar epithelium is covered by a single-cell-thick layer, composed of different subtypes of specialized 
IECs, including absorptive cells (the most abundant, up to 80% of all epithelial cells), goblet cells, 
enteroendocrine cells, Paneth cells (only found in small intestine), M cells and Tuft cells [420], all of which 
differentiate from epithelial stem cells [392]. Of note, mucus production by globet cells is of vital importance 
for keeping at bay luminal microbes [233,234], emphasized by observations in active enterocolitis of an altered 
thickness, continuity [442] and composition [58,88] of the intestinal mucus layer, as well as an altered mucin 
structure [293,79]. Moreover, globet cell and mucus depletion is characteristic of UC [231] and Muc2 knockout 
mice develop spontaneous colitis [578]. Paneth cells are specialized for the secretion of many antimicrobial 
peptides (AMPs), including defensins (cryptdins in mice), cathelicidins and lysozyme; representing key 
players in innate immunity in the gut. Indeed, a reduced expression of α-defensin mRNA has been detected in 
ileal biopsies from CD patients [596] and Paneth cell abnormalities were found to be associated with mucosal 
dysbiosis in the context of CD [314].  
An effective sealing and proper paracellular permeability is achieved thanks to the apical junctional complex 
(AJC), located at the enterocyte apical pole, and composed by tight junction (TJ) and subjacent adherens 
junction (AJ) protein complexes. Both TJ and AJ are reinforced by a dense perijunctional ring of actin and 
myosin [568]. TJs consist of the transmembrane proteins occludin, the claudin family of proteins and junctional 
adhesion molecules (JAMs), and its cytoplasmic plaque involves mainly the scaffolding zonula occludens 
family of proteins and cingulin [566]. AJs together with desmosomes, provide the adhesive strength required 
for maintenance of cell-cell interactions, whereas TJs are the responsible for sealing the paracellular space and 
also act as fence to prevent the mixing of membrane proteins between the apical and basolateral membranes, 
thus contributing to epithelial cell polarization [397]. In the setting of IBD, a compromised integrity of the 
epithelial barrier and an increased permeability have been recognized since the eighties, in both ulcerated and 
non-ulcerated epithelia [574,415,200] and in first-degree relatives [525,501,202]. Latter studies revealed 
altered TJ function, ultrastructure and protein composition in IBD patients [437,499] and reduced expression 
of occludin [281] as well as the AJ molecules E-cadherin and α-catenin in both CD and UC [120,247]. 
However, it is not known for certain whether impaired barrier function is secondary to gut inflammation and 
tissue damage, or if it is a self-determining event. Evidence suggesting prior barrier defects contributing to 
IBD come from reports documenting changes in intestinal permeability 8 years before onset of CD [224], 
increased intestinal permeability in 10-54% of first-degree relatives in the absence of clinical symptoms 
[416,341,201] and animal models of IBD that documented increased epithelial permeability prior to the 
inflammatory process [192]. In this regard, intestinal permeability has been reported to be a trustable 
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prognostic indicator of relapse to active disease in patients with CD during clinical remission [106,610]. In 
favor of a consequence rather than a cause, proinflammatory cytokines produced in excess in IBD like IFN-γ, 
TNF-α, and IL-13 can lead to cytoskeletal rearrangements that disrupt TJ and increase the epithelial 
permeability further aggravating inflammation in active disease [478,333,329,46]. Moreover, some 
experiments in transgenic mice with genetic defects in TJ associated proteins suggest that disruption of barrier 
function alone is not always enough to trigger disease [538,257]. Overall, intestinal barrier loss can be 
considered as one component that contributes to a multifactorial mechanism of IBD pathogenesis [398].  
Mucosal immune response dysregulation 
IECs do not regulate intestinal homeostasis by their own, but instead establish a dynamic crosstalk 
with intestinal microbes and local immune cell populations. Microbial cells in the intestinal lumen are 
estimated to outnumber our own somatic and germ cells by one order of magnitude (~1014) [444]. Thus, a 
sophisticated immune system in our GI tract, shaped after millions of years of co-evolution, is tasked to remain 
tolerant to this huge quantity of beneficial commensal microorganisms, while accurately prevents the invasion 
of occasionally incoming pathogens.  
Innate immune responses 
Innate immune cells from the intestinal mucosa can monitor microbial ligands using PRRs, and 
microbial metabolites using G-protein-coupled receptors (GPCRs) and solute carriers. Unlike other tissues, in 
the gut, incoming monocytes are continuously replenishing the macrophage pool in the intestine [23]. 
Interestingly, depending on the context, the same Ly6Chi monocyte precursors can give rise to hyporesponsive 
macrophages in homeostasis or proinflammatory macrophages in an inflammatory context [24]. In a resting 
healthy epithelium, gut-resident macrophages have a limited capacity to respond to bacterial adjuvants, despite 
they express a full repertoire of TLR receptors. In this sense, downregulation of its downstream mediators 
including MyD88, TRAF6, TRIF and CD14 [524,523,522] and/or increased expression of molecules that 
impair TLR signalling like IRAK-M and IkBNS [198], are responsible for their hyporesponsiveness. Similarly, 
IECs typically have low levels of TLRs, and some of these are exclusively located in the basolateral membrane 
of the cell, which allow epithelial cells to reside in the high bacterial concentration of the distal ileum and 
colon and respond only when the epithelial cell line is broken [629]. In intestinal DCs, the hyporesponsiveness 
is thought to be restricted to TLR4 [78]. Importantly, intestinal CD103+ DCs have the unique ability to induce 
the differentiation of peripheral Foxp3+ T regulatory (Treg) cells from naïve T cells in a process dependent on 
retinoic acid (RA) and active transforming growth factor (TGF)-β [540,85], thus playing a key role in the 
development of intestinal tolerance. In an inflammatory context, macrophages and DCs in the lamina propria 
(LP) are increased in absolute numbers and have an activated phenotype in both forms of IBD [487], mainly 
derived from incoming inflammatory monocytes that migrate to the inflammatory focus. These monocytes 
conserved normal TLR levels, as polymorphonuclear cells do. Thus, an extensive array of proinflammatory 
cytokines mainly IL1-β, TNF-α, IL-6, IL-8, members of the IL-12 family [382] and chemokines like MCP-1, 
MIP-1α, MIP-1β, RANTES, CXCL5 and fractalkine (CX3CL1), were all described to be augmented in IBD 
[483,572,173]. The selective inhibition of all these proinflammatory mediators has been proved to attenuate 
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the onset of experimental colitis [487]. On the other hand, accumulating evidence claims for deficient innate 
immune responses in CD. Increased CD susceptibility associated with NOD2 polymorphisms [218] (which 
encodes the receptor of the muramyl dipeptide bacterial wall molecule) and the therapeutic activity of 
granulocyte-macrophage colony-stimulating factor (GM-CSF) [273] support the hypothesis that CD is the 
result of defective bacterial killing. In this regard, several studies have reported neutrophil and/or macrophage 
dysfunction in CD patients [520,582,184,503] that would imply a deficient removal of bacterial antigens 
leading to the subsequent chronic inflammatory status [150]. However, in UC, neutrophil over-activation may 
imply collateral tissue damage as the extent of neutrophil infiltration correlates with the severity of the disease 
[60] and neutrophil chemotaxis and ROS production are both increased [502,449].  
Adaptive immune responses 
The traditional concept over the past decade that in CD Th1 and Th17 responses are selectively 
upregulated but not in UC, which was thought to represent a Th2-driven disease, has been challenged [112]. 
Mucosal levels of typical Th1 cytokines like IL-12, IL-18, IL-2, TNF-α and IFNγ are increased in CD patients 
[393,59,359,360] whereas numerous reports describe an atypical Th2 response in UC, mediated by natural 
killer (NK) T cells that secrete IL-13 [187,159], although the upregulation of IL-4 and IL-5 Th2 cytokines is 
variable in UC tissues [160]. On the other hand, an upregulation of prototypic Th2 cytokines like IL-5 and IL-
13, was observed in an animal model of human CD [27] and also of IL-4 and IL-5 in lesions of patients with 
CD [27]. Moreover, the efficacy of anti TNF-α treatment in dampening Th1 responses on UC patients [472], 
suggests that this T helper subset also plays an important role in UC. The production of IL-17 is stimulated by 
the production of IL-6, TGF-β and IL-23 by innate immune cells and APCs, especially dendritic cells. Levels 
of both IL-23 and IL-17 are increased in CD tissues and several types of experimental colitis [626,497,154]. 
Despite of that, administration of anti-IL-17A monoclonal antibody to patients with moderate to severe CD 
had no therapeutic effect and in some cases exacerbated the disease [217]. Moreover, anti-IL23p19 therapy 
failed to meet clinical remission end points [482]. Tregs are crucially involved in the maintenance of gut 
mucosal homeostasis by suppressing abnormal immune responses against commensal flora or dietary antigens. 
They have a potent anti-inflammatory role in experimental colitis [515,136], and also are depleted in peripheral 
blood of patients with active IBD [92].  
Leukocyte extravasation 
The steps of the leukocyte extravasation cascade comprise the sequential adhesion steps known as 
tethering, rolling, tight adhesion and transmigration [394]. Inflammatory cytokines upregulate local endothelial 
expression of adhesion molecules that cause circulating leukocytes to adhere to the inflamed endothelium [30]. 
Tethering and rolling are mediated by selectins and their carbohydrate ligands [304]. The selectins are a family 
of transmembrane mammalian lectins expressed on the surface of leukocytes (L-selectin), endothelial cells (P-
, E-selectins), and platelets (P-selectin) [242]. The importance of each selectin varies between organs and the 
inflammatory stimuli [304]. In animal models with intestinal inflammation, conflicting results were obtained 
as double deficient mice for E and P-selectins showed enhanced leukocyte recruitment and more severe disease 
[342], and no protection was observed after blocking neither E-selectin nor P-selectin or L-selectin [484]; 
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whereas others observed colitis severity attenuation by P-selectin blocking antibodies or in P-selectin deficient 
mice [627,588,168]. Nevertheless, more robust effects were observed with the blockade of tight adhesion 
molecules like Intercellular adhesion molecule-1 (ICAM-1) or CD54, Vascular Cell Adhesion Molecule-1 
(VCAM-1) or CD106, and Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1), all playing important 
roles in the dysregulated trafficking of leukocytes that occurs during IBD [83,62,107,237] and in mice models 
of intestinal inflammation [250,249,541]. Circulating T cells that bear the gut-homing α4β7 integrin bind to 
the MAdCAM expressing colonic endothelium [42], which increases its expression levels upon inflammation 
[83]. Likewise, VCAM-1 and ICAM-1 protein levels are rapidly upregulated in an inflammatory onset 
[124,72]. VCAM-1 is the ligand for α4β1 (VLA-4) [132] and can also bind α4β7 albeit with lower affinity 
[465]. ICAM-1 is the ligand for LFA-1 (αLβ2) [336] and Mac-1 (αMβ2) [114]. Thus, blockade of these 
adhesion molecules have proven efficacy in acute colitis models in mice and rats [38,182,553,608,137,627] 
and in human clinical trials [580]. On the leukocyte side, targeted blockade of a combinatorial epitope on the 
α4β7 integrins in cotton-top tamarins [193], in mice [422] and humans [140], and of β2 integrin (CD18) in rats 
[346] were successful in attenuating colitis. The selective expression of CCL25 by colonic endothelium 
mediates the gut-specific recruitment of T cells that express the chemokine receptor CCR9 [208]. However, 
during intestinal inflammation, CCR2 expressing CD4+ T lymphocytes are preferentially recruited to the 
inflamed ileum [84], and an amelioration of colitis was observed in monocytopenic CCR2-deficient mice [427] 
and in mice depleted of CCR2-expressing cells [643].  
1.1.5. Intestinal epithelial cell damage and mucosal repair  
 
Cell death is an integral part of tissue homeostasis. Elimination of damage or aged cells through 
programmed cell death (PCD) by apoptosis or autophagy processes is of particular importance for the GI tract, 
which is continuously exposed to environmental harmful agents [380]. However, in some settings, immune-
cell-derived triggers, cytotoxic drugs and physical stressors can lead to excessive IEC apoptosis and 
undiscriminating necrosis, causing extensive tissue damage. Upon infection, intracellular virus and bacteria 
induce host cell death through several distinct modalities, including apoptosis, necrosis, and inflammasome-
mediated pyroptosis [300,19]. Besides, activation of macrophages and T cells leads to TNF and FasL 
expression, which promotes apoptosis in mature epithelial cells and crypt cells [348,177,302]. Other 
proinflammatory cytokines like IFN-γ [471,177] or IL-12 [177] can also trigger epithelial apoptosis. Of note, 
the intestinal epithelium is much more sensitive to the apoptosis-inducing activity of TNF-α than other tissues 
[238,424] and apart of inducing apoptosis leads to the disruption of TJ [625], further fueling inflammation and 
tissue destruction. Neutrophil serine proteases such as elastase, proteinase-3 and cathepsin G, and matrix 
metalloproteinases like MMP-9, also contribute to further amplify tissue damage due to the relatively 
indiscriminate range of action of these molecules in terms of their target [280]. Apart from infections, other 
environmental agents can cause a disruption of the epithelial cell barrier. Ionizing radiation [221] and a variety 
of drugs like non-stereoidal anti-inflammatory drugs (NSAIDs) [606] or chemotherapy agents [433], provoke 
apoptosis of IECs. Indeed, many of these molecules are causative agents of IBD development or relapses 
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[271,550]. After epithelial injury and barrier breakdown, signals from nearby IECs, underlying stromal cells 
and immune cells promote rapid resealing of the epithelial cell lining to reestablish homeostasis. In a simplified 
way, epithelial repair is achieved by three distinct mechanisms: restitution, proliferation and differentiation 
[117]. 
Epithelial restitution 
Despite the need for an impenetrable defence, the intestinal epithelium is only one cell thick to allow 
for the exchange of nutrients and solutes. Thus, the integrity of the intestinal barrier can be easily compromised, 
and mechanisms or rapid gap sealing are required. To accomplish this, the first step in mucosal healing consist 
on a quick migration to the denuded area of cells surrounding the wound, which is called epithelial restitution. 
This process starts within minutes to hours of injury and is independent of proliferation [555,119]. During 
restitution, epithelial cells lose their columnar polarity and experience and extensive actin cytoskeletal 
rearrangement, mediated by Rho family of GTPases [485,204]. Cells lose their microvilli and 
apical/basolateral orientation, flatten, and extend their lamellipodia into the denudated area [63,287]. New 
focal attachments are formed at the leading edge mediated by integrins engagement [539,320,319] with 
clustering of focal adhesion kinase (FAK) [544,628] and where extracellular matrix (ECM) proteins play a key 
role [458,169,33]. GI restitution is modulated by several factors including: 1) growth factors 
[100,183,391,489,148,571,119,601,430]; 2) cytokines such as IL-2, IFN-γ and IL-1β [70,119]; 3) chemokines 
CXCL12 and CCL20 [587,521]; 4) prostaglandins [648] and 5) other luminal factors like short chain fatty 
acids (SCFAs) [600], bile acids [290], polyamines [453,591], lysophosphatidic acid (LPA) [197] and trefoil 
factors (TFF) [199].  
Epithelial proliferation 
After restitution, cell proliferation is triggered to increase the pool of enterocytes available to resurface 
the denudated area, generally beginning hours to days after injury [310]. Stem cells located at the base of the 
crypts experience asymmetric cell division, generating one rapidly cycling daughter cell, while the other 
daughter cell replaces the parent stem cell. The more rapidly proliferating daughter cells, also called transit-
amplifying (TA) cells, are the responsible for building tissue mass, and undergo a limited number of cell 
divisions before terminally differentiating into the functional cells of the tissue [29]. The proliferation phase 
is temporally and spatially distinct from migration, and at the molecular level these processes depend on 
excluding patterns of kinase activation and gene expression. For instance, EGF promotes p38 mitogen-
activated protein kinase (MAPK) migration or ERK-dependent proliferation, which oppose one another’s 
function [152]. TGF-β [264], LPA [537] and adenine nucleotides [118] stimulate migration, but blunt 
proliferation. In vivo, rapid and immediate migration of injured epithelia is followed by a surge of proliferation 
much later in time, supporting temporal disassociation of migration and proliferation [287,144,143]. Several 
molecules modulating intestinal epithelial proliferation are peptide growth factors, such as EGF, TGF-α, and 
insulin-like growth factor 1 (IGF-1) [323]; peptide hormones like neurotensin, cholecystokinin, bombesin, 
peptide YY [556,170] and glucagon-like peptide 2 [121]; prostaglandins [557]; cytokines like IL-6 [283], IL-
22 [423] and IL-10 [447] and TLR agonists, among the most important ones. TLRs activation in IECs promotes 
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the proliferation of epithelial stem cells by inducing the production of ligands for EGFR, such as amphiregulin 
and prostaglandin E2 [211,155]. Also, changes in ECM elasticity after intestinal damage promote the new 
formation of FAK-integrin complexes, cyclin D1 upregulation and progression through the cell cycle [412]. 
Importantly, type 2 immunity responses promote epithelial cell proliferation, in a way to favor worm expulsion 
and initiate the repair process of the damaged barrier [441]. In this sense, type 2 cytokine IL-4 [344] promotes 
proliferation acting directly on the IEC and indirectly, together with IL-13, induce the expression of the cell 
surface receptor Trem2 (with as yet undetermined ligand) on M2 macrophages, which have a critical role in 
the proliferative, but not in the migratory phase, of intestinal wound repair [506].  
Epithelial maturation and differentiation. 
Once the gap has been filled, epithelial maturation and differentiation is required to restore villus 
architecture as well as digestive, absorptive and defensive functions. The signaling pathways and transcription 
factors implicated in the regulation of cell fate determination and lineage specific differentiation in the intestine 
are becoming increasingly well understood. Among these molecular pathways we can find Wnt-β-catenin-TCF 
[334,272], Notch and its downstream effectors HES1 and Math1 [620], BMP-TGF-β-SMAD [186,34] and 
hedgehog signaling [576]. Moreover, E-cadherin-mediated cell-cell [500] and integrin-mediated cell-ECM 
adhesion [330], and an array of cytokines, hormones and growth factors, are also involved in ruling IECs 
maturation [251]. Noteworthy, imbalances in these processes ranging from death mechanisms of IECs to the 
recovery mechanisms including epithelial restitution, proliferation and maturation have been involved in IBD 
pathogenesis.  
1.1.7. Mice models of intestinal inflammation 
 
The development of murine models of acute and chronic intestinal inflammation have provided 
valuable insights into the complex mechanisms behind IBD pathogenesis. Mice models of IBD can be 
classified as spontaneous or inducible through chemicals, bacterial infection, immune cells adoptive transfer, 
transgenesis and gene depletion (Table 1.2.). 
Table 1.2. Mice models of intestinal inflammation 
Spontaneous 
Chemically 
induced 
Infection Adoptive transfer Transgenic Knockout 
C3H/HeJBir [562] 
Samp1/Yit[282] 
 
DSS [415] 
TNBS/DNBS[398,188] 
Oxazolone[51] 
Acetic acid[338] 
Carrageenan[141] 
Indomethacin [638] 
Peptidoglycan-
polysaccharide[471] 
 
Salmonella-
induced[185] 
Citrobacter 
rodentium[200] 
Adherent invasive 
E.coli[331] 
CD45RBhi  Rag1-/-
/SCID[377,451] 
BM  Cd3εTg26[207] 
Hsp60 CD8+  TCRβ-/-[551] 
STAT-4[628] 
dn-N-
cadherin[195] 
IL-7[617] 
IL-2[490] 
MUC2[600] 
IL-10[42] 
STAT3[569] 
XBP1[254] 
CRF2-4[550] 
TGF-β[531] 
Giα2[487] 
TCR-α[372] 
A20[308] 
NEMO[394] 
MDR1A[428] 
TNFΔARE [279] 
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DSS colitis model 
Dextran sodium sulfate (DSS)-induced colitis has become a widely used model for studying IBD in 
the mouse [87,401] and among the chemically induced colitis models, is one of the most used due to its rapid 
development, highly reproducibility and easy way of administration (by water intake). Moreover, acute or 
chronic models of intestinal inflammation can be achieved by modifying the concentration of DSS and the 
frequency of administration. Acute colitis is usually induced by continuous administration of 2-5% DSS for 
short period (5-9 days), whereas chronic colitis may be generated by continuous treatment of low 
concentrations of DSS or cyclical administration of higher concentrations of DSS intercalated with water 
intake [131]. Each version is used to study innate vs adaptive immune responses, respectively. This model is 
suitable for studying events triggered by temporary failure of mucosal homeostasis after epithelial cell 
shedding and loss of barrier integrity, and can also provide insight into the mechanisms that lead to mucosal 
healing after initial injury [258]. DSS is an anionic surfactant that disrupts the epithelial cell monolayer lining, 
leading to the entry of luminal bacteria and associated antigens and stimulating local inflammation [97]. 
Several mechanisms have been postulated about DSS-induced colonic mucosal inflammation. Recent results 
indicate that sulfate groups of the DSS molecules destabilize the mucus layers and make them more permeable 
to bacteria [421]. Moreover, it also exerts a direct toxic effect on the epithelial cells due to its surfactant 
properties and fusion with colonocyte membranes through the formation of nano-lipocomplexes with medium-
chain-length fatty acids (MCFAs) in the colon [292].  
 
Figure 1.4. Schematic progression of DSS-induced colonic damage. Control colon shows straight healthy crypts with 
their base sitting on the muscularis mucosae and plenty of big globet cells. As the damage goes on, globet cell depletion 
and crypts shortening are detected. Grade 1 lesion: loss of the basal one-third of the crypts, which fails to sit on the 
muscularis mucosae. No inflammation can be appreciated yet. Grade 2 lesion: loss of the basal two-thirds and focal 
thinning of the epithelium. Some inflammation in the lamina propria is beginning to be appreciated. Grade 3 lesion: Loss 
of the entire crypt with retainment of the surface epithelium. LP and submucosa show broader inflammatory infiltrate. 
Grade 4 lesion: Total disappearance of the epithelial cell lining and huge inflammatory infiltrate. Modified from Cooper 
HS. et al, 1993 [87]. 
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Interestingly, DSS-induced extensive pathology is mainly confined to the large intestine, specifically 
the distal colon, where an enormous number of microorganisms live and where the absorption of MCFAs takes 
place [97]. DSS administration induces changes in the expression of tight junction proteins [432] and increased 
expression of proinflammatory cytokines [617] as soon as day 1 after treatment. These modest initial effects 
are followed by increasingly drastic symptoms. During DSS administration, mice can exhibit pronounced 
weight loss, increased intestinal permeability, diarrhea, severe bleeding, hunched back, piloerection, anaemia 
and eventually death. The typical histological changes induced by acute DSS include mucin and globet cell 
depletion, epithelial erosion, ulceration, submucosa swelling and a mixed inflammatory infiltrate of 
neutrophils and macrophages in the LP and submucosa [419] (Figure 1.4) . Importantly, DSS-induced colitis 
model responds to typical treatments of human disease [347], thus represents a relevant model for the 
translation of data from mice to humans.  
Adoptive transfer colitis model  
 
Transfer of naïve (CD45RBhi) CD4+ T cells into syngeneic immunodeficient (lymphopenic) SCID or 
Rag1-/- recipients leads to wasting disease and colitis [436,364]. Intestinal inflammation develops after 5 to 10 
weeks after treatment. As lymphopenic recipient mice do not have any T cell population, nor Treg cells, they 
cannot dampen the expansion of naïve T cells into the Th1 and Th17 proinflammatory T cell populations that 
differentiate after several weeks in the intestine due to commensal microbiota stimulation. In this line, the 
transfer of mature CD4+CD45RBlow (which include Tregs) [435] or directly the transfer CD4+CD25+ Tregs 
[366] inhibits the induction of the disease. Macroscopically, mice inflamed colons are thickened and shortened 
compared to non-transferred control mice. Histopathological inspection of distal colon obtained from mice 
with active disease reveals a typical transmural inflammation, epithelial cell hyperplasia, polymorphonuclear 
leukocyte (PMN) and mononuclear leukocyte infiltration, crypt abscesses, and epithelial cell erosions [409] 
(Figure 1.5). This model is very useful for studying the mechanisms that govern Th1 and Th17 T-cell 
differentiation, the role by Tregs in suppressing or limiting intestinal inflammation, as other immunoregulatory 
promoters like some bacterial species [258]. Thus, this model helped to define and establish the basis of 
mucosal homeostasis dependence on a balance between proinflammatory effector and anti-inflammatory 
regulatory functions.   
Figure 1.5. Histological magnification of 
colon obtained from RAG-/- at 8 weeks 
following adoptive transfer with 
CD4+CD45RBhigh T cells. A large mixed 
leukocyte infiltrate composed primarily of 
granulocytes, T cells, and monocytes (inset) 
can be detected. Increased bowel thickness 
and transmural injury affecting all layers of 
the colon including loss of globet cells, 
epithelial disruption and erosion and even 
muscularis mucosae distortion are observed. 
From Ostantin DV. et al, 2008 [409]. 
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1.2. TETRASPANINS  
 
1.2.1. Introduction 
 
Tetraspanins belong to a family of small glycoproteins (20-30kDa) that contain four transmembrane 
(TM) regions spanning the plasma membrane. Tetraspanins have been found in all metazoans, plants and some 
protozoans and multicellular fungi [216]. The structure of tetraspanins is widely conserved across several 
species, and the expression of several tetraspanins in invertebrates (Drosophila, Schistosoma, Caenorhabditis 
Elegans) [559,191,558] indicates that these molecules appeared early during evolution. Tetraspanins uniform 
architecture and conserved motifs may suggest these molecules arise from a common ancestor through 
sequence divergence [161,216]. In humans and mice, 33 tetraspanin members have been identified. These 
proteins are widely distributed in cells and tissues and every mammal cells express some tetraspanins which 
are often expressed at 30,000–100,000 or more copies per cell [54]. Some of them are ubiquitous (CD81, 
CD82, CD9 or CD63), whereas others have a tissue-restricted expression (CD37 or CD53 in immune cells) 
[188]. Throughout many years, tetraspanins have been overlooked because of their small size, protruding only 
~3.5-5 nm above the plasma membrane [353,262] and hidden by their tall glycoprotein neighbours. 
Consequently, tetraspanins often elude biochemical and immunological detection and it was not until the 
nineties when these molecules started to be studied [190]. Interestingly, many tetraspanin proteins were 
originally identified as human tumour antigens. The first description of a tetraspanin protein occurred in 1981 
on preB and leukemic cells by Kersey et al. [253]. However, the first characterization of a tetraspanin protein 
(ME491/CD63) at the sequence level did not appear until 1988 and was identified as a melanoma-associated 
antigen [209]. After these discoveries, the existence of a family of related structures was finally unveiled in 
1990 and tetraspanins were detected apart from in cancer cells [356,405], in leukocytes [13,80] and human 
parasites [163,609]. 
1.2.2. Structure 
 
The four TM domains of tetraspanins are linked by one intracellular (IL) and two extracellular (EC1-
2) loops and have short intracellular N- and C- termini containing 8-21 amino acids, with a few exceptions 
[189,95,190,54] (Figure 1.6). The smallest EC domain, so-called SEL (Short Extracellular Loop) or EC1 
(Extracellular domain 1), possesses between 13 and 31 amino acids [190] and despite its high sequence 
divergence among the different tetraspanins has a conserved secondary structure in form of a β-strand enriched 
in hydrophobic residues [504]. The largest EC domain, LEL (Large Extracellular Loop) or EC2 (Extracelullar 
domain 2) is the most studied part of tetraspanins and also the only part whose structure was determined from 
crystal X-ray diffraction [263]. LEL possesses between 69-132 amino acids, and can be further subdivided 
into a constant region, containing conserved three α-helices (A, B and E), and a variable region containing 
helices C and D [534,190]. The constant region provides a putative dimerization interface [262], whereas the 
variable region contains various protein-protein interaction sites, specific for each tetraspanin and which 
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mediates most of tetraspanin interactions with their protein partners [505] (Figure 1.6). Although several 
classes of proteins contain four TM domains, they are not members of the tetraspanin family unless they 
contain distinctive structural features, including 4-6 conserved cysteine residues and a CCG motif which form 
critical disulphide bonds within the LEL, as well as some polar residues within the first, third and fourth TM 
domains [534]. These polar TM residues are involved in the association with other proteins and in the 
formation of strong hydrogen bonds between themselves, allowing the stabilization of the protein 
[504,275,641,172]. In addition, TM domain interactions can stabilize the conformation of the EC2 domain 
[68]. The cytoplasmic tails are short, containing generally less than 20 residues.  
 
Tetraspanins can be subjected to three major post-translational modifications: palmitoylation, N-glycosylation 
and ubiquitination. Palmitoylation takes place at several cysteine residues in the cytoplasmic tails near the 
membrane/cytoplasmic interface, which was demonstrated to regulate protein-protein interactions [640,96,40]. 
N-linked glycosylation occurs mainly at the LEL, which has up to three predicted sites [54], and whose role is 
less clearly understood although it has been demonstrated to be implicated in some protein interactions 
[335,403]. Finally, tetraspanins may also be ubiquitinated at cytoplasmic sites, entailing their degradation and 
consequent down-regulation [594,565,309].  
1.2.3. Tetraspanin enriched microdomains (TEMs). 
 
Tetraspanins do not have the characteristics of prototype membrane receptors. They have small 
cytoplasmic tails that lack known motifs involved in signal transduction [54], and there are only a few reports 
claiming tetraspanin ligands [239,443,595]. Instead, tetraspanins function as molecular facilitators (termed 
coined by Maecker et al. in 1997 [327] and organizers of multimolecular membrane complexes, which 
facilitate signal transduction processes [190]. Through the association with proteins and lipids, they organize 
specific membrane microdomains with a particular composition and detergent-solubilization properties, 
conforming the so-called tetraspanin-enriched microdomains or TEMs [618,189] also referred to as 
“tetraspanin web” [470]. TEMs are distinct from other well-known membrane domains, like lipid rafts 
(although TEMs involved also cholesterol as a major lipid component), caveolae and GPI-linked protein 
Figure 1.6. Prototypical tetraspanin 
structure. The four transmembrane (TM) 
domains contain conserved polar residues 
(green circles), and they flank the small and 
large extracellular loops (SEL and LEL, 
respectively). The LEL is subdivided into a 
constant region conserved among the 
tetraspanins (containing helices a, b and e), 
and a variable region composed by helices c 
and d, which are flanked by a CCG motif and 
further conserved cysteine residues (yellow 
circles). This region is folded as a result of 
disulphide bridges (black lines). Modified 
from Levy et al, 2005 [303]. 
Variable 
region 
Constant region 
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nanodomains [618]. The first proofs of the existence of TEMs came from biochemical and proteomic 
approaches concerning membrane solubilization by a wide range of detergents [296], followed by structural 
elucidation of tetraspanin dimerization [122] and by fluorescence and electron microscopy images of fixed 
cells [1,39]. Later on, cutting edge fluorescence microscopy techniques, as single-molecule tracking, 
phasorFLIM-FRET, and super-resolution microscopy, have more recently demonstrated that TEM 
organization and composition is highly dynamic [646,463,134,32]. These studies shed light into TEMs 
behaviour across the plasma membrane, where it is shown that TEMs platforms are dynamic, slowly diffuse 
throughout the membrane and show a continuous exchange of components characterized by their transience. 
In this line, some small tetraspanins ensembles move in an aleatory way through Brownian motion which 
intersperse with confined movements corresponding to their coalescence into enriched tetraspanins areas, 
conforming the TEMs. It could also happen that TEMs cluster into bigger immobilized platforms induced by 
the binding of tetraspanin partners to ligands and cytoskeleton constraints. Apart from this high dynamism, the 
composition of TEMs could differ between cells and in the same cell could exist different TEMs. Thus, this 
heterogeneous and dynamic composition allows tetraspanins to finely tune a breadth of biological processes 
[618]. Biochemical approaches have shown that TEMs follow a hierarchical network of associations based on 
the stoichiometry and strength of the interactions [189,54], where at least three levels have been proposed. The 
first level, comprises the direct and specific interaction of a tetraspanin and its tetraspanin partner, and are 
resistant to strong detergent conditions. The second level is characterized by interactions between tetraspanins, 
that are at the same time associated with their respective partners. These interactions are more labile, resistant 
to mild detergents and regulated by palmitoylation. Lastly, the third level consists on interactions between 
tetraspanins from second level complexes and which are very weak and only resistant to very mild detergents 
such as CHAPS. The inclusion into the tetraspanin microenvironment of their partner proteins confers these 
an adequate molecular density and local enrichment to efficiently exert their physiological functions, but also, 
tetraspanins could act as negative regulators by the sequestration of molecules far from other proteins required 
for signalling transmission or by altering their membrane representation for instance by inducing endocytosis 
or promoting protease cleavage. The first identification of tetraspanin-tetraspanin interactions was 
demonstrated by three laboratories, which also described that MHC-II and certain integrins associated with 
several tetraspanins [470,41,12]. Some years later, mass-spectrometry analyses elucidated an extensive 
number of tetraspanin-interacting proteins [297,276,93,11].  
1.2.4. Tetraspanin CD9 
 
Tetraspanin CD9, also known as motility-related protein 1 (MRP-1), DRAP27 or Tspan29, is one of 
the most studied tetraspanin members. This 24-25kDa tetraspanin contains two disulphide bridges in the LEL 
and a putative glycosylation site in the SEL [54]. CD9 was the first identified tetraspanin, originally described 
as a 24kDa protein expressed on B-lineage-derived acute lymphoblastic leukaemia cells and developing pre-
B lymphocytes, hence its original name, p24 [253]. However, it is now known that CD9 displays a much wider 
expression including many malignant tumour cells, as well as normal hematopoietic, endothelial, and epithelial 
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cells [618,54]. CD9 was cloned in 1991 [53] which helped to determine the primary structure of the molecule 
but also was useful to look for similarities with other known surface proteins to characterize the new tetraspanin 
family of proteins. CD9 was found to associate with several membrane proteins and a few intracellular 
signalling molecules including phosphatidylinositol 4-kinase (PI4-kinase) and several forms of protein kinase 
C (PKC) (see Table 1.3). However, CD9 can associate with other protein partners through indirect interactions 
in TEMs. All these interactions confer CD9 ability to contribute to various cellular activities.  
Table 1.3. CD9-interacting proteins. 
          
Numerous studies have analyzed the changes in CD9 mRNA and/or protein levels in cancer and its relationship 
to patient prognosis [645]. CD9 was found downregulated in many tumours where its expression inversely 
correlated with metastasis promotion. Indeed, CD9 was also called Motility Related Protein 1 (MRP -1), 
because it resulted to be the target of an antibody capable of inhibiting tumour cell migration and invasion 
[356].The reduced CD9 expression is associated with poor prognosis and/or metastasis in melanoma [514], 
non-small-cell lung cancer [195], and breast [358,213,357], colon [363], pancreatic [513], oesophageal [570], 
ovarian [210] and prostate [590] cancers. Decreased levels of CD9 in cancer cells may be achieved by promoter 
hypermethylation (Drucker et al., 2006). Additionally, CD9 expression have been described to be proapoptotic 
[403,371,476] and to inhibit proliferation of several tumour cell lines [639,410]. In this line, a plausible 
underlying mechanism for inhibiting proliferation might be the negatively regulation of cell surface EGFR 
expression levels by CD9 [552,589,374]. CD9 interacts with the membrane forms of the EGF ligands heparin-
binding EGF (pro-HB-EGF) [377,227], transforming growth factor alfa (pro-TGF-a) [511] and amphiregulin 
(pro-amphiregulin) [223] and enhances their juxtacrine proliferative effect [196,223]. On the contrary, CD9 
membrane expression is required for an efficient EGFR internalization, thus, deficiency or decreased 
expression of CD9 resulted in increased levels of EGFR and its phosphorylation and consequently, augmented 
proliferation [374,552,589]. Of note, CD9 associates with the metalloproteases ADAM10 [17] and ADAM-17 
[176], which are required for the efficient proteolytic release of a number EGFR ligands [48]. Thus, through 
all these mechanisms CD9 constitutes a key regulator of proliferation.  CD9 also plays a role in metastasis and 
transendothelial invasion, where its expression is locally relocated at site of migration [490,318]. Anti-CD9 
monoclonal antibodies were found to specifically inhibit the transendothelial migration of melanoma cells, an 
inhibitory effect likely caused by a strengthening of CD9-mediated heterotypic interactions of tumour cells to 
the endothelial monolayer [318]. These evidences suggest that CD9 may play a role of tumour suppressor. 
Integrins 
Adhesion 
molecules 
Immune 
system 
Growth 
factors 
Metalloproteinases 
Intracellular 
proteins 
Other 
proteins 
α1β1[321] 
α2β1[65,495,236] 
α3β1[41,495,236] 
α4β1[469,470] 
α5β1[469,495] 
α6β1[470,41] 
α6β4[236] 
αIIbβ3[317,222] 
αLβ2[457] 
ICAM-1 [31] 
EpCAM[498] 
Claudin-1[276] 
CD47[317] 
CD42[317,519] 
CD44[498,296,236] 
Syndecan[236] 
Fibronectin[316] 
 
MHC-II[133,575] 
FcγRI/II[241] 
FcɛRI[418] 
CD3[562] 
CD4[562] 
CD5[562] 
CD19[207] 
CD46[321] 
ProTGF-α[511] 
ProHB-
EGF[377] 
EGFR[374] 
ADAM-10[17] 
ADAM-17[176] 
 
PI4K[623] 
PKC[636] 
 
GPCR[311] 
c-kit[15] 
CD36[350] 
EWI-2[532] 
EWI-F[535,94] 
ERMs[477] 
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This is supported by in vivo trials of adenoviral CD9 gene delivery into tumours [548,355] or ectopic 
expression of CD9 by transfection of tumour cell lines prior their injection into nude mice [639]. In all the 
cases, mice injected with CD9 gene lived longer and developed less metastasis. However, this is not always 
the case. Some reports claim that CD9 expression positively correlates with progression and poor prognosis in 
some gastric cancers [530,205], chemoresistance in small lung cancer specimens and cell lines [266] and 
increased trans-endothelial invasion of multiple myeloma [109]. Thus, in summary, the role of CD9 in cancer 
progression might be disparate in different tumour cell types and stages of tumour development (e.g. the 
establishment of the primary tumour vs metastasis progression). In relation to this role of CD9 in tumour 
transendothelial invasion, this tetraspanin has been also reported to regulate the endothelial nanoscopic 
organization and expression levels of ICAM-1 and VCAM-1 upon TNF-α activation together with CD151, 
enabling the formation of the docking structure required for leukocyte extravasation [31,32]. Thanks to 
tetraspanin-induced generation of this docking structure, also known as transmigratory cup [73], it was first 
demonstrated that endothelial cells do play an active role during the diapedesis process embracing the 
leukocytes. Moreover, FLIM-FRET studies revealed that the interaction strength between CD9 and ICAM-1, 
between CD151 and VCAM-1, and between the two tetraspanins was similar [32]. Consequently, soluble CD9-
LEL-GST peptides or tetraspanin specific siRNA inhibit leukocyte transmigration and enhance their 
detachment by shear stress, supporting the functional role of CD9 in transendothelial migration [31]. 
CD9 can exert pro- or anti-migratory effects [434]. The regulatory effects of CD9 on cell migration may be 
mediated by integrin-dependent signalling such as phosphorylation of FAK [494] and activation of PI3K, Akt, 
and p38 kinases [101,274]. In addition to modulating integrin function, CD9 has the potential to regulate 
motility through the control of other transmembrane proteins and actin cytoskeleton rearrangement. In this 
regard, CD9 expression downregulates Wiskott-Aldrich syndrome protein family verprolin-homologous 
protein (WAVE) 2. WAVE2 is known to act as scaffolds that link upstream signals to the activation of the 
ARP2/3 complex, leading to nucleation of actin polymerization. However, the mechanism by which CD9 
regulates WAVE2 expression is not yet elucidated, but it is known to take place in a Wnt-independent way 
[215]. This is important because the same group demonstrated some years before that CD9 expression induced 
the downregulation of Wnt1, Wnt2b and Wnt5a proteins [214]. Again, the mechanism how CD9 exerts this 
downregulation is unknown. However, Wnt5a acts through Wnt-Ca2+ pathway which leads to actin 
reorganization and might modulate cell adhesion and motility. Additionally, CD9 associates with members of 
EWI family [532] and both CD9 and CD81 co-immunoprecipitate with ezrin-radixin-moesin (ERMs) family 
of proteins [477], which act as linkers of membrane components like the foregoing EWI proteins, among 
others, and the underlying cytoskeleton [142]. Interestingly, EWI proteins may also regulate clustering of 
integrins at the plasma membrane, where tetraspanins play a crucial role as intermediaries through TEMs 
formation [533,269]. Type IV collagen induces cell migration through a DDR1 and CD9-dependent pathway, 
and knockdown of either DDR1 or CD9 inhibits migration of breast cancer cells on this substrate [76]. Finally, 
CD9 has been described to directly interact with fibronectin through its LEL domain, which has been 
29 
 
demonstrated to be required for the proper haptotactic migration of CHO (Chinese-hamster ovary) cells 
overexpressing this tetraspanin [316]. 
CD9 in the immune system 
 
The immune roles of CD9 are diverse due to its broad expression in several hematopoietic cell types, 
including myeloid and lymphoid subsets. In myeloid cells, CD9 restricts LPS-induced macrophage activation 
and TNF-α production by preventing the TLR-4 co-receptor CD14 localization into lipid rafts. Through this 
mechanism, CD9 deficiency in mice enhances macrophage infiltration and lung inflammation after in vivo 
intranasal LPS administration [543]. Some Fc receptors seem to be included in TEMs in phagocytic cells. CD9 
antibody cross-linking stimulates intracellular signalling dependent on FcγRIIB and FcγRIII, thus promoting 
mouse macrophage activation [241]. FcεRI (Fc receptor for IgE), was also found to be a molecular partner of 
CD9 (and CD81) in human monocytes and skin-derived DCs [418] participating in FcεRI signalosome [181]. 
MHC-II is expressed on professional APCs and associates with several tetraspanins, including CD9 [133]. 
CD9 co-immunoprecipitates with I-A MHC-II molecules in mouse BM-derived DCs and B blasts, and I-A/I-
E heterologous multimerization is reduced in CD9-deficient BM-derived DCs [575]. Another study has also 
suggested that MHC-II, together with HLA-DM and CD86, were included in TEMs containing tetraspanins 
CD9, CD63, CD81 and CD82 [279]. However, deficiency in CD9 does not affect MHC-II clustering at the 
surface of mouse BM-derived DCs, while surface cholesterol content is essential for multimerization [52,255]. 
Besides, downregulation of CD9 in human cell lines does not affect surface expression of peptide-bound MHC-
II [203] and CD9 deficiency in BMDCs does not affect antigen proteolysis [462]. Recently, it has been reported 
that tetraspanin CD9 is important for MHC-II egress to the surface of mouse immature MoDCs and that surface 
expression of MHC-II is decreased in the absence of CD9. Indeed, mouse CD9-/- MoDCs induce less T-cell 
activation and proliferation than wild-type MoDCs, due to reduced surface expression of MHC-II [462]. This 
tetraspanin directly interacts with MHC-II, and CD9 engagement with antibodies promotes the formation of 
antigen-dependent conjugates between human CD14+ monocytes and T cells [644]. CD9 is differentially 
expressed on conventional and plasmacytoid DCs [647,354]. Interestingly, CD141+ human and CD8α+ mouse 
cDCs show high expression of CD9, together with CD53 and CD81 and CD82 [647]. However, further studies 
are necessary to ascertain whether specific tetraspanin expression profiles can be used as markers of cDC 
subsets and/or define APC functions. CD9 expression allows the recognition of immature and mature mouse 
pDCs subsets. CD9+Siglec-Hlow pDCs have an immature phenotype, producing high levels of type I IFN and 
other pro-inflammatory cytokines. These cells are mainly present in mouse bone marrow and spleen, and when 
stimulated can induce strong CD4+ and CD8+ T cell responses in vitro and in vivo. In contrast, tissue resident 
pDCs are negative for CD9, do not produce IFN-γ, and have a tolerogenic phenotype, increasing the numbers 
of Foxp3+CD4+ Treg cells in tumour-draining lymph nodes [45]. 
CD9 has also been implicated in immune cell migration. Human MoDC in vitro migration towards MIP-5 and 
MIP-1α chemokines was enhanced by 50% after treatment with anti-CD9 mAb [332]. However, monocyte 
transmigration across brain endothelial cell monolayers was significantly inhibited by the same anti-CD9 mAb, 
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in human in vitro models [493]. Bone marrow-derived macrophages (BMDM) from CD9 and CD81 double 
deficient mice show reduced motility, through a mechanism dependent on the regulation of MMP-2 and MMP-
9 expression and activity. Interestingly, these double deficient mice spontaneously develop pulmonary 
emphysema, with elevated numbers of alveolar macrophages and increased MMP activity [549]. A similar 
decrease in macrophage motility and increase in macrophage infiltration was observed in CD9-deficient mice 
after intranasal administration of LPS. An increase in MMP-2 and MMP-9 production and activity was also 
observed in BMDMs in the absence of CD9 [543]. In addition, CD9 was shown to regulate migration of B1 
cells from the peritoneal cavity to the spleen. LPS stimulation reduces the expression of integrins and CD9 on 
B1 cell surface, and both CD9 mAb pre-treatment or CD9 deficiency in B1 cells increase migration, by a 
mechanism dependent on α4 integrin [178]. In this line, increased CD9 expression enhanced the integrin 
dependent cell motility of B cells involving β1 integrins and the activation of protein tyrosine kinases [508]. 
On the contrary, CD9 have been found to negatively regulate LFA-1-mediated adhesion under shear flow, due 
to the alteration of its state of aggregation [457]. Thus, this tetraspanin may have a dual role at regulating β1 
or β2 integrin function.  
CD9 is highly expressed in marginal zone (MZ) B cells, antibody producing plasma cells and in the B1 subset, 
but not in splenic follicular (FO) B cells [607]. Nevertheless, CD9-/- mice do not display any impairment in B 
cell numbers and only a slight increase in IgM secreting cells was detected in steady-state animals, though B 
cell response to immunization was perfectly normal [69]. In T cells, CD9 has been described to act as a potent 
costimulatory molecule [547] that synergizes with CD28 [561] and facilitates the insertion of CD3 into lipid 
rafts [621]. However, engaging CD9 on T cells leads to costimulation by a mechanism distinct from the classic 
CD28 pathway and independent of NF-κB signalling pathway which fails to sustain IL-2 production [642]. 
Indeed, unlike CD28 costimulation, CD9 costimulation results in apoptosis of previous TCR-triggered T cells, 
rather than complete activation [414,546,622]. By immunoprecipitation studies, CD9 was found to interact 
with CD3, CD4, CD5, CD2, CD29 and CD44 on the T cell surface, being the most prominent one with CD5 
[562]. In humans, CD9 was detected to be preferentially expressed on the CD4+CD45RA+ naïve T cell 
population, and to favour both the self-antigen and recall antigen-induced T cell activation [265]. At the 
immune synapse, CD9 (together with CD151) modulates VLA-4 relocalization and supports high-affinity β1 
integrin accumulation, being crucial for FAK and ERK1/2 phosphorylation and IL-2 production [461]. 
Moreover, CD9 is required to support ALCAM-CD6 (APC-T cell) heterophilic interaction to properly induce 
T cell activation after conjugate formation [166]. 
In summary, IBD is a complex multifactorial disorder whose etiology is not fully understood and which 
remains incurable. Thus, further research is of high relevance to develop new therapeutic approaches. Due to 
the role of tetraspanin CD9 in several biological processes which might be relevant for IBD development such 
as regulation of the immune response as well as cell migration and proliferation, we decided to explore CD9 
role in the pathogenesis of two mouse models of intestinal inflammation.  
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2. OBJECTIVES 
 
Due to the relevant role of tetraspanin CD9 in key processes such as cell proliferation, migration and leukocyte 
biology and extravasation, we postulate that CD9 could be implicated in inflammatory bowel disease (IBD) 
development. 
In order to challenge our hypothesis, our main aims were: 
1) Assess CD9-/- mice susceptibility to the DSS colitis model compared to WT mice  
 
2) Determine in which cellular compartment CD9 might be exerting its functions   
 
3) Study the role of CD9 in a second model of murine experimental colitis mediated by T cells and T 
cell differentiation in vitro 
 
 
 
OBJECTIVES 
 
 
 
 
 
 
 
 
 
 
 
Objetivos 
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3. OBJETIVOS 
 
Debido al importante papel de la tetraspanina CD9 en procesos como la proliferación y migración celulares, 
así como la biología y extravasación leucocitarias, postulamos que CD9 podría estar implicada en el desarrollo 
de la enfermedad inflamatoria intestinal (EII). 
Para abordar nuestra hipótesis, nuestros objetivos principales fueron:  
1) Evaluar la susceptibilidad de los ratones CD9-/- en el modelo de colitis inducida por DSS en 
comparación con animales de cepa salvaje 
2) Determinar en qué compartimento celular CD9 está mediando su función 
3) Analizar el papel de CD9 en un segundo modelo de colitis mediado por células T y en la 
diferenciación de células T in vitro.  
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4. MATERIALS AND METHODS 
 
4.1. Mice 
 
Experiments were performed with sex and age matched (8-12-week-old) CD9-/- and WT mice on the 
C57BL/6 background. CD9-/- mice have been described previously (Le Naour F., 2000). Rag1-/- mice 
(Mombaerts P., 1992) used in the adoptive transfer colitis model were kindly provided by Dr. J. Mª González-
Granado (Centro Nacional de Investigaciones Cardiovasculares, CNIC). For chimeric reconstitution 
experiments, B6SJL CD45.1 mice (Jackson Laboratories) were used. All animals were housed in pathogen-
free conditions at the CNIC animal facility. Experimental procedures were approved by the local research 
ethics committee and conformed to EU Directive 2010/63EU and Recommendation 2007/526/EC, enforced in 
Spanish law under Real Decreto 53/2013. 
4.2. Genotyping of mice 
 
In order to genotype the mice and check the homozygosity of the deletion of CD9, a PCR was 
performed with the two pairs of primers of the Table 3.1 
Tabla 4.1. Genotyping primers. Table of primers used to genotype mice disclosed by gene name, sequence 5´-3´ and 
size of the amplification product. (bp: base pair). 
 
 
 
The pair of primers CD9Fw/CD9Rv amplifies the WT allele (354 bp), whereas the pair of primers 
CD9KOfw/CD9neoRv amplifies the mutant allele (550 bp). These two pairs of primers were employed in PCR 
reactions using the genomic DNA from mouse tails as template DNA. Genomic DNA was obtained from 
mouse tails using the protocol of the reactive REDExtractc-N-Amp tissue PCR kit (Sigma). As controls, 
genomic DNA from WT, heterozygous and homozygous mice were used. The amplification protocol is showed 
in the Table 3.2. 
Table 4.2. PCR amplification protocol. Table of PCR cycles for genotyping mice disclosed by phase, temperature, 
time and number of cycles. 
 
 
Specificity Primer Sequence (5´-3´) Amplification product 
WT allele CD9Fw TGCAGGCATGGAGGCGCAGC 354bp 
CD9Rv TGCCGGCCTCGCCTTTCCC 
Mutant 
allele 
CD9KOFw CTGGTCACACCCCCTAACGGAGC 550 bp 
CD9neoRv AGAGCTTGGCGGCGAATGGGCTGA 
Phase Temperature (°C) Time  Cycles 
1 95 5 min 1x 
 
2 
95 1 min  
30x 64 40 sec 
72 2 min 
3 72 5 min 1x 
MATERIALS AND METHODS 
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4.3. Induction and assessment of DSS-induced colitis  
 
Dextran sulfate sodium salt (DSS, MP Biomedicals; MW=36,000-50,000) was dissolved at 2% or 4% 
(w/v) in sterile drinking water provided to mice ad libitum. Mice were checked daily for development of colitis 
by monitoring body weight, fecal occult blood (Hemoccult II Sensa; Beckman Coulter) or gross rectal 
bleeding, and stool consistency. Overall disease severity was assessed by a clinical scoring system defined as 
follows: weight loss: 0 (no loss), 1 (1-5%), 2 (5-10%), 3 (10-20%), and 4 (>20%); stool consistency: 0 
(normal), 2 (loose stool), and 4 (diarrhea); and bleeding: 0 (no blood), 1 (Hemoccult positive), 2 (Hemoccult 
positive and visual pellet bleeding), and 4 (gross bleeding, blood around anus). At the end of the experiment, 
tissues were fixed in 10% neutral buffered formalin (Bio Optica) for 24h and transferred to 70% ethanol. After 
embedding in paraffin, transverse sections (4-5 μm) of proximal and distal colon were stained with H&E for 
histological studies. Images were digitized using Hamamatsu Nanozoomer 2.0 RS scan and NDP.scan 2.5 
digitization software. Three images of 2 serial sections cut at a separation of 100µm (6 sections in total) were 
evaluated for each mouse for each part of the colon (proximal and distal). Histological scoring evaluated 
inflammation severity, crypt damage, and ulceration. Inflammation severity was scored as follows: 0, rare 
inflammatory cells in the lamina propria; 1, increased numbers of granulocytes in the lamina propria; 2, 
confluence of inflammatory cells extending into the submucosa; 3, transmural extension of the inflammatory 
infiltrate. Crypt damage was scored as follows: 0, intact crypts; 1, loss of the basal one-third; 2, loss of the 
basal two-thirds; 3, entire crypt loss; 4, change of epithelial surface with erosion; 5, confluent erosion. 
Ulceration was scored as follows: 0, absence of ulcers; 1, 1 to 2 ulceration foci; 2, 3 to 4 ulceration foci; 3, 
confluent or extensive ulceration. Scores for each parameter were summed to give a maximum histological 
score of 11. 
4.4. T cell-mediated colitis 
 
Naive CD4+ T cells were sorted (FACSaria sorter, BD) from single-cell spleen suspensions of CD9-/- or 
WT mice. Live cells were isolated after labeling with antibodies to CD4, CD62, CD25, and CD45RB (Table 
4.3) and hoechst 33258 (Sigma-Aldrich). Cells were transferred to recipient Rag1-/- mice (4-5 x 105 cells per 
mouse) by intraperitoneal injection.  
4.5. Bone marrow chimeras 
Bone marrow transfer was used to create chimeric mice in which genetic deficiency for CD9 was confined 
to either circulating cells (CD9-/- >WT) or nonhematopoietic tissue (WT > CD9-/-). Briefly, bone marrows were 
collected from femur and tibia of congenic WT donor mice (expressing CD45.1 leukocyte antigen) or CD9-/- 
and WT donor mice (expressing CD45.2 leukocyte antigen) by flushing with PBS. Erythrocytes were lysed 
(ACK lysis buffer, Lonza) for 1 minute on ice. After a washing step, cells were resuspended in PBS at 1 x 
108/ml. This cell suspension (100 µl) was injected intravenously into 13 Gy-irradiated recipient mice 48h post-
irradiation. Four chimera groups were generated: WT > WT (WT cells expressing CD45.1 into WT mice 
expressing CD45.2); WT > CD9-/- (WT cells expressing CD45.1 into CD9-/- mice expressing CD45.2); WT > 
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WT (WT cells expressing CD45.2 into WT mice expressing CD45.1); CD9-/- > WT (CD9-/- cells expressing 
CD45.2 into WT mice expressing CD45.1). Bone marrow reconstitution was verified after 8 weeks by staining 
for CD45.1 or CD45.2 in blood cells with anti-CD45.1 or anti-CD45.2 specific antibodies (Table 4.3).  
4.6. In vivo permeability assay  
 
Food was withdrawn overnight and mice were gavaged with the permeability tracer FITC-dextran (Mw 
4000; Sigma-Aldrich) at 60 mg/100 g body weight. After 4h, blood was collected by heart puncture and serum 
FITC-dextran was measured with a fluorescence spectrophotometer (Fluoroskan Ascent; Thermo Labsystems) 
using emission and excitation wavelengths of 490 nm and 520 nm, respectively. FITC-dextran concentration 
was determined from a standard curve generated by serial dilution. 
4.7. Isolation and flow cytometry analysis of colonic leukocytes  
 
 Colons were dissected longitudinally, washed several times with PBS to remove feces, and cut into small 
pieces. Samples were digested with 0.25 mg/ml Liberase TM (Roche), 50µg/ml DNAseI (Roche), and 1mM 
DTT diluted in Hank’s Balanced Solution (HBSS) for 30 min at 37ºC. At the end of the incubation period, 
enzyme activity was blocked by adding 50 ml PBS supplemented with 0.5% BSA and 0.05mM EDTA (PBS-
BSA-EDTA), and the sample was mechanically disrupted by passing through a 70-micron cell strainer to 
obtain a cell suspension. When only epithelial cells were required, samples were incubated in 5mM EDTA, 
1mM DTT for 20 minutes before enzyme digestion. Before all staining procedures, colon cell suspensions 
were incubated with anti-mouse CD16/CD32 (Fc block) for 10 min at 4ºC in PBS-BSA-EDTA. For 
intracellular staining, cells were fixed and permeabilized using the CytoFix/Cytoperm kit (BD Biosciences). 
The antibodies used are listed in Table 4.3 Absolute cell numbers were obtained using TruCount Tubes (BD 
Biosciences). Cell samples were acquired in a FACSCanto Flow Cytometer (BD Biosciences), and the data 
were analyzed with FlowJo (Tree Star) or FACSDiva (BD Biosciences) software 
4.8. Flow cytometric bead array (CBA) 
 
 Serum TNF-α, IL-6 and IFNγ were determined using the mouse Th1/Th2/Th17 BD 
cytometric bead array (CBA).  
 
4.9. RNA extraction and real-time quantitative PCR 
 
RNA was isolated by disrupting colon tissue samples with TRIzol Reagent (1ml per 50-100mg tissue, 
Qiagen) and homogenizing in a tissue disruptor (Ika ultra-turrax T10 homogenizer). DSS traces were removed 
by the LiCl method (Ambion). Residual DNA contamination was eliminated with the Turbo DNA-free Kit 
(Ambion). Total RNA (1µg) was reverse transcribed to cDNA with a Reverse Trancription Kit (Applied 
Biosystems). Quantitative PCR was then performed in an AB7900_384 (Applied Biosystem) using SYBR 
Green (Applied Biosystems) as the reporter. Gene-specific primers used are listed in the 
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Table 4.3. List of antibodies for flow cytometry (FC). Table of antibodies used in FC experimental procedures 
disclosed by reference, brand, host and dilution 
 
 Table 4.4. List of qPCR primers. Table of primers used in qPCR disclosed by gene name and forward and reverse 
sequences. 
 
Antibody Reference Brand Host Dilution 
CD45.2-v450 560697 BD Pharmingen mouse 1:200 
CD45.2-PeCy7 560696 BD Pharmingen mouse 1:200 
CD45.1-PercPCy5.5 560580 BD Pharmingen mouse 1:200 
CD45RB-FITC 553099 BD biosciences rat 1:200 
EpCAM-FITC 118207 Biolegend rat 1:200 
EpCAM-PeCy7 118215 Biolegend rat 1:200 
CD31-APC 551262  BD Pharmingen rat 1:200 
Ki67-Alexa647 558615 BD Pharmingen mouse 1:200 
CD9-PE 12009181 eBioscience rat 1:200 
CD9-APC 17009182 eBioscience rat 1:200 
CD64-Alexa647 558539  BD Pharmingen mouse 1:200 
CD11b-FITC 553310  BD Pharmingen rat 1:200 
CD11c-PeCy7 558079  BD Pharmingen hamster 1:200 
CD16/32 Fc-block 70-0161 TONBO Biosciences rat 1:200 
CD3-FITC 555274 BD Pharmingen rat 1:200 
CD8-APC 558079  BD Pharmingen rat 1:200 
CD4-PeCy7 600042 TONBO Biosciences rat 1:200 
CD62L-PE 553151 BD biosciences rat 1:200 
CD25-APC 102011 Biolegend rat 1:200 
Ly6C-PerCP-Cy5.5 560525 Becton Dickinson rat 1:200 
Ly6G-PeCy7  605931 TONBO Biosciences rat 1:200 
MHC-II I-A/I-E-FITC 553623  BD Pharmingen rat 1:300 
Gene                       Forward Primer (5´- 3´)                                                   Reverse Primer (5´- 3´) 
Zo1 GAGCGGGCTACCTTACTGAAC   GTCATCTCTTTCCGAGGCATTAG 
Tricellulin TTCCGAAGCCTATCGTGATGC GAACACAGCCTTATAGCGTTCT 
Claudin-5 TATGAATCTGTGCTGGCGCT GTGCTACCCGTGCCTTAACT 
Claudin-7 CAGGCCACTCGAGCCTTAAT GCAAGACCTGCCACAATGAAA 
Claudin-8 GCAACCTACGCTCTTCAAATGG TTCCCAGCGGTTCTCAAACAC 
Claudin-10 AATCGTCGCCTTCGTAGTCTC GTTGGCAAAATAAGTGGCTGTG 
Muc1 GGCATTCGGGCTCCTTTCTT TGGAGTGGTAGTCGATGCTAAG 
Muc2 TGACTGCCGAGACTCCTACA CCAGCTTGTGGGTGAGGTAG 
Tff3c GATTACGTTGGCCTGTCTCC TGAAGCACCAGGGCACATTT 
Il6 TAGTCCTTCCTACCCCAATTTCC TTGGTCCTTAGCCACTCCTTC 
Nlrp3 CGAGACCTCTGGGAAAAAGCT GCATACCATAGAGGAATGTGATGTACA 
Il1b GCAACTGTTCCTGAACTCAACT ATCTTTTGGGGTCCGTCAACT 
Il12p35 TACTAGAGAGACTTCTTCCACAACAAGAG CTGGTACATCTTCAAGTCCTCATAGA 
Il12p40 GGAAGCACGGCAGCAGAAT AACTTGAGGGAGAAGTAGGAATGG 
inos CAGGAAGTAGGTGAGGGCT AATCTTGGAGCGAGTTGTGG 
Ifng CGGCACAGTCATTGAAAGCC TGCATCCTTTTTCGCCTTGC 
Il17 TTTAACTCCCTTGGCGCAAAA CTTTCCCTCCGCATTGACAC 
Il22 ATGAGTTTTTCCCTTATGGGGAC GCTGGAAGTTGGACACCTCAA 
Il10 ATAACTGCACCCACTTCCCA GGGCATCACTTCTACCAGGT 
Il2 TTGTGCTCCTTGTCAACAGC CTGGGGAGTTTCAGGTTCCT 
TNFa CAGGCGGTGCCTATGTCTC CGATCACCCCGAAGTTCAGTAG 
Tgfb CCTGCAAGACCATCGACATG TGTTGTACAAAGCGAGCACC 
Gapdh AGCTTGTCATCAACGGGAAG TTTGATGTTAGTGGGGTCTCG 
c-myb GAGCACCCAACTGTTCTCG CACCAGGGGCCTGTTCTTAG 
c-fos CGGGTTTCAACGCCGACTA TTGGCACTAGAGACGGACAGA 
Ccdn1 GCGTACCCTGACACCAATCTC CTCCTCTTCGCACTTCTGCTC 
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4.10. In vitro T cell differentiation 
 
Naive CD4+ T cells were obtained by incubating single-cell suspensions of spleen and lymph nodes with 
biotinylated antibodies to CD8, CD16, CD19, F4/80, Gr-1, MHC class II (I-Ab), CD11b, CD11c, and DX5 
followed by incubation with Streptavidin Microbeads (MACS, Miltenyi Biotec). CD4+ T cells were isolated 
by negative selection in an auto-MACSTM Pro Separator (Miltenyi Biotec). Next, cells were activated with 
plate-bound anti-CD3 (5µg/ml) and anti-CD28 (2µg/ml) in RPMI 1640 medium (Sigma-Aldrich) 
supplemented with 10% FCS, 2x 10-3 M L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 50 µM 2-
mercaptoethanol, and the corresponding cytokine cocktail: for Th0, anti-IFNγ (4 μg/ml), anti-IL-4 (4 μg/ml), 
and IL-2 (10ng/ml); for Th1 anti-IL-4 (4 μg/ml), IL-12 (10ng/ml), and IL-2 (10ng/ml); for Th17 anti-IFNγ (4 
μg/ml), anti-IL-4 (4 μg/ml), IL-6 (20 ng/ml), IL-23 (10 ng/ml), and TGF-β1 (5ng/ml); and for Treg anti-IFNγ 
(4 μg/ml), anti-IL-4 (4 μg/ml), and TGF-β1 (10ng/ml). after 72h of culture IFNγ, IL-17, or IL-10 in the 
supernatant were measured by ELISA (Ready-SET-Go, eBiosciences). For FACS analysis, intracellular 
cytokine staining was preceded by restimulation for 4h with 50 ng/ml phorbol dibutyrate (PMA) and 500 ng/ml 
ionomycin in the presence of brefeldin A (1μg/ml) (BD Biosciences).  
4.11. Immunohistochemical analysis 
 
For IHC staining, colon sections were deparaffinized, boiled in antigen retrieval solution (10 mM Tris 
Base, 1 mM EDTA Solution, 0.05% Tween 20, pH 9.0 for Ki67 and 10 mM sodium citrate, 0.05% Tween 20, 
pH = 6 for caspase-3), and incubated with the rabbit monoclonal anti-mouse Ki67 primary antibody (Master 
Diagnostica, clon SP6) or anti active caspase-3 rabbit polyclonal antibody (R&D system, catalog AF835). 
Bound antibodies were detected with anti-rabbit EnVision FLEX-HRP detection system (Agilent). Staining 
was developed with DAB substrate (Dako K3468), and slides were counterstained with Mayers Hematoxylin. 
Ki67 staining in epithelial cells was quantified in at least 4 fields (20X magnification) from each DSS-treated 
mouse (6-7 mice per group). Active caspase-3 staining in epithelial cells were quantified in the whole colon 
sections from each DSS-treated mouse (4-5 mice per group). Image J (1.46r) was used to measure intensities 
relative to the total area corresponding to the complete epithelial layer in each image.  
4.12. Statistical analysis 
 
 Data are presented as mean ± SD. Normal data distribution was assessed with the 
Kolmogorov Smirnov test, and the statistical significance of between-group differences was assessed 
by one-tailed unpaired Student t test,  one-way ANOVA with Newman Keuls multiple comparison t-
test, or two-way ANOVA with Bonferroni multiple comparison  as required. All statistical analyses 
were performed with GraphPad Prism (GraphPad Software Inc.). 
 
 
 
 
 
 
 
 
 
 
Results 
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5. RESULTS 
 
5.1. CD9-/- mice are protected against DSS-induced colonic injury 
 
To explore the function of CD9 in colitis development, we challenged CD9-/- and WT mice with the toxic 
compound DSS (2% solution) in drinking water for 7 days. Due to the colitogenic properties of DSS, animals 
experience progressive weight loss, severe diarrhea and intestinal bleeding. CD9-/- mice lost less than 10% of 
their initial body weight, whereas WT counterparts lost around 20% at the end of the treatment (Figure 5.1a). 
In addition, to monitor disease activity, we recorded a daily disease activity index (DAI) combining weight 
loss, stool consistency, and bleeding. From day 4, DAI values were lower in CD9-/- mice than in WT 
counterparts (Figure 5.1b).  
 
 
 
 
 
 
 
 
 
Due to tissue destruction, colon shortening in DSS-treated animals can be observed. Autopsy revealed that 
DSS-treated CD9-/- mice had significantly larger colons than WT counterparts (Figure 5.2. ), in accordance to 
the differences observed in body weight drop and DAI scores between both groups.  
RESULTS 
a b 
Figure 5.2. Macroscopic colon damage in DSS-treated WT and CD9-/- mice. (a) Representative images 
of colon shrinkage. (b) Quantification of the changes in colon length. n = 10–12 mice per group. 
a b 
Figure 5.1. CD9-deficiency reduces sensitivity to dextran sodium sulfate (DSS)-induced 
colitis. (a) Body-weight loss in WT and CD9-/- mice after administration of 2% DSS in drinking 
water for 7 days. Controls for each genotype were administered with unadulterated drinking water. 
(b) Disease activity index (DAI) score in WT and CD9-/- mice after administration of 2% DSS for 
7 days. n = 10–12 per group. Data represent means ± SD; *P < 0.05; **P < 0.005; ***P < 0.001, 
unpaired t-test. 
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Histology revealed a better preservation of tissue architecture in CD9-/- mice, in both the proximal and the 
distal colon. DSS-treated WT animals showed more pronounced epithelial denudation, crypt distortion, 
leukocyte infiltration of the lamina propria, and submucosal swelling (Figure 5.3a). Histological sections were 
scored for the severity of DSS-induced inflammation as described in Materials & Methods. DSS-induced 
extensive pathology is practically confined to the large intestine, specifically the distal colon where an 
enormous number of microorganisms live. In both proximal and distal colon, histological scores were lower 
in CD9-/- mice than in WT mice, with the difference more pronounced in the distal colon (Figure 5.3b). 
 
  a 
b 
Figure 5.3. Colon histopathological examination. (a) Representative photomicrographs of proximal colon (near 
the cecum) and distal colon (near the anus) from WT and CD9-/- mice at day 7 of DSS administration (H&E; 
magnifications: 4X and 10X). (b) Histological scores obtained from H&E-stained proximal and distal colon tissue 
sections from DSS-treated WT and CD9-/- mice. Data are pooled from two independent experiments (n = 4). Values 
represent mean ± SD of the mean: *P < 0.05; **P < 0.005; ***P < 0.001, unpaired t-test. 
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5.2. CD9 exacerbates tissue injury and decreases mouse survival after a lethal 
DSS dose 
 
Intestinal epithelial integrity is necessary for efficient defence against intraluminal toxins, antigens, and 
enteric bacteria. Cells are tightly joined in a healthy epithelium, and transepithelial permeability can thus be 
determined as an index of epithelial integrity. To monitor gut barrier function in vivo, we treated CD9-/- and 
WT animals with 2% DSS for 7 days and then orally administered 4KDa FITC-Dextran. Fluorescence 
spectrophotometry detection of serum FITC after 4h revealed markedly lower gastrointestinal permeability in 
CD9-/- mice than in WT mice (Figure 5.4). Serum FITC levels in non-treated animals showed no significant 
between-genotype differences and remained below 5ug/ml, consistent with an intact intestinal barrier function 
in the steady state (Figure 5.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consistent with the FITC-Dextran data, qPCR of colon samples from DSS-treated CD9-/- mice revealed 
elevated expression of genes encoding epithelial tight junction proteins, such as ZO-1, tricellulin, and claudin 
Figure 5.4. Enhanced epithelial barrier 
integrity in CD9-/- mice after DSS challenge. In 
vivo colon permeability, indexed from the serum 
level of 4 kDa FITC-dextran 4 h after feeding by 
gavage. Data are pooled from two independent 
experiments, n = 5–6 animals per group. Data 
were analyzed by one-way ANOVA and the 
Newman–Keuls multiple comparison test; ***P 
< 0.001. 
Figure 5.5. Enhanced preservation of the epithelial barrier in CD9-/- mice after DSS 
treatment. (a) qPCR analysis of tight junction and (b) mucin gene expression in colon samples 
after 7 days of DSS exposure. Data are from one experiment repeated two times with similar 
results. unpaired t-test. ns= non-significant, *P < 0.05; **P < 0.005. 
a 
b 
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family members (Figure 5.5a). CD9-/- colon also showed elevated expression of genes encoding epithelial 
globet cell proteins, such as the secretory mucin glycoproteins MUC1, MUC2, and trefoil factor 3 (TFF3), 
indicating normal intestinal function (Figure 5.5b).  
In a further approach, we exposed mice to a lethal DSS dose (4%) for 7 days followed by unadulterated 
drinking water for a further 8 days. At the end of the experiment all WT mice had died, whereas only 45% of 
the CD9-/- group were dead (Figure 5.6a). Moreover, the surviving CD9-/- mice showed a recovery in body 
weight (Figure 5.6b). These results show that CD9 impedes epithelial repair and contributes to colon injury 
at both sublethal and lethal DSS doses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3. Reduced myeloid cell infiltration and proinflammatory cytokine expression 
in the colon of CD9-/- mice 
 
To characterize the immune mechanisms of colonic mucosa damage, we analyzed CD9-/- and WT 
colon cells by flow cytometry. After 7-day exposure to 2% DSS, CD9-/- colon showed markedly lower 
neutrophil and macrophage infiltration than WT colon (Figure 5.7a and b). In contrast, in non-treated mice, 
gut populations of these immune cell subsets were comparable between genotypes (Figure 5.7a and b), as 
were lamina propria (LP) (Figure 5.8a and b), intraepithelial lymphocyte (IELs) (Figure 5.8c), and mesenteric 
lymph nodes (MLNs) populations (Figure 5.8d).  
 
 
a b 
Figure 5.6. Increased survival and recovery of CD9-/- mice after lethal 4% DSS dose administration. (a) 
Kaplan–Meier survival for WT and CD9-/- mice given 4% DSS in drinking water. **P < 0.01, Log-rank (Mantel–
Cox) test. (b) Percentage of initial body weight of WT and CD9-/- mice after 7-day intake of 4% DSS chased by 
unadulterated water. n = 11–12 per group: *P < 0.05; **P < 0.005; ***P < 0.001; unpaired t-test for WT and CD9-
/- groups. 
55 
 
 
 
 
 
 
a b 
Figure 5.7. CD9-/- mice exhibit lower leukocyte infiltration in the colon after 2% DSS administration. (a) Flow 
cytometry analysis of whole colon from WT and CD9-/- mice after 7-day 2% DSS intake. Representative dot plots and 
percentage quantification of neutrophils (Ly6G+) and macrophages (CD64+) populations gated in CD45+ cells. (b) Total 
neutrophil and macrophage numbers in the CD45+-gated population. Data are pooled from two independent experiments. 
n = 6-7 mice per group with two repeats and analysis by one-way ANOVA and the Newman–Keuls multiple comparison 
test. *P < 0.05; **P < 0.005. 
Figure 5.8. Immune cell populations 
in the colon and MLNs do not differ 
between CD9-/- and WT mice in 
steady state. Flow cytometry analysis 
of immune cell populations from 
untreated mice revealed no between-
genotype differences in (a) lamina 
propria (LP) macrophages 
(CD11b+CD64+), DCs (gated on 
MHCII+CD11c+CD64-) and lymphoid 
CD4+ and CD8+ T cell; (b) 
intraepithelial lymphocytes (IELs), γδ 
and CD8+ T cells and (c) mesenteric 
lymph nodes (MLNs) DCs, T and B 
cells. Total numbers and percentages 
from the CD45+-gated population. Data 
are representative of three independent 
experiments. n = 5 mice per group; 
unpaired t-test. 
a 
b 
c 
d 
WT
CD9-/-
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DSS-treated CD9-/- mice also had lower serum levels of IL-6 and TNFα than WT mice, whereas IFNγ was 
similarly increased in response to DSS in both genotypes (Figure 5.9a). Analysis of colon samples by qPCR 
revealed lower DSS-induced levels of IL-6, IL-1β, NLPR3, iNOS, IL12p35, and IL12p40 mRNA in CD9-/-
animals (Figure 5.9b), whereas IFNγ, IL-22, IL-17, IL-10, IL-2 and TGF-β showed no significant between-
genotype differences (Figure 5.9c).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
a 
Figure 5.7. CD9-/- mice display decreased proinflammatory cytokines in serum and colon after 2% DSS 
administration. (a) Serum levels of TNFα, IL-6, and IFNγ (b,c) qPCR analysis of colonic proinflammatory 
cytokine mRNA expression. Bars denote the mean ± SD of n = 4–5 mice per genotype. Data were analyzed by 
two-way ANOVA and the Bonferroni multiple comparison test. 
b 
WT
CD9-/-
c 
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5.4. CD9-/- bone marrow cells transplanted into WT mice do not provide 
protection against colonic injury  
 
As tetraspanin CD9 is expressed in leukocytes, but also in non-hematopoietic cells like endothelial 
and epithelial cells, we next investigated in each compartment the possible implication of the absence of CD9 
in mediating colitis protection. For that, two groups of chimeric mice were generated using the CD45.1 and 
CD45.2 haplotypes. Reconstitution experiments were carried out with WT CD45.1 mice and CD9-/- or WT 
CD45.2 mice, with irradiation and transplantation in either direction. Reconstitution levels were checked by 
flow cytometry of the blood cell populations, showing levels of 95 to 99 percent (Figure 5.10a). Moreover, 
CD9 expression was checked. Between 34 to 40 percent of blood cells were positive for CD9 in the 
corresponding groups in which donor WT mice were used, and negative in the group were donor CD9-/- mice 
were employed (Figure 5.10b). 
 
 
 
 
After checking reconstitution levels, chimeric mice were administered with 2% DSS for 6 days. Protection 
against DSS-induced colitis was observed only when irradiated CD9-/- mice were used as recipients of WT 
bone marrow, as these mice display reduced weight loss (Figure 5.11a), DAI scores (Figure 5.11b), and colon 
shortening than their chimeric counterparts (Figure 5.11c). Histology revealed typical DSS-induced changes 
in the distal and proximal colon of WT recipients and less pronounced alterations in CD9-/- recipients 
reconstituted with CD45.1 WT bone marrow (Figure 5.12a and b). 
 
Figure 5.8. FACS analysis of chimeric mice blood samples. (a) CD45 haplotypes were used to discriminate 
between donor and receptor mice cell populations. (b) Confirmation of CD9 expression or abscence in the donor 
compartment.  
a 
b 
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a b c 
Figure 5.10. Reduced histological damage in chimeric CD9-/- recipients after DSS treatment. (a) H&E stained 
proximal and distal colon sections. (b) Histological injury scores. Representative experiment repeated twice, n = 6–
7 per group. Data were analyzed by unpaired t-test; ns = non-significant, **P < 0.005. 
 
b 
a 
Figure 5.9. Lack of CD9 in the resident non-hematopoietic compartment confers the reduced susceptibility 
to DSS-mediated colitis. Lethally irradiated WT CD45.1 mice were rescued with WT or CD9-/- CD45.2 bone 
marrow, whereas lethally irradiated WT and CD9-/- CD45.2 mice were rescued with WT CD45.1 bone marrow. 
Three months post-transplantation mice were treated with 2% DSS. (a) Body weight evolution, (b) disease activity 
index and (c) colon shortening. Representative experiment repeated twice, n = 6–7 per group. All between-group 
comparisons were analyzed by unpaired t-test; *P < 0.05; **P < 0.005; ***P < 0.001. 
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CD9-/- recipients had lower DSS-induced levels of serum IL-6 measured by ELISA (Figure 5.13a), and colon 
samples from CD9-/- recipients also had lower induced transcript expression of proinflammatory cytokines IL-
6, TNF-α, IL-1β, IL12p35 and IL12p40, and inflammatory mediators such as NLPR3 measured by qPCR 
(Figure 5.13b). These results underscore the conclusion that susceptibility to DSS-induced colitis is increased 
by CD9 expression in the non-hematopoietic compartment. 
 
The main two non-hematopoietic compartments are endothelial and epithelial cells. Thus, we wonder how 
CD9 expression levels behave during the advance of DSS treatment in these two cell types. CD9 membrane 
expression increases in endothelial cells (CD31+) since day 3 of treatment and sustains until day 6 (Figure 
5.14a). On the contrary, in epithelial cells (EpCAM+), a drop in CD9 membrane levels is detected at the end 
of the treatment on day 6 (Figure 5.14b). Of note, CD9 expression levels are higher at all-time points in 
endothelial cells than in epithelial cells. 
 
  a b 
Figure 5.12. FACS analysis of CD9 expression levels in the resident compartment in colon tissue at days 0 
(D0), 3 (D3) and 6 (D6) of DSS treatment. (a) Geometric mean (GeoMean) levels of membrane CD9 in live 
endothelial cells gated as CD45- CD31+ and in (b) live epithelial cells gated as CD45- EpCAM+. AU: arbitrary 
units. Experiments were perfomed three times, giving similar results. Bars denote the mean ± SD of n = 5 mice 
per genotype. Data were analyzed by one-way ANOVA and the Newman-Keuls multiple comparison test. 
 
Figure 5.11. CD9-/- recipients display a reduced proinflammatory status upon DSS challenge (a) Serum IL-
6 measured by ELISA. (b) qPCR analysis of proinflammatory cytokine expression in the colon of WT or CD9-/- 
CD45.2 recipients. Experiments were perfomed twice, giving similar results. n = 6–7 per group. Data were 
analyzed by unpaired t-test; ns = non-significant. *P < 0.05; **P < 0.005. 
b a 
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5.5. CD9 expression does not sensitize IECs to DSS-induced apoptosis 
 
To investigate the molecular mechanism underlying the protective effect of CD9 loss on DSS-induced 
colitis, we determined the apoptotic levels in WT and CD9-/- recipient mice IECs after DSS treatment. For that, 
we analyse the levels of active caspase-3, a biochemical marker of apoptosis. Caspase-3 staining showed that 
both WT and CD9-/- mice epithelia had very low levels of apoptosis, and no differences were found between 
both groups of mice (Figure 5.15a and b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.6. Enhanced colonocyte proliferation after DSS-induced injury in CD9-/- mice  
We next investigated proliferative capacity of IECs in the presence or absence of CD9. After DSS-
induced epithelial cell damage, the colonic epithelium actively proliferates to restore intestinal barrier integrity. 
Flow cytometry analysis of the proliferation marker Ki67 in colonic EpCAM+ intestinal epithelial cells (IECs) 
from mice revealed that CD9 deficiency supports elevated colonic epithelial cell proliferation after DSS 
exposure (Figure 5.16a). Remarkably, although the percentage of Ki67+ cells was slightly higher in CD9-/- 
Figure 5.13. Apoptosis analysis after DSS exposure in chimeric mice show no differences between WT and 
CD9-/- recipients. (a) Representative activated caspase-3 immunohistochemistry staining images (10x) after 6 days 
of 2% DSS treatment. Positive cells are pointed by arrows. (b) Quantification of activated caspase-3 staining (n=5 
mice per genotype). Each dot corresponds to the percentage of positive area relative to the total epithelial layer. 
Between group comparisons were analyzed by unpaired t-test. ns, non significant. 
a 
b 
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colon after 2 and 4 days of DSS exposure, the significant difference was observed at day 6. This is coincident 
with significant lower body weight loss (Figure 5.16b) and higher colon length in CD9-/- mice (Figure 5.16c).  
 
 
 
 
Moreover, CD9-/- colon showed higher mRNA expression of the cell cycle genes c-myb, cyclin D1 and c-fos 
(Figure 5.17), which supports an enhanced proliferation in the absence of CD9.  
 
 
 
 
 
 
 
Proliferation in DSS-exposed colon of mouse chimeras was determined by counting immunostained Ki67+ 
cells in colon crypts on histological sections (Figure 5.18a). The percentage of Ki67+ colonic cells was higher 
after DSS exposure in CD9-/- recipients than in WT recipients (Figure 5.18b). Taken together, these results 
demonstrate that CD9 limits epithelial cell proliferation in response to injury. 
 
 
 
 
a c b 
Figure 5.14. CD9 limits epithelial cell proliferation upon dextran sodium sulfate (DSS) challenge. (a) FACS 
analysis of Ki67+ cells in the EpCAM+CD45− gated population after days 2, 4, and 6 days 2% DSS exposure. (b) 
Body weight loss and (c) colon shortening, n = 5–6 mice per group. Between-group comparisons were analyzed by 
unpaired t-test; *P < 0.05; **P < 0.005; ***P < 0.001. 
Figure 5.15. CD9-/- colon expresses 
higher levels of cell cycle genes mRNA 
after DSS-induced damage. qPCR 
analysis of colonic mRNA expression of 
the cell-cycle genes, ccdn1, c-myb and c-
fos. Data are pooled from two independent 
experiments, n = 4-6 mice per group. Data 
were analyzed by unpaired t-test; ns = non-
significant. *P < 0.05. 
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Due to the described interaction of CD9 with EpCAM [498], we analyzed membrane expression levels of this 
molecule in IECs upon DSS damage. However, no differences were detected, and EpCAM decreases after 4 
and 6 days of DSS treatment in WT and CD9-/- mice colon epithelial cells (Figure 5.19). 
  
a 
b 
Figure 5.16. CD9-/- IECs proliferate more than WT IECs after DSS exposure. (a) Ki67 
immunohistochemical staining on proximal and distal colon sections from 6-day DSS-treated chimeric mice. 
Two independent 10X images are shown per section. (b) Quantification of Ki67+ cells in the epithelial layer of 
colons from 6-day DSS-fed chimeric mice. Each dot corresponds to one analyzed image; 5-6 images were 
analyzed per mouse, n=5 mice per genotype. All between-group comparisons were analyzed by unpaired t-test; 
***P < 0.001. 
Figure 5.17. IECs EpCAM levels do not differ 
between CD9-/- and WT mice. Mice were 
administered a 2% DSS solution and EpCAM 
membrane expression levels in colon IECs were 
analyzed by flow cytometry. A marked reduction is 
observed at days 4 and 6 of DSS exposure compared 
to day 2 in both groups of mice. Bars denote the mean 
± SD of n = 5-6 mice per genotype. Geo Mean: 
geometric mean; AU: arbitrary units.  
63 
 
5.7. Differential microbiota is not the cause of the decreased DSS susceptibility 
in CD9-/-mice 
 
Due to the known relevance that differences in mice microbiota composition might exert in DSS 
susceptibility, cohousing experiments were performed in which the mice were caged together for several weeks 
in order to share their microbiota constituents. However, cohoused WT and CD9-/- mice display the same 
susceptibility to DSS as their non-cohoused counterparts showing similar weight loss (Figure 5.18a), colon 
shortening (Figure 5.18b) and neutrophils and macrophages infiltration into the colon (Figure 5.18c). Thus, 
this result discards a possible role of a differential microbiota in the protection detected in CD9-/- mice.  
 
 
 
 
 
a 
c 
Figure 5.18. Cohoused WT and CD9-/- mice experience the same susceptibility to 2% DSS damage than their 
non-cohoused counterparts. Female CD9-/- and WT mice were cohoused after weaning for 8 weeks. (a) Body weight 
change. (b) Representative colon pictures and colon length measurements. (c) Quantification of neutrophils (Ly6G+) 
and macrophages (CD64+) populations gated in CD45+ CD11b+ cells in mice colon tissue. Percentage from CD45+ 
cells (left) and total numbers normalized using TruCount beads (right) are shown. Statistical analysis was performed 
by one-way ANOVA and the Newman–Keuls multiple comparison test. *P < 0.05; **P < 0.005; ***P < 0.001; ns = 
non-significant, n = 6-7 mice per group. 
b 
64 
 
5.8 CD9 expressed on CD4+ T cells does not contribute to immune-cell adoptive 
transfer-mediated colitis. 
 
Colitis can be initiated by adoptive transfer of syngeneic splenic CD4+CD62L+CD25-CD45RBhi naïve 
T cells into T and B cell-deficient recipient Rag1-/- mice which cause a disruption in T cell homeostasis. Due 
to the important role of CD9 in T-lymphocytes physiology, we decided to further explore possible CD9-
mediated immune mechanisms in IBD by using this alternative model of colitis through the intraperitoneal 
transfer into Rag1-/- mice of naïve T cells sorted from WT or CD9-/- mice. Body weight was recorded over 2 
months, showing no between-group differences (Figure 5.21a). Colon shortening was also similar in both 
genotypes (Figure 5.21b and c). Consistent with these findings, histological inspection revealed a similar 
extent of transmural inflammation in injected animals (Figure 5.21d).  
 
  
a b 
d 
c 
Figure 5.19. CD4+ T cell-expressed CD9 does not contribute to adoptive transfer-mediated colitis. (a) Body 
weight after intraperitoneal adoptive transfer of CD4+CD45RBhi CD62L+CD25- T cells from WT and CD9-/- 
donors into Rag1-/- recipients. (b,c) Colon length at sacrifice on day 57. (d) Representative 3.5x and 10x 
magnification H&E-stained colonic sections from Rag1-/- mice injected with WT and CD9-/- CD4+ cells, showing 
transmural infiltration affecting all colon layers in both settings. Data are from a representative experiment 
repeated three times with similar results. n = 5-6 mice per group; unpaired t-test. ns, non significant. 
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Several weeks after the transfer, a mixed immune cellular infiltration can be detected in the mice lamina propria 
(Figure 5.21d) composed by polymorphonuclear cells, macrophages and mononuclear cells corresponding to 
the expanded CD4+ T cell population that now became proinflammatory Th1 and Th17 cells. By flow 
cytometry similar increases in neutrophil and macrophage infiltration were detected independently of the 
expression of CD9 in CD4+ T cells (Figure 5.22a). Additionally, restimulation of mesenteric lymph node 
CD4+ cells with CD3/CD28 revealed no significant differences in Th1 and Th17 effector cell populations or 
cytokine production (Figure 5.22b).  
Figure 5.20 FACS analysis of myeloid 
cell infiltration in the adoptive transfer 
colitis model. (a) Representative dot plots 
are shown on the left; quantification of 
CD45+-gated cell percentages and total 
numbers is shown on the right. (b) Flow 
cytometry analysis of intracellular 
staining for IFNγ and IL-17 in T cells from 
the mesenteric lymph nodes (MLNs) of 
RAG1-/- mice 2 months after CD4+ T cell 
transfer. Cells were cultured for 72 h on an 
anti-CD3/CD28-coated plate and 
brefeldin A was added for the last 4 h. 
Representative dot plots and bar 
quantifications are shown of CD4+CD25+-
gated cells. n = 5–6 mice per group; 
unpaired t-test. ns, non significant. 
a 
b 
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5.9 T cell differential subset skewing in vitro shows no differences with CD9 expression 
 
In parallel, naïve CD4+ T cells from CD9-/- and WT mice were skewed in vitro using recombinant 
cytokines and polyclonal stimulus to in-deep explore CD9 role in T cells. However, like in the in vivo model 
of colitis described under section 4.8, no between-genotype differences were observed in the percentages of 
Th1, Th17, and Treg cells (Figure 5.23a and b) nor cytokine production (Figure 5.23c).  
 
 
Figure 5.21. In vitro T cell differentiation towards Th1, Th17, and Treg CD4+ T cell subsets. (a) Representative 
dots plots are shown of intracellular IFNγ, IL-17, and IL-10 in sorted populations, with quantification on (b). (c) 
Cytokine release was quantified by ELISA. Data are from a representative independent experiment of three performed 
and are presented as mean ± SD. n = 5 per genotype; unpaired t-test. ns, non significant. 
a 
b 
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5. DISCUSSION 
 
Inflammatory bowel disease (IBD) arises through close interaction between genetics, immunology, 
environment, and microbiome. The development and progression of this multifactorial disorder is affected by 
several factors, including diet, lifestyle, and behaviour. DSS-induced colitis has become a widely used model 
for studying IBD in the mouse [87,401]. DSS is a chemical colitogen toxic to gut epithelial cells, interfering 
with intestinal barrier function and stimulating local inflammation. This model is suitable for studying events 
triggered by temporary failure of mucosal homeostasis after epithelial cell shedding and loss of barrier 
integrity, and can also provide insight into the mechanisms that lead to mucosal healing (MH) after initial 
injury [258]. In this thesis work we report protection against DSS-induced colonic mucosal damage in CD9-
deficient (CD9-/-) mice. These mice show lower DAI scores throughout treatment, larger colons, and have a 
less severe histological injury. The protection conferred by CD9 absence was confirmed by the increased 
survival of CD9-/- mice upon administration of a lethal 4% DSS dose.  
5.1. CD9 and epithelial permeability 
 
Epithelial preservation in vivo was demonstrated by lower colonic transepithelial FITC-dextran 
leakage in CD9-/- mice, and the importance of CD9 in the control of intestinal epithelial barrier function and 
integrity was further demonstrated by preserved expression of tight junction and other barrier-related genes in 
CD9-/- mice. Reduced intestinal epithelial barrier function is associated with a variety of gastrointestinal 
diseases, including irritable bowel syndrome (IBS) [337,67], steatohepatitis (NASH) [491] and IBD 
[228,14,329]. IBD patients have shown several defects in the key players of the intestinal epithelial barrier 
function, ranging from defensins, mucus layer components to the adhesion molecules that regulate paracellular 
permeability [164,478] and increased intestinal permeability has been correlated with IBD [598,610,106]. 
Nevertheless, it is difficult to elucidate whether the loss of barrier function is a cause or just a consequence of 
intestinal inflammation. Supporting the first, many genetic risk loci in IBD have been found in genes related 
to epithelial barrier function [256]. However, some studies report that the expression pattern of TJ proteins are 
unaltered in patients with inactive IBD [633], and suggest that TJ disturbances are more likely to be a 
consequence rather than a cause. In any case, experimental evidence using mouse models with genetic defects 
in tight-junction-associated proteins demonstrate that these defects usually are insufficient to cause disease in 
the absence of other insults [257,538,294]. This notion is supported by findings of increased permeability in a 
subset of unaffected first-degree relatives with CD [416,248] and in healthy mucosa of the proper IBD patients 
[526,527]. In mice studies, increased paracellular permeability accelerates experimental colitis and 
preservation of tight junction barrier function delays disease progression. In clinical practice, several studies 
have documented that changes in intestinal permeability can predict IBD relapse during clinical remission 
[610,18]. Although there are no currently available FDA-approved agents that target specifically the epithelial 
barrier, many promising approaches have been proposed and are being investigated. Currently, anti-TNF-α 
therapy is capable of reduce mucosal inflammation and restore intestinal permeability in IBD patients. In 
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addition, some probiotics, certain fatty acids like butyrate, or zinc element also mitigate mucosal barrier 
dysfunction [352]. However, further research is required before therapeutically manipulating intestinal 
permeability. CD9 directly interacts with tight junction protein claudin-1, which has been detected by chemical 
cross-linking followed by mass spectrometry analysis, and to claudins-2, 3 and 7 to a much lower extent and 
only detected by co-immunoprecipitation in mild detergent conditions [276]. However, CD9 stabilizes the 
expression of claudins when they are not in tight junctions, and concordantly, depletion of CD9 by small 
interfering RNA had no effect on paracellular permeability [276]. Functional experiments assessed by in vivo 
FITC-dextran leakage analysis, demonstrated that there were no differences between both genotypes in the 
paracelullar permeability in steady state. Thus, a priori, there are no epithelial barrier differences in non 
inflammatory conditions, that could predispose or protect beforehand one group of animals versus the other 
one. Conversely, great differences were observed after DSS challenge, in which CD9-/- mice display an 
enhanced barrier integrity. Apart from a direct toxic effect of DSS to colonocytes, the increase amount of 
proinflammatory cytokines detected in WT mice, including TNF-α and IL-1β, may also account for tight 
junction proteins downregulation [6,5]. Other works observed a decreased expression in ZO-1 in mice [432], 
and sealing claudins 3,5,7 and 8 in mice and rats [631,611] after DSS treatment, which is in concordance with 
our results. Of note, IBD patients also display these reductions [408,633]. Interestingly, it has been reported 
that tetraspanin CD9 is mainly localized at lateral cell-cell junctions in polarized epithelial cells in association 
with integrins, but the localization of these complexes takes place independently of the cadherin-catenin 
molecular system [376,619] which have been described to be necessary for the correct assembly of tight 
junctions [175]. Thus, CD9 regulation of intercellular epithelial cell adhesion may not influence junctional 
adhesions and paracellular sealing. Regarding other non-classical junction proteins, CD9 has also been 
described to interact with epithelial cell adhesion molecule (EpCAM) [297,498]. EpCAM is a transmembrane 
glycoprotein which mediates homotypic cell-cell adhesion in normal epithelia [312] but it is also considered a 
cancer marker because its expression is markedly increased in various carcinomas [577,564] and it has been 
described to participate in epithelial cell proliferation, migration, and transduction of mitogenic signals 
[370,369]. EpCAM inclusion in TEMs (CD9 and D6.1A) forms a complex together with a specific CD44 
variant isoform (CD44v), which is required to support tumour apoptosis resistance [498]. Claudin-7 interacts 
with EpCAM [288] and recruits it into TEMs [395], and the complex composed of CD44, claudin-7, EpCAM, 
and Tspan8 promotes cancer progression while the individual molecules do not have this effect [285]. 
However, in relation to IBD, contradictory reports exist on the role of this molecule. On one hand, EpCAM 
colon tissue expression is significantly decreased in UC [157], and on the other hand, no differences are 
detected in neither CD nor UC and EpCAM and its diminished expression is just considered a specific marker 
of congenital tuft enterophaty (CTE) disorder [368]. Though it has been reported by using EpCAM-deficient 
mice that this molecule contributes to formation of functional tight junctions in the intestinal epithelium by 
recruiting claudin proteins [301], no DSS colitis, or any other experimental colitis model has been performed 
in EpCAM-deficient mice. In our kinetic experiment in DSS treated mice, a decreased was noticed in the levels 
of this molecule at days 4 and 6, in accordance with other reports [157]. However, no differences were observed 
between CD9-/- and WT mice at any time point.  
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5.2 CD9 and inflammatory cell recruitment 
 
CD9 is quite ubiquitously expressed, and we therefore performed chimeric reconstitution experiments 
to determine which cell compartment is responsible for mediating DSS-induced toxicity. Our data clearly 
demonstrated that protection in CD9-/- animals was not dependent on the hematopoietic cell compartment. In 
CD9-/-colon, crypt and villous distortion is minimal and surface epithelium is more preserved; this keeps 
luminal pathogens outside the lamina propria, and therefore proinflammatory cytokine and chemokine release 
is lower and there is less inflammatory cell recruitment. Specifically, the myeloid-derived cytokines involved 
in the inflammatory response in DSS acute colitis iNOs, TNF-α, IL-6, IL-12, and the inflammasome drivers 
NLRP3 and IL-1β were enhanced in WT mice versus CD9-/- mice, but no differences were observed in either 
IFNγ, IL-17, or IL-22 cytokines which are mainly produced by lymphoid cells. Accordingly, increased 
neutrophil and macrophage infiltration was observed in WT versus CD9-/- mice. In this regard, several studies 
have underscored the role that innate cells such as neutrophils and macrophages play in DSS-induced intestinal 
inflammation. Large neutrophil and macrophage infiltration is observed upon DSS administration, and 
inhibitors or promoters of these cells recruitment dampen or enhance DSS damage, respectively 
[261,139,617,481]. Likewise, the acute version of DSS colitis takes place also in immunodeficient SCID [116], 
Rag1-/- [259] and Rag2-/- [277] mice, meaning that neither T nor B cells are required for the induction of the 
disease. However, the role of T cells in DSS-induced colitis should not be obviated. Though comparable results 
were obtained at a high dose of DSS (5%), colitis progression was much more tolerable in Rag1-/- mice than 
in WT BL6 mice when a lower dose was used (1,5%), accompanied by improved symptomatic and histological 
parameters [259]. Moreover, multiple works report that a Treg/Th1-Th17 dysbalance worsens disease outcome 
in DSS-induced colitis, even in the acute version of the model [425,612,212,25,49,634,99,592]. Thus, we 
analysed by qPCR, apart from IFNγ, IL-17 and IL-22 the levels of IL-10, TGF-β and IL-2 in the colon of DSS-
treated mice, however, no between-genotype differences were detected.  
DSS colitis can be exacerbated by both granulocyte [261,91,603,378,481] and monocyte/macrophage 
[496,277,261,481] recruitment. After the breakdown of mucosal homeostasis provoked by DSS, neutrophils 
arrive to eliminate extracellular microorganisms through phagocytosis, degranulation, production of ROS, and 
release of DNA neutrophil extracellular traps or NETs [267]. Unfortunately, the activity of many enzymes and 
chemicals produced by neutrophils is not specific to pathogens, so they can damage host tissues when released 
extracellularly, contributing to the aggravation of mucosal inflammation. Thus, in an innate model such as 
DSS acute colitis, neutrophils are detrimental. However, in other colitis models such as the T cell adoptive 
transfer colitis model, in which disease is induced by transfer of CD45RBhigh T cells lacking regulatory T cells 
into T-cell-deficient RAG-1-/- recipients, depletion of neutrophils by a monoclonal antibody given at the time 
of T-cell transfer into the RAG-1-/- recipients resulted in greater severity of colitis and earlier death. Increased 
mortality was also observed when neutrophil depletion was delayed until day 14, around the time that the 
initial symptoms of colitis developed [282]. Interestingly, these results resemble what happens in human 
disease. In UC, unrestricted neutrophil activation may cause significant tissue damage that further leads to 
chronic pathology and the extent of neutrophil infiltration correlates with the severity of the disease [60], 
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whereas in CD, defective neutrophils may not be able to limit invasion by microorganisms, leading to 
subsequent uncontrolled inflammatory reaction. Additionally, the proinflammatory and antimicrobicidal 
activities of macrophages may participate in the inflammation-associated tissue damage as well. For example, 
in Ccr2-/- mice, which have a paucity of monocyte derived cells in circulation and tissues due to a failure in 
classical monocyte release from the bone marrow [507], or animals depleted of CCR2-expressing cells [643], 
there is an amelioration of DSS-driven colitic inflammation. The same happens when monocyte recruitment is 
impaired by α1β1 or β7 integrin treatments [277,496]. Importantly, though CD9 is expressed in both neutrophils 
and monocyte/macrophage cell populations, the reconstitution experiments ruled out a contribution to colon 
protection from CD9 deficiency in innate immune cells. Whether CD9 expression in leukocytes may have a 
role in extravasation, one may expect the opposite effect that the one observed in the CD9-/- DSS-treated mice, 
that is, CD9-/- cells might migrate more, based on previous reports performed in other cell types like B1 innate-
like B cells, eosinophils but also in macrophages. In B1 peritoneal cells, CD9 expression diminishes upon 
TLR4 stimulation and allows for B1 cell egress from the peritoneum to the spleen. Experiments performed 
using CD9-/- B1 cells, corroborate the previous observation and demonstrate that a higher number of CD9-/- 
cells reached to the spleen. However this effect was not due to CD9 downregulation of surface integrins, as no 
differences in those were observed after anti-CD9 antibody induced-downregulation, but most likely to 
increased cell motility [178]. Compared with peripheral blood eosinophils, transmigrated eosinophils in 
allergen-challenged chambers exhibit reduced CD9 expression levels, and their adhesion properties are 
inhibited by antibodies against CD9 [145,146]. Furthermore, CD9-/- mice display an enhanced macrophage 
infiltration after lung intranasal administration of LPS, when compared to WT mice, due to enhanced MMP-2 
and MMP-9 production and activity [543]. In this line, CD81 and CD9 double deficient mice spontaneously 
develop pulmonary emphysema, and also exhibit elevated numbers of alveolar macrophages and increased 
MMP activity [549]. Although the decreased expression of CD9 in inflammatory cells could promote their 
migratory capacities, the early maintenance of the epithelial barrier integrity that we observed in CD9-/- mice 
would prevent for the massive bacterial invasion to the lamina propria and, consequently, inflammatory cells 
recruitment. On the other hand, endothelial expression of CD9 is required for an efficient leukocyte 
extravasation through its regulation of the endothelial adhesive platforms (EAPs) [31]. In favour of the 
phenotype observed in this work, CD9 downregulation by the use of siRNA or CD9 TEMs alteration by CD9-
large extracelullar loop (LEL)-glutation S-transferase (GST) peptides in human umbilical vein endothelial cells 
(HUVECs), interfered with ICAM-1 and VCAM-1 function and prevented lymphocyte transendothelial 
migration in shear flow chamber experiments ex vivo [31]. Indeed, blockade of these adhesion molecules have 
proven efficacy in acute colitis models in mice and rats [38,182,553,608,137,627]. Thus, the role of endothelial 
CD9 could not be completely ruled out, and additional research with endothelium-specific deletion of CD9 
would be required to solve this issue. 
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5.3. CD9 and epithelial proliferation and apoptosis 
 
Flow cytometry and immunohistochemistry analysis revealed a higher percentage of Ki67 IECs in 
DSS-exposed CD9-/- colon. In the distal colon, the percentage Ki67+ cells is lower than in the proximal colon 
which likely reflects the more severe colitis in the middle and distal third of the colon described for DSS-
exposed mice [419]. Though DSS may also induce some damage in the small intestine [624], it is mostly 
confined to the large intestine, and mainly the distal part of it, where an enormous number of microorganisms 
live [97]. On the other hand, DSS toxicity provokes a decreased proliferation in the first days of treatment 
(days 2-4) followed by an increase in proliferation generated as a regenerative response aimed to restore the 
epithelial barrier (days 6-8) [379,456]. Notably, the difference in proliferation among WT and CD9-/- mice was 
observed after 6 days of DSS exposure, suggesting that it is related to mechanisms of post-injury epithelial 
recovery. Several other works exemplify how augmenting epithelial cell proliferation leads to DSS-induced 
colitis protection. Some of the mechanisms involve growth factors [102,512,351,604,338,130], cytokines such 
as IL-22 [423] or IL-18 [399], TLR signaling [211,56,450,156], NLRP3 inflammasome [632], focal adhesion 
kinase (FAK) activation [412], cell cycle transcription factors such as KLF5 [343], or the NF-κB pathway in 
epithelial cells [396,127]. After DSS treatment, the intestinal epithelium undergoes a wound healing process. 
First, IECs rapidly cover the denudated ulcers by a process known as epithelial restitution, that is independent 
of proliferation but induces it afterwards to recover the pool of enterocytes [220]. The exposure of the Toll-
like receptors of the basolateral surface of the IEC triggers proliferation that contributes to mucosal repair after 
injury and mice with gene deletions affecting TLR signaling such as Tlr2-/-, Tlr4-/- and Myd88-/- mice exhibit 
exacerbation of DSS colitis [71,156,450]. It has been described that CD9 sequesters CD14 from lipid rafts, 
preventing the formation of the LPS receptor complex. Thereby, in the absence of CD9, TLR4 signaling after 
LPS triggering is enhanced [543]. Thus, the enhanced proliferation observed in the CD9 deficient mice may 
be promoted by increased TLR4 signaling in IECs. Besides, and also interconnected with TLR signaling 
[211,56], activation of EGFR has been shown to be necessary to maintain intestinal homeostasis in the setting 
of acute mucosal damage [428,36]. EGFR signaling has been described to be of particular relevance in IBD, 
where it has been observed a decrease in the signaling by this receptor [400,206,21,7]. Importantly, EGF was 
effective in a double-blind clinical trial in UC [517]. Supporting this notion, numerous studies in mice have 
demonstrated a protective role of EGFR in intestinal inflammation. Mice with impaired EGFR activity 
[123,128] or devoid of the EGFR ligand TGF-α [130] are more susceptible to experimental colitis, whereas 
mice overexpressing TGF-α [129] or rats treated with exogenous EGF [440] are resistant. Moreover, probiotic 
bacteria-derived soluble protein p40, from Lactobacillus rhamnosus GG, ameliorates DSS colitis in mice by 
an EGFR- and Akt-dependent mechanism [615]. In this setting, CD9 could be playing several roles. EGFR 
signaling is increased in CD9-deficient cell lines [374,552,589]. On one hand, expression of CD9 specifically 
attenuates EGFR signalling through the downregulation of surface expression of the receptor by dynamin-2 
mediated endocytosis [552]. However, other reports claim that CD9 decreases the phosphorylation of EGFR 
at tyrosines Y1173 and Y1086 and attenuates EGFR induced PI3K/Akt and MAPK/Erk signaling and 
proliferation, but without affecting EGFR expression levels at the cell surface [589]. Nonetheless, regardless 
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the mechanism, all the reports coincide in the antiproliferative effects of CD9 through EGFR signaling 
dampening. In the intestinal mucosa, there are several members of the family of EGF-related growth factors 
that can activate EGFR signalling and many of them such as TGF-α, HB-EGF, amphiregulin (AR) and 
epiregulin (EPR) are released after tumour necrosis factor α-converting enzyme (TACE/ADAM17) shedding 
[375,542,475]. Accordingly, ADAM17-/- [512] or TLR4-/- [450,156] mice display an increased susceptibility 
to DSS-induce colitis, due to reduced EGFR ligands generation and decrease IECs proliferation. In this regard, 
CD9 has been described to negatively regulate ADAM17 [176] and thereby, in CD9-/- IECs, an increase activity 
of this metalloproteinase would entail an increase in EGFR ligands release. Moreover, EpCAM extracellular 
and intracellular domains are sequentially cleaved by ADAM17 and presenilin-2 (PSEN2), respectively [328]. 
The released intracellular EpCAM domain interacts with the transcriptional regulators FHL2, β-catenin and 
Lef-1 to form a nuclear complex that stimulates transcription of proliferative and oncogenic genes including 
c-Myc and cyclins [328,370]. However, increased ADAM17 cleavage of EpCAM in these reports entails 
reduced levels of EpCAM surface expression, and in CD9-/- mice no differences were observed in EpCAM 
levels measured by flow cytometry (geo mean levels). Thus, the increment in proliferation detected in CD9-/- 
mice might not be explained by this mechanism. Other regenerative mediators such as TGF-β, IL-22 and IL-
10 have been measured in mice colon, but no differences were observed compared with WT mice.  
On the other hand, CD9 absence does not increase IEC proliferation per se and only supports MH after 
injury. Indeed, dysplasia was not observed in any healthy CD9-/- animal nor after DSS exposure. However, this 
model is acute and very short in time, so to accurately evaluate if CD9 deficiency could lead to tumour 
progression after damage, a longer experiment should be performed like the chronic version of the DSS model 
where the animals are given repeated cycles of the chemical interspersed with water intake [286,402]. 
Additionally, an inducible mouse model of colon carcinogenesis through the use of the mutagenic agent 
azoxymethane (AOM), alone or combined with DSS, could be use to explore CD9 pro-neoplastic role [381]. 
The absence of CD9 have been extensively studied in gastrointestinal cancers, where its reduced expression is 
associated with a poor prognosis and entails an increased risk of metastasis [363,66,373]. The amount of CD9 
is inversely correlated to the lymph node status in gastric cancers and in esophageal squamous cell carcinomas 
[372,570]. Moreover, the reduced CD9 expression is related to a poor prognosis in patients with pancreatic 
cancers [513]. On the contrary, there is only one report that claims that CD9 expression promotes cancerous 
cell proliferation and consequent metastasis generation due to the enhanced mitogenic activity of HB–EGF 
[205]. Thus, clarifying the consequences of CD9 depletion in mouse models in vivo would be critical before 
developing an anti-CD9 therapy for the treatment of IBD.  
Besides a direct control of proliferation, CD9 might regulate epithelial restitution. CD9 absence could 
be favouring the rapid reseal of the intestinal epithelial barrier and promote IECs migration through several 
mechanisms. CD9 deficiency leads to impaired localization of talin1 to focal adhesions [434] and decreases 
both stress fiber formation and integrin clustering [162,494], which correlates with increased motility. 
Accordingly, increased integrin-mediated affinity between the enterocyte and the underlying ECM may impair 
epithelial restitution [448]. Moreover, lack of CD9 in IECs might increase p-EGFR induced restitution (apart 
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from proliferation) through p38 MAPK signalling [151]. In addition, CD9 expression has been demonstrated 
to downregulate pro-migratory Wnt5a and its target genes, which modulate cell adhesion and motility. Thus, 
in the absence of the tetraspanin, an increased cell motility through this mechanism could be plausible. Finally, 
CD9 regulates actin cytoskeleton rearrangements through its interaction with EWI-2 [532,93,477]. EWI-2 
inhibits cell migration on both fibronectin and laminin [637] and contributes to CD9-dependent inhibition of 
gliobastoma cells migration [268]. In this sense, the absence of the tetraspanin might enhance the migratory 
capabilities of the cell.  
A tight balance between proliferation and apoptosis is crucial for homeostasis maintenance in the gut 
[111,380]. The development of many infectious and immune-mediated diseases, such as gastritis, coeliac 
disease and IBD, may be triggered by the prevalence of pro-apoptotic signals [451,413,365], whereas 
prolonged cell survival, due to apoptosis inhibition, may give rise to neoplastic clones [349]. In IBD, high 
levels of apoptosis in the epithelium have been reported in both UC and CD [529,113,226,179], but the precise 
nature and role of IECs death in the pathogenesis of IBD has not been elucidated to date. Whether a causative 
relationship exists or it is secondary to the chronic inflammatory state of these patients, is not certainly known 
[47]. Regarding DSS mice colitis model, the exact mechanism of epithelial damage is unknown, but an 
increment in apoptosis [16,585] and necrosis [97,167] is detected upon administration of the chemical. 
Moreover, augmented levels of apoptosis due to cell-intrinsic defects [90,445,452] or provoked by pro-
inflammatory cytokines [602,613] exacerbates the disease. Though the foregoing works report an exacerbation 
of DSS-induced colitis in the case of increased apoptotic levels, there are some others which describe a 
protection of mice with reduced apoptotic levels [630,551,599]. On the other hand, CD9 ligation with the 
activating antibody ALB6 in a gastric cancer line (MKN-28), induces apoptosis through the specific activation 
of c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) and p38 mitogen-activated protein 
kinase (MAPK) pathway, as well as caspase-3 and the p46 Shc isoform [371]. Thus, we analyse the levels of 
cleaved caspase-3 in the epithelial layer of chimeric mice, but found no differences between CD9-/- and WT 
epithelium, ruling out a possible implication of this mechanism in the protection of CD9-/- mice upon DSS 
exposure.  
Several reports support a role for the microbiota in DSS-induced experimental colitis. Interestingly, 
not only microbiota composition can shift upon DSS treatment [180,401] but initial gut microbiota structure 
might affect DSS sensitivity and some bacterial species can reduce DSS susceptibility or increase it [305,61]. 
Cage sharing (cohousing) of mice reduces natural microbiota variation via coprophagy and direct animal to 
animal contact, and is now a widely accepted method for normalising microbiota communities before trial 
treatments being applied [362]. Therefore, as CD9-/- and WT mice lines were carried out in a separate way due 
to the inability to work with littermates, cohousing of CD9-/- and WT mice was performed for several weeks 
and then DSS treatment susceptibility was evaluated. However, no differences were observed between both 
genotypes, meaning that an intrinsic but not an environmental component was the responsible for the 
differences detected among both groups of mice. 
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5.4. CD9 and T cells 
 
CD9 plays an important role in T cell activation. T cell co-stimulation by engagement of CD9 with 
monoclonal antibodies was as potent as that induced by engagement of CD28 [547]. Interestingly, the 
tetraspanin triggers T cell co-stimulation by a different pathway from CD28 and NF-kB [642], though both 
co-stimulatory molecules can work synergistically. The combination of anti-CD9 and anti-CD28 co-
stimulation, induced the production of higher levels of IL-2 and IFN-γ accompanied by higher proliferative 
rates compared with the individual co-stimulation by engaging separately only one of the molecules [561]. 
Other groups confirmed this observation and detected higher levels of IL-2 production in Jurkatt T cells after 
anti-CD9 engagement [289]. Unlike the effects of CD28, which suppresses apoptosis and promotes cell 
proliferation, CD9 crosslinking promotes apoptosis after T cell activation and fails to sustain a T cell 
proliferative response [414,622,546]. These actions might be due to CD9 interaction with CD3 itself and other 
co-stimulatory molecules like CD4, CD5, CD2, CD29 (β1 integrin) and CD44 [562]. For instance, CD9 co-
stimulatory capabilities have been linked to the co-localisation of this tetraspanin with lipid rafts [621]. 
Moreover, downregulation of CD9 by shRNA in primary T lymphoblasts entail a marked reduction in T cell 
activation and IL-2 secretion due to impaired β1 integrin recruitment to the immune synapse [461]. However, 
despite all these works document a role for CD9 in T cell biology, no in depth analysis of the CD9-/- mice 
immune system has been performed. There is only one work regarding B cell responses where CD9 absence 
does not affect neither B cell development nor B cell response to immunization [69]. Naïve T cell proliferation 
is the first step after the efficient interaction of the TCR and CD4 co-receptor to the antigen-MHCII complex 
exposed by professional antigen presenting cells (APCs). Subsequent microenvironmental cues involving the 
cytokine milieu together with antigen dose (strength and/or duration of TCR signalling) and costimulatory 
molecules further drive T cell differentiation into specific effector T cells [322]. For instance, IL-2 production, 
which is markedly decreased in CD9-downregulated T cells or strongly increased after anti-CD9 engagement, 
has been described to be involved in promoting the differentiation of Th1 [510,307] and Th2 cells [308,89], 
while inhibiting Th17 [295] and T follicular helper (Tfh) cell [26] development, though promoting Th17 cell 
expansion once cells develop [8]. Moreover, IL-2 is crucial for Treg homeostasis and suppressive activity 
[492]. On the other hand, deficiency of the co-stimulatory molecules CD28, which works synergistically with 
CD9 [561], or CD5, to which CD9 binds more strongly [562], provoke alterations in effector T cell generation. 
CD28 deficiency entails impaired Th2 [260] and Treg responses [635,4]. CD5-/- mice display increased 
numbers of CD4+CD25+FoxP3+ thymocytes and peripheral natural Tregs, and reduced Th17 cell expansion. 
Moreover, CD5 co-stimulation induces Th17 development by promoting the expression of the interleukin IL-
23R and sustained STAT3 activation [545]. Thus, due to the potential influence that CD9 might exert in the 
foregoing events during T cell responses, we decided to explore whether CD9 deficiency had any 
transcendence in T cell differentiation and expansion in vitro and in vivo. However, we did not detect any 
differences between CD9-/- and WT CD4+ T cells neither in polyclonal differentiation experiments nor in the 
adoptive transfer colitis model, which is mediated by a strong Th1/Th17 expansion [258]. On the other hand, 
it has been recently demonstrated in our group an impairment in the T cell stimulatory capacity of CD9-/- 
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monocyte-derived DCs (moDCs), but not conventional DCs (cDCs), due to compromised MHC-II targeting 
to the plasma membrane [462]. During intestinal inflammation, Ly6Chi monocytes give rise to migratory 
antigen-presenting cells which can induce CD4+ T cell activation at day 7 of DSS-induced colitis [643]. In 
accordance, other reports describe how the same Ly6hi monocyte precursor can give rise to anti-inflammatory 
macrophages in homeostasis but inflammatory dendritic cells during colitis development [24,460]. However, 
chimeric mice with WT or CD9-/- DCs in CD45.1 WT recipients, behave the same way upon DSS exposure. 
Nonetheless, to further evaluate the role of CD9 in antigen presentation by colitic DCs, other experimental 
approaches such as DSS chronic colitis or injecting CD9-deficient DCs along with CD4+ naïve WT T cells in 
the adoptive transfer colitis model, are more suitable.  
5.5. Future perspectives: IBD and CD9 
 
There is no cure for IBD. Current IBD treatments have the goal to induce and maintain remission, or 
achieve extended periods of time when patients do not experience symptoms [384]. On top of that, many 
therapeutic agents are only effective transiently, while in some patients they fail to work at all. IBD is a chronic 
condition, and affected people will typically need treatment throughout their lives. The actual treatment of IBD 
consists of 1) anti-inflammatory drugs 5-aminosalicylic acid (5-ASA) and corticosteroids, 2) 
immunosuppresive drugs azathioprine (AZA), 6-mercaptopurine (6-MP), methotrexate (MTX) and calcineurin 
inhibitors (cyclosporin-A and tacrolimus), and 3) anti-TNF-α antibodies (infliximab, adalimumab, 
certolizumab). Treatment’s choice depends on the clinical goal (induction or maintenance of remission), extent 
and severity of disease, response to current or previous medication and the occurrence of complications [2]. 
However, due to the lack of a 100% effectiveness and the differences in patients’ responsiveness accounting 
for a complex multifactorial disorder, new drugs are being developed and many of them success to induce an 
improvement in IBD symptoms. New therapies explore blocking immune effector cells activation, blocking 
biologic activity of proinflammatory cytokines and their receptors, inhibiting T cell–APC interactions, 
selectively blocking effector cell extravasation, inducing apoptosis of activated effector cells or enhancing 
regulatory cell activity. Indeed, the gut-specific integrin blocker Vedolizumab (anti α4β7 heterodimer) 
[82,516] have been recently introduced for clinical IBD therapy. On the basis of the success of Vedolizumab, 
further strategies targeting gut T-cell homing are currently being tested in clinical trials, like anti-MadCAM-1 
[115] anti-β7 antibodies [583]. Apart from anti-TNF-α, other anti-cytokine therapies against IL-6 [225], IL-12 
[331] and IL-23 [141] have been successful. Indeed, Ustekinumab, a monoclonal antibody directed against the 
p40 common subunit of IL-12 and IL-23 was recently approved for CD therapy in the USA and in Europe 
[141]. Moreover, blockade of cytokine signalling pathways through targeting of intracellular JAK kinases 
[584,479], phosphodiesterase (PDE)4 [531], or SMAD7 (TGF-β signalling inhibitor) [361] are currently under 
evaluation in clinical trials, with promising results. Other potential strategies which have been already 
validated in mice models of colitis are directed against transcription factors controlling cytokine gene 
transcription like RORγt [605] or GATA3 [431], and no longer may be evaluated in human patients [149]. 
Additionally, non-immune therapy has also been investigated. The use of growth factors to achieve epithelial 
barrier restitution and healing have entered early clinical trials, like EGF [517], KGF [480], GH [194,518] and 
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glucagon-like peptide 2 analogues [64], whereas others are currently in preclinical evaluation. However, these 
early clinical trials are small and short in time. Thus, due to the risk that the use of growth factors might imply 
in carcinogenesis and fibrosis, larger and longer in time studies are still required [278,28]. Importantly, recent 
clinical studies have revealed mucosal healing as the major prognostic predictor of long-term remission in IBD 
patients [385,153], suggesting that epithelial regeneration is critical to improving IBD therapy [426]. Thus, the 
goals of treating IBD patients have evolved over the past few years to include mucosal healing in addition to 
clinical remission [581]. However, pharmacological anti-inflammatory agents such as glucocorticosteroids or 
5-aminosalicylic acid do not heal the bowel mucosa [473], and the efficacy of growth factors such as GH and 
EGF has yet to be established [383]. There is thus a clear need to identify new therapeutic targets for MH. Our 
results indicate that CD9 depletion enhances IEC proliferation, resulting in a high regenerative response and 
reduced susceptibility to DSS-induced colitis. Our findings thus reveal a critical role for the tetraspanin CD9 
in colon inflammation and suggest a novel therapeutic opportunity. Growing recent evidence suggests that 
targeting tetraspanins by an array of tools including monoclonal antibodies, soluble large-loop proteins, and 
RNAi technology may be used to improve the course of IBDs. Of note, animal models of IBD provide valuable 
information about in vivo mechanistic insights on the role that single pathways have in IBD pathogenesis, and 
allow for the testing of novel therapies at the preclinical level. Nevertheless, it should be noted that none of 
the existing models truly recapitulates the complex and waving nature of the human disease. Therefore, the 
limitations of each model must always be taken into account before directly applying experimental findings to 
the human condition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions 
 
85 
 
6. CONCLUSIONS 
 
The findings presented herein support the following conclusions: 
1) The absence of CD9 protects against DSS-induced colonic injury in vivo. CD9-/- mice display a 
reduced myeloid cell infiltration and proinflammatory cytokine expression in the colon after DSS 
challenge, along with decreased epithelial cell barrier damage and permeability compared to WT 
mice. 
 
2) The CD9-deficient non-hematopoietic component is the one involved in conferring the protection in 
DSS-induced colitis. 
 
3) CD9-deficient intestinal epithelial cells do not have decreased apoptotic levels but increased 
proliferative rates than CD9 expressing intestinal epithelial cells. 
 
4) CD9 deficiency on CD4+ T cells does not alter CD4+ effector T cell generation neither in vivo nor in 
vitro.  
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7. CONCLUSIONES 
 
Los resultados presentados en este trabajo permiten concluir: 
1) La ausencia de CD9 protege frente al daño intestinal provocado por la administración de DSS in 
vivo. Los animales CD9-/- muestran una reducción en los niveles de infiltración de células 
mieloides y de expresión de citoquinas pro-inflamatorias en el colon tras el tratamiento con DSS, 
junto con un menor daño de la barrera epitelial y menor permeabilidad en comparación con los 
animales de cepa salvaje. 
 
2) La deficiencia de CD9 en el compartimento no hematopoyético es la responsable de conferir la 
protección a los animales en el modelo de colitis inducida por DSS. 
 
3) Las células epiteliales intestinales deficientes de CD9 no experimentan una menor apoptosis, pero 
si un incremento de su capacidad proliferativa en comparación con las células epiteliales 
intestinales de ratones de cepa salvaje tras el daño ejercido por la administración de DSS. 
 
4) La deficiencia de CD9 en células T CD4+ no altera la generación de células T efectoras in vivo ni 
in vitro. 
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Tetraspanin cD9 limits Mucosal 
healing in experimental colitis
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Olga Moreno-Gonzalo1,2 and Francisco Sánchez-Madrid1,2,3*
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Tetraspanins are a family of proteins with four transmembrane domains that associate 
between themselves and cluster with other partner proteins, conforming a distinct class 
of membrane domains, the tetraspanin-enriched microdomains (TEMs). These TEMs 
constitute macromolecular signaling platforms that regulate key processes in several 
cellular settings controlling signaling thresholds and avidity of receptors. In this study, 
we investigated the role of CD9, a tetraspanin that regulates major biological processes 
such as cell migration and immunological responses, in two mouse models of colitis that 
have been used to study the pathogenesis of inflammatory bowel disease (IBD). Previous 
in vitro studies revealed an important role in the interaction of leukocytes with inflamed 
endothelium, but in vivo evidence of the involvement of CD9 in inflammatory diseases is 
scarce. Here, we studied the role of CD9 in the pathogenesis of colitis in vivo. Colitis was 
induced by administration of dextran sodium sulfate (DSS), a chemical colitogen that 
causes epithelial disruption and intestinal inflammation. CD9−/− mice showed less severe 
colitis than wild-type counterparts upon exposure to DSS (2% solution) and enhanced 
survival in response to a lethal DSS dose (4%). Decreased neutrophil and macrophage 
cell infiltration was observed in colonic tissue from CD9−/− animals, in accordance with 
their lower serum levels of TNF-α, IL-6, and other proinflammatory cytokines in the colon. 
The specific role of CD9 in IBD was further dissected by transfer of CD4+ CD45RBhi 
naive T cells into the Rag1−/− mouse colitis model. However, no significant differences 
were observed in these settings between both groups, ruling out a role for CD9 in IBD 
in the lymphoid compartment. Experiments with bone marrow chimeras revealed that 
CD9 in the non-hematopoietic compartment is involved in colon injury and limits the 
proliferation of epithelial cells. Our data indicate that CD9 in non-hematopoietic cells 
plays an important role in colitis by limiting epithelial cell proliferation. Future strategies to 
repress CD9 expression may be of therapeutic benefit in the treatment of IBD.
Keywords: tetraspanins, cD9, mucosal healing, dextran sodium sulfate, colitis
inTrODUcTiOn
Inflammatory bowel disease (IBD) defines a group of intestinal disorders, principally, ulcerative 
colitis (UC) and Crohn’s disease (CD). Both diseases are characterized by chronic inflammation of 
the gastrointestinal tract interspersed with relapsing phases (1). Much progress has been made in 
understanding UC and CD disease mechanisms, for example, through genome-wide association 
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studies in patients; however, these diseases remain incompletely 
understood. Identified genetic risk loci have revealed defects in 
IBD patients affecting genes crucial for intestinal homeostasis, 
including epithelial barrier function, restitution, and wounding 
(2). Moreover, recent clinical studies have revealed mucosal 
healing (MH) as the major prognostic predictor of long-term 
remission in IBD patients (3, 4), suggesting that epithelial regen-
eration is critical to improving IBD therapy (5).
Tetraspanins are proteins that span the cell membrane 
four times and play an important role in plasma membrane 
organization through the formation of tetraspanin-enriched 
microdomains, which enable them to associate with multiple 
proteins, including other tetraspanins (6). The tetraspanin CD9 
is broadly expressed on the surface of several cell types, including 
many malignant tumor cells, as well as normal hematopoietic, 
endothelial, and epithelial cells (7, 8). Soon after its identification, 
CD9 was found to associate with several integrins (9), enabling 
CD9 to exert pro- or anti-migratory effects (10). CD9 can also 
interact with the immunoglobulin superfamily members EWI-2 
and EWI-F (11), DDR1 (12), other tetraspanins (e.g., CD81 and 
CD151) (13), claudin-1 (14), ADAM10 (15), and ADAM17 (16) 
metalloproteases, epidermal growth factor receptor (EGFR) (17), 
and membrane-bound EGFR ligands (18, 19). Moreover, CD9 
has been reported to regulate endothelial nanoscopic organiza-
tion and expression levels of ICAM-1 and VCAM-1 upon TNF-α 
activation, enabling formation of the docking structure required 
for leukocyte extravasation (20, 21). Anti-CD9 agonistic antibod-
ies or ectopic expression of CD9 both exert an antiproliferative 
effect on human colon carcinoma cell lines (22). However, the 
role of CD9 in IBD has not been previously addressed in vivo. 
Here, we show that CD9 acts as a limiting factor for epithelial 
regeneration and colonic MH in dextran sodium sulfate (DSS)-
induced colitis.
MaTerials anD MeThODs
Mice
Experiments were performed with sex and age matched (8- to 
12-week old) CD9−/− and WT mice on the C57BL/6 background. 
CD9−/− mice have been described previously (23). Rag1−/− mice 
(24) used in the adoptive transfer colitis model were kindly 
provided by Dr. J. M. Fernández-Granado (CNIC). For chimeric 
reconstitution experiments, B6SJL CD45.1 mice (Jackson 
Laboratories) were used. All animals were housed in pathogen-
free conditions at the CNIC animal facility. Experimental proce-
dures were approved by the local research ethics committee and 
conformed to EU Directive 2010/63EU and Recommendation 
2007/526/EC, enforced in Spanish law under Real Decreto 
53/2013.
induction and assessment  
of Dss-induced colitis
Dextran sulfate sodium salt (DSS, MP Biomedicals; MW = 36,000–
50,000) was dissolved at 2 or 4% (w/v) in sterile drinking water 
provided to mice ad libitum. Mice were checked daily for devel-
opment of colitis by monitoring body weight, fecal occult blood 
(Hemoccult II Sensa; Beckman Coulter) or gross rectal bleeding, 
and stool consistency. Overall disease severity was assessed by a 
clinical scoring system defined as follows: weight loss: 0 (no loss), 
1 (1–5%), 2 (5–10%), 3 (10–20%), and 4 (>20%); stool consist-
ency: 0 (normal), 2 (loose stool), and 4 (diarrhea); and bleeding: 
0 (no blood), 1 (Hemoccult positive), 2 (Hemoccult positive 
and visual pellet bleeding), and 4 (gross bleeding, blood around 
anus). At the end of the experiment, tissues were fixed in 10% 
neutral buffered formalin (Bio Optica) for 24 h and transferred 
to 70% ethanol. After embedding in paraffin, transverse sections 
(4–5 µm) of proximal and distal colon were stained with H&E 
for histological studies. Images were digitized using Hamamatsu 
Nanozoomer 2.0 RS scan and NDP.scan 2.5 digitization software. 
Three images of two serial sections cut at a separation of 100 µm 
(six sections in total) were evaluated for each mouse for each 
part of the colon (proximal and distal). Histological scoring 
evaluated inflammation severity, crypt damage, and ulceration. 
Inflammation severity was scored as follows: 0, rare inflammatory 
cells in the lamina propria; 1, increased numbers of granulocytes 
in the lamina propria; 2, confluence of inflammatory cells extend-
ing into the submucosa; 3, transmural extension of the inflam-
matory infiltrate. Crypt damage was scored as follows: 0, intact 
crypts; 1, loss of the basal one-third; 2, loss of the basal two-thirds; 
3, entire crypt loss; 4, change of epithelial surface with erosion; 5, 
confluent erosion. Ulceration was scored as follows: 0, absence of 
ulcers; 1, 1–2 ulceration foci; 2, 3–4 ulceration foci; 3, confluent 
or extensive ulceration. Scores for each parameter were summed 
to give a maximum histological score of 11.
T cell-Mediated colitis
Naive CD4+ T  cells were sorted (FACSaria sorter, BD) from 
single-cell spleen suspensions of CD9−/− or WT mice. Live 
cells were isolated after labeling with antibodies to CD4, CD62, 
CD25, and CD45RB (eBiosciences) and hoescht 33258. Cells 
were transferred to recipient mice (4–5 × 105 cells per mouse) by 
intraperitoneal injection.
Bone Marrow chimeras
Bone marrow transfer was used to create chimeric mice in which 
genetic deficiency for CD9 was confined to either circulating cells 
(CD9−/− >  WT) or nonhematopoietic tissue (WT >  CD9−/−). 
Briefly, bone marrows were collected from femur and tibia of 
congenic WT donor mice (expressing CD45.1 leukocyte antigen) 
or CD9−/− and WT donor mice (expressing CD45.2 leukocyte 
antigen) by flushing with PBS. Erythrocytes were lysed (ACK lysis 
buffer, Lonza) for 1 min on ice. After a washing step, cells were 
resuspended in PBS at 1 × 108/ml. This cell suspension (100 µl) was 
injected intravenously into 13 Gy-irradiated recipient mice 48 h 
postirradiation. Four chimera groups were generated: WT > WT 
(WT cells expressing CD45.1 into WT mice expressing CD45.2); 
WT >  CD9−/− (WT  cells expressing CD45.1 into CD9−/− mice 
expressing CD45.2); WT >  WT (WT  cells expressing CD45.2 
into WT mice expressing CD45.1); CD9−/− > WT (CD9−/− cells 
expressing CD45.2 into WT mice expressing CD45.1). Bone 
marrow reconstitution was verified after 8  weeks by staining 
for CD45.1 or CD45.2 in blood cells with anti-CD45.1 or anti-
CD45.2 specific antibodies (BD Biosciences).
FigUre 1 | Continued
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FigUre 1 | CD9-deficiency reduces sensitivity to dextran sodium sulfate (DSS)-induced colitis. (a) Top, body-weight loss in WT and CD9−/− mice after 
administration of 2% DSS in drinking water for 7 days. Controls for each genotype were administered with unadulterated drinking water. Bottom, disease activity 
index (DAI) score in WT and CD9−/− mice after administration of 2% DSS for 7 days. n = 10–12 per group; *P < 0.05; **P < 0.005; ***P < 0.001, unpaired t-test.  
(B) Macroscopic colon damage in DSS-treated WT and CD9−/− mice. Top, Colon shrinkage. Bottom, changes in colon length. Representative colons are shown of 
n = 10–12 mice per group. (c) Representative photomicrographs of proximal colon (near the cecum) and distal colon (near the anus) from WT and CD9−/− mice at 
day 7 of DSS administration (H&E; magnifications: 4× and 10×). (D) Histological scores obtained from H&E-stained proximal and distal colon tissue sections from 
DSS-treated WT and CD9−/− mice. Data are pooled from two independent experiments (n = 4). Values represent mean ± SD of the mean: *P < 0.05; **P < 0.005; 
***P < 0.001, unpaired t-test.
FigUre 2 | Continued
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FigUre 2 | Enhanced epithelial barrier integrity and survival in CD9−/− mice after dextran sodium sulfate (DSS) challenge (a) In vivo colon permeability, indexed from 
the serum level of 4 kDa FITC-dextran 4 h after feeding by gavage. Data are pooled from two independent experiments, n = 5–6 animals per group. Data were 
analyzed by one-way ANOVA and the Newman–Keuls multiple comparison test; ***P < 0.001. (B) qPCR analysis of tight junction and mucin gene expression in 
colon samples after 7 days of DSS exposure. Data are from one experiment repeated two times with similar results. (c) Kaplan–Meier survival for WT and 
CD9−/− mice given 4% DSS in drinking water. **P < 0.01, Log-rank (Mantel–Cox) test. (D) Percentage of initial body weight of WT and CD9−/− mice after 7-day intake 
of 4% DSS chased by unadulterated water. n = 11–12 per group: *P < 0.05; **P < 0.005; ***P < 0.001; unpaired t-test for WT and CD9−/− groups in (B,c).
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In Vivo Permeability assay
Food was withdrawn overnight and mice were gavaged with the 
permeability tracer FITC-dextran (MW 4,000; Sigma-Aldrich) 
at 60 mg/100 g body weight. After 4 h, blood was collected by 
heart puncture and serum FITC-dextran was measured with a 
fluorescence spectrophotometer (Fluoroskan Ascent; Thermo 
Labsystems) using emission and excitation wavelengths of 490 
and 520  nm, respectively. FITC-dextran concentration was 
determined from a standard curve generated by serialdilution.
isolation and Flow cytometry analysis  
of colonic leukocytes
Colons were dissected longitudinally, washed several times 
with PBS to remove feces, and cut into small pieces. Samples 
were digested with 0.25 mg/ml Liberase TM (Roche), 50 µg/ml 
DNAseI (Roche), and 1  mM DTT diluted in Hank’s Balanced 
Solution for 30 min at 37°C. At the end of the incubation period, 
enzyme activity was blocked by adding 50 ml PBS supplemented 
with 0.5% BSA and 0.05 mM EDTA (PBS–BSA–EDTA), and the 
sample was mechanically disrupted by passing through a 70-μm 
cell strainer to obtain a cell suspension. When only epithelial cells 
were required, samples were incubated in 5 mM EDTA, 1 mM 
DTT for 20 min before enzyme digestion. Before all staining pro-
cedures, colon cell suspensions were incubated with anti-mouse 
FcRII/III (clone 2.4G2, TONBO Biosciences) for 10 min at 4°C 
in PBS-BSA-EDTA. Flow cytometry analysis of DSS-induced 
inflammation was performed with anti-mouse antibodies to the 
following antigens: CD45 (BD Horizon) and CD11b, CD64, and 
Ly6G (BD Pharmingen). For epithelial cell proliferation analysis, 
antibodies were used targeting EpCAM (Biolegend) and Ki67 
(BD Pharmingen). Absolute cell numbers were obtained using 
TruCount Tubes (BD Biosciences). Cell samples were acquired 
in a FACSCanto Flow Cytometer (BD Biosciences), and the 
data were analyzed with FlowJo (Tree Star) or FACSDiva (BD 
Biosciences) software.
Flow cytometric Bead array (cBa)
Serum TNF-α, IL-6, and IFNγ were determined using the mouse 
Th1/Th2/Th17 BD CBA.
rna extraction and real-time  
Quantitative Pcr
RNA was isolated by disrupting colon tissue samples with TRIzol 
Reagent (1 ml per 50–100 mg tissue, Qiagen) and homogenizing 
in a tissue disruptor (Ika ultra-turrax T10 homogenizer). DSS 
traces were removed by the LiCl method (Ambion). Residual 
DNA contamination was eliminated with the Turbo DNA-free 
Kit (Ambion). Total RNA (1  µg) was reverse transcribed to 
cDNA with a Reverse Trancription Kit (Applied Biosystems). 
Quantitative PCR was then performed in an AB7900_384 
(Applied Biosystems) using SYBR Green (Applied Biosystems) 
as the reporter. Gene-specific primers used are listed in Table 
S1 in Supplementary Material. Expression of each gene of 
interest was normalized to housekeeping gene GAPDH. Data 
are presented as relative fold differences calculated by the 2−ΔΔCt 
method.
In Vitro T cell Differentiation
Naive CD4+ T  cells were obtained by incubating single-cell 
suspensions of spleen and lymph nodes with biotinylated 
antibodies to CD8, CD16, CD19, F4/80, Gr-1, MHC class II 
(I-Ab), CD11b, CD11c, and DX5 followed by incubation with 
Streptavidin Microbeads (MACS, Miltenyi Biotec). CD4+ 
T cells were isolated by negative selection in an auto-MACSTM 
Pro Separator (Miltenyi Biotec). Next, cells were activated with 
plate-bound anti-CD3 (5 µg/ml) and anti-CD28 (2 µg/ml) in 
RPMI 1640 medium (Sigma-Aldrich) supplemented with 10% 
FCS, 2 × 10−3 M l-glutamine, 100 U/ml penicillin, 100 µg/ml 
streptomycin, 50 µM 2-mercaptoethanol, and the correspond-
ing cytokine cocktail: for Th0, anti-IFNγ (4 µg/ml), anti-IL-4 
(4  µg/ml), and IL-2 (10  ng/ml); for Th1 anti-IL-4 (4  µg/ml), 
IL-12 (10 ng/ml), and IL-2 (10 ng/ml); for Th17 anti-IFNγ (4 µg/
ml), anti-IL-4 (4 µg/ml), IL-6 (20 ng/ml), IL-23 (10 ng/ml), and 
TGF-β1 (5 ng/ml); and for Treg anti-IFNγ (4 µg/ml), anti-IL-4 
(4 µg/ml), and TGF-β1 (10 ng/ml). After 72 h of culture, IFNγ, 
IL-17, or IL-10 in the supernatant were measured by ELISA 
(Ready-SET-Go, eBiosciences). For FACS analysis, intracellular 
cytokine staining was preceded by restimulation for 4 h with 
50 ng/ml phorbol dibutyrate (PMA) and 500 ng/ml ionomycin 
in the presence of brefeldin A (1 µg/ml) (BD Biosciences).
immunofluorescence and 
immunohistochemical analysis
For IF and IHC staining, colon sections were deparaffinized, 
boiled in antigen retrieval solution (10  mM Tris Base, 1  mM 
EDTA Solution, 0.05% Tween 20, pH 9.0 for Ki67 and 10  mM 
sodium citrate, 0.05% Tween 20, pH  =  6 for caspase-3), and 
incubated with the rabbit monoclonal anti-mouse Ki67 primary 
antibody (Master Diagnostica, clon SP6) for IF or anti active 
caspase-3 rabbit polyclonal antibody for IHC (R&D system, 
catalog AF835). Bound antibodies were detected with a goat 
anti-rabbit 647 (ThermoFischer Scientific) for IF or the anti-
rabbit EnVision FLEX-HRP detection system (Agilent) for IHC. 
Staining was developed with DAB substrate (Dako K3468), and 
slides were counterstained with Mayers Hematoxylin. Ki67 and 
FigUre 3 | Continued
6
Saiz et al. Role of Tetraspanin CD9 in Experimental Colitis
Frontiers in Immunology | www.frontiersin.org December 2017 | Volume 8 | Article 1854
FigUre 3 | CD9−/− mice exhibit lower leukocyte infiltration and proinflammatory cytokines in serum and colon after 2% dextran sodium sulfate (DSS) administration. 
(a) Flow cytometry analysis of whole colon from WT and CD9−/− mice after 7-day 2% DSS intake. Representative dot plots and percentage quantification of CD45+ 
populations show similar DSS-induced infiltration by neutrophils (Ly6G+) and macrophages (CD64+) in both genotypes. (B) Total neutrophil and macrophage 
numbers in the CD45+-gated population, determined by TruCount Tubes. Data are pooled from two independent experiments. For (a,B), n = 6–7 mice per group 
with two repeats and analysis by one-way ANOVA and the Newman–Keuls multiple comparison test. *P < 0.05; **P < 0.005; ***P < 0.001. (c) Serum levels of 
TNF-α, IL-6, and IFNγ measured by cytometric bead array assay. (D) qPCR analysis of colonic proinflammatory cytokine mRNA expression. Bars denote the 
mean ± SD of n = 4–5 mice per genotype. Data from (c,D) were analyzed by two-way ANOVA and the Bonferroni multiple comparison test.
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active caspase-3 staining in epithelial cells were quantified in the 
whole colon sections from each DSS-treated mouse (4–5 mice 
per group). Image J (1.46r) was used to measure Ki67 positive 
individual nuclei and to measure caspase-3 intensity relative to 
the total area corresponding to the complete epithelial layer in 
each image.
statistical analysis
Data are presented as mean  ±  SD. Normal data distribution 
was assessed with the Kolmogorov Smirnov test, and the sta-
tistical significance of between-group differences was assessed 
by one-tailed unpaired Student’s t-test or one-way ANOVA 
with Newman–Keuls multiple comparison t-test, as required. 
All statistical analyses were performed with GraphPad Prism 
(GraphPad Software Inc.).
resUlTs
cD9−/− Mice are Protected against  
Dss-induced colonic injury
To explore the function of CD9 in colitis development, we chal-
lenged CD9−/− and WT mice with the toxic compound DSS (2% 
solution) in drinking water for 7 days. CD9−/− animals lost less 
than 10% of their initial body weight, whereas WT counterparts 
lost around 20% (Figure 1A, top). To monitor disease activity, we 
recorded a daily disease activity index (DAI) combining weight 
loss, stool consistency, and bleeding. From day 4, DAI values 
were lower in CD9−/− mice than in WT counterparts (Figure 1A, 
bottom). Autopsy revealed that DSS-treated CD9−/− mice had 
significantly larger colons than WT counterparts (Figure  1B). 
Histology revealed a better preservation of tissue architecture 
in CD9−/− mice, in both the proximal and the distal colon. DSS-
treated WT animals showed more pronounced epithelial denuda-
tion, crypt distortion, leukocyte infiltration of the lamina propria, 
and submucosal swelling (Figure 1C). Histological sections were 
scored for the severity of DSS-induced inflammation as described 
in Section “Materials and Methods.” In both proximal and distal 
colon, histological scores were lower in CD9−/− mice than in WT 
mice, with the difference more pronounced in the distal colon 
(Figure 1D).
cD9 exacerbates Tissue injury  
and Decreases Mouse survival  
after a lethal Dss Dose
Intestinal epithelial integrity is necessary for efficient defense 
against intraluminal toxins, antigens, and enteric bacteria. Cells 
are tightly joined in a healthy epithelium, and transepithelial 
permeability can thus be determined as an index of epithelial 
integrity. To monitor gut barrier function in vivo, we treated 
CD9−/− and WT animals with 2% DSS for 7 days and then orally 
administered 4KDa FITC-Dextran. Fluorescence spectropho-
tometry detection of serum FITC after 4 h revealed markedly 
lower gastrointestinal permeability in CD9−/− mice than in WT 
mice (Figure 2A). Serum FITC levels in non-treated animals 
showed no significant between-genotype differences and 
remained below 5 μg/ml, consistent with an intact intestinal 
barrier function in the steady state (Figure  2A). Consistent 
with the FITC-Dextran data, qPCR of colon samples from 
DSS-treated CD9−/− mice revealed elevated expression of 
genes encoding epithelial tight junction proteins, such as 
ZO-1, tricellulin, and claudin family members (Figure  2B). 
CD9−/− colon also showed elevated expression of genes encod-
ing epithelial globet cell proteins, such as the secretory mucin 
glycoproteins MUC1, MUC2, and trefoil factor 3, indicating 
normal intestinal function (Figure 2B). In a further approach, 
we exposed mice to a lethal DSS dose (4%) for 7 days followed 
by unadulterated drinking water for a further 8  days. At the 
end of the experiment all WT mice had died, whereas only 
45% of the CD9−/− group were dead (Figure  2C). Moreover, 
the surviving CD9−/− mice showed a recovery in body weight 
(Figure 2D). These results show that CD9 impedes epithelial 
repair and contributes to colon injury at both sublethal and 
lethal DSS doses.
reduced Myeloid cell infiltration and 
Proinflammatory cytokine expression  
in the colon of cD9−/− Mice
To characterize the immune mechanisms of colonic mucosa dam-
age, we analyzed CD9−/− and WT colon cells by flow cytometry. 
After 7-day exposure to 2% DSS, CD9−/− colon showed markedly 
lower neutrophil and macrophage infiltration than WT colon 
(Figures 3A,B). In contrast, in non-treated mice, gut populations 
of these immune cell subsets were comparable between genotypes 
(Figures 3A,B), as were mesenteric lymph nodes, intraepithelial 
lymphocyte and lamina propria populations (Figure S1 in 
Supplementary Material). DSS-treated CD9−/− mice also had 
lower serum levels of IL-6 and TNFα than WT mice, whereas 
IFNγ was similarly increased in response to DSS in both geno-
types (Figure 3C). Analysis of colon samples by qPCR revealed 
lower DSS-induced levels of IL-6, IL-1β, NLPR3, iNOS, IL-12p35, 
and IL-12p40 mRNA in CD9−/−animals, whereas IL-17, IL-22, 
and IFNγ showed no significant between-genotype differences 
(Figure 3D).
8Saiz et al. Role of Tetraspanin CD9 in Experimental Colitis
Frontiers in Immunology | www.frontiersin.org December 2017 | Volume 8 | Article 1854
FigUre 4 | Continued
FigUre 4 | CD4+ T cell-expressed CD9 does not contribute to adoptive transfer-mediated colitis or T cell differential subset skewing. (a) Top, body weight 
after intraperitoneal adoptive transfer of CD4+CD45RBhi CD62L+CD25− T cells from WT and CD9−/− donors into Rag1−/− recipients. Bottom, colon length at 
sacrifice on day 57. Data are from a representative experiment repeated three times with similar results. n = 5–6 mice per group; unpaired t-test. ns, non 
significant. (B) Representative 3.5× and 10× magnification H&E-stained colonic sections from Rag1−/− mice injected with WT and CD9−/− CD4+ cells, 
showing transmural infiltration affecting all colon layers in both settings. (c) FACS analysis of myeloid cell infiltration. Representative dot plots are shown on 
the left; quantification of CD45+-gated cell percentages and total numbers is shown on the right. (D) Flow cytometry analysis of intracellular staining for 
IFNγ and IL-17 in T cells from the mesenteric lymph nodes (MLNs) of RAG1−/− mice 2 months after CD4+ T cell transfer. Cells were cultured for 72 h on an 
anti-CD3/CD28-coated plate and brefeldin A was added for the last 4 h. Representative dot plots and bar quantifications are shown of CD4+CD25+-gated 
cells. n = 5–6 mice per group; unpaired t-test. (e) In vitro T cell differentiation toward Th1, Th17, and Treg CD4+ T cell subsets. Representative dots plots 
are shown of intracellular IFNγ, IL-17, and IL-10 in sorted populations, with quantification on the right (top row). Cytokine release was quantified by ELISA 
(bottom). Data are from a representative independent experiment of three performed and are presented as mean ± SD. n = 5 per genotype; unpaired 
t-test.
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cD9 expressed on cD4+ T cells Does  
not contribute to immune-cell adoptive 
Transfer-Mediated colitis
To further explore possible CD9-mediated immune mecha-
nisms in IBD, we used an alternative model of colitis induced 
by intraperitoneal transfer into Rag1−/− mice of CD4+CD62L+ 
CD25−CD45RBhi naive T cells sorted from WT or CD9−/− mice. 
Body weight was recorded over 2 months, showing no between-
group differences (Figure 4A, top). Colon shortening was also 
similar in both genotypes (Figure 4A, bottom). Consistent with 
these findings, histological analysis revealed a similar extent 
of transmural inflammation in injected animals (Figure 4B), 
and flow cytometry showed similar increases in neutrophil 
and macrophage infiltration (Figure  4C). Restimulation of 
mesenteric lymph node CD4+ cells with CD3/CD28 revealed 
no significant differences in Th1 and Th17 effector cell 
populations or cytokine production (Figure 4D). Likewise, no 
between-genotype differences were observed in the percent-
ages of Th1, Th17, and Treg cells upon in vitro polyclonal dif-
ferentiation of CD4+ naive T cells from CD9−/− and WT mice 
(Figure 4E).
cD9−/− Bone Marrow cells Transplanted 
into WT Mice Do not Provide Protection 
against colonic injury
We next investigated the possible role of CD9 in myeloid cell 
populations or the resident non-hematopoietic cell compartment 
(mainly endothelial and epithelial cells). Two groups of chimeric 
mice were generated using the CD45.1 and CD45.2 haplotypes. 
Flow cytometry showed reconstitution levels of 95–99% (data not 
shown). Reconstitution experiments were carried out with WT 
CD45.1 mice and CD9−/− or WT CD45.2 mice, with irradiation 
and transplantation in either direction. Protection against DSS-
induced colitis was observed only when irradiated CD9−/− mice 
were used as recipients of WT bone marrow (Figures  5A,B). 
Histology revealed typical DSS-induced changes in the distal and 
proximal colon of WT recipients and less pronounced alterations 
in CD9−/− recipients reconstituted with CD45.1 WT bone marrow 
(Figures 5C,D). Only CD9−/− recipients had lower DSS-induced 
levels of serum IL-6 measured by ELISA (Figure  5E), and 
colon samples from CD9−/− recipients also had lower induced 
transcript expression of proinflammatory cytokines measured 
by qPCR (Figure 5F). These results underscore the conclusion 
that susceptibility to DSS-induced colitis is increased by CD9 
expression in the non-hematopoietic compartment.
enhanced colonocyte Proliferation after 
Dss-induced injury in cD9−/− Mice
After DSS-induced epithelial cell damage, the colonic epithelium 
actively proliferates to restore intestinal barrier integrity. Flow 
cytometry analysis of the proliferation marker Ki67 in colonic 
EpCAM+ intestinal epithelial cells (IECs) from mice revealed 
that CD9 deficiency supports elevated colonic epithelial cell 
proliferation after DSS exposure (Figure 6A, top). However, no 
differences were detected in the proliferation of epithelial cells 
extracted from non-treated animals (Figure S2 in Supplementary 
Material). Remarkably, although the percentage of Ki67+ cells 
was slightly higher in CD9−/− colon after 2 and 4  days of DSS 
exposure, the significant difference was observed at day 6. This 
is coincident with significant lower body weight loss and higher 
colon length in CD9−/− mice (Figure  6A, bottom). Moreover, 
CD9−/− colon showed higher mRNA expression of c-myc, c-fos, 
and cyclin D1 (Figure 6B). Analysis of the apoptosis marker cas-
pase-3 was carried out by IHC in DSS-treated chimeric mice, with 
no differences between genotypes (Figure S3 in Supplementary 
Material). Proliferation in DSS-exposed colon of these animals 
was determined by counting immunostained Ki67+ cells in colon 
crypts on histological sections. The percentage of Ki67+ colonic 
cells was higher after DSS exposure in CD9−/− recipients than 
in WT recipients (Figures 6C,D). Taken together, these results 
demonstrate that CD9 limits epithelial cell proliferation in 
response to injury.
DiscUssiOn
Inflammatory bowel disease arises through close interaction 
between genetics, immunology, environment, and microbi-
ome. The development and progression of this multifactorial 
disorder is affected by several factors, including diet, lifestyle, 
and behavior. Moreover, perturbations of the gut microbiota 
due to antibiotic medication may also play an important role 
in IBD. DSS-induced colitis has become a widely used model 
for studying IBD in the mouse (25, 26). DSS is a chemical 
colitogen toxic to gut epithelial cells, interfering with intesti-
nal barrier function and stimulating local inflammation. This 
FigUre 5 | Continued
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FigUre 5 | Lack of CD9 in the resident non-hematopoietic compartment confers the reduced susceptibility to dextran sodium sulfate (DSS)-mediated colitis. 
Lethally irradiated WT CD45.1 mice were rescued with WT or CD9−/− CD45.2 bone marrow, whereas lethally irradiated WT and CD9−/− CD45.2 mice were rescued 
with WT CD45.1 bone marrow. Three months post-transplantation mice were treated with 2% DSS. (a) Body weight evolution. (B) Disease activity index and  
colon shortening. (c) H&E stained proximal and distal colon sections. (D) Histological injury scores. (e) Serum IL-6 measured by ELISA. (F) qPCR analysis of 
proinflammatory cytokine expression in the colon of WT or CD9−/− CD45.2 recipients. Experiments were perfomed twice, giving similar results. n = 6–7 per group.  
All between-group comparisons were analyzed by unpaired t-test; *P < 0.05; **P < 0.005; ***P < 0.001.
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model is suitable for studying events triggered by temporary 
failure of mucosal homeostasis after epithelial cell shedding 
and loss of barrier integrity, and can also provide insight into 
the mechanisms that lead to MH after initial injury (27). Here, 
we report protection against DSS-induced colonic mucosal 
damage in CD9-deficient mice. These mice show lower DAI 
scores throughout treatment, larger colons, and have a less 
severe histological injury. The protection conferred by CD9 
absence was confirmed by the increased survival of CD9−/− 
mice upon administration of a lethal 4% DSS dose. Epithelial 
preservation in  vivo was demonstrated by lower colonic 
transepithelial FITC-dextran leakage in CD9−/− mice, and the 
importance of CD9 in the control of intestinal epithelial barrier 
function and integrity was further demonstrated by preserved 
expression of tight junction and other barrier-related genes in 
CD9−/− mice.
CD9 is ubiquitously expressed, and we therefore performed 
chimeric reconstitution experiments to determine which 
cell compartment is responsible for mediating DSS-induced 
toxicity. Our data clearly demonstrated that protection in 
CD9−/− animals was not dependent on the hematopoietic cell 
compartment. In CD9−/− colon, crypt and villous distortion is 
minimal and surface epithelium is more preserved; this keeps 
luminal pathogens outside the lamina propria, and therefore 
proinflammatory cytokine and chemokine release is lower 
and there is less inflammatory cell recruitment. Specifically, 
the myeloid-derived cytokines involved in the inflammatory 
response in DSS acute colitis iNOs, TNF-α, IL-6, IL-12, and 
the inflammasome drivers NLRP3 and IL-1β were enhanced in 
WT mice versus CD9−/− mice, but no differences were observed 
in either IFNγ, IL-17, or IL-22 cytokines. DSS colitis can be 
exacerbated by granulocyte recruitment (28–30). However, the 
reconstitution experiments ruled out a contribution to colon 
protection from CD9 deficiency in innate immune cells. The 
role of endothelial CD9 could not be completely discarded, and 
additional research with endothelium-specific deletion of CD9 
would be required to resolve this issue. In addition, CD9 plays an 
important role in T cell activation (31–34). However, our data in 
the adoptive T cell transfer-mediated colitis model and in vitro 
T cell polyclonal experiments showed no significant differences 
in the differentiation and activation of CD9-deficient and WT 
Th1 and Th17 T cell subsets.
Flow cytometry and immunohistochemistry analysis 
revealed a higher percentage of Ki67 IECs in DSS-exposed 
CD9−/− colon. In the distal colon, the percentage Ki67+ cells 
is lower than in the proximal colon. This likely reflects the 
more severe colitis in the middle and distal third of the colon 
in DSS-exposed mice, causing a predominantly distal injury 
characterized by epithelial ulceration and impaired regenera-
tion (35). Notably, the difference in proliferation was observed 
after 6  days of DSS exposure, suggesting that it is related to 
mechanisms of post-injury epithelial recovery. CD9 absence 
thus does not increase IEC proliferation per se and only sup-
ports MH after injury. Indeed, hyperplasia and dysplasia were 
not observed in any CD9−/− animals after cessation of DSS 
exposure.
Dextran sodium sulfate treatment leads to the exposure of the 
Toll-like receptors on the IEC basolateral surface. This triggers a 
proliferation that contributes to mucosal repair after injury, and 
DSS-induced colitis is exacerbated in mice with gene deletions 
affecting TLR signaling such as Tlr2−/−, Tlr4−/−, and Myd88−/− 
(36–38). TLR signaling is linked to EGFR activation (39), which 
is required for intestinal homeostasis in the setting of acute 
mucosal damage (40, 41). CD9 could be playing several roles in 
these settings. EGFR signaling is increased in CD9-deficient cell 
lines (17, 42), and CD9 also negatively regulates ADAM17 (16) 
metalloproteinase activity, which is known to shed some EGFR 
ligands. CD9 deficiency will thus translate into increased EGFR 
phosphorylation and activation. Aside from a direct control of pro-
liferation, CD9 might regulate epithelial restitution, its deficiency 
ultimately resulting in increased epithelial proliferation (43). 
In this context, CD9 absence might facilitate rapid resealing of 
the intestinal epithelial barrier and could promote IEC migra-
tion through impaired localization of talin-1 to focal adhesions 
(10) or increase CXCR4/CXCL12-mediated migration (44), a 
route that directly regulates epithelial cell migration, barrier 
maturation, and restitution (45). Compared with CD9-positive 
cells, CD9-negative or depleted epithelial and tumor cells have 
a much higher migratory capacity, thereby supporting epithelial 
restitution (42, 46).
Inflammatory bowel disease is effectively treated with 
anti-TNF-α monoclonal antibody (Infliximab), either as 
monotherapy or in combination with other immunomodula-
tors, and current efforts are directed toward the crucial goal 
of achieving MH in order to accomplish long-term remission 
(4, 47). However, pharmacological anti-inflammatory agents 
such as glucocorticosteroids or 5-aminosalicylic acid do not 
heal the bowel mucosa (4), and the efficacy of growth factors 
such as GH and EGF has yet to be established (48). There is 
thus a clear need to identify new therapeutic targets for MH. 
Our results indicate that CD9 depletion enhances IEC prolif-
eration, resulting in a high regenerative response and reduced 
susceptibility to DSS-induced colitis. Our findings thus reveal 
a critical role for the tetraspanin CD9 in colon inflammation 
and suggest a novel therapeutic opportunity. Growing recent 
evidence suggests that targeting tetraspanins by an array of 
FigUre 6 | Continued
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FigUre 6 | CD9 limits epithelial cell proliferation upon dextran sodium sulfate (DSS) challenge. (a) Top, FACS analysis of Ki67+ cells in the EpCAM+CD45− gated 
population after days 2, 4, and 6 days 2% DSS exposure (upper panel). Bottom, body weight loss and colon shortening, n = 5–6 mice per group. (B) qPCR analysis 
of colonic mRNA expression of the cell-cycle genes c-myb, ccdn1, and c-fos. Data are pooled from two independent experiments, n = 4–6 mice per group. (c) 
Ki67 immunofluorescence staining on proximal and distal colon sections from untreated or 6-day DSS-treated chimeric mice. Representative magnification images 
are shown. (D) Quantification of Ki67+ cells in the epithelial layer of proximal (upper), and distal (lower) colons from 6-day DSS-fed chimeric mice. Each dot 
corresponds to the percentage of Ki67+ nuclei from all the epithelial nuclei of whole colon sections n = 4–5 mice per genotype. Between-group comparisons were 
analyzed by unpaired t-test for (a,B) and Mann–Whitney U-test for (D); *P < 0.05; **P < 0.005; ***P < 0.001.
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tools including monoclonal antibodies, soluble large-loop 
proteins, and RNAi technology may be used to improve 
the course of IBDs.
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Professional antigen-presenting cells (APCs) include dendritic cells, monocytes, and 
B  cells. APCs internalize and process antigens, producing immunogenic peptides 
that enable antigen presentation to T  lymphocytes, which provide the signals that 
trigger T-cell activation, proliferation, and differentiation, and lead to adaptive immune 
responses. After detection of microbial antigens through pattern recognition receptors 
(PRRs), APCs migrate to secondary lymphoid organs where antigen presentation to 
T lymphocytes takes place. Tetraspanins are membrane proteins that organize special-
ized membrane platforms, called tetraspanin-enriched microdomains, which integrate 
membrane receptors, like PRR and major histocompatibility complex class II (MHC-II), 
adhesion proteins, and signaling molecules. Importantly, through the modulation of the 
function of their associated membrane partners, tetraspanins regulate different steps 
of the immune response. Several tetraspanins can positively or negatively regulate the 
activation threshold of immune receptors. They also play a role during migration of APCs 
by controlling the surface levels and spatial arrangement of adhesion molecules and their 
subsequent intracellular signaling. Finally, tetraspanins participate in antigen processing 
and are important for priming of naïve T cells through the control of T-cell co-stimulation 
and MHC-II-dependent antigen presentation. In this review, we discuss the role of tetra-
spanins in APC biology and their involvement in effective immune responses.
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iNTRODUCTiON
Professional antigen-presenting cells (APCs), which include dendritic cells (DCs), monocytes/
macrophages, and B cells, are essential players of the immune system. Once an infection occurs, the 
innate immune system is stimulated, beginning the inflammation process to prevent the infection 
from spreading. Then, adaptive immune responses are required for the effective and specific clearance 
of the pathogen. This vital task lies on APCs, which operate at the interface between the innate and 
adaptive immunities. First, APCs detect foreign pathogens thanks to specialized receptors, known 
as pattern recognition receptors (PRRs). PRRs recognize conserved repeated motifs in microbial 
species, called pathogen associated molecular patterns (PAMPs), and enable APCs to discriminate 
between self and non-self (1). After engulfment of exogenous pathogens, APCs use their unique 
machinery to break down molecular antigens into small peptides and present a representative 
repertoire of these through a specialized immune receptor, namely, the major histocompatibility 
complex class II (MHC-II) molecule. This process triggers APC activation and maturation, with 
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upregulation of surface expression of MHCII and co-stimulatory 
molecules. APC migration from peripheral tissues to secondary 
lymphoid organs is a key step for the generation of proper adap-
tive immunity, since antigen presentation to naïve T lymphocytes 
by APCs takes place primarily in secondary lymphoid organs (2). 
DCs have been extensively characterized and different subsets 
have been described (3, 4). Moreover, these cells precisely alter-
nate their sentinel capacities with their antigenic presentation 
properties to favor antigen detection and migration, and antigen 
processing and presentation.
Tetraspanins belong to a family of small proteins (20–30 kDa) 
that contain four transmembrane regions spanning the plasma 
membrane. They also share other structural features: a small and a 
large extracellular loop with conserved residues, and short N- and 
C- terminal tails (5). In humans and mice, 33 tetraspanin members 
have been identified. These proteins are widely distributed in cells 
and tissues. Some of them are ubiquitous (CD81, CD82, CD9, or 
CD63), whereas others have a tissue-restricted expression (CD37 
or CD53 in immune cells) (6). Tetraspanins do not have the char-
acteristics of prototype membrane receptors. They have small cyto-
plasmic tails that lack known motifs involved in signal transduction 
(5), and there are only few reports claiming tetraspanin ligands (7). 
Instead, tetraspanins function as molecular organizers of multimo-
lecular membrane complexes, which facilitate signal transduction 
processes (8). Through the association with proteins and lipids, 
they organize specific membrane microdomains with a particular 
composition and detergent-solubilization properties, conforming 
the so-called tetraspanin-enriched microdomains (TEMs) (9, 10). 
TEMs are distinct from other well-known membrane domains, like 
lipid rafts, caveolae, and GPI-linked protein nanodomains (10).
Early studies using biochemical approaches have shown that 
TEMs follow a hierarchical network of associations based on the 
strength of the interactions (5, 9). The first level comprises the 
direct and specific interaction of a tetraspanin with its protein 
partner and is resistant to strong detergent conditions. The second 
level is characterized by interactions between tetraspanins. These 
interactions are more labile, resistant to mild detergents, and 
regulated by palmitoylation. Cutting edge fluorescence microscopy 
techniques, as single-molecule tracking, phasorFLIM-FRET and 
super-resolution microscopy, have more recently demonstrated 
that TEM organization and composition is highly dynamic (10–14). 
Accordingly, several studies have suggested that TEM composition 
can differ between cells. Through the organization of TEMs, tet-
raspanins regulate the function of their associated partners, finely 
tuning a breadth of biological processes. They may have overlapping 
functions in some cases or can have unique roles or even opposing 
functions. Their importance for several pathological and physi-
ological processes has been discussed in detail elsewhere (15–22).
Tetraspanins have been widely studied in the mammalian 
immune system, and thanks to the generation of tetraspanin knock-
out mice a deeper comprehension is being achieved. Interestingly, 
the existence of tetraspanins in the innate immune system of inver-
tebrates and non-mammalian vertebrates has also been described. 
Marine gastropod mollusks show ubiquitous expression of CD63 
and Tspn33, which are upregulated upon different immune 
stimulation challenges, like toll-like receptor (TLR) ligands, bacte-
ria or viral infection (23). Similarly, CD9 expression is induced in 
lamprey fish after LPS stimulation (24), or in turtles after bacterial 
infection (25). CD37 expression is highly increased in Atlantic 
salmons after a secondary viral infection (26). Conversely, treat-
ment with several immune stimulators downregulate CD9, CD53, 
and CD63 expression in leukocytes from teleost fishes (27, 28). 
The study of the innate defense mechanisms in non-mammalian 
vertebrates can give additional hints for the comprehension of 
vertebrate innate immunity. In mammals, tetraspanins are master 
regulators of APC function, mediating the crosstalk between the 
immunogenic environment and APCs, and the interplay between 
innate and adaptive immune cells.
Herein, we will review the function of tetraspanins in regulat-
ing each step of APC function: at the cellular level, by modulat-
ing clustering and trafficking of immune receptors; during the 
process of APC migration, and finally during MHC-II-dependent 
antigen presentation. We will also discuss the growing evidence 
on tetraspanins as markers of specific DC subsets.
Tetraspanins, Negative Regulators  
of PRRs
Recognition and uptake of microbial antigens by APCs is 
mediated by PRRs, which bind conserved pathogen structures 
known as PAMPs (1). Membrane-bound PRRs include TLRs, 
C-type lectin receptors (CLRs), scavenger receptors (SRs) and 
NOD-like receptors. The efficiency of antigen recognition 
greatly depends on the supramolecular organization of PRRs at 
the APC surface, and tetraspanins play an important role in this 
process (Figure 1).
Toll-like receptors multimerization at the APC surface pro-
motes the recruitment of signaling molecules (29), a process influ-
enced by the inclusion of TLRs and associated co-receptors into 
TEMs. LPS stimulation triggers TLR-4 and CD81 co-clustering 
in peripheral blood monocytes (30). How CD81 regulates TLR-4 
signaling has not been assessed; however, it has been shown that 
CD9 restricts LPS-induced macrophage activation and TNF-α 
production by preventing the TLR-4 co-receptor CD14 localiza-
tion into lipid rafts (Figure 1). Through this mechanism, CD9 
deficiency in mice enhances macrophage infiltration and lung 
inflammation after in  vivo intranasal LPS administration (31). 
In DCs, bacterial antigens can be recognized by TLR-dependent 
pathways, sensing cell surface or endosomal antigens, and by cyto-
solic pathways, like the cytosolic sensor stimulator of IFN genes 
(STING) (32). Interestingly, CD81 negatively regulates STING/
IFNAR signaling through its interaction with Rac1 and the inhi-
bition of STAT-1 activation, thus leading to reduced TNF-α and 
NO production by inflammatory monocytes and DCs (Figure 1). 
As a consequence, CD81 deficient mice are protected against 
systemic Listeria monocytogenes infection (33).
Among the CLRs, Dectin-1 specifically recognizes β-glucans 
in fungal cell walls and is important for efficient immune response 
against fungi (34). Dectin-1 associates with tetraspanins CD37 
and CD63 at the membrane of APCs when using CHAPS 1% 
(35, 36), a mild detergent extraction condition that only keeps 
third level molecular interactions within TEMs (7, 10). Dectin-1 
direct association with CD37 was however observed in transfected 
HEK293 cells when using Triton X-100 1%, which preserves 
FigURe 1 | Tetraspanins act as molecular organizers of pattern recognition receptors (PRRs). (A) CD9 sequesters TLR4 co-receptor CD14 into tetraspanin-
enriched microdomains (TEMs), impairing its localization into lipid rafts, and thus preventing TLR4 downstream signaling. (B) CD36 coupling to the adaptor FcRγ is 
mediated by the complex formed between CD36, β1, and/or β2 integrins, and CD9 and/or CD81 tetraspanins. CD36 association with tetraspanins regulates its 
engagement with Src and Syk kinases, and its internalization when bound to ligands like oxidized low-density lipoproteins. (C) CD9 collaborates with FcγRIIb and 
FcγRIII upon macrophage activation, and, together with CD81, associates with Fc𝜀RI. (D) CD37 stabilizes membrane C-type lectin receptor Dectin-1 and inhibits 
IL-6 production. (e) CD81 interaction with Rac-1 prevents STAT-1 activation downstream of interferon-α/β receptor (IFNAR) stimulation. (F) The interaction between 
ubiquitinated Tspan6 and MAVS (mitochondrial antiviral signaling) interferes with RIG-I (retinoic acid-inducible gene I)-induced recruitment of downstream molecules 
TRAF3, MITA, and IRF3 to MAVS after viral RNA detection.
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tetraspanin-partner primary complexes, but not in B cells (36), 
indicating that this interaction could be affected by other proteins 
expressed on APCs or that it is dynamically dependent on the 
cell activation status. CD37 stabilizes Dectin-1 surface expression 
and impairs its internalization, and Dectin-1-mediated TNF-α  
and IL-6 production in response to yeast cell walls (36) (Figure 1). 
Accordingly, CD37−/− mice are protected against systemic Candida 
albicans infection, producing high levels of IL-6 and specific IgA 
antibodies (37). On the other hand, CD37 mRNA expression pos-
itively correlates with Dectin-1 and IL-6 mRNA in brains of mice 
infected with Toxoplasma gondii (38); however, further studies 
are necessary to evaluate this effect at the protein level and if there 
is any causal relationship. CD63 also seems to cooperate with 
Dectin-1 during yeast phagocytosis by human monocyte-derived 
DCs (MoDCs) (35), being specifically recruited to phagosomes 
containing Cryptococcus neoformans (39) in a process depend-
ent on acidification and thought to be required for tethering the 
antigen-loading machinery together.
CD36 is a SR that recognizes proteinaceous or lipidic antigens 
from microbes, or self-ligands. In mouse macrophages, CD81 
and CD9 are required for CD36 internalization after binding 
to oxidized low-density lipoprotein (oxLDL) ligands (40, 41). 
CD9 would be important for signaling in response to oxLDL, 
since oxLDL uptake and subsequent JNK phosphorylation are 
impaired in CD9−/− macrophages (40). Moreover, CD9 and 
CD81-dependent scaffolding of CD36, and β1 and β2 integrins 
in membrane multimolecular complexes is essential for CD36 
association with FcγR (Fc receptor for IgG) and with Src and Syk 
kinases; and for its subsequent antigen uptake (41) (Figure 1). CD9 
is also associated with the scavenger-like receptor CD5, which 
recognizes β-glucans expressed on fungi (42), although there is no 
experimental evidence about the functional implications of this 
interaction.
Pathogens can be opsonized with IgGs produced in response 
to microbial invasion, and recognized by FcγRs associated with 
PRRs. This combined stimulation triggers cytokine production and 
pathogen-specific innate immune responses. FcγRs seem to be 
included in TEMs in phagocytic cells. CD9 antibody cross-linking, 
but not Fc fragment alone, stimulates intracellular signaling depend-
ent on FcγRIIB and FcγRIII, thus promoting mouse macrophage 
FigURe 2 | Tetraspanins act as key players in antigen-presenting cell (APC) migration. CD81 facilitates rolling and arrest under shear flow, increasing the avidity  
of VLA-4 integrin. Tetraspanins CD9 and CD151 congregate the endothelial adhesion receptors (ICAM-1 and VCAM-1) in clusters called endothelial adhesive 
platforms, thus controlling their adhesive properties and leukocyte extravasation. CD9 and CD81 deficiency results in an increase of MMP-2 and MMP-9 
metalloproteinases production and activity, required for interstitial migration. Once in the tissue, CD81 tetraspanin controls cell migration via Rac-1-dependent 
mobilization of preformed integrin clusters at the leading edge and contributes to the formation of lamellipodia. While migratory immature dendritic cells (DCs) are 
CD37hi and CD82lo, mature DCs at the lymph nodes are CD37lo CD82hi, and display reduced migratory capacity and efficient antigen presentation machinery.
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activation (43). Antibody cross-linking of tetraspanin CD82 
enhances FcR-dependent activation of intracellular signaling in 
human monocytic cell lines (44). Importantly, IgG-opsonized 
HIV-1 particles are targeted to TEMs in endosomes of immature 
DCs (45). Other Fc receptors are also associated with TEMs, as 
the FcεRI (Fc receptor for IgE), which is a molecular partner of 
CD9 and CD81 in human monocytes and skin-derived DCs (46) 
(Figure 1). The importance of TEMs as organizers of FcεRI signa-
losome in mast cells has been recently reviewed elsewhere (47).
Tetraspanins can also regulate signaling of cytoplasmic PRRs, 
like the RIG-I-like receptors (RLRs). RLRs recognize viral RNA 
and trigger signaling pathways that induce type I IFN responses 
(48). In the presence of viral RNA, ubiquitination of human tet-
raspanin 6 (Tspn6) promotes its interaction with RIG-I, MDA5, 
and mitochondrial antiviral signaling (MAVS) signalosome, 
impairing the activation of IFN-stimulated response element 
(ISRE), NF-κB, and IFN-β promoters (49) (Figure 1).
In summary, increasing evidence shows that tetraspanins usu-
ally act as negative regulators of PRR clustering and/or signaling. 
Thus, tetraspanins constitute key players to avoid uncontrolled 
immune responses, which are harmful to the host.
Tetraspanins Tightly Control APC 
Migration
Leukocyte migration is of fundamental importance for the efficient 
development of immune responses against pathogens. Innate 
immune cells capture antigens in peripheral tissues and then 
migrate to secondary lymphoid organs where antigen presenta-
tion to T lymphocytes takes place. Immune cells can also migrate 
out of the bloodstream toward the inflammation site, where adap-
tive immune responses occur (Figure 2). Thus, leukocytes modify 
their adhesive properties depending on the immune scenario 
(50). Innate immune cells usually need inflammation signals to 
initiate migration, whereas naïve lymphocytes efficiently migrate 
to secondary lymphoid organs, and after activation signals acquire 
specific migratory patterns. Tetraspanins have emerged as key 
regulators of cell migration, since they modulate the function 
of proteins involved in cell-cell adhesion, cell-ECM (extracel-
lular matrix) adhesion, cytoskeletal protrusion/contraction, and 
proteolytic ECM remodeling. Indeed, tetraspanins associate with 
integrins, cadherins, members of the Ig superfamily, signaling 
molecules like Rac and Rho GTPases, and matrix metalloprotein-
ases (MMP); regulating their membrane compartmentalization, 
intracellular trafficking, and proteolytic activity. Most of the 
information on tetraspanin regulation of cell migration comes 
from studies with adherent and tumor cells and has been reviewed 
in detail (20, 51). In this section, we will delineate the importance 
of tetraspanins for migration and extravasation of APCs.
Early studies employed cross-linking with monoclonal anti-
bodies (mAbs) to investigate the role of tetraspanins in immune 
cell migration. Human MoDC in vitro migration toward MIP-5 and 
MIP-1α chemokines was increased by the treatment with mAbs 
against CD9, CD63, CD81, or CD82 (35). These chemokines are 
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strong chemoattractants required for the recruitment of inmature 
DCs to the surrounding tissue at the sites of injury (52, 53). 
After antigen capture, DCs mature, lose their responsiveness to 
inflammatory chemokines and express CCR7 (54, 55). CCR7 is 
the receptor for CCL19 and CCL21, which are chemokines highly 
present in lymphoid T-cell zones of secondary lymphoid organs 
(56), where DCs home to present their processed antigen to 
T lymphocytes. Opposite to that observed with MoDC migration 
toward MIP-5 and MIP-1α, the same mAb against CD81 (clone 
JS-81) or a CD81 ligand [the Hepatitis C Virus E2 envelope gly-
coprotein (57)] inhibited MoDC migration in response to CCL21 
in vitro (58). These contradictory results could be due to different 
chemokine stimuli or to technical issues. Subsequent studies were 
all in line with a positive role for tetraspanins in cell migration. 
Monocyte transmigration across brain endothelial cell monolay-
ers was significantly inhibited by an anti-CD9 mAb and several 
anti-CD81 mAbs, in both rodent and human in  vitro models, 
by acting on the leukocyte side and on endothelial tetraspanins 
(59, 60). Accordingly, CD81 mAb (clone Eat2) administration 
reduced spinal cord inflammation in  vivo, alleviating autoim-
mune encephalomyelitis (EAE) (59). Ly6C+ monocytes, which 
can derive in MoDCs (61), are key determinants for Th17 dif-
ferentiation in the EAE mouse model (62, 63). Moreover, since 
ICAM-1 and VCAM-1 adhesion molecules are the ligands of leu-
kocyte integrins Mac-1 (αMβ2) and LFA-1 (αLβ2) (for ICAM-1) 
and VLA-4 (α4β1) (for VCAM-1), we must emphasize the impor-
tance of endothelial tetraspanins as organizers of ICAM-1 and 
VCAM-1 containing docking structures during leukocyte extra-
vasation (11, 64). Importantly, loss-of-function studies have 
demonstrated that CD81 is essential for cell rolling, arrest, and 
migration. In both monocytic cell lines and mouse primary 
splenocytes, CD81 facilitates rolling and arrest under shear flow, 
increasing the avidity of integrin VLA-4 (65) (Figure 2). The link 
between tetraspanins and MMP during immune cell migration 
has also been investigated. Bone marrow-derived macrophages 
(BMDMs) from CD9 and CD81 double deficient mice show 
reduced motility, through a mechanism dependent on the regula-
tion of MMP-2 and MMP-9 expression and activity (Figure 2). 
Interestingly, CD81 and CD9 double deficient mice spontane-
ously develop pulmonary emphysema, with elevated numbers of 
alveolar macrophages and increased MMP activity (66). A similar 
increase in MMP-2 and MMP-9 production and activity was 
observed in BMDMs from CD9-deficient mice, which showed 
decreased macrophage motility with an increase in macrophage 
infiltration after intranasal administration of LPS (31).
It is important to mention that DC motility behavior depends 
on the environmental context. DC migration on two-dimensional 
(2D) surfaces, like endothelial cell surfaces of the circulatory 
system, require adhesive forces and integrin functionality; whereas 
migration in three-dimensional (3D) environments, as interstitial 
ECM, is ameboid and less adhesive, and largely driven by cytoskel-
etal deformability (67–69). Importantly, tetraspanins fine-tune DC 
migratory capabilities by tightly controlling Rac1 and RhoA spatio-
temporal activation. CD81 controls the migration of MoDCs, by 
regulating the formation of lamellipodia, and the mobilization 
of preformed integrin clusters at the leading edge of migratory 
cells (70). This tetraspanin is essential for the formation of actin 
protrusions through a mechanism dependent on its interaction 
with the small GTPase Rac-1 (70, 71) (Figure 2). Integrin adhesive-
ness and lamellipodia formation are required for DCs migration on 
2D surfaces, thus this kind of migration is impaired in the absence 
of CD81. However, CD81 is not required for DCs migration within 
3D collagen scaffolds, corresponding with unaffected Rho-A activ-
ity (70) and pointing out the differential molecular requirements 
of DCs migration. CD37 also promotes Rac-1 activation, while 
CD82 inhibits RhoA (72). Consequently, CD37 deficient DCs have 
impaired migration from the skin to the draining lymph nodes 
in vivo, and reduced ex vivo DC migration in response to CCL19 (73). 
CD82 deficient DCs display the opposite phenotype (72). Absence 
of CD37 in BMDCs also reduces adhesion to fibronectin under low 
shear flow, and cell spreading (73), while CD82 deficiency increases 
DC spreading (72). Thus, CD37hiCD82lo DCs would correspond to 
immature cells, showing increased migration and reduced capac-
ity to activate naïve T cells, while CD37loCD82hi DCs would have 
an activated phenotype, being less motile and endowed with the 
proper presentation machinery to efficiently activate naïve T cells 
(72) (Figure 2). It is becoming increasingly clear that through the 
regulation of cytoskeletal rearrangement, integrins, and signaling 
molecules, tetraspanins constitute key players in APCs migration.
MHC-ii Trafficking and Antigen 
Presentation Take Place within TeMs
Upon their arrival to the lymph nodes, DCs transfer the informa-
tion collected at peripheral tissues to T  lymphocytes triggering 
adaptive immune responses. This process of antigen presentation 
is mediated by MHC-II molecules, which are able to stably bind 
to antigenic peptides, and then present these fragments of exog-
enous proteins to effector T lymphocytes. MHC-II is expressed 
on professional APCs and associates with several tetraspanins, 
including CD9, CD37, CD53, CD81, and CD82, at the surface of 
APCs (74–76). It has been suggested that different tetraspanins 
may play a role in MHC-II clustering (Figure 3). CD37 negatively 
regulates MHC-II clustering, thus limiting antigen presentation 
by mouse splenic CD11c+ DCs. CD37 knock-out splenic DCs 
show increased T-cell stimulatory capacity, by a mechanism 
strictly dependent on peptide-bound MHC-II signals (77). CD81 
and CD9 co-immunoprecipitate with I-A MHC-II molecules in 
mouse BM-derived DCs and B blasts, and I-A/I-E heterologous 
multimerization is reduced in CD9-deficient BM-derived DCs 
(78). However, functional analyses were not performed in the 
study of Unternaehrer and collaborators. Another study has also 
suggested that MHC-II, together with HLA-DM and CD86, was 
included in TEMs containing tetraspanins CD9, CD63, CD81, 
and CD82 (79). This study was performed using the CDw78 
antibody, which recognizes a specific determinant on an MHC-II 
subpopulation. However, this biochemical analysis of MHC-II 
multimerization was performed using mild detergent conditions 
(CHAPS 1%). It was later demonstrated that CD9 and CD81 
co-immunoprecipitation with MHC-II I-A/I-E multimers only 
occurs under these mild detergent conditions (80), not being 
observed when using more stringent conditions (Triton X-100). 
Thus, deficiency in CD9 or CD81 does not affect MHC-II clus-
tering at the surface of mouse BM-derived DCs, while surface 
FigURe 3 | Tetraspanins regulate major histocompatibility complex class II (MHC-II) trafficking and surface expression at antigen-presenting cells (APCs). After 
synthesis, MHC-II molecules are transported to the plasma membrane of APCs in association with the chaperone Ii, which drives MHC-II internalization through 
clathrin-coated pits. Then, Ii is sequentially degraded by different proteases at the MHC-II-enriched endosomal compartment (MIIC), until MHC-II molecules remain 
bound only to the CLIP (class II-associated invariant chain peptide) fragment. Peptides derived from internalized antigens are subsequently loaded to MHC-II 
molecules with the help of the class-II-like chaperone HLA-DM. Several tetraspanins are greatly enriched at the MIIC compartment, and peptide-bound MHC-II 
molecules coupled to Ii are included into tetraspanin-enriched microdomains (TEMs). Tetraspanin CD9 is required for the efficient egress of MHC-II from MIIC to  
the cell surface, and it is essential for MHC-II endocytosis and recycling. CD82 together with CD63 accumulate in LAMP-1-enriched endolysosomal tubules that 
emanate from the MIIC. In MIIC intraluminal vesicles, CD63 is associated with MHC-II and HLA-DM; while CD82 only interacts with HLA-DM. In addition, CD82 is 
preferentially associated with peptide-bound MHC-II, and it is found in phagosomes prior to their fusion with lysosomes. At the APC surface, tetraspanins CD9, 
CD53, CD81, and CD82 are associated with MHC-II, and tetraspanin CD37 negatively regulates MHC-II clustering. Moreover, TEMs containing CD9, CD63, CD81, 
and CD82 include MHC-II, HLA-DM, and CD86 molecules.
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cholesterol content is essential for multimerization (80, 81). In 
addition, it was later demonstrated that the CDw78 determinant 
also recognizes peptide-bound MHC-II molecules coupled 
to the chaperone class-II associated invariant chain (Ii) (82). 
Intracellular trafficking of MHC-II molecules in APCs is a tightly 
regulated process, essential for proper antigen internalization, 
processing and subsequent presentation to T lymphocytes. Newly 
synthesized MHC II molecules associate with the chaperon Ii in 
the endoplasmic reticulum, which prevents premature peptide 
loading of MHC-II until MHCII-Ii complex enters the endocytic 
pathway (83) (Figure  3). The observation that peptide-bound 
MHC-II molecules coupled to the chaperone Ii (recognized by 
the CDw78 determinant) are included in TEMs (79, 82) suggests 
that tetraspanins could regulate MHC-II trafficking at the MHC 
Class II compartment (MIIC). Accordingly, there is considerable 
evidence supporting this hypothesis.
The MIIC is a multilamellar compartment that has similarities 
with late endosomes, being enriched in classical late endocytic 
markers, like LAMP-1, and in resident proteases, like cathepsins 
(84–86). Several tetraspanins, including CD37, CD53, CD63, 
CD81, and CD82, are highly enriched at the MIIC of human 
MoDCs and B cell lines (76, 87–89) (Figure 3). MHC-II diffusion 
rates are comparable to the diffusion values of CD63 and CD82, 
indicating inclusion into TEMs (89). Indeed, CD63 associates with 
MHC-II at both intraluminal vesicles and limiting membranes of 
the MIIC, and with the chaperone HLA-DM at the intraluminal 
vesicles. On the contrary, CD82 associates with HLA-DM at MIIC 
intraluminal vesicles and limiting membranes, but it only associ-
ates with MHC-II molecules at the limiting membrane (88, 89). 
CD82 would be mostly associated with peptide-bound MHC-II 
molecules, since it does not interact with MHC-II-coupled to 
Ii (88). Accordingly, CD82 and MHC-II are recruited together 
to phagosomes containing fungi or bacteria, before the fusion 
with lysosomes (90). Moreover, CD82 deficiency in DCs slightly 
reduces the maturation of MHC-II/peptide complexes (72). 
However, despite abundant evidence that tetraspanins dynami-
cally interact with MHC-II and HLA-DM at the MIIC, they do 
not seem to be essential for peptide loading to MHC-II molecules. 
Downregulation of CD9, CD63, CD81, and CD82 in human cell 
lines does not affect surface expression of peptide-bound MHC-II 
(89), and CD9 deficiency in BMDCs does not affect antigen pro-
teolysis (91). The dynamic interactions between these molecules 
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at the MIIC compartment would rather indicate that TEMs are 
important organizers of MHC-II trafficking in APCs.
After being loaded with antigenic peptides, MHC-II molecules 
egress from the MIIC to the APC surface, a process that remains 
largely undefined. Recently, it has been reported that tetraspanin 
CD9 is important for MHC-II egress to the surface of mouse 
immature MoDCs (91). CD9-deficient MoDCs display increased 
accumulation of MHC-II molecules in acidic compartments, in 
which MHC-II colocalizes with LAMP-1. As a consequence, surface 
expression of MHC-II is decreased in the absence of CD9 (91). Upon 
DC maturation, tubular extensions emanate from the MIIC in a pro-
cess dependent on microtubules and microtubule-adaptor proteins 
(92–94), thus transporting peptide-bound MHC-II molecules to 
the plasma membrane (95, 96). In mouse BMDCs stimulated with 
LPS, these dynamic tubular extensions are enriched in LAMP-1 and 
tetraspanins CD63 and CD82 and show accumulation of fluores-
cent OVA protein (93) (Figure 3). In mature MoDCs, CD9 is not 
involved in MHC-II egress from the MIIC to the plasma membrane, 
which would take place only in a CD9-independent manner (91). 
Therefore, transport of peptide-bound MHC-II to the cell surface 
might be dependent on different TEMs, whose composition would 
be tightly controlled before and after cell maturation.
After arriving at the APC plasma membrane, peptide-bound 
MHCII molecules are actively endocytosed and then recycled 
back to the surface via early endocytic compartments. MHC-II 
endocytosis occurs through clathrin- and dynamin-independent 
pathway(s) (83). Early studies suggested that in immature DCs, 
MHC-II internalization is facilitated through ubiquitination by 
the ubiquitin E3 ligase MARCH-I (97, 98). MHC-II ubiquitination 
would be less efficient in mature DCs due to reduced MARCH-I 
expression, which would result in an increase in MHC-II surface 
expression (98, 99). However, subsequent studies have challenged 
this view (100–102). MHC-II ubiquitination enhances the kinetics of 
degradation of peptide-bound MHC-II molecules in immature DCs 
(101) and prevents recycling of internalized molecules back to the 
membrane (102), without affecting endocytosis. MHC-II recycling 
back to the surface is highly increased upon DC maturation, greatly 
contributing to boost MHC-II surface expression (102). Other 
members of the MARCH family have been shown to be involved 
in tetraspanin turnover. CD81 is targeted to lysosomes in the pres-
ence of MARCH-IV and -VIII, but not MARCH-I. Accordingly, 
MARCH-IV downregulation by siRNA increases CD81 surface 
expression (103). The effect of MARCH proteins on CD81 turnover 
could also affect the expression levels of CD81-interacting partners 
included in TEMs. Importantly, a recent study showed that CD9 
is essential for MHC-II endocytosis in both immature and mature 
MoDCs, by a mechanism independent on MHC-II ubiquitination. 
Moreover, CD9 deficiency prevents MHC-II recycling in mature 
MoDCs (91). Tetraspanins are therefore important players in 
MHC-II trafficking and surface expression at APCs.
Tetraspanins are relevant for antigen presentation to T  lym-
phocytes. Early studies have suggested that disruption of TEMs 
by cholesterol depletion, which is an essential component of these 
microdomains (104), affects the capacity of APCs to stimulate 
T cell activation (79, 81). However, cholesterol depletion can also 
disrupt lipid rafts, which are also required for proper antigen pres-
entation (105). More recently, the specific functions of individual 
tetraspanins during antigen presentation have been established. 
CD37 negatively regulates MHC-dependent antigen presentation 
to CD4+ and CD8+ T cells, while CD151 inhibits T-cell co-stim-
ulation by mouse CD11c+ splenic DCs. As a consequence, mouse 
deficiency in those tetraspanins triggers CD4+ and CD8+ T-cell 
hyperstimulation (77). Sheng and collaborators have suggested 
that CD37 and CD151 could negatively regulate MHC cluster-
ing; however, despite the functional evidence demonstrated in 
their study, the molecular mechanisms behind CD37 and CD151 
function remain to be determined. A similar phenotype was 
also observed with Tssc6−/− and CD37−/−Tssc6−/− mice, through 
a mechanism independent on DC costimulatory signals (106). 
CD63 knock-down in human B cell lines also enhances MHC-II-
dependent CD4+ T cell stimulation, but in this case, the mechanism 
seems to be related with increased production of extracellular 
vesicles (107). In this sense, T cell activation can be induced by 
extracellular vesicles derived from mature DCs (18, 108), which 
are enriched in MHC-I and MHC-II, and several tetraspanins, 
like CD9, CD63, CD81, and CD82 (87, 109). MHC-II sorting into 
extracellular vesicles has been suggested to depend on its recruit-
ment to TEMs (110–112). Together, these data suggest negative 
roles for some tetraspanins during antigen presentation. However, 
other tetraspanins can have the opposite effect. Indeed, mouse 
CD9−/− MoDCs induce less CD4+ T-cell activation and prolifera-
tion than wild-type MoDCs, due to reduced surface expression of 
MHC-II (91). Strikingly, CD9-deficient Flt3L conventional DC 
(cDC) showed similar T-cell stimulatory capacity as wild-type 
cDCs, triggering comparable CD4+ T proliferation in vivo (91). 
The role of CD9 in antigen presentation seems therefore to be 
DC subset-specific, and it would be interesting to investigate the 
molecular mechanisms behind this difference. CD9 interacts with 
MHC-II, and engagement of this tetraspanin with antibodies pro-
motes the formation of antigen-dependent conjugates between 
human CD14+ monocytes and T cells (113). CD9 could also play 
a role in antigen presentation through extracellular vesicles, since 
both are found at the MIIC and exosomes from mature splenic 
mouse DC lines (114). Together, these studies indicate that the 
strength of antigen presentation by professional APCs can be 
tightly regulated by TEM composition, with some tetraspanins 
playing positive roles while others limit T-cell activation signals.
Tetraspanins Define Distinct DC Subsets
Dendritic cells can be classified in several subsets that differentially 
control the strength and duration of T-cell responses. The main 
populations that have been described are plasmacytoid DCs 
(pDCs) and cDCs, which can be divided into several subpopula-
tions. Monocytes can also be precursors of different subsets of 
DCs found in different tissues in the steady state and can generate 
MoDCs during inflammatory reactions (61). Both human and 
mice individual DC subsets display different TEM composition 
(115). In addition, expression of specific tetraspanins can be modu-
lated by DC differentiation and maturation. For instance, CD9 is 
differentially expressed on conventional and pDCs (115, 116).
Regarding cDCs, it has been suggested that they have a higher 
capacity to sense, process and present phagocytosed antigens to 
T cells than pDCs. cDCs are classified in two main subsets: CD141+ 
(BDCA3+) in humans and CD8α+ (CD11b−CD11c+) in mice; or 
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CD1c+ (BDCA1+) in humans and CD4+ (CD11b+CD11c+) in 
mice (3, 4). Murine and human DC subsets have some similari-
ties in their functional properties. In mice, CD8α+ cDC are found 
in lymphoid tissues and show similar phenotype and functional 
specialization to CD103+ cDCs, which are found in non-lymphoid 
organs. Both subsets express comparable levels of TLRs, CLRs, and 
chemokine receptors and have a higher capability to cross-present 
antigens to CD8+ T lymphocytes compared to CD11b+ DCs (3). 
Interestingly, CD141+ human and CD8α+ mouse cDCs show high 
expression of tetraspanins CD9, CD53, and CD81 (115), which 
associate with MHC-I (75, 117). CD141+ cDCs also display high 
levels of CD37, CD82, CD151, and Tspan31 (115). The other main 
subset of cDC is CD11b+ cDCs, which seem to be more efficient 
in MHC-II-dependent antigen presentation to CD4+ T lympho-
cytes, thus triggering polarization to Th2 and Th17 responses (3). 
The tetraspanin expression profile was somewhat variable when 
comparing CD1c+ human and CD11b+CD11c+ mouse cDCs 
(115). Indeed, CD1c+ human cDCs express very high levels of 
CD37, CD53, and CD81 and display intermediate to high levels of 
CD9, CD82, and CD151. In mice, CD4+CD11b+ cDCs show inter-
mediate to low levels of CD9, CD53, CD81, and CD151 (115). As 
previously discussed, several of these tetraspanins are described 
to regulate different steps of MHC-II trafficking and antigen 
presentation by APCs. However, further studies are necessary to 
ascertain whether specific tetraspanin expression profiles can be 
used as markers of cDC subsets and/or define APC functions.
Plasmacytoid DCs, both in humans and mice, have the capac-
ity to produce large amounts of type I interferons (IFN-α/β) in 
response to invading pathogens (118, 119). pDCs (BDCA2+ 
in humans, and B220+ in mice) are a small subset, and in mice 
express low levels of MHC-II, co-stimulatory molecules, integrin 
CD11c, and PRRs (119). Importantly, tetraspanins can be used 
as markers for the identification of different mouse and human 
pDC subpopulations. CD9 expression allows the recognition 
of immature and mature mouse pDCs subsets. CD9+Siglec-Hlow 
pDCs have an immature phenotype, producing high levels of 
type I IFN and other pro-inflammatory cytokines. These cells 
are mainly present in mouse bone marrow and spleen, and when 
stimulated can induce strong CD4+ and CD8+ T  cell responses 
in  vitro and in  vivo (120). In contrast, tissue resident pDCs are 
negative for CD9, do not produce IFN-α, and have a tolerogenic 
phenotype, increasing the numbers of Foxp3+CD4+ Treg cells in 
tumor-draining lymph nodes (120). Therefore, these two pDC 
subsets (CD9+ and CD9−) define cells at different maturation 
stages at steady state. Upon infection, cell activation would induce 
migration of CD9+ pDCs to the periphery, allowing the secretion 
of inflammatory cytokines at the infection site. Interestingly, upon 
maturation, CD9+ pDC upregulate markers of pDC differentiation 
but gradually lose CD9 expression (120). Distinct pDC mouse 
subsets can also be distinguished when looking at tetraspanin 
CD81. A small subpopulation of B220+CD5+CD81+ cells could 
be observed in blood, spleen, and bone marrow. This small subset 
does not produce IFN-α, while splenic CD5−CD81− pDCs secrete 
high amounts of the cytokine (121). Similar CD81− and CD81+ 
pDC subpopulations were observed in humans. Human pDCs 
are divided in two subsets depending on CD2 expression (122), 
and it has been recently demonstrated that CD2high pDCs include 
CD2hiCD5−CD81− and CD2hiCD5+CD81+ cells (121). Similarly to 
mice, human CD2hiCD5+CD81+ pDCs represent a relatively rare 
subpopulation that produce little or no IFN-α (121). This subset 
can, however, secrete other pro-inflammatory cytokines, like 
IL-12p40 and IL-6, and is capable of inducing B-cell proliferation 
and differentiation to plasma cells. In addition, CD2hiCD5+CD81+ 
pDCs are efficient inducers of CD4+ T cell proliferation and Treg 
differentiation (121). Interestingly, antibodies against CD81 and 
CD9, but not CD63, specifically inhibited IFN-α production by 
pDCs when co-cultured with HCV-infected hepatoma cells. This 
effect was specifically related to CD81 expression in pDCs and 
required Rac GTPase activity (123). Hence, the absence of tetras-
panins CD9 and CD81 seems to identify small pDC subpopula-
tions that do not produce type I IFN. However, whether these 
tetraspanin expression profiles define overlapping pDC subsets 
and/or if differential expression of tetraspanins is associated with 
specific APC phenotypes remain to be determined.
CONCLUSiON
In APCs, surface immune receptors and adhesion molecules, such 
as MHC molecules, co-receptors, PRRs, and integrins, associate 
with tetraspanins. Through the inclusion of these receptors in 
TEMs, tetraspanins can regulate their clustering, internalization, 
and intracellular trafficking, then affecting their downstream 
signaling. TEMs are thus important regulators of proper antigen 
uptake, processing and presentation. In addition, by modulat-
ing cytoskeleton-dependent processes, like outside-in integrin 
signaling, actin polymerization and cell spreading, tetraspanins 
are also key players in APC migration. Increasing evidence shows 
that different subsets of DCs having distinct requirements for 
antigen presentation and/or motility capabilities express specific 
repertoires of tetraspanins. This fine-tuned regulation warrants 
appropriate adaptive immune responses. Therefore, tetraspanins 
are potential targets for therapeutical interventions aiming to 
balance exaggerated immune responses in pathological inflam-
mations and in immune-mediated chronic diseases.
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The complexity of the pathogenesis of inflammatory bowel disease (ulcerative colitis
and Crohn’s disease) has led to the quest of empirically drug therapies, combining
immunosuppressant agents, biological therapy and modulators of the microbiota.
Helminth parasites have been proposed as an alternative treatment of these diseases
based on the hygiene hypothesis, but ethical and medical problems arise. Recent
reports have proved the utility of parasite materials, mainly excretory/secretory products
as therapeutic agents. The identification of extracellular vesicles on those secreted
products opens a new field of investigation, since they exert potent immunomodulating
effects. To assess the effect of extracellular vesicles produced by helminth parasites
to treat ulcerative colitis, we have analyzed whether extracellular vesicles produced by
the parasitic helminth Fasciola hepatica can prevent colitis induced by chemical agents
in a mouse model. Adult parasites were cultured in vitro and secreted extracellular
vesicles were purified and used for immunizing both wild type C57BL/6 and RAG1−/−
mice. Control and immunized mice groups were treated with dextran sulfate sodium
7 days after last immunization to promote experimental colitis. The severity of colitis
was assessed by disease activity index and histopathological scores. Mucosal cytokine
expression was evaluated by ELISA. The activation of NF-kB, COX-2, and MAPK were
evaluated by immunoblotting. Administration of extracellular vesicles from F. hepatica
ameliorates the pathological symptoms reducing the amount of pro-inflammatory
cytokines and interfering with both MAPK and NF-kB pathways. Interestingly, the
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observed effects do not seem to be mediated by T-cells. Our results indicate that
extracellular vesicles from parasitic helminths can modulate immune responses in
dextran sulfate sodium (DSS)-induced colitis, exerting a protective effect that should
be mediated by other cells distinct from B- and T-lymphocytes.
Keywords: inflammatory bowel disease, DSS-ulcerative colitis, Fasciola hepatica, extracellular vesicles
INTRODUCTION
Ulcerative colitis and Crohn’s disease are two major clinical
entities included in IBD, which may affect 0.5% of Western world
population (1 million people in the United States, and 2.5–3
million people in Europe), with 37 new cases per 105 inhabitants
in Europe (Molodecky et al., 2012; Kaplan and Ng, 2017). IBD
is also spreading in developing countries, where the prevalence
is lower than in developed ones (Molodecky et al., 2012; Ng
et al., 2013). Most of IBD patients are affected in their productive
age, originating not only important social problems, but also
economic losses (Kaplan, 2015).
The etiology of the disease is not well understood and
because of the complexity of this pathology, the development of
effective treatments will require studies using multidisciplinary
approaches, where animal models have proved to be highly
informative (Lin and Hackam, 2011).
Due to the absence of a curative treatment for IBD, there
have been numerous attempts to incorporate new therapies.
Some of these include new drugs or nutritional supplements to
correct or enhance the effectiveness of the currently authorized
treatments. In fact, the complexity of the pathogenesis of these
diseases has led to empirically evolved current drug therapies,
which primarily treat inflammation. The latest therapies attempt
to restore the intestinal immune balance by efficiently combining
immunosuppressant agents, biological therapy and modulators
of the microbiota (Vanhove et al., 2016).
Interestingly, previous epidemiologic studies and clinic trials
suggested that helminths, either by natural or artificial infections,
might protect people from IBD (Smallwood et al., 2017). This
has been confirmed by Ramanan et al. (2016), which have
demonstrated that alteration of commensal and pathogenic
bacteria produced by gastrointestinal helminths infection in turn
protects the host against IBD (Ramanan et al., 2016). Still, major
concerns of the helminthic therapy are related to ethical issues
and the ability of controlling the course of the infection. In
this sense, the identification of helminth-derived molecules that
ultimately mediate host immune modulation is attracting much
attention.
Extracellular vesicles, including exosomes and microvesicles,
have been described as participating in intercellular
communications with important roles in physiological and
pathological processes, where they can be used as diagnostic and
Abbreviations: COX-2, cyclooxygenase 2; DAI, disease activity index; DSS,
dextran sulfate sodium; EVs, extracellular vesicles; FABPs, fatty acid-binding
proteins; Fh, Fasciola hepatica; IBD, inflammatory bowel disease; IL, interleukin;
MAPK, mitogen activated protein kinase; MPO, myeloperoxidase; NF-kB, nuclear
factor kappa B; TEM, transmission electron microscopy; TNF-α, tumor necrosis
factor alpha.
therapeutic weapons (Yáñez-Mó et al., 2015; Barile and Vassalli,
2017). EVs have been described to participate in inflammation,
like EVs from granulocytes, which have been used for IBD
treatment in a mice model (Wang et al., 2016; Song et al., 2017).
Fasciola hepatica is a flatworm that excretes/secretes a large
number of molecules to the host-parasite interplay, including
immune modulators (Dalton et al., 2013). Our group has
identified some of these molecules in EVs released by parasite
adults in culture (Marcilla et al., 2012; Cwiklinski et al., 2015;
Fromm et al., 2015). To assess the functional role of these
EVs in the host and exploring their usefulness as therapeutic
agents against IBD, we have studied their potential in preventing
ulcerative colitis in a DSS induced colitis model in C57BL/6 mice.
Our data support that F. hepatica EVs (FhEVs) can protect from
IBD in this model, since their inoculation prevents intestinal
damage in acute colitis by altering the local immune response.
Thus, FhEVs might be employed for preventing relapses in IBD
patients and could be explored as a potential new therapy for
treating IBD.
MATERIALS AND METHODS
Materials
Unless otherwise specified, all reagents were purchased from
Sigma-Aldrich (Madrid, Spain) and Bio-Rad Laboratories
(Madrid, Spain). DSS, colitis grade (36–50 kDa) was purchased
from MP Biomedical (United States). Specific antibodies for
COX-2, p38 and p65 subunit nuclear factor-κβ (NF-κB)
were purchased from Millipore (Billerica, MA, United States);
antibodies against p38 MAPK and P-p38 MAPK were obtained
from were obtained from Cell Signaling Technology (Danvers,
MA, United States) and Santa Cruz Biotechnology (Santa
Cruz, CA, United States), respectively. Anti-GAPDH polyclonal
sera was kindly provided by Dr. Daniel Gozalbo, Universitat
de València. ELISA kits for cytokines were purchased from
Affymetrix eBioscience (San Diego, CA, United States).
Isolation and Characterization of
Fasciola hepatica Extracellular Vesicles
Extracellular vesicles from F. hepatica adults (FhEVs) were
purified and monitored by TEM as previously described (Marcilla
et al., 2012). Briefly, adult parasites, collected from cow livers
from local abattoirs, were thoroughly washed with PBS and
cultured in 0.2 µm filtered RPMI -1640 culture medium
containing 100 U penicillin and 100 µg/mL streptomycin (all
from Sigma), at concentrations of 2 worms/mL at 37◦C for
5 h. After the incubation period, the parasite culture media was
collected and centrifuged at low speed (first at 300 g/10 min,
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and then at 700 g/30 min) to remove larger debris, and the
resulting supernatant was centrifuged at 15,000 g for 45 min
at 4◦C. Supernatants were then filtered using an ultrafiltration
membrane (0.2 µm; Schleicher and Schuell) and centrifuged at
120000 g/1 h at 4◦C in an Optima TL100 tabletop ultracentrifuge
(Beckman) using a TLA-55 rotor.
Extracellular vesicles were aliquoted, frozen-drying in PBS
containing 20% sucrose, and kept at 4◦C until use. Before
inoculating animals, protein content was determined following
Bradford’s method (Bio-Rad).
Animals
Female C57BL/6 mice (Harlan Interfauna Iberica, Barcelona,
Spain), 6–8 weeks of age, weighing 18–20 g were previously
acclimatized in 12 h light/dark cycles at 22◦C and 60% humidity,
for 7 days before performing the experiments, and fed with
a standard laboratory rodent diet and water ad libitum. All
animal care and experimental protocols were approved by the
Institutional Ethics Committee of the Universitat de València and
Generalitat Valènciana, Spain (No. 2015/VSC/PEA/00045 type 2,
12-03-2015).
Rag1−/− mice were housed in pathogen-free conditions
at the CNIC animal facility. Experimental procedures were
approved by the local research ethics committee and conformed
to EU Directive 2010/63EU and Recommendation 2007/526/EC,
enforced in Spanish law under Real Decreto 53/2013.
Induction of Dextran Sulfate Sodium
(DSS) Colitis and Inoculation With FhEVs
Acute colitis was induced in mice by administering drinking
water with 3% (w/v) DSS for 7 days, as previously described
(Giner et al., 2016). Animals were randomly assigned to four
groups: Control group (mice received only regular drinking
water); DSS group (mice received 3% DSS in drinking water);
FhEV + DSS group (mice were subcutaneously inoculated three
times with F. hepatica EVs resuspended in PBS, and received 3%
DSS in drinking water); and FhEV group (mice subcutaneously
inoculated three times with F. hepatica EVs, and received regular
drinking water) (see Figure 1B). At day 49 mice were sacrificed,
their colons were removed and samples analyzed. Every effort was
made to minimize animal suffering and reduce the number of
animals used.
Disease Activity Index
Disease Activity Index was used to assess the severity of colitis
as indicated by Giner et al. (2013). Mice were checked daily
for development of colitis by monitoring body weight, fecal
occult blood (Hemoccult R© II Sensa; Beckman Coulter), or gross
rectal bleeding, and stool consistency. Overall disease severity
was assessed by a clinical scoring system defined as follows:
weight loss: 0 (no loss), 1 (1–5%), 2 (5–10%), 3 (10–15%), and
4 (>15%); stool consistency: 0 (normal), 2 (loose stool), and 4
(diarrhea); and bleeding: 0 (no blood), 1 (Hemoccult R© positive),
2 (Hemoccult R© positive and visual pellet bleeding), and 4 (gross
bleeding, blood around anus).
Histological Analysis
Distal colon parts were cut and fixed as previously reported
(Giner et al., 2016). Five-micrometer tissue sections were stained
with hematoxylin and eosin and evaluated using an Optiphot
Nikkon, microscope by an expert pathologist (CM). A well-
accepted histology score in an scale of 0 to 6 was used (Melgar
et al., 2008) (0 = no signs of damage; 1 = few inflammatory
cells, no signs of epithelial degeneration; 2 = mild inflammation,
few signs of epithelial degeneration; 3 = moderate inflammation,
few epithelial ulcerations; 4 = moderate to severe inflammation,
ulcerations in more than 25% of the tissue section; 5 = moderate
to severe inflammation, large ulcerations of more than 50% of
the tissue section; and 6 = severe inflammation and ulcerations
of more than 75% of the tissue section). In addition, the precise
percentage of ulcerated mucosa in every transversal section of the
colon was recorded. Median histopathology score and median
percentage of ulcerated mucosa were used for comparison
between groups.
Cytokine Production in Tissue
TNF-α, IL-6, IL-17A, and IL-10 concentrations were measured as
previously described (Giner et al., 2016), by using specific enzyme
immunoassay kits, following manufacturer’s instructions. Reads
were done in an iMarkTM microplate absorbance reader (Bio-
Rad, CA, United States). Values of cytokines were expressed as
pg per mg of total protein.
Determination of Neutrophil Infiltration in
Colon Tissue
Neutrophil infiltration was determined by assaying MPO activity,
as previously described (Giner et al., 2011, 2013). Absorbance was
measured spectrophotometrically at 630 nm, and MPO activity
was expressed as the amount of enzyme necessary to produce a
change in absorbance of 1.0 Unit g−1 of tissue (Recio et al., 2000).
Cytosolic and Nuclear Protein Extraction
The differential extraction of proteins from intestines and their
concentration were determined as previously reported (Giner
et al., 2011).
Western Blot Analysis
Equal amounts of protein (25 µg) were separated by SDS-
PAGE in 10% polyacrylamide gels, transferred onto nitrocellulose
membranes, blocked, and incubated overnight at 4◦C with
anti-COX-2 (1:8000), anti-p65 NF-κB (1:500) subunit, or anti-
GAPDH, anti-p38 MAPK, anti-Pp38 MAPK (all at 1:1000). Blots
were washed with TBS (10 mM Tris-HCl pH 7.4, NaCl 150 mM),
incubated with secondary antibodies (1:10000), and immune
reactive bands were visualized with the aid of AmershamTM ECL
Select western blotting system (GE Healthcare, Madrid, Spain)
(Marcilla et al., 1995; Giner et al., 2013).
To unify Western blot densitometry to result in the processed
images, data from the DSS group were taken as reference and
assigned the value of 100. Relative percentages of the other groups
were then calculated.
Frontiers in Microbiology | www.frontiersin.org 3 May 2018 | Volume 9 | Article 1036
fmicb-09-01036 May 18, 2018 Time: 16:54 # 4
Roig et al. F. hepatica EVs Prevent DSS-Colitis in Mice
Statistical Analysis
The results are expressed as the mean ± SE values. Statistical
significance was determined with a one-way analysis of variance
(ANOVA), and Dunnett’s t-test for multiple comparisons using
GraphPad Prism, version 6 (GraphPad Software Inc., La Jolla,
CA, United States). Values of p < 0.05 were considered to be
statistically significant, and the symbols ∗, # and + were used to
indicate the statistical significance.
Software
Images for all Western blot experiments were acquired with a
ChemiDoc MP imager (Bio Rad, CA, United States). Digital
images were processed and band density measurements were
made with the aid of NIH Image J software (Schneider et al.,
2012).
RESULTS
Preventive Treatment With F. hepatica
EVs Ameliorates Clinical Symptoms and
Attenuates Histological Alterations in
DSS-Induced Acute Colitis
Previous evidence suggests that EVs from parasitic helminths
could be potential new therapeutic alternatives against
autoimmune diseases (Buck et al., 2014; Montaner et al.,
2014). We therefore assessed their putative preventive effect in
IBD. EVs were purified from F. hepatica parasites cultured as
described previously (Marcilla et al., 2012), showing to be a clean
and homogeneous preparation, with most vesicles ranging in the
size of 50–100 nm (Figure 1A).
To test whether FhEVs could prevent colitis, C57BL/6
mice were injected subcutaneously with 10 µg of
FhEVs/mouse/injection on days 0, 15, and 30 before colitis
induction by DSS at day 42 (Figure 1B). We used these amounts
of EVs based on previous studies (Trelis et al., 2016). FhEVs-
treated mice were considerably less susceptible to DSS-induced
colitis and lost around 10% of their initial body weight, whereas
non-treated mice lost around 20% after 7 days of DSS treatment
(data not shown). Accordingly, DAI of FhEVs-treated colitic
mice was lower than in colitic mice on day 5 after the initiation
of DSS treatment. Moreover, this difference gradually increased
over time (Figure 1C). On autopsy, a significant colonic
shortening was detected in the DSS-administered groups as
compared to the water-administered ones injected or not with
FhEVs. However, between DSS-treated mice, FhEVs injected
mice had significant larger colons than their non-injected
counterparts (Figures 1D,E).
FhEVs Attenuate Histological Alterations
and Suppress Neutrophil Infiltration
Upon DSS Challenge
Histologic analyses of colonic sections revealed complete
disruption of the colonic architecture in colitic mice, whereas
FhEVs-treated colitic mice display a better preservation of tissue
architecture and reduced epithelial denudation, crypts distortion,
and leukocyte infiltration of the lamina propria (Figure 2A),
thus resulting in a lower histopathological mean score in this
group (Figure 2B). Consistent with the histological findings, the
ulceration score of FhEVs-treated colitic mice was significantly
lower than in DSS-induced colitic mice (Figure 2C).
Furthermore, the reduction in neutrophil infiltration observed
by histological inspection in FhEVs-treated colitic mice was
confirmed by the reduced MPO activity detection in colon tissues
from these mice (Figure 2D). Altogether, these results strongly
support the view that injection of FhEVs could ameliorate DSS-
induced murine experimental colitis.
FhEVs Decrease Pro-inflammatory
Cytokines in Colon Tissues
To address the effect of FhEVs in colitis we next analyzed the
immune response involved by determining the tissue levels of
cytokines known to participate in IBD (Giner et al., 2016).
Amounts of TNF-α, IL-6, IL-17A, and IL-10 were determined in
intestine by ELISA. As shown in Figures 3A,B, treatment with
FhEVs markedly prevented the increase in the levels of the pro-
inflammatory cytokines TNF-α and IL-6 observed in the intestine
of DSS-treated mice.
Recent studies have identified that the expression of genes
involved in Th17 immune response can distinguish patients with
ulcerative colitis from patients with Crohn disease (Rosen et al.,
2017). To address whether Th17 response was also modified in
the mice model of ulcerative colitis, IL-17A levels in intestine
were determined by ELISA. As shown in Figure 3C, IL-17A
levels were lower in FhEVs-treated colitic mice in comparison
to DSS-induced colitic mice, indicating the anti-inflammatory
effect of FhEVs. As a parameter of the anti-inflammatory activity
of regulatory T lymphocytes (Treg), IL10 was also monitored.
Interestingly, the amount of this cytokine did not change
significantly in the groups of mice analyzed (Figure 3D). Taken
together these results indicated that F. hepatica EVs exerted their
preventive effect by altering the pro-inflammatory effect of DSS,
not depending of a role of Treg cells.
FhEVs Decrease the Activation of the
Pro-inflammatory Effector Molecules
COX-2, NFkB, and Phosphorylated p38
MAPK in DSS-Induced Acute Colitis
It is well known that several key factors participate in the
inflammatory cascade leading to colitis (Talero et al., 2008; Giner
et al., 2011). In this context, different studies have documented
the role of COX-2 in mediating the prolonged epithelial secretion,
and the barrier dysfunction observed in colonic inflammation
in mice (Zamuner et al., 2003; Sanchez-Fidalgo et al., 2013).
To address whether F. hepatica EVs administration could also
affect the expression of COX-2, as pro-inflammatory mediator in
DSS-induced colitis, we next analyzed its levels in colon tissue
by western blot. As shown in Figure 4, the DSS-induced colitic
mice showed higher levels of COX-2 in colon tissues than their
FhEVs-pretreated counterparts (only 33% of COX-2 was detected
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FIGURE 1 | Treatment with Fasciola hepatica EVs ameliorates clinical symptoms and partially avoids colon shortening in DSS-induced acute colitis. (A) Extracellular
vesicles were obtained by differential ultracentrifugation and ultrastructure was confirmed by TEM. (B) Schematic time schedule of immunization with F. hepatica EVs
(FhEVs) and DSS-induction of colitis in C57B/L6 mice. (C) Disease activity index (DAI) was evaluated daily using the parameters of weight loss, diarrhea, and
bleeding as described in methods. Statistical significance between two experimental groups was assessed using the Independent-Sample t-test (∗∗∗p < 0.001,
significantly different between the control and DSS group; ∗p < 0.05 significantly different between the immunized group and the DSS group; using one-way ANOVA
followed by Dunnett’s t-test). (D,E) Colon length was measured as an indirect marker of inflammation.
as compared to the levels observed in DSS-induced colitic mice,
Figure 4B).
Furthermore, colonic cells showed variations in different
signaling pathways as in the mitogen-activated protein
kinase (p38 MAPK), and NF-kB pathways. As shown in
Figure 4, DSS increased the phosphorylation of p38 MAPK,
but pre-treatment of colitic mice with FhEVs produced
lower levels of phosphorylation of p38 MAPK (around 39%),
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FIGURE 2 | Histopathological changes in the colons of acute colitis mice. (A) Distal colon tissue samples were examined using haematoxylin-eosin staining (5× and
10×). (B) Histopathological score of colon tissue samples as a mean histopathology score in DSS and FhEVs+DSS mice. (C) Percentage of ulcerated colonic
mucosa in DSS and FhEVs+DSS mice. (D) Myeloperoxidase (MPO) activity was determined by a spectrophotometric method and expressed as the amount of
enzyme necessary to produce a change in absorbance of 1.0 unit/mg of tissue. Each bar chart represents the mean ± SEM for at least three independent
experiments (n = 3 animals) (###p < 0.001, significantly different from the DSS group vs. control group; ∗∗∗p < 0.001 significantly different between the DSS group
and the group immunized with FhEVs; using one-way ANOVA followed by Dunnett’s t-test).
although still higher than in colon from control and FhEVs-
injected mice groups (both without DSS administration)
(Figure 4B).
The levels of NF-kB in the nuclear fraction of colon cells were
also quantified, and colon tissues from both DSS-induced colitis
mice contained higher levels of this nuclear factor than controls.
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FIGURE 3 | Effect of FhEVs on the profile of cytokine levels in colon tissue samples. At day 49 cytokine levels in colon homogenates were determined by ELISA. The
amount of cytokines was expressed as pg per mg of protein. (A) TNFα levels, (B) IL-6 levels, (C) IL-17A levels, (D) IL-10 levels. Each bar chart represents the
mean ± SEM for at least three independent experiments (n = 3 animals). ###p < 0.001 significantly different from the DSS and control for TNFα and IL6; ##p < 0.01
significantly different from the DSS and control for IL17A; ∗∗∗p < 0.001 significantly different from the DSS and immunized group for IL6; ∗∗p < 0.01 significantly
different from the DSS and immunized group for TNFα and IL6, using one-way ANOVA followed by Dunnett’s t-test.
Nevertheless, FhEVs treated colitic mice contained around 25%
less amount of NF-kB when comparing to DSS-induced colitic
mice (Figures 4A,B).
Altogether, our results indicate that F. hepatica EVs interfere
with signaling pathways involved in acute ulcerative colitis
promoted by DSS, and suggest their role in preventing pro-
inflammatory cascades in which these key molecules participate.
The Preventive Effect of FhEVs in Colitis
Is Not Mediated by Lymphocytes
To assess whether lymphocytes were the cells accounting for the
protection, similar in vivo experiments of immunization with
FhEVs before DSS administration were carried out in Rag1−/−
mice. These mice lack lymphoid B and T cells (Mombaerts et al.,
1992), and are susceptible to DSS-induced colitis (Kim et al.,
2006; Kiesler et al., 2015). Rag1−/− mice were injected with
FhEVs subcutaneously. Interestingly, FhEVs exhibited protection
against the chemical treatment (Figure 5), similarly to what
happened in C57BL/6 mice (see Figures 1, 2).
Fasciola hepatica EVs-treated mice lost around 9% of their
initial body weight, whereas non-treated mice lost around 18%,
after 7 days of DSS treatment (data not shown). Accordingly,
the DAI of FhEVs-treated colitic mice was lower than in colitic
mice on day 4 after the initiation of DSS treatment, increasing
this difference over time (Figure 5A). DSS-administered mice
treated with FhEVs had significant larger colons than their non-
injected counterparts, although not reaching the length observed
in control animals (Figure 5B).
When histological analyses of colonic sections were
performed, they revealed large disruption areas of the colonic
architecture in colitic mice, whereas FhEVs-treated colitic
mice displayed preservation of tissue architecture and reduced
epithelial denudation and crypts distortion (Figure 5C).
Altogether, these results supported the notion that neither T nor
B cells are involved in the preventive effect observed with the
parasite EVs.
DISCUSSION
Intestinal bowel disease is one of the most important diseases
affecting developing countries, and it is currently spreading in
undeveloped ones (Molodecky et al., 2012; Ng et al., 2013). The
etiology of the disease is not well understood, with a complex
pathology which has no effective treatment available. In fact,
the development of effective treatments require studies using
multidisciplinary approaches, where animal models have proven
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FIGURE 4 | Effects of FhEVs on COX-2 and NF-kB expression, and phosphorylation of p38MAPK (pp38) in DSS-induced acute colitis in mice. At day 49 colon
tissues were powdered in a mortar with liquid nitrogen, and tissue proteins were extracted. (A) Representative western blot analyses are shown (from three different
experiments, n = 3). The amount of COX-2 was determined by densitometry analysis, and normalized to GAPDH content for each sample. The amount of
phosphorylated p38MAPK (pp38MAPK) and p65 NF-kappaB were determined by densitometry analysis, and normalized to p38MAPK content. Quantification
measures were done using NIH ImageJ software (Schneider et al., 2012), considering the amount of protein in DSS group as 100%. (B) The histograms representing
the data derived from representative western blots following densitometry analysis of each group are also shown.
highly useful (Lin and Hackam, 2011). DSS-induced colitis model
has been widely used to explore new therapeutic options (Wirtz
and Neurath, 2007; Kiesler et al., 2015).
Among the new treatments, the use of biologicals is gaining
attention (Rogler, 2015; Maizels, 2016). In this context, and
following the Hygiene hypothesis (Strachan, 1989), clinical trials
with parasitic helminths have been initiated, and some are
underway (Smallwood et al., 2017). Some concerns about using
helminths to treat IBD have arisen, with the possibility of
producing malignancy (Bonovas et al., 2016). In fact, a recent
report has shown that the treatment with the parasitic nematode
Heligmosomoides polygyrus can induce tumor progression in a
DSS-induced colitis in Balb/c mice (Pastille et al., 2017).
Along with those potential clinical problems, the use of
parasites to treat IBD also face ethical problems (McSorley
and Maizels, 2012), so the alternative of using parasite defined
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FIGURE 5 | Lymphocytes do not mediate the preventive effect of FhEVs in DSS-induced colitis. (A) Disease activity index (DAI) evaluated daily combining the
parameters of weight loss, diarrhea, and bleeding in Rag1−/− mice (n = 7 animals) as described in methods. Statistical analyses were performed using a one-way
ANOVA followed by Dunnett’s multiple comparison post hoc test (∗∗∗p < 0.001, FhEVs+DSS versus DSS). (B) Colon length was measured as an indirect marker of
inflammation. Statistical significance between two experimental groups was assessed using the Independent-Sample t-test (###p < 0.001, significantly different
between the control and DSS group; ∗∗p < 0.01 significantly different between the immunized group and the control; ++p < 0.01 significantly different between the
immunized group and the DSS group; using one-way ANOVA followed by Dunnett’s t-test). (C) The histopathological changes of colons in mice were examined
using H&E staining (5× and 10×).
products, like excretory/secretory products (ESP), or isolated
molecules seem to be a good option. In this context, studies
with a crude extract from the laminated layer of Echinococcus
granulosus (a tapeworm parasite) showed not only its preventive
effect but also played a beneficial role in maintaining the integrity
of the intestinal mucosal barrier against DSS-induced injury
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(Soufli et al., 2015). Those results supported the role of EVs as
promoters of the epithelial barrier function (Xu et al., 2016).
Previous studies had shown that EVs administered either
orally or injected could reach the colon of mice and exert
their therapeutic effect on induced colitis (Ju et al., 2013; Yang
et al., 2015). Very recently, Wang et al. (2017) have reported
a protective effect in a similar mice model when using EVs
produced by dendritic cells previously exposed to eggs from the
parasitic trematode Schistosoma japonicum (Wang et al., 2017).
In this regard, our data highlight that the parasite F. hepatica
EVs have a potent modulatory effect on the immune response in
DSS-induced colitis in mice. We provide evidence that F. hepatica
EVs can prevent DSS-induced colitis by down regulating pro-
inflammatory cytokines like TNFα, IL-6, and IL17A, as well
as suppressing MAPK/NF-κB signaling pathways. Accordingly,
FhEVs treatment decreased MPO activity, indicating a reduction
in neutrophil infiltration in damaged colon and which has also
been corroborated in the histological sections. In accordance,
reduce levels of cytokines TNF-α and IL-17A have been detected
in the colon of FhEVs-treated mice, which are inducers of
neutrophil transmigration (Kolls and Lindén, 2004; Griffin et al.,
2012). DSS colitis can be exacerbated by granulocyte recruitment
(Natsui et al., 1997; Williams and Parkos, 2007; Sander et al.,
2008; Chami et al., 2014; Kishida et al., 2015). The activity
of many enzymes and chemicals produced by neutrophils is
not specific to pathogens, so they can damage host tissues
when released extracellularly, contributing to the aggravation of
mucosal inflammation. Likewise, in UC, unrestricted neutrophil
activation may cause significant tissue damage that further leads
to chronic pathology and the extent of neutrophil infiltration
correlates with the severity of the disease (Bressenot et al., 2015).
Therefore, the reduced neutrophil infiltration in FhEVs-treated
mice, would provide for the protection effect detected in this
model of acute colitis induced by DSS, and may be crucial for
the treatment of UC patients. In Rag1−/− mice, a decreased
neutrophil infiltration is also observed in the histology sections
after FhEVs treatment, in accordance with the results obtained in
C57B/L6 mice. It is important to remark that though Rag1−/−
mice have no mature T and B lymphocytes (Mombaerts et al.,
1992), develop totally normal granulocytes, like WT mice, as has
been demonstrated in reports which use these mice in infection
models (Smith et al., 2009; Seymour et al., 2015; Carey et al., 2016;
Papp et al., 2016).
Furthermore, our results suggest that neither lymphocytes
nor IL-10 are involved in the protective effect by FhEVs in
DSS-induced colitis mice model. This seems to be at odds with
previous reports showing that either splenic B cells or EVs from
granulocytic myeloid-derived suppressor cells, attenuate DSS-
induced colitis by promoting Tregs expansion, and inhibit Th1
cells proliferation (Reyes et al., 2015; Wang et al., 2016).
The accurate identification of the molecules responsible for
the anti-inflammatory effect is underway, but suitable candidates
are molecules previously identified in FhEVs, like FABPs
(Cwiklinski et al., 2015), which have been shown to induce anti-
inflammatory response in animal models by diminishing the
levels of TNFα (Ramos-Benitez et al., 2017). Other exosome-
contained molecules like miRNAs represent potential candidates
as they may act as immunomodulators of the intestinal innate
immune response (Buck et al., 2014). Interestingly, a repertoire
of miRNAs with immune-regulatory function have been found in
F. hepatica EVs previously by our group (Fromm et al., 2015).
Resident intestinal macrophages and colonic dendritic cells
have been reported to have a high anti-inflammatory phenotype
and are hypo-responsive to microbial stimuli in rodents and
humans (Bilsborough and Viney, 2004; Kelsall and Leon, 2005;
Smith et al., 2005). In line with this, it has been described that
depletion of both dendritic cells and macrophages from the
intestinal lamina propria in C57BL/6, BALB/c, and SCID mice
(without T and B cells) increased DSS colitis severity. These
mice had increased neutrophilic inflammation, epithelial injury,
and enhanced mucin depletion from globet cells (Qualls et al.,
2006). On the other hand, helminth infections are associated with
the induction of immunosuppressive M2/Alternatively Activated
Macrophages (AAMs) (Loke et al., 2000; Herbert et al., 2004).
It is therefore conceivable that FhEVs are enhancing the anti-
inflammatory functions of these innate cell populations as
they are protective in Rag1−/− mice that lack T and B cells
populations. Other helminth infections have been shown to
prevent colitis development independently of Tregs stimulation,
through the inhibition of prostaglandins by AAMs (Ledesma-
Soto et al., 2015) or recruitment of a novel macrophage
population distinct to AAMs or Gr1+ macrophages (Smith
et al., 2007). Moreover, in addition to their immunosuppressive
role, lamina propria macrophages play an important role in
the regeneration of damaged epithelium by controlling the
epithelial progenitor niche after DSS-induced colitis (Pull et al.,
2005). On the other hand, the reduced neutrophil infiltration
detected in FhEVs-treated mice might be a consequence of the
decreased epithelial barrier damage and diminished production
of pro-inflammatory cytokines from the resident myeloid cell
populations in the gut as observed in the foregoing reports,
because of the preventive role of these exosomes. Moreover,
some reports described that subcutaneously injected exosomes
can be detected in several organs including the gastrointestinal
tract even after 24 h of administration, and cleared from the
bloodstream in a few minutes (Wiklander et al., 2015). However,
in our experimental settings the exosomes are administered
12 days before DSS administration, which makes us to think
that they are exerting their role in the gut resident populations.
A plausible mechanism may be epigenetic reprogramming of
these innate cell populations, a process that has been recently
termed as trained immunity (Netea et al., 2016), or even
of the intestinal epithelial cells. Whether, in addition, FhEVs
could be exerting their function by altering granulopoiesis at
the bone marrow level, or influencing in endothelial cells the
level of expression of adhesion molecules, requires further
experimentation and biodistribution analyses.
Apart from the induction of strong Th2 responses and
IgE production, which can be discarded in our experimental
setting due to the maintenance of the protective effect in
Rag1−/− mice that lack mature T and B lymphocytes, helminths
also promote the expansion of eosinophils, mast cells and
basophils which could not be discarded. Levels of these cell
populations can be measured by flow cytometry to evaluate if
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there were differences among FhEVs-treated versus non-treated
mice. Interestingly, among these cell populations, the only one
which have been described to promote a protective role in
acute DSS colitis are the eosinophils, due to the production of
anti-inflammatory lipid mediators (Masterson et al., 2015). To
further elucidate which innate cell population is mediating the
protection, adoptive transfer experiments could be performed by
injecting specific sorted cell populations derived from FhEVs-
immunized Rag1−/− mice into non-immunize ones. Our most
likely candidates are macrophages, as stated in the foregoing
works. Besides, macrophages are highly phagocytic cells that
could be acquiring a highest number of exosomes. Moreover, the
role of dendritic cells is typically focused on T cell polarization,
which are not involved. Specific deletion of macrophages can be
performed by the use of liposomal clodronate agent. If they turn
to be involved in the conferred protection to DSS-colitis, it would
be very informative to evaluate the role of FhEVs in M1 and
M2 polarization, which could be performed by flow cytometry
or RNA-seq.
Our findings suggest that other immune cells aside
lymphocytes are involved in the protective response (Masterson
et al., 2015; Coakley et al., 2017; Wang et al., 2017; Campbell
et al., 2018). Future studies will address the identification of the
immune cells involved in the FhEVs protective effect and the
mechanisms behind it. The fact that the conferred protection
against intestinal inflammation is mediated by EVs is of great
importance to move this research forward into translational
applications.
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Psoriasis is one of the most common chronic inflammatory skin dis-
eases, affecting about 2% of the population worldwide1. It is defined 
by a thickened epidermis (acanthosis) caused by keratinocyte prolif-
eration and massive infiltration of leukocytes into the skin. Psoriatic 
lesions contain larger amounts of the pro-inflammatory cytokines 
interleukin 17 (IL-17), IL-21, IL-22 and IL-23, which has led to the 
classification of psoriasis as a disease mediated by IL-17-producing 
helper T cells (TH17 cells)2. The importance of IL-23 and IL-17 in 
psoriatic patients is demonstrated by the efficacy of treatment with 
monoclonal antibodies to IL-17 and to the cytokine receptor IL-23R3. 
Furthermore, intradermal administration of recombinant IL-23 
to mice induces a psoriasiform dermatitis that mimics the human 
disease in histological and immunological aspects4.
In addition to IL-17, IL-22 also acts as a master regulator of pso-
riasis5–7. Polymorphisms in IL22 result in enhanced susceptibility 
to psoriasis8, and serum concentrations of IL-22 positively correlate 
with disease severity and negatively correlate with responsiveness to 
therapy9. IL-22 signaling in keratinocytes induces expression and 
phosphorylation of the transcription factor STAT3, which increases 
epidermal proliferation and de-differentiation10. IL-22 expression is 
regulated by the ligand-dependent transcription factor AhR in TH17 
cells and some populations of γδ T cells11 and innate lymphocytes12. 
Currently described endogenous ligands for AhR also include 
naturally occurring dietary substances, such as L-tryptophan 
(L-Trp)-derived metabolites13. After being exposed to light, L-Trp can 
be metabolized to several products, including the high-affinity AhR 
agonist FICZ (6-formylindolo [3, 2-b] carbazole). A light-independent, 
H2O2-dependent pathway for the systemic generation of FICZ from 
L-Trp has also been described14. Uptake of aromatic amino acids 
by activated lymphoid cells is conducted mainly via the system L1 
transporter, an heterodimer comprising the heavy chain CD98 (also 
known as SLC3A2 or 4F2) and the light chain LAT1 (‘L-type amino 
acid transporter 1’; also known as SLC7A5). Regulation of amino 
acid transport through the LAT1-CD98 heterodimer is linked to 
T cell–activation and T cell–differentiation processes15.
Although TH17 cells were once considered an important source of 
IL-17 and IL-22 in psoriatic skin, evidence now indicates that these 
cytokines are produced mainly by a population of dermal γδ T cells 
already identified in both humans and mice16–19. Skin γδ T cells bear 
several markers of memory and effector T cells, including CD69 
(ref. 20). Lymphocytes from CD69-deficient mice show enhanced 
differentiation toward the TH17 lineage21, and CD69-deficient mice 
exhibit increased severity of TH17 cell–mediated inflammatory 
diseases, including collagen II–induced arthritis22, allergic asthma 
and skin contact hypersensitivity23, autoimmune myocarditis24 and 
colitis25. Whether CD69 exerts an immunomodulatory effect on pso-
riasis by controlling IL-17 and IL-22 responses in skin γδ T cells has 
remained unexplored until now.
In this study we found that CD69-deficient mice developed 
an attenuated skin inflammatory response to the administration of 
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CD69 controls the uptake of L-tryptophan through 
LAT1-CD98 and AhR-dependent secretion of IL-22 
in psoriasis
Danay Cibrian1, María Laura Saiz1, Hortensia de la Fuente1, Raquel Sánchez-Díaz2, Olga Moreno-Gonzalo1, 
Inmaculada Jorge2, Alessia Ferrarini2, Jesús Vázquez2, Carmen Punzón3, Manuel Fresno3,  
Miguel Vicente-Manzanares1, Esteban Daudén4, Pedro M Fernández-Salguero5, Pilar Martín2 &  
Francisco Sánchez-Madrid1,2
The activation marker CD69 is expressed by skin  T cells. Here we found that CD69 controlled the aryl hydrocarbon receptor 
(AhR)-dependent secretion of interleukin 22 (IL-22) by  T cells, which contributed to the development of psoriasis induced by 
IL-23. CD69 associated with the aromatic-amino-acid-transporter complex LAT1-CD98 and regulated its surface expression and 
uptake of L-tryptophan (L-Trp) and the intracellular quantity of L-Trp-derived activators of AhR. In vivo administration of L-Trp, an 
inhibitor of AhR or IL-22 abrogated the differences between CD69-deficient mice and wild-type mice in skin inflammation. We 
also observed LAT1-mediated regulation of AhR activation and IL-22 secretion in circulating Vγ9+  T cells of psoriatic patients. 
Thus, CD69 serves as a key mediator of the pathogenesis of psoriasis by controlling LAT1-CD98-mediated metabolic cues.
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IL-23, with decreased expression of IL-22 and STAT3 in the epidermis. 
We also found that CD69 associated with the heterodimeric amino-
acid transporter LAT1-CD98 and regulated the uptake of L-Trp. 
This promoted the AhR-induced secretion of IL-22 by skin γδ T cells.
RESULTS
IL-23-induced psoriasiform inflammation requires CD69 
To assess the role of CD69 in psoriasis, we administered consecutive 
intradermal injections of mouse IL-23 protein into the ears of 
wild-type and CD69-deficient mice. IL-23 induced more swell-
ing, epidermal acanthosis, dermal inflammation and keratinocyte 
proliferation (Ki67+ nuclei) in the ears of wild-type mice than in 
those of CD69-deficient mice (Fig. 1a–c). IL-23 also significantly 
increased the total number of CD45+ cells in wild-type mice rela-
tive to that in CD69-deficient mice (Fig. 1d). These were mostly 
CD45+CD11c−CD11b+ myeloid (non-dendritic) cells, particularly 
Gr-1+F4/80−neutrophils, F4/80lo monocytes and F4/80hi macro-
phages (Fig. 1d). Immunohistochemistry also revealed more Ly6G+ 
neutrophils and F4/80+ monocytes and macrophages in wild-type 
mice than in CD69-deficient mice after treatment with IL-23 
(Fig. 1c) These results indicated that the absence of CD69 prevented 
the development of psoriasis after intradermal injection of IL-23.
Reduced expression of IL-22 and STAT3 in CD69 deficiency
We next determined whether CD69 controls the expression of inflam-
matory mediators in the skin. IL-23 induced higher expression of 
Cxcl1, S100a8 and S100a9 mRNA in wild-type mice than in CD69-
deficient mice, while both genotypes showed a similar increase in 
Ccl20 mRNA (Fig. 2a). IL-23 treatment increased the expression of 
Il6, Tnf, Il1b and IL-17 mRNA to a similar extent in wild-type mice 
and CD69-deficient mice, while the expression of Tgfb mRNA in the 
skin was not altered (Fig. 2b,c). In contrast, IL-23 induced a very 
modest increase in IL-22 expression in the skin of CD69-deficient 
relative to that in the skin of wild-type mice (Fig. 2d). Neither 
genotype showed detectable expression of IL-22 or IL-17 in CD4+  
T cells obtained from the ear-draining lymph nodes of mice 
given injection of IL-23, followed by re-stimulation of the cells 
in vitro (data not shown). These results indicated that the weak 
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Figure 1 CD69-deficient mice develop a 
mild form of IL-23-induced psoriasis. (a) Ear 
thickness of CD69-deficient (CD69-KO) and 
wild-type (WT) mice after each intradermal 
injection of IL-23 (horizontal axis) (top left), 
and dermal and epidermal thickness and 
quantification of Ki67+ nuclei in histological 
sections of ears from CD69-deficient and  
wild-type mice after ten doses of IL-23 (top right 
and bottom row). Each symbol (top right and  
bottom row) represents an individual image;  
small horizontal lines indicate the mean (± 
s.d.). (b) Hematoxylin-and-eosin (H&E)-stained 
sections of ear skin from CD69-deficient and 
wild-type mice treated with PBS or IL-23 (left 
margin). Scale bars, 100 µm (top and middle) 
or 50 µm (bottom); original magnification,  
×10 (top and middle) or ×20 (bottom).  
(c) Immunohistochemistry of Ki67, Ly6G and 
F4/80 (above images) in the skin of CD69-
deficient and wild-type mice treated with PBS 
or IL-23 (left margin). Scale bars, 25 µm (top 
and second row), 50 µm (third row) or 100 µm  
(bottom two rows); original magnification, ×40 
(top and second row) or ×20 (bottom three 
rows). (d) Flow cytometry (left) of cells that 
infiltrated the ears of CD69-deficient and wild-
type mice (above plots) given ten doses of PBS 
or IL-23 (left margin). Numbers adjacent to 
outlined areas indicate percent of CD45+ cells 
among live gated cells (top group), or Gr-1+ 
granulocytes (top left), F4/80lo cells (bottom 
left) or F4/80hi monocytes and macrophages 
(bottom right) among CD45+CD11b+CD11c− 
live gated cells. Right, quantification of the 
populations gated at left (per 1 × 104 live gated 
cells). FSC, forward scatter. NS, not significant 
(P >0.05); *P < 0.05, **P < 0.01, ***P < 0.001 
and ****P < 0.0001 (unpaired t-test (a, top 
left), one-way analysis of variance (ANOVA) 
with Newman-Keuls multiple-comparisons post-
test (a, top right and bottom row) or two-way 
ANOVA with Bonferroni’s multiple-comparisons 
test (d, right)). Data are representative of three 
experiments (mean ± s.d. (a, top left) or mean + 
s.e.m. (d); n = 5 mice per group).
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cutaneous inflammatory response to IL-23 injection observed in the 
CD69-deficient mice might have been related to attenuated skin pro-
duction of IL-22.
Expression of the cytokine receptor IL-22R in skin is restricted 
to non-hematopoietic cells, such as keratinocytes and fibroblasts. In 
these cells, the binding of IL-22 to IL-22R activates STAT3 (ref. 26). 
Injections of IL-23 into the ear caused a uniform increase in epidermal 
STAT3 expression and phosphorylation (at Ser727 and Tyr705) in 
wild-type mice, compared with only patchy induction of these param-
eters in CD69-deficient mice (Fig. 2e,f). This indicated that CD69 
controlled the expression of IL-22 and STAT3.
Enhancement of the expression of AhR and IL-22 by CD69
CD69 is a negative regulator of the secretion of IL-17 by TH17 
cells27, but its effect on IL-22 secretion is not known. This is a 
crucial question, since IL-22 is produced by TH17 lymphocytes13. 
Naive CD4+ T cells from CD69-deficient mice polarized for 48 h 
in vitro into TH17 cells secreted less IL-22 than did their wild-type 
counterparts (Supplementary Fig. 1a). Moreover, flow cytometry 
after intracellular staining showed that CD69-deficient TH17 cells 
had lower expression of AhR than that of wild type TH17 cells 
(Supplementary Fig. 1b). We found that expression of mRNA from 
the AhR target genes Il22, Ahr, Ahrr, Cyp1a and Cyp1b was impaired 
in CD69-deficient TH17 cells relative to that in wild-type TH17 cells 
(Supplementary Fig. 1c).
In IL-23-driven psoriasis, IL-22 and IL-17 are secreted by dermal 
γδ T cells16,18. To characterize the resident T cell populations in the 
skin of both wild-type mice and CD69-deficient mice, we analyzed 
total skin-cell suspensions and separated dermal and epidermal lay-
ers by flow cytometry. These experiments indicated that CD3hi cells 
were dendritic epidermal γδ T cells, while 50–80% of dermal CD3lo 
cells were γδ T cells (Supplementary Fig. 1d). Both CD3hi γδ T cell 
populations and CD3lo γδ T cell populations in untreated skin had 
high expression of CD69 (Supplementary Fig. 1e). Although CD69 
expression is linked to the generation and migration of skin-resident 
memory T cells28, the frequency of skin-resident epidermal (CD3hi) 
and dermal (CD3lo) γδ T cell populations was similar in wild-type 
mice and CD69-deficient mice (Supplementary Fig. 1f).
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Figure 2 CD69 deficiency weakens IL-23-triggered  
IL-22 expression and STAT3 signaling in the epidermis.  
(a,b) Quantitative PCR analysis of mRNA encoding  
chemoattractant factors (a) and cytokines (b) among  
total mRNA in the ears of CD69-deficient and wild-type  
mice (key) treated with PBS or IL-23 (below plots); results  
(calculated by the change-in-cycling-threshold (2−∆∆Ct)  
method) were normalized to those of the control gene Gapdh  
and are presented relative to those of PBS-treated  
wild-type mice, set as 1. (c) Expression of Il17 mRNA  
and IL-17A protein (c) and Il22 mRNA and IL-22 protein  
(d) in ear skin from mice as in a,b (mRNA results presented  
as in a,b). (e) Immunohistochemistry of total STAT3 and  
STAT3 phosphorylated at Ser727 (p-STAT3(Ser727)) or  
Tyr705 (p-STAT3(Tyr705)) (left margin) in ears from mice  
as in a,b. Scale bars, 25 µm; original magnification, ×40.  
(f) Quantification of epidermal STAT3, presented  
(in arbitrary units (AU)) as signal intensity (top) or proportion  
of STAT3 area among total epidermal area analyzed (below),  
and frequency of nuclei positive for phosphorylated STAT3  
(as at left) among keratinocytes (bottom two plots).  
Each symbol represents an individual image; small  
horizontal lines indicate the mean (± s.d.). *P < 0.05  
and **P < 0.001 (two-way ANOVA with Bonferroni’s  
multiple-comparisons test (a–d) or one-way ANOVA with  
Newman-Keuls multiple-comparisons test (f)). Data are  
representative of three experiments, with at least five  
images per group in e,f (error bars (a–d), s.e.m.;  
n = 5 mice per group).
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Simultaneous intradermal injection of IL-23 (into the ears) and 
systemic (intraperitoneal) administration of the secretion inhibitor 
brefeldin A to wild-type mice promoted the accumulation of IL-22 
in dermal CD3lo γδ T cells (Supplementary Fig. 2a). Moreover, flow 
cytometry of dermal γδ T cells sorted from wild-type mice and stimu-
lated in vitro with IL-23 plus IL-1β revealed an acute peak of IL-22 
(maximal at 24 h after stimulation) and higher AhR expression than 
that of unstimulated cells (Supplementary Fig. 2b). However, the 
secretion of IL-17 from sorted dermal γδ T cells was sustained for up 
to 72 h after stimulation (Supplementary Fig. 2b).
Sorted CD69-deficient dermal γδ T cells released less IL-22 than 
did wild-type dermal γδ T cells when stimulated with IL-23 and IL-
1β in vitro, whereas their IL-17 production was similar (Fig. 3a). 
Moreover, the expression of AhR induced by IL-23 and IL-1β in vitro 
stimulation was lower in CD69-deficient dermal γδ T cells than in 
wild-type dermal γδ T cells (Fig. 3b).
To parse the function of CD69 in IL-22 secretion by dermal γδ  
T cells in vivo, we prepared skin-cell suspensions 12 h after the 
administration of a single dose of IL-23 into the ears of wild-type and 
CD69-deficient mice, followed by stimulation of the cell suspensions 
with the phorbol ester PMA and ionomycin. Flow cytometry showed 
lower IL-22 expression in CD69-deficient dermal γδ T cells than in 
wild-type dermal γδ T cells (Fig. 3c). Simultaneous intradermal 
injection of IL-23 and intraperitoneal administration of brefeldin A 
resulted in lower expression of IL-22 in dermal γδ T cells from CD69-
deficient mice than in those from wild-type mice (Fig. 3d).
We observed a similar expression of the transcription factor RORγt 
in dermal γδ T cells from CD69-deficient and those from wild-type 
mice (Supplementary Fig. 2c). Likewise, phosphorylation of STAT3 
and STAT5 following stimulation with IL-23 plus IL-1β was simi-
lar in CD69-deficient dermal γδ T cells and wild-type dermal γδ  
T cells (Supplementary Fig. 2c). Flow cytometry of skin suspensions 
from mice with sequence encoding green fluorescent protein (GFP) 
reporter knocked into the gene encoding IL-23R29 showed that der-
mal γδ T cells (CD3lo) were the main population among IL-23R+ 
(GFP+) cells in the skin at steady state, while epidermal γδ T cells 
(CD3hi) were IL-23R− (GFP−) (Supplementary Fig. 2d). Staining of 
IL-23R showed that the number of IL-23R+ dermal γδ T cells and their 
molecular density of IL-23R were similar for CD69-deficient mice and 
wild-type mice (Supplementary Fig. 2e).
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Figure 3 CD69 regulates the expression of AhR and IL-22 in dermal resident γδ T cells.  
(a) Flow cytometry (top) of dermal γδ T cells sorted from CD69-deficient and wild-type mice  
and stimulated for 24 h in vitro with IL-23 plus IL-1β. Numbers in quadrants indicate percent  
cells in each (throughout). Below, frequency of IL-22+ or IL-17+ cells gated as above.  
(b) Expression of AhR in dermal γδ T cells as in a. Isotype, isotype-matched control antibody.  
(c) Flow cytometry (left) of skin-cell suspensions obtained from the ears of CD69-deficient  
and wild-type mice (above plots) 12 h after a single dose of PBS or IL-23 (left margin),  
followed by stimulation of cells for 4 h in vitro with PMA and ionomycin. Right, frequency  
of IL-22+ or IL-17+ cells gated as at left (n = 8 mice per group). (d) Flow cytometry (left) of  
cells obtained from CD69-deficient and wild-type mice (above plots) 12 h after injection of a single dose of PBS and brefeldin A or IL-23 and brefeldin A 
(left margin). Right, frequency of IL-22+ or IL-17+ cells gated as at left. Each symbol represents an individual mouse (n = 8 per group); small horizontal 
lines indicated the mean (± s.d.). (e) Ear thickness of lethally irradiated CD69-deficient and wild-type host mice (CD45.2+) reconstituted by intravenous 
injection of wild-type whole bone marrow cells (CD45.1+) for 2 months, then given seven doses of PBS or IL-23 intradermally (assessed after each dose; 
horizontal axis). (f) Flow cytometry (left) analyzing dermal γδ T cells in CD69-deficient or wild-type (CD45.2+) host chimeric mice as in e. Numbers 
adjacent to outlined areas indicate percent CD45.2+ (host-resident) dermal or epidermal γδ T cells identified by high expression (top right; epidermal) 
or low expression (bottom right; dermal) of the γδ TCR. Right, quantification of total dermal γδ T cells (per ear) in host mice as at left after intradermal 
treatment with PBS or IL-23 (horizontal axis). (g) Flow cytometry (top) of cells from mice as in e. Numbers adjacent to outlined areas indicate percent 
CD45.1+CD11b+ cells among live cells (left group) or Ly6G+Ly6C+ cells among CD45.1+CD11b+F4/80− gated cells (right group). Bottom, frequency 
of CD45.1+CD11b+ and CD45.1+CD11b+F480−Ly6G+Ly6C+ cells as above. *P < 0.05, **P < 0.01 and ***P < 0.001 (unpaired t-test (a,b) or two-way 
ANOVA and Bonferroni’s multiple-comparisons test (c,d,f,g)). Data are representative of three experiments (a,b; mean + s.e.m.; n = 3 or 4 mice per 
experiment), one experiment (c,d; mean + s.d. of n = 8 mice per group in c) or two experiments (e–g; mean + s.e.m. of n = 5 mice per group).np
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CD69 is known to modulate the trafficking 
of effector T cells30. To investigate whether 
CD69-mediated egress of lymphocytes from 
the lymph node was involved in the IL-23 
skin-inflammation model, we transferred 
wild-type (CD45.1+) whole bone marrow 
cells intravenously into lethally γ-irradiated 
CD69-deficient or wild-type (CD45.2+) host mice (Fig. 3e). After 
2 months of reconstitution, we administered IL-23 intradermally to 
the mice. CD69-deficient host mice displayed less skin inflamma-
tion than that of wild-type host mice (Fig. 3e). Flow cytometry of 
skin-cell suspensions showed a similar increase in host-derived 
(CD45.2+) dermal γδ T cells in CD69-deficient mice and wild-
type host mice after treatment with IL-23 (Fig. 3f). We observed 
significantly more infiltrating CD11b+ myeloid cells and Ly6G+Ly6C+ 
neutrophils of donor (CD45.1+) origin in the skin of wild-type mice 
than in that of CD69-deficient mice (Fig. 3g). Because skin-resident 
dermal γδ T cells are radioresistant and proliferate in situ20, they 
persisted in the bone-marrow-chimeric hosts, which would account 
for the differences between the wild-type hosts and CD69-deficient 
hosts. These observations ruled out the possibility of a role for the 
migration of CD69+ T lymphocytes from the lymph nodes as a 
triggering mechanism.
IL-22- and AhR-mediated skin inflammation downstream of CD69
To address whether the attenuated skin inflammation observed in 
CD69-deficient mice was due to reduced secretion of IL-22 from 
the skin, we simultaneously injected IL-22 and IL-23 intrader-
mally into wild-type mice and CD69-deficient mice. We observed 
a similar degree of ear swelling in mice of each genotype (Fig. 4a), 
as well as substantial acanthosis (Fig. 4b) and similar infiltration 
of myeloid cells into the skin (Fig. 4c), proliferation of dermal 
γδ T cells (Fig. 4d,e), and expression of Il1b and IL-22-related 
genes, such S100a7, S100a8 and S100a9, in mice of each genotype 
(Fig. 4f). Moreover, intradermal injection of IL-22 alone induced 
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Figure 4 IL-22 mediates skin inflammation 
downstream of CD69. (a) Ear thickness of 
CD69-deficient and wild-type mice during the 
administration of eight doses of IL-23 plus  
IL-22 (500 ng of each; horizontal axis).  
(b) H&E-stained sections of ears from wild-type 
and CD69-deficient mice (above plots) treated 
with eight doses of PBS or with IL-23 plus  
IL-22 (left margin). Scale bars, 50 µm; original 
magnification, ×20. (c) Flow cytometry (top) 
of cells in skin suspensions from mice as in a. 
Numbers adjacent to outlined areas indicate 
percent CD49f+CD45− keratinocytes (top left) 
or CD49f−CD45+ cells (bottom right) among 
live gated cells (left group), CD11b+F4/80+ 
macrophages (top) or CD11b+F4/80− cells 
(bottom) among CD45+CD11c− live gated cells 
(middle group), or Ly6G+Ly6C+ neutrophils 
(top), Ly6G−Ly6C− cells (bottom left) or 
Ly6G−Ly6C+ cells (bottom right) among live 
CD45+ CD11b+F4/80− gated cells (right group). 
Below, total CD45+ cells, macrophages and 
neutrophils (per ear) in mice as above.  
(d) Flow cytometry (left) of skin suspensions 
from mice as in a. Numbers adjacent to outlined 
areas indicate percent γδTCR−CD3+ T cells 
(bottom), γδTCR+CD3+ dermal T cells (top right) 
and γδTCR++CD3++ epidermal T cells (top left) 
among live CD45+ gated cells. Right, total 
dermal γδ T cells (per ear) in mice as at left.  
(e) Flow cytometry (left) of skin suspensions 
from mice as in a. Numbers adjacent to  
outlined areas indicate percent Ki67+ cells 
among CD45+CD3loγδTCRlo gated cells.  
Right, total dermal Ki67+ γδ T cells as at left. 
(f) Quantitative PCR analysis of Il1b, S100a7, 
S100a8 and S100a9 mRNA in the skin of mice 
as in a (presented as in Fig. 2a,b). P values 
(NS), unpaired t-test (a) or two-way ANOVA 
followed by Bonferroni’s multiple-comparisons 
test (c–f). Data are representative of two 
independent experiments with similar results 
(mean ± s.d. (a) or mean + s.e.m. (c–f); n = 5 
mice per group in each experiment).
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similar ear swelling and expression of Il1b, 
S100a8 and S100a9 in CD69-deficient skin 
and wild-type skin (Supplementary Fig. 3a). 
These observations suggested that the effect 
of IL-22 in the context of IL-23-induced 
skin inflammation was independent of 
CD69 expression.
Direct involvement of AhR in the secre-
tion of IL-22 by dermal γδ T cells was 
addressed by simultaneous administration 
of three intradermal injections of IL-23 
into the ears of AhR-deficient and wild-
type mice, as well as intraperitoneal 
administration of brefeldin A. Flow cytometry of skin-cell 
suspensions showed fewer IL-22+ dermal γδ T cells in AhR- 
deficient mice than in wild-type mice, while the number of 
IL-17+ γδ T cells was increased similarly in the skin of each geno-
type (Supplementary Fig. 3b). In addition, we stimulated sorted 
CD69-deficient and wild-type dermal γδ T cells in vitro with IL-23 
plus IL-1β in the presence of the AhR inhibitor CH-223191, 
which prevented secretion of IL-22 by cells of each genotype 
(Supplementary Fig. 3c). To assess whether IL-22 secretion 
depended on CD69 in γδ T subsets in locations other than the skin, we 
studied splenic CD27− γδ T cells, which secrete IL-17 and IL-22 after 
being stimulated with IL-23 (ref. 31). These cells expressed CD69 
after being stimulated with IL-23 and/or IL-1β (Supplementary 
Fig. 3d). Splenic CD27− γδ T cells from CD69-deficient mice had 
lower expression of IL-22 than that of their wild-type counterparts, 
and this was abrogated by CH-223191 (Supplementary Fig. 3e). 
These observations indicated that activation of AhR was required 
for CD69 to regulate the IL-23-induced IL-22 expression.
To address whether inhibition of AhR controlled IL-23-dependent 
skin inflammation, we injected IL-23 intradermally into wild-type 
and CD69-deficient mice, together with daily intraperitoneal admin-
istration of CH-223191. This treatment decreased inflammation in 
wild-type mice but had a very modest effect on CD69-deficient mice 
(Fig. 5a,b). Systemic administration of CH-223191 also reduced the 
number of IL-23-driven Ly6G+Ly6C+ neutrophils in wild-type skin to 
numbers similar to those in CD69-deficient skin (Fig. 5c). Also, the 
expression of Il22 mRNA and of the IL-22 target genes S100a9 and 
S100a7 in whole skin was significantly lower in wild-type mice that 
received CH-223191 plus IL-23 than in wild-type mice that received 
IL-23 alone and was similar to that in CD69-deficient mice treated 
with IL-23 (Fig. 5d). These results indicated that AhR and IL-22 
contributed to skin inflammation controlled by CD69.
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Figure 5 IL-23-induced skin inflammation 
is prevented by inhibition of AhR. (a) Ear 
thickness of CD69-deficient and wild-type 
mice during the administration of seven doses 
of IL-23 (horizontal axis) with concomitant 
daily intraperitoneal injection of CH-223191 
or vehicle (DMSO). (b) H&E-stained sections 
of ears from wild-type and CD69-deficient 
mice treated intradermally with seven doses 
of IL-23 along with systemic administration of 
CH-223191 or DMSO. Scale bars, 100 µm; 
original magnification, ×10. (c) Flow cytometry 
of cells from wild-type and CD69-deficient mice 
treated as in a (left margin). Numbers adjacent 
to outlined areas indicate percent CD45+ cells 
among live gated cells (left), CD11b+F4/80+ 
macrophages (top) or CD11b+F4/80− cells 
(bottom) among CD45+CD11c− live gated cells 
(middle), or Ly6G+Ly6C+ neutrophils among 
CD11b+F4/80− gated cells (right). Right, 
frequency of CD45+ cells among live-gated 
skin cells (top) and of Ly6C+Ly6G+ cells in the 
CD45+CD11c−CD11b+F4/80− subset (bottom) 
in wild-type and CD69-deficient mice treated 
with PBS or IL-23 (horizontal axis) and with CH-
223191 or DMSO (key). (d) Quantitative PCR 
analysis of Il22, S100a9 and S100a7 mRNA  
in the skin of mice as in a (presented as in  
Fig. 2a,b). *P < 0.05, **P < 0.01 and  
***P < 0.001 (two-way ANOVA with Bonferroni’s 
multiple-comparisons test). Data are 
representative of two independent experiments 
with similar results (mean ± s.d. (a) or mean + 
s.e.m. (c,d); n = 5 mice per group).
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CD69 associates with LAT1-CD98 and controls amino acid uptake
To address the mechanism by which CD69 regulated the AhR- 
mediated expression of IL-22, we used mass spectrometry to explore 
possible interactions of CD69 with regulators of AhR. We found 
that CD69 associated with several nutrient transporters, including 
CD98, LAT1, MOT1 and GTR1 (Supplementary Table 1 and 
Supplementary Fig. 4a). The LAT1-CD98 complex is a major intake 
receptor for aromatic amino acids such as L-Trp, which is a source of 
ligands for AHR14. Immunoprecipitation experiments showed that 
CD69 associated with both chains of the LAT1-CD98 transporter in 
human Jurkat T cells activated with PMA and ionomycin (Fig. 6a). 
Confocal imaging and a proximity-ligation assay also indicated an 
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Figure 6 CD69 associates with LAT1-CD98 and controls the uptake of amino acids.  
(a) Immunoblot analysis (IB) of proteins immunoprecipitated (IP), with antibody to CD69  
or control antibody (Ctrl), from human Jurkat (J77) cells activated with PMA plus ionomycin,  
and of lysates without immunoprecipitation (Lys), probed with antibodies to CD98, LAT1  
and CD69 (left margin). (b) Immunofluorescence microscopy of LAT1, CD98 and CD69 in  
J77 cells activated as in a. DAPI, DNA-binding dye. (c) In situ proximity-ligation  
assay (left) of CD69-LAT1 and CD69-CD98 interactions in non-activated J77 cells  
stably transfected to express CD69 (J77-CD69) or untransfected J77 cells (J77).  
Right, quantification of the results at left. (d,e) Flow cytometry analyzing membrane and  
total expression of LAT1 and CD98 by activated CD4+ T cells (d) and membrane  
expression of LAT1 on sorted dermal γδ T cells (e). (f) Uptake of 3H-labeled amino  
acids (AAs) by CD27+ γδ T cells sorted from the spleen and lymph nodes of wild-type  
and CD69-deficient mice, at various times (horizontal axes; top row), and uptake of  
those amino acids (AAs) after 15 min, in the presence or absence of BCH (horizontal axes)  
(bottom row). (g) Uptake of labeled amino acids at 15 min by CD27− γδ T cells sorted from the spleen and lymph nodes of  
mice as in f, bottom. (h) Targeted mass spectrometry (left) quantifying L-Trp and FICZ in Jurkat T cells incubated in L-Trp-enriched  
medium and left untreated (Control) or treated with BCH, presented as mass-spectrometry-2-extracted values reflecting the intensity (AU) of each 
compound in each sample, with retention times used for identification (three biological replicates: top, middle, left); far right (red), ion chromatograms 
of reference standards for L-Trp and FICZ (confirmation of retention times; presented as at left). (i) Flow cytometry analyzing the uptake of FICZ by 
wild-type activated CD4+ T cells after 16 h of incubation with no FICZ or 1 µM FICZ (top row) or by CD69-deficient and wild-type activated CD4+  
T cells after 1 h of incubation with 100 nM FICZ (bottom row), with or without BCH, at 4 °C or 37 °C (key). Each symbol (c,i) represents an individual 
replicate (cell (c) or well (i)); small horizontal lines indicate the mean (± s.d.). *P < 0.05, **P < 0.01 and ***P < 0.001 (unpaired t-test (c,e) or one- or 
two-way ANOVA and Newman-Keuls or Bonferroni’s test (d,f,g)). Data are representative of two experiments (a–c,f,g,i; mean + s.e.m. in f,g), three 
experiments with at least n = 5 replicates (wells) per group (d,e; mean + s.d.) or three independent experiments with one biological replicate (h).
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association of CD69 with CD98 and LAT1 on the plasma membrane 
of activated Jurkat T cells (Fig. 6b,c).
Activated CD4+ T cells from CD69-deficient mice had lower 
surface expression of LAT1 but not lower total expression of LAT1 
than that of their wild-type counterparts, while plasma-membrane 
expression and global expression of CD98 were similar in cells of 
each genotype (Fig. 6d). Membrane expression of LAT1 was also 
significantly higher in sorted wild-type dermal γδ T cells than in 
their CD69-deficient counterparts (Fig. 6e). After stimulation with 
antibody to the invariant signaling protein CD3 (anti-CD3), wild-
type CD4+ T cells and CD69-deficient CD4+ T cells showed a similar 
increase in Slc7a5 mRNA (which encodes LAT1) and Slc3a2 mRNA 
(which encodes CD98) (Supplementary Fig. 4b); this suggested that 
CD69 might have been regulating LAT1 dynamics and/or its stability 
at the membrane. Moreover, no significant difference between acti-
vated CD4+ T cells from CD69-deficient and those from wild-type 
mice was observed in the expression of mRNA encoding other amino 
acid transporters, except for higher expression of Slc38a2 mRNA 
(which encodes the transporter SNAT2), regulated by amino-acid 
starvation32, in CD69-deficient CD4+ T cells than in their wild-type 
counterparts (Supplementary Fig. 4c).
Assays of the uptake of 3H-labeled L-Trp, L-Phe and L-Leu 
showed that CD69-deficient γδ T cells isolated from spleen and 
lymph nodes had slower uptake of L-Trp via LAT1 than that of 
their wild-type counterparts (Fig. 6f,g). Likewise, less uptake 
of amino acids via LAT1 was detected in CD69-deficient CD4+  
T cells than in wild-type CD4+ T cells (Supplementary Fig. 5a). 
Incubation with an antibody that promotes CD69 internalization23 
also triggered the internalization of LAT1 in CD4+ T cells but had 
no effect on surface expression of CD98 (Supplementary Fig. 5b). 
HEK-293 human embryonic kidney cells were co-transfected with 
plasmids encoding CD69-GFP and LAT1-Cherry fusion proteins 
and then incubated with labeled anti-CD69; this showed co-inter-
nalization of CD69 and LAT1 (Supplementary Fig. 5c). Moreover, 
antibody-induced internalization of CD69 impaired the uptake 
of L-Trp and L-Phe in CD4+ wild-type T cells relative to their 
uptake after treatment with control antibody, but it had no effect 
on amino acid uptake in CD69-deficient cells (Supplementary 
Fig. 5d). These observations indicated that CD69 was associated 
with LAT1 and regulated its localization at the plasma membrane 
and amino acid transport.
Mass-spectrometry analysis showed less intracellular accumula-
tion of FICZ (a metabolic and photoxidative product of L-Trp that 
activates AhR) in Jurkat T cells cultured in L-Trp-enriched medium 
treated with the LAT1 inhibitor BCH than in cells not treated with 
BCH (Fig. 6h). Moreover, through use of the intrinsic fluores-
cence of FICZ, we observed enhanced intracellular transport of 
FICZ into T cells at 37 °C but not at 4 °C (Fig. 6i). Uptake of FICZ 
from the extracellular medium was lower in CD69-deficient T cells 
than in wild-type T cells, and these differences were abrogated 
by the LAT1 inhibitor (Fig. 6i). These results demonstrated that 
LAT1-CD98 facilitated the intracellular transport of FICZ in a 
CD69-regulated manner.
CD69-LAT1-CD98 regulate mTORC and AhR-mediated  
IL-22 expression
The LAT1-mediated transport of amino acids is required for 
activation of the metabolic-checkpoint-kinase complex mTORC 
pathway33. CD69-deficient and wild-type naive CD4+ T cells were 
polarized toward TH17 cells in vitro and mTORC signaling was 
assessed as phosphorylation of the kinases mTORC1, S6 and 4E-BP1 
(at 24–96 h). CD69 expression was dispensable for early activation 
of mTORC at 24 h after engagement of the T cell antigen receptor 
(TCR) (Supplementary Fig. 6a). However, the maintenance of 
mTORC signaling is influenced by amino acid uptake33. TH17 cells 
from CD69-deficient mice showed impaired phosphorylation of S6 
and 4E-BP1 after 96 h relative to that of their wild-type counterparts 
(Supplementary Fig. 6b).
We next addressed the role of LAT1-CD98–mediated transport of 
aromatic amino acids in AhR-dependent responses. Addition of the 
LAT1 inhibitor BCH abrogated IL-22 production in CD69-deficient 
and wild-type TH17 cells (Supplementary Fig. 6c). In contrast, addi-
tion of the AhR ligand FICZ induced the secretion of IL-22 from 
cells of each genotype (Supplementary Fig. 6c). Culture of TH17 
cells with L-Trp-enriched Iscove’s modified Dulbecco’s medium 
(IMDM)13 restored the secretion of IL-22 from CD69–deficient TH17 
to the secretion of IL-22 by wild-type cells (Supplementary Fig. 6c). 
Moreover, in the presence of LAT1 inhibitor BCH, the IL-22 expres-
sion in dermal γδ T cells stimulated in vitro with IL-23 plus IL-1β was 
reduced in wild-type cells to an amount similar to that observed in 
their CD69-deficient counterparts (Fig. 7a). Conversely, culture in 
IMDM or the addition of FICZ induced similar IL-22 expression 
in CD69-deficient dermal γδ T cells and wild-type dermal γδ T cells 
(Fig. 7a). Supplementation of RPMI medium with L-Trp also 
increased the release of IL-22 from CD69-deficient and wild-type 
CD4+ TH17 cells (Fig. 7b), although differences in IL-17 secretion 
remained (Fig. 7b). Expression of the AhR-regulated genes Ahrr and 
Il22 was higher in CD69-deficient and wild-type CD4+ naive cells 
polarized in vitro into the TH17 subset and cultured in RPMI medium 
supplemented with L-Trp or IMDM than in cells activated with anti-
CD3 and antibody to the costimulatory receptor CD28 (anti-CD28) 
(the ‘TH0-polarizing’ condition) (Fig. 7c). The addition of BCH 
decreased the expression of Ahrr and Il22 mRNA in CD69-deficient 
and wild-type cells (Fig. 7c).
Psoriatic skin displays increased expression of the tryptophan-
degrading enzymes IDO (indoleamine 2,3-dyoxigenase) and 
TDO (tryptophan 2,3-dioxygenase), which catalyze the first 
step in L-Trp catabolism by the kynurenine pathway, and 
higher expression of the enzyme L-kynureninase, which further 
degrades kynurenine34. Thus, we assessed their expression in whole 
skin after intradermal injection of IL-23 alone or IL-23 plus IL-22. 
The expression of mRNA encoding IDO or L-kynureninase was 
induced similarly in CD69-deficient skin and wild-type skin, while 
the expression of mRNA encoding TDO was not induced by IL-23 
(Supplementary Fig. 6d).
To determine whether uptake of L-Trp in vivo by dermal γδ  
T cells modulated psoriasis in CD69-deficient and wild-type 
mice, we administered L-Trp daily (intraperitoneally) simultane-
ously with intradermal injection of IL-23. The administration of 
L-Trp resulted in similar skin swelling in CD69-deficient mice 
and wild-type mice (Fig. 7d) and similar numbers of infiltrating 
CD45+CD11b+F4/80+ macrophages and CD45+CD11b+F4/80-
Ly6G+Ly6C+ neutrophils in the skin of CD69-deficient mice 
and that of wild-type mice (Fig. 7e,f). We also observed similar 
numbers of IL-22+ dermal γδ T cells in CD69-deficient mice and 
wild-type mice following the administration of L-Trp (Fig. 7g). 
Hence, these results indicated that CD69 regulated the surface 
expression of LAT1, the uptake of L-Trp, an intracellular increase in 
FICZ, and subsequent AhR activation and IL-22 secretion in dermal 
γδ T cells (Supplementary Fig. 7).
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Upregulation of CD69, LAT1 and IL-22 
in psoriasis
We next assessed whether CD69+ γδ T cells 
were present in skin samples from patients with 
moderate to severe psoriasis. CD69 expres-
sion was detected by immunofluorescence 
in Vγ9+ T cells in psoriatic skin lesions 
(Fig. 8a). The frequency of Vγ9+CD69+ T cells 
positively correlated with the psoriasis area 
severity index (Fig. 8b). Immunofluorescence 
staining showed that IL-22-secreting 
Vγ9+ T cells in the dermal layer expressed CD69 (Fig. 8c). In agree-
ment with that, expression of IL22 and TNF mRNA was higher in 
psoriatic skin than in biopsies of healthy skin (Fig. 8d).
The frequency of circulating CD69+CLA+Vγ9+ T cells was greater in 
psoriatic patients than in healthy control subjects (Fig. 8e). To assess 
the ability of these cells to produce IL-22, we stimulated circulating γδ 
T cells from psoriatic patients in vitro with a cytokine ‘cocktail’ (IL-23 
plus IL-1β plus IL-6 plus TGF-β). IL-22 expression in human Vγ9+ γδ 
T cells was decreased by the addition of inhibitors of AhR or LAT1 
(Fig. 8f,g). Quantitative RT-PCR analysis of mRNA from whole-
skin biopsies showed significantly higher expression of SLC7A5 and 
CD69 mRNA in psoriatic lesions than in unaffected regions, whereas 
SLC3A2 mRNA was not expressed differentially in these regions 
(Fig. 8h). These results demonstrated LAT1-mediated regulation of 
AhR and IL-22 in γδ T cells from patients with psoriasis.
DISCUSSION
The pathogenesis of psoriasis involves cross-talk between skin- 
resident innate immune cells and keratinocytes, which is orchestrated 
by cytokines such as IL-22 and IL-17 (refs. 1,35). Here we found 
that CD69 associated with the transporter complex LAT1-CD98 and 
enhanced the uptake of L-Trp, a metabolic precursor of AhR ligands 
that promoted IL-22 secretion13,14. The transcriptional activity of 
STAT3 induced by IL-22 in keratinocytes upregulates the expres-
sion of pro-inflammatory molecules such as keratin 17, S100A7, 
S100A8 and S100A9, as well as several CXCL chemokines6,36. 
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Figure 7 CD69 regulates AhR-induced secretion 
of IL-22 by dermal γδ T cells in vitro and  
in vivo through control of L-Trp uptake. (a) Flow 
cytometry (left) analyzing the expression of  
IL-22 and IL-17 by wild-type and CD69-
deficient sorted dermal γδ T cells stimulated 
in vitro with IL-23 plus IL-1β in RPMI medium 
alone or supplemented with BCH or FICZ, or in 
IMDM (above plots). Right, frequency of IL-22+ 
cells as at left. (b) ELISA of IL-22 and IL-17 in 
supernatants of wild-type and CD69-deficient 
CD4+ TH17 cells cultured in RPMI medium 
alone or supplemented with L-Trp or FICZ, or in 
IMDM (horizontal axes). (c) Quantitative PCR 
analysis of Ahrr and Il22 mRNA in TH0 and 
TH17 cells cultured for 48 h in vitro in various 
conditions in RPMI medium (for Ahrr) or in 
IMDM (for Il22) (horizontal axes) (presented as 
in Fig. 2a,b). (d) Ear swelling of CD69-deficient 
and wild-type mice during the administration of 
IL-23 plus L-Trp. (e) Flow cytometry of cells  
in ears from mice given systemic injection of 
L-Trp in addition to intradermal administration 
of PBS or IL-23 (numbers adjacent to outlined 
areas, as in Fig. 5c). (f) Frequency (top right) 
and total number (top left and bottom row) 
of CD45+ cells from live gated skin cells 
(top left) and of Ly6C+Ly6G+ cells in the 
CD45+CD11b+F4/80− subset (top right).  
(g) Flow cytometry (left) of dermal γδ T cells in 
CD69-deficient and wild-type mice treated with 
IL-23 and L-Trp and given injection of brefeldin 
A. Right, frequency and total number of IL-22+ 
cells, and total dermal γδ T cells. Each  
symbol (c,i) represents an individual replicate 
(well); small horizontal lines indicate the mean 
(± s.d.). *P < 0.05, **P < 0.01 and ***P < 0.001  
(two-way ANOVA and Bonferroni’s test).  
Data are representative of two experiments 
(mean + s.e.m. (a–c,f,g) or mean ± s.d. (d);  
n = 5 mice per group in d–g).
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IL-22 also induces keratinocyte proliferation through the PI3K- 
Akt-mTORC signaling pathway37. The deficient expression of 
IL-22 and activation of STAT3 in the skin of CD69-deficient mice we 
found here provides a mechanistic link that explains the attenuated 
dermal inflammation and keratinocyte proliferation observed 
after administration of IL-23.
γδ TCR–deficient mice display attenuated psoriatic plaque for-
mation in response to IL-23 (ref. 16) and imiquimod18. The role of 
CD69 as an enhancer of AhR activity and IL-22 release in γδ T cells 
in vitro and in vivo correlates well with clinical data showing increased 
CD69 expression on Vγ9+ T cells from the skin and the bloodstream 
of psoriatic patients.
CD69 associated with the amino-acid transporter complex LAT1-
CD98 on the plasma membrane of activated T cells and controlled the 
activation of mTORC. Further studies are needed to ascertain whether 
CD69 regulates other targets of mTORC, such as the autophagy route38 
and HIF-1α through AhR39. Different regions of CD98 control the 
uptake of amino acids and β1-integrin-mediated cell proliferation40. 
However, published studies have shown no difference in the prolif-
eration rate of CD69-deficient T lymphocytes and that of wild-type 
T lymphocytes41, which suggests that the association of CD69 with 
the LAT1-CD98 complex in activated immune cells modulates the 
uptake of amino acids specifically.
Cytoplasmic L-Trp acts as a chromophore that is converted 
by exposure to light into active AhR ligands, including FICZ13. 
The characterization of a light-independent metabolic route for the 
generation of FICZ from the intracellular pool of L-Trp14 suggests 
that regulation of entry of the precursor might determine the amount 
of cellular FICZ and AhR activation. Our results demonstrated that 
LAT1-CD98 regulated the intracellular accumulation of FICZ.
Inhibition of AhR protects against inflammation induced by IL-23 
without substantial alteration of the keratinocyte layers. However, 
depletion of AhR in keratinocytes disrupts epidermal homeosta-
sis, which enhances psoriasis in response to imiquimod, although 
lower expression of IL-22 in the skin of fully AhR-deficient mice 
than in the skin of wild-type mice has been detected42. Differences 
between the IL-23-induced psoriasis model and imiquimod-induced 
psoriasis model exist2. Toll-like-receptor-7-independent epidermal 
hyperproliferative responses induced by keratinocyte damage are 
involved in the induction of psoriasis in the imiquimod model18,43. 
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AhR controls the terminal differentiation of epidermal cells and the 
expression of genes encoding proteins linked to skin barrier func-
tion, such as filaggrin44,45. Hence, AhR in keratinocytes is required 
for skin homeostasis, but its activation in inflammatory cells 
mediates inflammation.
CD69 did not affect the secretion of IL-17 by innate γδ T cells, 
in contrast to its effect on CD4+ TH17 T cells27. The greater 
secretion of IL-17 by CD69-deficient CD4+ TH17 cells than by wild-
type CD4+ TH17 cells is due to increased phosphorylation of STAT3 
and increased RORγt expression27. This was not observed in dermal 
γδ T cells, owing to the fact that the transcription factors that control 
the TH17 differentiation CD4+ T cells, such as STAT3, are not required 
for the development of IL-17+ (RORγt+) γδ T cells that originated in 
fetal thymus46,47.
Prevention of the uptake of L-Trp via LAT1 abrogated the AhR-
dependent secretion of IL-22 from human peripheral γδ T cells 
from psoriatic patients, which would suggest a possible role for 
the uptake of dietary L-Trp in psoriasis. Notably, in vivo adminis-
tration of L-Trp increased the severity of inflammatory responses 
elicited by IL-23 independently of CD69 expression. Overall, these 
data indicate that L-Trp catabolism has an important role in the 
pathophysiology of psoriasis, not only due to the regulation of 
kynurenine but also by its effect on other metabolites that might 
contribute to skin inflammation. In conclusion, our study has 
established a biological role for CD69 in the control of amino acid 
uptake and the regulation of AhR activation and IL-22 expression 
in γδ and TH17 cells and indicates that CD69 contributes to the 
development of psoriasis.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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ONLINE METHODS
Mice. Wild-type, CD69-deficient, OT-II and OT-II CD69-deficient mice 
(C57BL/6 background) were previously described27. Homozygous AhR-deficient 
and wild-type littermate mice (C57BL/6 background) were obtained from 
P. M. Fernández-Salguero’s group (University of Extremadura, Badajoz, Spain). 
IL-23R-GFP.KI reporter mice (C57BL/6 background) were previously 
described29. For experiments with chimeric mice, wild-type B6SJL CD45.1 
mice (Jackson) were used as donor of bone marrow progenitor cells. Sex- and 
age-matched mice (8–12 weeks) were used for in vitro and in vivo experiments. 
All animals were kept in pathogen-free conditions at the animal facility of 
Centro Nacional de Investigaciones Cardiovasculares. Experimental proce-
dures were approved by the local Committee for Research Ethics and are in 
accordance to Spanish and European guidelines.
Human subjects. Patients with moderate to severe psoriasis that were recruited 
in the study had a psoriasis area and severity index of ≥8.0 and washout periods 
of 14 d for topical corticosteroids; 28 d for conventional systemic therapy, 
including corticosteroids, methotrexate, cyclosporine, acitretin and photo-
therapy; and 84 d for biological agents. Skin punch biopsies (5 mm) were 
obtained from lesional-plaque-type psoriasis and non-lesional area. Healthy 
skin biopsies were also collected from nine surgical patients without cutaneous 
disease. Half of each skin biopsy was immediately frozen and processed for 
RNA extraction, while remaining sample was embedded in OCT for immun-
ofluorescence staining. Blood samples were also collected from ten psoriatic 
patients and five healthy volunteers, for flow cytometry analysis. The study was 
approved by the Hospital La Princesa ethics committee. All the participants 
gave their written informed consent.
Establishment of psoriasis-like model. CD69-deficient and wild-type 
mice were intradermally injected in the ears with 20 µl of vehicle (PBS) or 
500 ng of recombinant mouse IL-23 (eBioscience) using a 33-gauge needle. 
Injections were repeated on alternate days for a total of seven to ten doses. 
Ear thickness was measured on days without injections with an AccuteRemote 
0.5-mm-thickness gauge dial micrometer (TECLOCK). All measurements 
were performed blinded. Mice were sacrificed and skin samples were collected 
for staining with H&E and immunohistochemistry. If required, half of ears 
were rapidly frozen in liquid nitrogen for subsequent isolation of total RNA or 
detection of tissue cytokines. Recombinant mouse IL-22 (eBioscience) (500 ng 
in 20 µl of PBS) was intradermally injected alone or in combination with 
IL-23, where indicated. In addition, in some experiments mice received an 
intraperitoneal injection of CH-223191 (10 mg per kg body weight) or vehicle 
(DMSO) together with the IL-23 intradermal administration. When indicated, 
250 µg/mice of secretion inhibitor brefeldin A dissolved in ethanol (SIGMA) 
was intraperitoneally administrated 5 h before sacrifice. For experiments 
with chimeric mice, wild-type and CD69-deficient mice (CD45.2 haplotype) 
were lethally irradiated (13 Gy divided in two sessions) and transplanted with 
5 × 106 per mice of whole bone marrow cells obtained from B6 SJL (CD45.1 
haplotype) wild-type mice. Reconstitution was allowed for 2 months before 
starting the protocol of IL-23 injections. In some experiments, mice received 
a daily intraperitoneal administration of L-Trp (50 mg per kg body weight) 
or its vehicle (DMSO) along the IL-23 protocol. L-Trp dose was chosen by 
published assays that proved it to be safe for mice and that it induced Cyp1a1 
transcriptional expression in the liver48. As described, FICZ can be found in 
light-oxidized preparation of L-Trp13; for this reason, fresh solutions were 
daily prepared and kept protected from light.
Skin histology and immunohistochemistry staining. Skin samples were 
fixed in formaldehyde and embedded in paraffin using routine methods. Slices 
(4–5 µm) were stained with H&E and analyzed by two evaluators ‘blinded’ to 
sample identity. Consecutive images were acquired at several magnifications 
with an optical microscope (DM2500; Leica) equipped with a CCD camera 
(DFC420; Leica), with Leica Application Suite software (version 4.3.0). Dermal 
and epidermal thickness were measured every 100 µm, from the ear surface 
to a depth of about 5 mm, using ImageJ software. For immunohistochemical 
staining, skin sections were deparaffinized, boiled in antigen retrieval solu-
tion (10 mM sodium citrate, 0,05% Tween 20, pH6), and incubated with the 
following primary monoclonal antibodies (Supplementary Table 2): rabbit 
anti-mouse Ki67 (Master Diagnostica),rat anti-mouse F4/80 and Ly6G 
(Abcam), rabbit anti-mouse STAT3, phospho-STAT3 (Tyr 705) and phospho-
STAT3 (Ser727) (Cell Signaling); followed by specific secondary antibodies 
from Dako (Supplementary Table 2): envision flex system for Ki67, Rabbit 
anti rat HRP for F480 and Ly6G; and Goat anti Rabbit HRP for STAT3-related 
antibodies. Slides were developed with DAB substrate (Dako K3468) and then 
counterstained with Mayers hematoxylin. Epidermal Ki67+ frequency was 
determined as the number of Ki67+ nuclei observed each 100 µm, also from 
the ear surface to a depth of about 5 mm, n = 5 mice per group. STAT3 stain-
ing in keratinocytes was quantified in at least five fields (×40 magnification) 
from each IL-23-treated mouse (five mice per group). Fields were quantified 
for mean gray value in the epidermal layer with ImageJ software. Percentage 
of epidermal area stained for STAT3 was also assessed. Nuclear staining of each 
phosphorylation site for STAT3 in keratinocytes was also counted as indicative 
of its transcriptional activity.
RNA extraction and real-time quantitative PCR. RNA from mouse and 
human samples was isolated using a QIAGEN RNeasy Kit (Qiagen). Residual 
DNA contamination was removed with the Turbo DNA-free Kit (Ambion). 
Total RNA (200ng) was reverse transcribed to cDNA with a Reverse 
Trancription Kit (Applied Biosystem). Quantitative PCR was then performed in 
an AB7900_384 (Applied Biosystem) using SYBR Green (Applied Biosystems) 
as reporter. Gene-specific primers used are listed in Supplementary Table 3. 
Expression of each gene of interest was normalized to at least two housekeeping 
genes (Actb or Gapdh). Data (calculated by the 2−∆∆Ct method or the standard- 
curve method (for human samples)) are presented as results for CD69- 
deficient mice relative to those of wild-type mice samples, or treated samples 
relative to control samples, or psoriatic patients relative to the mean value 
obtained for healthy donors.
Flow cytometry and sorting of skin  T cells. Animals were euthanized 
and ears were collected and digested with Liberase TM (Roche) (0.25 mg/ml 
in free-serum medium RPMI), for 60 min at 37 °C. Enzyme was inhibited 
by adding 50 ml of PBS supplemented with 0.5% of BSA and 0.05mM of 
EDTA (PBS-BSA-EDTA) and tissue was mechanically disrupted and fil-
tered to obtain a skin cell suspension. Epidermis and dermis separation was 
conducted after incubation of ears with trypsin-EDTA solution 1X (Sigma), 
45 min at 37 °C. The two layers were separated with forceps, and the epider-
mis was directly homogenized while the dermis was incubated with Liberase 
TM by 30 min. Incubation of skin cell suspensions with anti-FcRII/III (clone 
2.4G2; Supplementary Table 2) was always conducted before staining. 
For flow cytometry analysis of IL-23 -induced inflammation the following 
anti-mouse antibodies were used (Supplementary Table 2): CD45, F480 and 
γδTCR obtained from eBioscience, CD11c, CD11b, GR1, Ly6G, Ly6C and 
CD3 from BD Bioscience. Absolute count of cells in the skin was conducted 
using BD Trucount Tubes (BD). For sorting skin γδ T cells, cell suspensions 
obtained from ears were stained with DAPI, anti-CD3 (BD Biosciences) and 
anti-γδTCR (eBioscience). Directed labeled antibodies against mouse IL-23R 
(R&D) and RORγt (EBioscience) (Supplementary Table 2) were also used in 
skin suspensions. To analyze the expression of CD69 in human circulating 
γδ T cells, freshly obtained peripheral blood mononuclear cells (PBMCs) 
(1 × 106) from psoriatic patients and healthy subjects were stained with the 
following mouse anti-human mAbs: anti-CLA (BD Bioscience), anti-TCR Vγ9 
(BioLegend) and anti-CD8, anti-CD69, anti-CD4 and anti-CD3 (BD Bioscience) 
(Supplementary Table 2). Cell samples were acquired in a FACSCanto Flow 
Cytometer (BD), and analyzed with FlowJo software (Tree Star).
Cell cultures for TH17 and  T cells. Cells were routinely cultured in RPMI 
1640 medium (Sigma-Aldrich) supplemented with 5% FCS, 2 mM L-glutamine, 
100 U/ml penicillin 100 µg/ml streptomycin, and 50 nM of β-mercaptoetha-
nol. In some cases, IMDM (Sigma-Aldrich) was used, supplemented as for 
RPMI. Also, in some cases, RPMI medium was supplemented with 11 mg/liter 
L-Trp (Invitrogen) to adjust it to the concentrations found in IMDM. Naive 
CD4+ T cells were obtained by negative selection using an auto-MACSTM 
Pro Separator (Miltenyi Biotec) and subjected to in vitro TH17 differentiation 
(1 × 106 cells/ml) with the following cytokine cocktail: blocking anti-IFN-γ 
(5 µg/ml) and anti-IL-4 (5 µg/ml) mAbs, IL-6 (50 ng/ml), IL-23 (10 ng/ml), 
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IL-1β (10 ng/ml) and TGF-β1 (5 ng/ml) for 2-4 d (Supplementary Table 2). 
Naive CD4+ T cells obtained from OT-II and OT-II CD69-deficient were cul-
tured in the presence of irradiated antigen-presenting cells (T cell–depleted 
splenocytes) and OVA peptide 323-339 (OVA; 10 µg/ml). Those experiments 
with OT-II mice were specifically used for flow cytometry analysis and ELISA. 
When TH17 cells were required for mRNA analysis expression and western 
blot, naive CD4 T cells were isolated from wild-type and CD69-deficient mice 
and were activated with plate-bound anti-CD3 (5 µg/ml) plus anti-CD28 
(2 µg/ml) (Supplementary Table 2), using the same cytokine cocktail described 
above for OT-II mice. The AhR ligand 6-formylindolo (3,2-b) carbazole (FICZ) 
(Enzo Life Science) (350 nM), the AhR specific inhibitor CH-223191 (Sigma) 
(3 µM) and the LAT1/CD98 inhibitor 2-amino-2-norbornanecarboxylic 
acid (BCH) (Sigma) (50 mM) were added at the start of some cultures. Before 
intracellular cytokine staining, cells were restimulated for 4 h with 50 ng/ml 
phorbol dibutyrate (PMA) and 500 ng/ml ionomycin in the presence of 
brefeldin A (1 µg/ml) (BD Biosciences).
Sorted dermal and epidermal γδ T cells (1 × 104 cells/ml) from CD69- 
deficient and wild-type mice were incubated for 24 h on plate-bound anti-CD3 
(5 µg/ml), soluble anti-CD28 (2 µg/ml) (Supplementary Table 2) and IL-23 
plus IL-1β (10 ng/ml each one). For γδ T cells, no re-stimulation was required, 
and only brefeldin A (1 µg/ml) was added for last 4 h of culture.
Both γδ and in vitro–skewed TH17 cells were fixed and permeabilized 
with Fix & Perm solution (BD Biosciences) and stained with anti-IL-22 
(eBioscience) and anti-CD69, anti-CD25 and anti-IL-17 (BD Pharmingen) 
(Supplementary Table 2). IL-22 and IL-17 production in the cultures 
supernatants was quantified with the IL-22/IL-17 Ready-Set-Go ELISA kits 
(eBioscience). In some experiments, AhR nuclear expression was analyzed by 
flow cytometry using the Foxp3/Transcription Factor Staining Buffer Set (eBio-
science) and rabbit anti-mouse AhR (Enzo Life Science) followed by Alexa-647 
conjugated Goat anti rabbit. CD98 expression was detected with an Alexa 647-
conjugated rat anti-mouse antibody (BioLegend) while for LAT1 expression 
a rabbit anti mouse antibody (Santa Cruz Biotech) followed by an Alexa-647 
conjugated goat anti rabbit was used (all antibodies, Supplementary Table 2). 
Directed labeled 647-mouse anti STAT5 (pY694) and PE-mouse anti-STAT3 
(pY705) (BD Bioscience) was used with Fix&Perm kit (life technologies) modi-
fied for methanol permeabilization (antibodies, Supplementary Table 2). 
Mouse isotype-matched control antibodies obtained from BD were used as 
required (Supplementary Table 2).
IL-22 production in human γδ T cells. PBMCs from psoriatic patients (n = 3) 
were adjusted at 1 × 106 cells/ml in culture medium EX-VIVO 15 (Lonza, 
Belgium) supplemented with L-Trp (15 mg/L) and expanded with zoledronic 
acid (5 µM) as previously reported49. At day 0 (d0), PBMCs (1 × 106) were 
stimulated in a 24-well plate in the presence or absence of IL-23 (50 ng/ml), 
IL-1b (50 ng/ml), IL-6 (100 ng/ml) and TGF-β (1 ng/ml). Where indicated, 
LAT-1 inhibitor BCH (50 mM) or CH-223191 (3 µM) were also added to the 
cultures. At d2, IL-2 (100 U/ml) was added and cells were analyzed for IL-22 
production at d4 of culture. First, PBMCs were incubated with human PercP-
anti-Vδ2 (Biolegend) during 30 min at 4 °C, then cells were fixed (PFA 2%  
10 min TA) and incubated in saponin (0.3% 10 min TA) before incubation with 
APC anti-human IL-22 (eBioscience). Cells were analyzed in a FACSCanto 
flow cytometer. Dead cell were excluded using fixable viability staining 510 
(BD Biosciences). IL-22 secretion was quantified in the supernatant using 
Human IL-22 Ready-Set-Go ELISA kit (eBioscience).
Immunofluorescence staining and in situ proximity ligation assay (PLA). 
Frozen sections of human skin biopsies were fixed in cold acetone and blocked 
in PBS containing 5% of donkey serum and 100 mM/ml human γ-globulin 
(Sigma-Aldrich, St Louis, MO, USA). Sections were incubated with the following 
anti-human primary Abs (Supplementary Table 2): mouse monoclonal 
anti-CD69 (TP1.55), rabbit polyclonal anti-IL-22 (Bios, Mass USA) and 
goat anti-TCR-γ9 (Santa Cruz Biotechnology) for 1 h. The secondary Abs 
used were: AlexaFluor 488-conjugated donkey anti-rabbit, AlexaFluor 
568-conjugated donkey anti-goat and AlexaFluor 647-conjugated donkey 
anti-mouse. Nuclei were counterstained with DAPI. Immunofluorescence 
pictures were taken using a Zeiss LSM Confocal microscope and analyzed 
with LSM image browser software.
J77 Jurkat cells or CD69-stable overexpressing J77 Jurkat cells were fixed 
in ice-cold methanol at -20 °C for 10 min and blocked with 1% BSA and 10% 
donkey serum in PBS for 2 h at room temperature. Then cells were incubated 
with mouse anti human CD69 mAb (TP1/55), Rabbit anti human LAT1 (Cell 
Signaling) or rabbit anti human CD98 (Santa Cruz) for 1 h at 37 °C (anti-
bodies, Supplementary Table 2). Secondary antibodies from donkey species 
(Supplementary Table 2) or PLA detection kit reagents (SIGMA) were added 
for visualization of co-localization or proximity assay of these molecules in the 
membrane. For each duolink pair confocal microphotographs quantification 
of red dots per cells was conducted using Imaris Software.
Amino acid uptake assay. Naive CD4+ T cells obtained from CD69- 
deficient and wild-type mice were cultured (1 × 106 cells/ml) in RPMI medium 
for 24 h, in the presence of anti-CD3 (5 µg/ml) and anti-CD28 (2 µg/ml) 
(Supplementary Table 2). Similarly, spleen/lymph-nodes γδ T cells were 
sorted as CD27+ and CD27− and stimulated for 24 h with IL-23 (10 ng/ml) 
and IL-1β (10 ng/ml) in RPMI medium (1 × 105 cells/ml). 3H-radiolabeled 
L-Trp, L-Phe and L-Leu (PerkinElmer) were added (0.5 µCi/ml) in HBSS 
(GIBCO) with a final extracellular L-Leu concentration of 5 µM. Amino acid 
uptake was measured at 5, 10, 15 and 20 min at 37 °C. Uptake was stopped 
by the addition of 20 mM cold L-Leu to quench System L. For the purpose 
of kinetic analysis, uptake at 5-min was defined as the initial uptake rate and 
data were analyzed only at the time interval where incorporation was linear. 
At the end of the assay period, cells were harvested onto glass-fiber filters using 
a Tomtec 96-well parallel harvester and washed vigorously for 30 s with PBS 
solution. β-radioactivity was counted in a Beckman LS 6500 Multi-Purpose 
Scintillation Counter (Beckman Coulter). Nonspecific binding of radioactivity 
to the filters (based on wells containing radiolabeled substrate without cells) 
was typically <10% of the total signal and was subtracted from each data point. 
Five replicates were assessed for each data point.
CD69 internalization assay. Plasmid for LAT1-mCherry expression was pro-
vided by D. Rotin(University of Toronto, USA). CD69-eGFP plasmid has been 
generated in our lab. HEK 293 cells maintained in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 4 mM L-glutamine and 10% FBS were 
transfected with plasmids expressing LAT1-mCherry and CD69-eGFP using 
Lipofectamine Reagent (ThermoFisher). Mouse anti human CD69 monoclonal 
antibody (TP1/55; Supplementary Table 2) was directly labeled with Zenon 
Alexa-647 labeling Kit (Life Technologies) and incubated for 30 min with 
transfected cells at 37 °C. Cells were washed with PBS and fixed with 1% para-
formaldehyde. Immunofluorescence pictures were taken using a Zeiss LSM 
Confocal microscope and analyzed with LSM image browser software.
Proteomic study design and in-gel protein digestion. For the proteomics 
assay, naive CD4+ T cells obtained from CD69-deficient and wild-type mice 
were activated with PMA (50 ng/ml) plus ionomycin (750 ng/ml) for 18 h. 
After assessing CD69 expression by flow cytometry in wild-type cells, about 
5 × 106 whole cells were incubated with hamster anti-mouse CD69 mAb 
(clone: H1. 2F3, Abcam) and isotype-matched control mAb (hamster anti-
mouse CD31, clone 2H8, AbD Serotec) (Supplementary Table 2), already 
immobilized in Dynabeads Protein G (Life Technologies), in serum-free RPMI 
medium, for 1 h at 4 °C. Thereafter, cells were lysed in ice-cold 1% CHAPS 
lysis buffer containing 1 mM CaCl2 and protease inhibitor cocktail (Complete, 
Roche) for 1 h at 4 °C. Magnetic separation of beads allows collecting proteins 
associated to CD69 and consecutive washes with ice-cold lysis buffer for 4 h 
for reduction of nonspecific interactions.
Proteins were digested in the gel using the following protocol. 15 µl of beads 
were resuspended in 30 µl of sample buffer and loaded into SDS-PAGE gel. 
The run was stopped as soon as the front entered 2 mm into the resolving 
gel. The protein band was excised and digested with 20 ng/µl trypsin at 10:1 
protein: trypsin (w/w) ratio. The resulting peptides were desalted onto C18 
OMIX tips (Agilent Technologies) before LC-MS/MS analysis.
Mass spectrometry. Analyses were performed using a nano-HPLC Easy nLC 
1000 coupled to a linear ion trap-Orbitrap Elite hybrid mass spectrometer 
(Thermo Scientific). Peptides samples were loaded onto a home-made C18 
reversed-phase (RP) nano-column (100 µm I.D., 45 cm) and separated in 
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a continuous gradient consisting of 8–35% B for 20 min and 35–90% B for 
2 min (B = 90% acetonitrile, 0.1% formic acid) at 300 nL/min. A Picotip 
emitter nanospray needle (New Objective) was used for peptide ionization. 
An enhanced FT-resolution spectrum in the mass range of m/z 390–1,600 
followed by data-dependent MS/MS spectra of the 20 most intense parent 
ions were acquired along the chromatographic run. Normalized CID collision 
energy was set to 35% and a 2-Da of parent ion mass isolation width.
Peptide identification and statistics. Peptide identification from MS/MS 
spectra was done using Sequest running under Proteome Discoverer 1.4 
(Thermo Scientific), allowing two missed cleavages, and using 800 ppm and 
0.02 ppm precursor and fragment mass tolerances, respectively. Met oxida-
tion and Cys carbamydomethylation were selected as dynamic modifications. 
The MS/MS raw files were searched against the Human Uniprot database 
(March 2013) and results were analyzed using the probability ratio method. 
Post-search result filtering by mass error was done as described. For each 
scan, if the mass deviation fell outside the ± 5 ppm window, the corresponding 
XCorr was rescored to 0, whereas the pRatio was reassigned a value of 2. 
The false-discovery rate (1% FDR) was estimated from the search results 
against a decoy database.
Co-immunoprecipitation and immunoblot analysis. A human-Jurkat-
cell-derived T cell line (J77) activated with PMA (50 ng/ml) and Ionomycin 
(500 ng/ml) for 18 h was used for co-immunoprecipitation experiments. 
The following mouse anti human mAbs generated in the laboratory were 
used (Supplementary Table 2): anti-CD69 (TP1/8), anti-CD98 (FG1/8), and 
anti-CD13 (Tea1/8) as negative control, using the same protocol and lysis 
buffer described for the proteomic assay. Co-immunoprecipitated proteins 
were separated by SDS-PAGE and immunoblotted with the following rabbit 
polyclonal anti human Abs (Supplementary Table 2): anti-CD69 (Abcam) 
and anti-CD98 (Santa Cruz Biotechnology). Anti-human LAT1 antiserum 
was provided by P. Taylor (Dundee, UK).
Immunoblot analysis of mTORC signaling was conducted with in vitro 
cultured TH17 cells from CD69-deficient and wild-type mice. After the lysis 
with RIPA buffer supplemented with protease and phosphatase inhibitor 
cocktails (Roche), the lysates were separated by SDS-PAGE and immunob-
lotted with the following rabbit Abs (Supplementary Table 2): antibody to 
mTORC1 phosphorylated at Ser2448, antibody to total mTORC1, antibody 
to S6 phosphorylated at Ser235 and Ser236, antibody to total S6, anti-
body to 4E-BP1 phosphorylated at Thr37 and Thr46, and antibody to total 
4E-BP1 (Cell Signaling). Control of protein quantity was assessed with rabbit 
anti mouse β actin antibody (Santa Cruz; Supplementary Table 2). All primary 
antibodies were detected with HRP conjugated goat anti-rabbit (Pierce; 
Supplementary Table 2). Protein bands were analyzed using the LAS-3000 
CCD system and Image Gauge 3.4 (Fuji Photo Film Co., Tokyo, Japan).
Treatment of samples for L-Trp and FICZ quantification. Three biological 
replicates of 50 × 106 Jurkat T cells were incubated in RPMI 1640 medium 
w/o amino acids (US Biological Life Sciences) supplemented with 5% FCS, 
2 mM L-glutamine, 100 U/ml penicillin 100 µg/ml streptomycin, non-essential 
amino acids (Hyclone) and L-Trp (50 mg/ml), and were treated or not with 
BCH (50 mM) for 24 h. The cell pellets were thawed on ice and subjected to 
three freeze–thaw cycles for complete cell disruption, protein precipitation and 
metabolite extraction. Samples were suspended in 100 µL mixture composed 
by MeOH:MTBE (1:1 v/v), vortex-mixed, placed in liquid nitrogen for 10 s 
and thaw in an ice bath (for 10 s) three times. Samples were then sonicated for 
6 min and vortex-mixed for 1 min. The entire protocol was repeated three 
times. Subsequently samples were centrifuge at 18,000g for 20 min at 10 °C and 
the supernatants were collected (extract A) and stored at –20 °C. The residual 
cell pellets were extracted again with 100 µL of MeOH:MTBE (1:1 v/v), 
following the same procedure. Supernatants were collected after centrifugation 
(extract B) and the two extracts were combined.
Cell culture medium samples were thaw on ice and vortex-mixed few 
seconds. Then, 300 µL of MeOH:MTBE (1:1 v/v), were added to 100 µL 
of sample, vortex-mixed and incubated on ice for 20 min. Supernatants 
were collected by centrifugation at 18000g for 20 min at 4 °C. Finally, 
cells and media extracts were diluted 1:5 (for analysis of FICZ) and 1:1,000 
(for the analysis of Trp) with acetonitrile:water (10:90 v/v) containing 0.1% 
of formic acid. Samples were vortex-mixed, centrifuged at 18,000g for 
10 min at 10 °C to allow particle precipitation and transfer in a HPLC glass 
vial with 300 µL insert.
Liquid chromatography–mass spectrometry determination of FICZ and 
L-Trp. LC-MS grade water, formic acid, acetonitrile, and HPLC grade methyl 
tert-butyl ether (MTBE) and Tryptophan (Trp) were purchased from Sigma-
Aldrich. Methanol (MeOH), was purchased form Fischer Chemical and 
formylindolo (3,2-b)carbazole (FICZ) from Enzo Life Science.
High-resolution parallel reaction monitoring (PRM) of FICZ and Trp were 
carried out on an Easy-nLC 1000 nano HPLC (Thermo Scientific, Waltham, 
Massachusetts, USA) coupled to a trihybrid quadrupole-linear ion trap-orbitrap 
mass spectrometer (Orbitrap Fusion Tribrid, Thermo Scientific) operating 
in positive polarity mode. A volume of 10 µL of diluted extracts were loaded 
onto an Easy-Spray (Thermo Scientific) C-18 reversed-phase nano-column 
(75 µm I.D., 50 cm) and metabolites were separated with mobile phase 
composed by A) water with 0.1% of formic acid and B) acetonitrile:water 
(90:10 v/v) with 0.1% of formic acid, at 200 nL/min and 50 °C. For analysis of 
FICZ, the gradient started at 35% B to 100% B in 10 min, holding 100% B for 
12 min and returned to starting condition in 2 min, keeping the re-equilibration 
time for 30 min. For analysis of Trp, the gradient started at 35% B to 100%  
B in 15 min, holding 100% B for 9 min and returned to starting condition in 
2 min, keeping the re-equilibration time for 30 min.
Metabolites were monitored by targeting the corresponding [M+H]+  
ions to acquire complete MS2 spectra. Precursor ion of the FICZ and Trp 
(corresponding to m/z 285.10224 and 205.09715, respectively) were isolated by 
the quadrupole analyzer and targeted for higher-energy collisional dissociation 
(HCD). HCD collision energy was optimized for each compound and frag-
ments were detected with 15000 resolution in orbitrap. Targeted parameters 
included a 3 Thompson isolation window around the m/z values of interest, 
2.7 kV spray voltage and 310 °C as capillary temperature. Data analysis was 
performed with Xcalibur 2.2 (Thermo Scientific).
Statistical analysis. After analysis of data distribution with Kolmogorov 
Smirnov test, the statistical significance was assessed by one-tailed unpaired 
Student’s t-test, one-way ANOVA with Newman-Keuls multiple-comparisons 
t-test or two-way ANOVA with Bonferroni’s multiple-comparisons post-test, 
as required. For kinetic assay of amino acid uptake, a linear regression with 
slopes comparison was conducted. All analysis was performed with GrapPhad 
software. Differences were considered significant at P < 0.05.
48. Mukai, M. & Tischkau, S.A. Effects of tryptophan photoproducts in the circadian 
timing system: searching for a physiological role for aryl hydrocarbon receptor. 
Toxicol. Sci. 95, 172–181 (2007).
49. Kondo, M. et al. Expansion of human peripheral blood gammadelta T cells using 
zoledronate. JoVE 55, 3152 (2011).
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signalling by the intracellular bacteria Listeria
monocytogenes
Olga Moreno-Gonzalo1,2, Marta Ramı´rez-Huesca1,2, Noelia Blas-Rus1,2, Danay Cibria´n1,2,3,
Marı´a Laura Saiz1,2, Inmaculada Jorge4, Emilio Camafeita4, Jesu´s Va´zquez3,4,
Francisco Sa´nchez-Madrid1,2,3*
1 Cell-cell Communication Laboratory, Vascular Pathophysiology Area, Centro Nacional Investigaciones
Cardiovasculares (CNIC), Madrid, Spain, 2 Servicio de Inmunologı´a, Hospital Universitario de la Princesa,
Instituto Investigacio´n Sanitaria Princesa (IIS-IP)-Universidad Auto´noma de Madrid (UAM), Madrid, Spain,
3 CIBER CARDIOVASCULAR, Madrid, Spain, 4 Proteomics Unit, Vascular Pathophysiology Area, Centro
Nacional Investigaciones Cardiovasculares (CNIC), Madrid, Spain
* fsmadrid@salud.madrid.org
Abstract
Recent evidence on HDAC6 function underlines its role as a key protein in the innate
immune response to viral infection. However, whether HDAC6 regulates innate immunity
during bacterial infection remains unexplored. To assess the role of HDAC6 in the regulation
of defence mechanisms against intracellular bacteria, we used the Listeria monocytogenes
(Lm) infection model. Our data show that Hdac6-/- bone marrow-derived dendritic cells
(BMDCs) have a higher bacterial load than Hdac6+/+ cells, correlating with weaker induction
of IFN-related genes, pro-inflammatory cytokines and nitrite production after bacterial infec-
tion. Hdac6-/- BMDCs have a weakened phosphorylation of MAPK signalling in response to
Lm infection, suggesting altered Toll-like receptor signalling (TLR). Compared with Hdac6+/+
counterparts, Hdac6-/- GM-CSF-derived and FLT3L-derived dendritic cells show weaker
pro-inflammatory cytokine secretion in response to various TLR agonists. Moreover,
HDAC6 associates with the TLR-adaptor molecule Myeloid differentiation primary response
gene 88 (MyD88), and the absence of HDAC6 seems to diminish the NF-κB induction after
TLR stimuli. Hdac6-/- mice display low serum levels of inflammatory cytokine IL-6 and corre-
spondingly an increased survival to a systemic infection with Lm. The impaired bacterial
clearance in the absence of HDAC6 appears to be caused by a defect in autophagy. Hence,
Hdac6-/- BMDCs accumulate higher levels of the autophagy marker p62 and show defective
phagosome-lysosome fusion. These data underline the important function of HDAC6 in den-
dritic cells not only in bacterial autophagy, but also in the proper activation of TLR signalling.
These results thus demonstrate an important regulatory role for HDAC6 in the innate
immune response to intracellular bacterial infection.
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Author summary
Listeria monocytogenes (Lm) is a food-borne intracellular bacterium that causes listeriosis
to 1.600 people each year, being responsible of approximately 260 deaths. This pathogen
mostly affects immunocompromised individuals and pregnant women. It is particularly
dangerous for the later due to its ability to pass across the placenta and the blood-brain
barrier. Lm is extensively used as a Gram positive infection model in the laboratory to
study innate and adaptive immune responses. HDAC6 is an important regulatory enzyme
of the tubulin and actin cytoskeletons. Its inhibition or deficiency quells the immune
response against different virus infections. Previous work has shown its involvement in
the regulation of viral RNA-sensing activity and in interferon signalling. In this study, we
report that HDAC6 is an essential component of the innate immune response to fight
against intracellular bacterial infections. Genetic ablation of HDAC6 impairs activation of
the pertinent Toll-like receptor pathway to induce the pro-inflammatory transcriptional
program of the cell. Moreover, this enzyme controls cytoskeletal proteins that mediate the
fusion of phagosome-contained bacteria with the lysosome during pathogen degradation.
Introduction
Histone deacetylase 6 (HDAC6) is a cytoplasmic deacetylase involved in the regulation of
several biological processes, including migration, transport, angiogenesis, and tumour pro-
gression [1–5]. This enzyme is able to deacetylate α-tubulin and cortactin, regulating not
only the microtubule cytoskeleton, but also actin [6, 7]. Both cytoskeletal interactions under-
line a crucial role of HDAC6 in many cellular functions such as phagosome-lysosome fusion,
cargo transport through microtubules, and cell motility [8–10]. The role of HDAC6 has also
been described in two of the main cellular degradation mechanisms: autophagy, through
interaction with the autophagy marker p62; and the proteasome, mediated by deacetylation
of HSP90 and its intersection with the ubiquitin-proteasome system (UPS) [11–15]. In addi-
tion, HDAC6 is involved in the transport of damaged mitochondria (mitophagy) and mis-
folded proteins (aggrephagy) to lysosomes and the proteasome for degradation [16–18]. The
absence of HDAC6 impairs the deacetylation of mitofusin 1, preventing the mitochondrial
fusion induced by glucose deprivation and causing excessive ROS production that provokes
oxidative damage [19].
HDAC6 regulates the replication of human immunodeficiency virus (HIV) by deacetylating
Tat and thus inhibiting viral transactivation [20, 21]. HDAC6 also participates in Sendai virus
infection through the deacetylation of β-catenin, which acts as a co-activator of IRF3-mediated
transcription [22]. During infection with Influenza Virus A (IVA), HDAC6 appears to play a
dual role. IVA capsids mimic misfolded-protein aggregates to take advantage of the host cell
aggresome pathway, thereby achieving disassembly and successful viral uncoating [23]. On the
other hand, HDAC6-mediated microtubule deacetylation impairs the IVA cycle, preventing
trafficking of viral components to the viral assembly site in the host plasma membrane and the
spread of infection to surrounding cells [24]. The role of HDAC6 in the adaptive CD4 + T-cell
response has been studied in several autoimmune and inflammatory situations such as colitis
and cardiac allograft rejection; however, little is known about its role in innate immunity and
bacterial diseases [25, 26].
Listeria monocytogenes (Lm) is a Gram-positive bacteria that causes severe infection in
immunocompromised individuals and is able to cross the blood-brain barrier and the placenta
[27]. Lm is widely used as a model of innate and adaptive immune responses to intracellular
Role of HDAC6 in bacterial infection
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bacterial infection [27–29]. From the first hours of infection, professional phagocytic cells trap
bacteria in the blood and target organs, exerting a degree of control on bacterial growth [28].
After internalization by phagocytic cells, Lm is eliminated by fusion of the phagosome with
lysosomes; however, some bacteria escape the phagosome into the cytoplasm through the
action of listeriolysin O (LLO). In the cytoplasm, Lm replicates and is able to infect neighbour-
ing cells [30–32]. Interestingly, phagosome-contained bacteria are also eliminated by the
action of reactive oxygen species (ROS) and nitric oxide (NO), produced by NADPH oxidase
2 (NOX2) and inducible NO synthase (iNOS), respectively [33]. Moreover, Lm bacteria con-
tain an ARP2/3-mimicking protein that enables their propulsion to neighbouring cells through
the directional assembly of actin filaments (actin rockets) [34]. Lm can spread from cell to cell
without exiting the intracellular compartment by a process called paracytophagy, which evades
immune detection. However, the host cell is able to develop a specific CD8+T cell response to
cytosolic Lm, which is crucial for the control of infection [35–38].
Early control of Listeria burden largely depends on the innate immune response occurring
in the spleen, which relies on two main cell populations of dendritic cells (DCs). On one hand,
a subset of monocyte-derived DCs namely TNF/iNOS–producing DCs (Tip-DCs) has the abil-
ity to produce TNFα and NO [39]. The other splenic DC subset is CD8α+ conventional DCs
(cDCs), and it is responsible for the final resolution of infection against Listeria through the
antigen presentation of bacterial-derived antigens to specific CD8+T cells to induce cytotoxic-
ity [40, 41]. The response of dendritic cells (DC) to live Lm is mediated by toll-like receptors
(TLRs), nucleotide-binding oligomerization domain (NODs)-like receptors (NLRs), and other
cytosolic receptors and involves two signalling pathways: TLR-dependent and independent
signalling. TLR-dependent signalling, triggered by sensing of cell-surface and endo-phagoso-
mal bacteria, mediating the activation of a MyD88-dependent response; and the cytosolic
pathway, triggered by bacterial DNA after the escape of Lm into the cytosol, is responsible for
the activation of sensor stimulator of interferon (IFN) genes (STING). STING activation leads
to IFN regulatory factor (IRF)3–dependent production of IFN-β and activation of downstream
signals that control the transcription of IFN target genes essential for antiviral and antibacterial
responses [42, 43].
To determine the role of HDAC6 in the innate response to bacterial infection, we explored
the impact of HDAC6 deficiency on the response of myeloid cells to Lm. Our results reveal
that Hdac6-/- BMDCs are less efficient than Hdac6+/+ at clearing Lm. This is due to defective
maturation of phagosome-contained bacteria. Moreover, Hdac6-/- DCs display lower activa-
tion after Lm infection and TLR stimuli. These data support the view that HDAC6 positively
regulates innate defence mechanisms against Lm and that its absence weakens the pro-inflam-
matory response.
Results
Deficient intracellular bacteria clearance in Hdac6-/- BMDCs
To assess the possible role of HDAC6 in innate immune responses during bacterial pathogene-
sis, we performed a time-course infection with Lm in granulocyte and monocyte colony-stim-
ulating factor (GM-CSF)-derived BMDCs from Hdac6+/+ and Hdac6-/- mice. Increasing levels
of HDAC6 expression were detected in the Hdac6+/+ DCs as the infection progressed (Fig 1A).
However, BMDC differentiation was not noticeably affected in the absence of HDAC6 (S1 Fig
part A). Next, Hdac6+/+ and Hdac6-/- BMDCs were infected for different times with Gram-neg-
ative bacteria (Salmonella Typhimurium and Escherichia coli DH5α) and Gram-positive bacte-
ria (Listeria monocytogenes and Staphylococcus aureus) at a multiplicity of infection (MOI) of
10, with colony-formed units (CFUs) corresponding to intracellular live bacteria. Bacterial
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Fig 1. Deficient intracellular bacteria clearance in Hdac6-/- BMDCs. A) Western blot analysis of HDAC6 in a time-course of infection of BMDCs
with Lm. Tubulin was used as a loading control. HDAC6 levels were quantified in five independent experiments. p0.001,  p0.01p0.05. B)
CFUs obtained at 0 and 6 hpi from BMDCs infected with L. monocytogenes, S. Typhimurium, E. coli DHDα, and S. aureus at a MOI of 10. Data from
0 hpi are shown as a bacteria entry control. p0.001, ns>0.05 non-significant; n = 6. C) CFUs of Lm-infected BMDCs obtained at 0, 6, 24 and 32
hpi with a MOI = 10. p0.001, p0.05, ns>0.05 non-significant; n = 6. D) CFUs of Lm-infected BMDCs obtained at 0, 2, 4 and 6 hpi with a
MOI = 10 and 1. p0.001, p0.05, ns>0.05 non-significant; n = 6. E) BMDCs were infected with Lm or Lm-RFP for 6 h and the bacterial signal
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entry was similar in Hdac6+/+ and Hdac6-/- DCs at 0 h post-infection (hpi), while bacterial pro-
liferation, measured at 6 hpi, was significantly higher in Hdac6-/- BMDCs for both types of
intracellular pathogens, Lm and S. Typhimurium (Fig 1B). This was not due to differences in
cell viability at 6 hpi (S1 Fig part B). In contrast, no significant difference was observed in the
proliferation of the non-intracellular pathogens S. aureus and E. coli, indicating that HDAC6 is
an important component of cellular mechanisms for the clearance of intracellular pathogens
(Fig 1B).
Time-course analysis showed that differences between Lm infection in Hdac6+/+ and
Hdac6-/- BMDCs CFUs peaked at 6 hpi and were sustained until 24 hpi (Fig 1C). This effect
was clearly observed at a MOI of 10, which did not affect cell viability (Fig 1D and S1 Fig part
B). A similar pattern was observed with macrophage colony-stimulating factor (M-CSF)-
derived macrophages, demonstrating the lineage independence of the role of HDAC6 in bacte-
rial clearance (S1 Fig part C). Although the difference between Hdac6+/+ and Hdac6-/- cells was
observed in both macrophages and DCs, the clearance capacity of macrophages was ten-fold
higher than that of DCs at 6 hpi (S1 Fig part C).
Bacterial load was also determined by flow cytometry using two strategies: a specific anti-
body against Lm, and RFP-expressing bacteria. Both approaches showed that Hdac6-deficient
DCs contained more bacteria at 6 hpi (Fig 1E). Higher numbers of bacteria in Hdac6-/- BMDCs
were also detected by confocal fluorescence microscopy at 6 hpi (Fig 1F). Some bacteria co-
localized with filamentous actin, showing clear actin rockets (Fig 1F). Image quantification
confirmed that Hdac6-/- BMDCs contained more bacteria per cell and more total bacteria,
remarking a higher percentage of cells hosting a large number of bacteria in Hdac6-/- cells (see
distribution of bacteria per cell, 6–7) (S1 Fig part D). ImarisCell Module view of Fig 1F images
showed the number of bacteria per cell using actin transparency to easily visualize individual
bacteria (S1 Fig part E).
To ascertain whether Hdac6-/- cells display higher bacterial burden than Hdac6+/+ cells in
vivo, Hdac6+/+ and Hdac6-/- mice were intravenously injected with Lm and total CFUs per
gram of liver and spleen were determined at 6 hpi. In agreement with the higher numbers of
Lm observed in GM-CSF-DCs and M-CSF-Macrophages, we observed increased bacterial
titres in spleen and liver cell suspensions (Fig 2A). Next, to determine the specific cell popula-
tions underlying this phenotype, a multicolour gating strategy was used to identify the myeloid
cell compartment, including monocytes, neutrophils, Tips DCs, total cDCs, cCDs CD8- and
cDCs CD8+ (S2 Fig part A). Higher numbers of Lm were observed in different myeloid cells at
6 hpi (Fig 2B and S2 Fig part B). These data highlight the impairment of Hdac6-/- myeloid cells
to clear intracellular Lm.
Impaired bacterial clearance in Hdac6-/- BMDCs is caused by a defect in
autophagy
To test the involvement of autophagy in the mechanism by which HDAC6 regulates Lm infec-
tion, we treated DCs with 3-methyladenine (3-MA), an inhibitor of autophagosome formation.
Treatment with 3-MA increased bacterial load in Hdac6+/+ BMDCs at 6 hpi, while having no
was determined by flow cytometry. The panel shows representative histograms and the geometric mean of the Lm signal. p0.001,  p0.01;
n = 6. F) Confocal microscopy determination of bacterial load at 6 hpi. Left panel: Maximum intensity z-projections of confocal microscopy images
of Lm-infected Hdac6+/+ and Hdac6-/- BMDCs at 6 hpi. The panel shows DAPI (blue), Lm (red), β-actin (green), merged views of three channels,
and magnified views of the boxed areas from the merged view. Yellow indicates Lm and β-actin co-localization. Scale bars 20 μm (main panels) and
10 μm magnified views). Right panel: ImarisCell Module analysis of the number of cells and the number of bacteria per cell in all pictures (10
pictures per genotype). Statistical analysis of Imaris quantification of total bacteria and bacteria per cell in Hdac6+/+ and Hdac6-/- BMDCs.
p0.001,  p0.01; n = 10.
https://doi.org/10.1371/journal.ppat.1006799.g001
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effect on Hdac6-/- BMDCs (Fig 3A), suggesting autophagy as the bacterial clearance mecha-
nism impaired in Hdac6-deficient DCs. A similar result was observed upon treatment of
BMDCs with bafilomycin A1, an inhibitor of vascular proton pump that indirectly inhibits
phagosome-lysosome fusion, and with the lysosome acidification inhibitors chloroquine and
NH4Cl (Fig 3A). In contrast, increasing autophagy flux with rapamycin did not restore the
impaired autophagy in Hdac6-/- BMDCs (Fig 3B). No significant effects were observed with
control vehicles (S3 Fig part A). To explore other possible mechanisms, we treated BMDCs
with inhibitors of NADPH oxidase (DPI) and iNOS (1400W). These treatments did not alter
the difference in CFU number at 6 hpi between treated and non-treated Hdac6+/+ and Hdac6-/-
BMDCs, indicating that the activity of either enzyme is not accounting for the existing pheno-
type (Fig 3B).
The defective autophagy phenotype of Hdac6-/- BMDCs was not due to transcriptional
alterations to autophagy or lysosome components, since Lm-infected Hdac6+/+ and Hdac6-/-
BMDCs showed no mRNA expression differences at 6 hpi in the autophagy components
LC3A and B, p62, ATG2, 5, 7 and 12, and Beclin-1 or in the lysosome components LAMP-1
and 2 (S3 Fig part B).
To determine whether these findings can be extended to other phagocytic cells, we carried
out CFU assays with macrophages obtained from Hdac6+/+ and Hdac6-/- mice four days after
intraperitoneal thioglycollate injection. Higher bacterial load was observed only in Hdac6-/-
Fig 2. Deficient intracellular bacteria clearance in Hdac6-/- splenic myeloid populations. A) Quantification of
bacterial load in target organs (spleen and liver) at 6 hpi in Hdac6+/+ and Hdac6-/- mice injected with a lethal dose of
Lm. Bacterial load is expressed by CFUs per gram of liver (left graph) and per gram of spleen (right graph). p0.01,
n = 6. B) The charts show geometric means of Lm of different splenic populations (monocytes, neutrophils, Tips DCs,
total cDCs, cDCs CD8- and cDCs CD8+) gated in the live CD3-CD19-DX5- population of Hdac6+/+ and Hdac6-/- mice
injected with a lethal dose of Lm at 6 hpi. p0.01; n = 6.
https://doi.org/10.1371/journal.ppat.1006799.g002
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Fig 3. Impaired bacterial clearance in Hdac6-/- BMDCs is caused by a defect in autophagy. A) Total CFUs in Lm-
infected BMDCs treated with inhibitors. CFUs were detected at entry (0 hpi) and 6 hpi (bacterial proliferation) using the
autophagy inhibitors (3-MA and bafilomycin A1 and the lysosome acidification inhibitors (NH4Cl and cloroquine),
ns>0.05 non-significant; n = 6. B) Total CFUs at 0 and 6 hpi in Lm-infected BMDCs treated with the autophagy activator
(rapamycin), the NADPH oxidase inhibitor (DPI) and the iNOS inhibitor (1400W). p0.001; n = 6. C) Total CFUs at 0
and 6 hpi in Lm-infected thioglycollate-elicited macrophages treated with or without bafilomycin A1. p0.001, ns>0.05
non-significant; n = 6. D) Western-blot analysis of autophagy markers over the time-course of Lm infection in Hdac6+/+
and Hdac6-/- BMDCs. Left panels: Levels were detected of p62, LC3bI and II and HDAC6 in control cells and cells treated
Role of HDAC6 in bacterial infection
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macrophages at 6 hpi, and this difference was abrogated by treatment with bafilomycin A1
(Fig 3C). These data indicate that the phenotype observed in BMDCs is also extendable in
other Hdac6-deficient phagocytic cells such as peritoneal macrophages, indicating a wide-
spread defect in intracellular killing ability due to lack of HDAC6. Moreover, the killing ability
shown by peritoneal macrophages is similar to that of M-CSF-derived macrophages and
higher than GM-CSF-derived DCs (Fig 3C compared with S1 Fig part C).
To gain further insight into the autophagy mechanism affected by HDAC6, we monitored
the autophagosome markers p62 and LC3bI and II in Lm-infected BMDCs. Hdac6-/- BMDCs
showed a 2-fold higher accumulation of p62 than Hdac6+/+ cells at 6 hpi and increased LC3bII
level in Hdac6+/+ cells from 1 to 6 hpi (Fig 3D). However, differences in p62 and LC3b levels
were not noticed at early times of Lm infection of Hdac6+/+ and Hdac6-/- BMDCs, indicating
that the induction of autophagy is not affected in the absence of HDAC6 (Fig 3D). The treat-
ment with bafilomycin A1 enhances the accumulation of p62 during the infection at the same
level in both genotypes, abrogating the deficiency in autophagy observed in Hdac6+/+ BMDCs
(Fig 3D). Although rapamycin also increased p62 accumulation at early times in Hdac6+/+ and
Hdac6-/- BMDCs, only Hdac6+/+ cells are able to diminished p62 at 6 hpi (Fig 3D). This treat-
ment confirmed the results obtained in the CFUs functional assays with this inhibitor (Fig 3D
compared with Fig 3B). The similarity of the autophagy defect detected in Hdac6-/- BMDCs in
control condition to that in rapamycin-treated Hdac6-/- cells, suggests an impairment in
phagocytic vesicle fusion with the lysosome.
Hdac6-/- BMDCs accumulate p62
In order to further understand the defective autophagy of Hdac6-/- BMDCs, the accumulation
of p62 was studied in more detail. Flow cytometry at 6 hpi revealed significantly higher p62
content in Hdac6-/- BMDCs, indicating accumulation of this phagosome marker due to defec-
tive fusion of this organelle with the lysosome (Fig 4A). Bafilomycin A1 treatment completely
abrogated this difference, suggesting that Hdac6-/- BMDCs displayed an impairment in the
final step of autophagy (Fig 4A). More signal of Lm is displayed in Hdac6-/- DCs (Fig 4A). In
this regard, bafilomycin A1 treatment increased the low Lm signal in Hdac6+/+ DCs to the
level observed in Hdac6-/- cells (Fig 4A).
Confocal fluorescent analysis of Lm-infected DCs revealed increased levels of p62 in
Hdac6-/- BMDCs (Fig 4B). Hdac6-/- BMDCs also showed a higher percentage of p62-Lm co-
localization than Hdac6+/+ cells, indicating that Hdac6-/- cells have more number of phago-
some-contained bacteria (Fig 4B in accordance with p62 accumulation observed in Figs 3D
and 4A). Confocal fluorescent microscopy study of actin and Lm revealed more frequent co-
localization in Hdac6-/- than in Hdac6+/+ BMDCs, indicating that more bacteria are at the
cytoplasm to form actin rockets in Hdac6-deficient cells (Fig 4C). Moreover, more signal of
acetylated-cortactin is detected in Hdac6-/- BMDCs and also higher percentage of acetylated-
cortactin-Lm co-localization (Fig 4D). These data could explain the accumulation of p62
and the delay in phagocytic vesicle fusion observed in Hdac6-/- BMDCs, necessary to degrade
phagocytosed Lm.
with bafilomycin A1 and rapamycin. Tubulin was used as a loading control. HDAC6 was as a genotype check of Hdac6+/+
and Hdac6-/- BMDCs and to monitor HDAC6 induction during infection. Right panels: Accompanying charts show
quantification of the p62 percentage of control, bafilomycin A1 and rapamycin western blots.  p0.01,  p0.05, ns>0.05
non-significant; n = 5.
https://doi.org/10.1371/journal.ppat.1006799.g003
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Fig 4. Hdac6-/- BMDCs accumulate higher levels of p62. A) Left panels: The charts show geometric means of p62 and
Lm gated in the MHCII+CD11c+ population of Hdac6+/+ and Hdac6-/- BMDCs without infection (NI) and at 6 hpi, with
and without bafilomycin A1 treatment. The representative histograms on the right show p62 and Lm with and without
bafilomycin A1. p0.001,  p0.01, ns>0.05 non-significant; n = 6. B) Confocal microscopy analysis of p62-Lm co-
localization in Lm-infected Hdac6+/+ and Hdac6-/- BMDCs at 6 hpi. Panels show DAPI (blue), Lm (red), p62 (green), and
merged views of the three channels, with magnified views of the boxed areas. Yellow indicates p62-Lm co-localization.
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Defective pro-inflammatory cytokine response to Lm in Hdac6-/- BMDCs
The effect of HDAC6 on the response of BMDCs to Lm was evaluated by measuring pro-
inflammatory cytokine gene induction. The relative mRNA levels of type I interferons (inter-
ferons α and β) were lower in Hdac6-/- BMDCs at 6 hpi (Fig 5A). Accordingly, expression of
downstream interferon-response genes such as Mx1, IFIT3, and ISG15 was also lower in
Hdac6-/- BMDCs (Fig 5A). Lack of HDAC6 also decreased the relative mRNA levels of the pro-
inflammatory cytokines TNFα, IL-1β and IL12p40, indicating impaired cytokine activation
after infection (Fig 5A). Similarly, Hdac6-/- DCs expressed lower levels than their Hdac6+/+
counterparts of the chemokine receptor CXCR1 and chemokines CXCL5 and CXCL10 (Fig
5A). These data demonstrate that Hdac6-deficient DCs have a weakened activation response
to Lm infection at 6 hpi, which suggests a defect in bacterial clearance, consistent with the
increased bacterial load in these cells. To confirm these data, we monitored pro-inflammatory
cytokines and IFN-β in the supernatants of Lm-infected DCs. Early after infection, TNFα,
IL-1β, IL-6, IL12p70 and IFN-β levels were lower in supernatants from Hdac6-/- cells than in
those from Hdac6+/+ cells, and this difference held at 12 and 24 hpi (Fig 5B). To exclude a
defect in cytokine secretion, we compared cytokine levels in supernatants (S) with the levels in
supernatants plus their corresponding cell pellets (S+P). Both analyses showed decreased cyto-
kine levels in Hdac6-/- cells, indicating an impaired antibacterial response in Hdac6-deficient
DCs (S4 Fig).
Measurement of nitrite in supernatants of infected-BMDCs revealed higher nitric oxide
production by Hdac6+/+ DCs than in Hdac6-/- DCs at 24 hpi (Fig 6A). In agreement, western
blot revealed lower levels of inducible nitric oxide synthase (iNOS) in Hdac6-/- BMDCs at 4
and 6 hpi (Fig 6B), indicating a delay of the enzyme induction in Hdac6-/- BMDCs. Likewise,
flow cytometry after exposure of DCs to live or heat-killed L. monocytogenes (HKLM) revealed
higher expression of iNOS in Hdac6+/+ BMDCs in both cases (Fig 6C). These data support the
involvement of HDAC6 in the activation of DC-mediated iNOS microbicidal responses to Lm
infection and in the clearance of this intracellular pathogen.
Hdac6-/- BMDCs show defective activation of Toll-like receptor signalling
pathway
The diminished activation response against Lm in Hdac6-/- BMDCs is consistent with impaired
TLR-related signalling. To investigate this question, we determined the phosphorylation levels
Scale bars 20 μm (main panels) and 10 μm (magnified views). Right panel: The chart shows ImarisCell Module analysis of
the number of cells and the number of bacteria per cell in all pictures (10 pictures per genotype). Co-localization
percentages were obtained by measuring the p62 channel on the bacterial surface using a threshold of 100. The statistical
analysis of Imaris quantifications corresponds to the percentage of p62-Lm co-localization at 6 hpi. p0.05; n = 10. C)
Confocal microscopy analysis of actin-Lm co-localization in Lm-infected Hdac6+/+ and Hdac6-/- BMDCs at 6 hpi. Panels
show DAPI (blue), Lm (green), β-actin (red), and merged views of the three channels, with magnified views of the boxed
areas. Yellow indicates β-actin-Lm co-localization. Scale bars 20 μm (main panels) and 10 μm (magnified views). Right
panel: The chart shows ImarisCell Module analysis of the number of cells and the number of bacteria per cell in all
pictures (10 pictures per genotype). Co-localization percentages were obtained by measuring the actin channel on the
bacterial surface using a threshold of 40.6. The statistical analysis of Imaris quantifications corresponds to the percentage
of actin-Lm co-localization at 6 hpi.  p0.001; n = 10. D) Confocal microscopy analysis of acetylated cortactin-Lm co-
localization in Lm-infected Hdac6+/+ and Hdac6-/- BMDCs at 6 hpi. Panels show DAPI (blue), Lm (red), acetylated
cortactin (green), and merged views of the three channels, with magnified views of the boxed areas. Yellow indicates
acetylated cortactin-Lm co-localization. Scale bars 20 μm (main panels) and 10 μm (magnified views). Right panel: The
chart shows ImarisCell Module analysis of the number of cells and the number of bacteria per cell in all pictures (10
pictures per genotype). Co-localization percentages were obtained by measuring the acetylated cortactin channel on the
bacterial surface using a threshold of 184. The statistical analysis of Imaris quantifications corresponds to the percentage
of acetylated cortactin-Lm co-localization at 6 hpi.  p0.001; n = 10.
https://doi.org/10.1371/journal.ppat.1006799.g004
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Fig 5. Defective pro-inflammatory cytokine response to Lm in Hdac6-/- BMDCs. A) PCR analysis of type-I interferons
(PanIFN-α and IFN-β), interferon downstream proteins (Mx1, IFIT3 and ISG15), pro-inflammatory cytokines (TNF-α, IL-
1β and IL-12p40) chemokine receptor (CXCR1) and chemokines (CXCL5 and CXCL10) of Hdac6+/+ and Hdac6-/- BMDCs
non-infected (NI) and infected with Lm at 6 hpi (arbitrary units). p0.001,  p0.01,  p0.05; n = 5–6. B) ELISA
analysis of the pro-inflammatory cytokines TNFα, IL1β, IL6 and IL12p70 (pg/ml) and IFN-β in supernatants of Hdac6+/+ and
Hdac6-/- BMDCs at 6, 12 and 24 hpi with Lm. p0.001,  p0.01,  p0.05 ns>0.05 non-significant; n = 5–6.
https://doi.org/10.1371/journal.ppat.1006799.g005
Role of HDAC6 in bacterial infection
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006799 December 27, 2017 11 / 32
of TLR downstream mediators by western blot. Compared with Hdac6+/+ BMDCs, Hdac6-/-
BMDCs showed weaker phosphorylation signals for ERK and AKT after Lm infection (Fig
7A). We next examined the effect of HDAC6 deficiency on TLR-signalling pathways using
other TLR stimuli, including HKLM and LPS. AKT phosphorylation in Hdac6-/- BMDCs was
decreased after LPS or HKLM treatment compared to Hdac6+/+, confirming defective TLR
activation (S5 Fig part A). These effects are not related to a defect in Lm-induced transcrip-
tional induction since mRNA levels of different Lm-related TLRs (TLR1, 2, and 6) were similar
in Hdac6+/+ and Hdac6-/- BMDCs (S5 Fig part B). Moreover, Hdac6-/- BMDCs showed weaker
phosphorylation of mTORC1 pathway proteins (mTORC1 downstream substrates p70S6K
and S6), consistent with a less pronounced pro-inflammatory response after TLR-activation by
pathogen-associated molecular patterns (PAMPs) (Fig 7B).
To determine if Hdac6-/- BMDCs showed a similarly defective response to other TLR ago-
nists, we first examined secretion of pro-inflammatory cytokines in response to agonists of
TLR1-2 (Pam3GSK4), TLR-4 (LPS), TLR-7-9 (Imiquimod), and multiple TLRs (heat-killed
Salmonella Typhimurium; HKST). Hdac6-/- BMDCs showed a defective cytokine response to
these stimuli, determined from the release of TNFα, IL-6, IL-1β and IL12p70 (Fig 8A–8D).
To assess the pro-inflammatory cytokine response to TLR3 and TLR5 ligands, we gener-
ated Fms-related tyrosine kinase 3 ligand dendritic cells (FLT3L-DCs). Differentiation
with the cytokine FLT3L yielded similar percentages of CD24+ and CD24- subpopulations
(CD11c+CD11b+B220-CD24+ and CD11c+CD11b+B220-CD24-, respectively) from Hdac6+/+
Fig 6. Defective iNOS response to Lm in Hdac6-/- BMDCs. A) Lm-activated iNOS activity. Nitrite levels in supernatants of Lm-infected BMDCs at 6,
12 and 24 hpi. p0.001; n = 5. B) Western-blot analysis of iNOS induction over the time-course of Lm infection. β-actin was used as a loading
control (top panel). The chart shows quantification of iNOS at 4 and 6 hpi.  p0.01,  p0.05; n = 4 (lower panel). C) The panel shows representative
histograms of iNOS expressed by Hdac6+/+ and Hdac6-/- BMDCs after exposure to live Lm or HKLM for 24 h (left). The right chart shows the geometric
mean of iNOS expression. Non-infected (NI) BMDCs were used as a control of iNOS induction. p0.01; n = 6.
https://doi.org/10.1371/journal.ppat.1006799.g006
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and Hdac6-/- DCs, indicating that differentiation is unaffected by HDAC6 absence (S6 Fig
part A). The TLR agonists Pam3GSK4 (TLR1-2), Poly(I:C) (TLR3), LPS (TLR4), flagellin
(TLR5), Imiquimod (TLR-7-9), Lm, HKLM, and HKST (which activates several TLRs simul-
taneously) elicited similar cytokine secretion profiles in GM-CSF DCs and FLT3L-DCs (Fig
9A and S6 Fig part B compared to Fig 8A–8D). Hdac6-/- DCs of both derivations showed an
impaired cytokine response to each TLR agonist, indicating that HDAC6 likely regulates a
common TLR signalling adaptor.
Fig 7. Hdac6-/- BMDCs show defective activation of the Toll-like receptor signalling pathway. A) Western-blot analysis of MAPK activation over the
time-course of Lm infection in Hdac6+/+ and Hdac6-/- BMDCs. Total and phosphorylated ERK and AKT were detected. Tubulin was used as a loading
control (left). Accompanying charts show quantification of phERK/totalERK and phAKT/totalAKT ratios relative to the loading control, ns non-
significant; n = 7 (right). B) Western-blot analysis of mTORC1 pathway activation over the time-course of Lm infection in Hdac6+/+ and Hdac6-/-
BMDCs. Levels of phosphorylated and total p70S6K and S6 were detected. Tubulin was used as a loading control (top panel). Accompanying charts
show quantification of php70S6K/total70S6K (n = 5) and phS6/totalS6 (n = 7) ratios relative to the loading control.  p0.01, ns non-significant;
(lower panel).
https://doi.org/10.1371/journal.ppat.1006799.g007
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Fig 8. Hdac6-/- BMDCs show defective inflammatory cytokine response to Toll-like receptor stimuli. A) ELISA
analysis of the pro-inflammatory cytokines TNFα, IL-1β, IL-6 and IL12p70 (pg/ml) in supernatants of Hdac6+/+ and
Hdac6-/- BMDCs after treatment for 6, 12 and 24 h with Pam3GSK4. p0.001,  p0.01,  p0.05, ns>0.05 non-
significant; n = 5–6. B) ELISA analysis of the pro-inflammatory cytokines TNFα, IL-1β, IL-6 and IL12p70 (pg/ml) in
supernatants of Hdac6+/+ and Hdac6-/- BMDCs after treatment for 6, 12 and 24 h with LPS. p0.001,  p0.01,
ns>0.05 non-significant; n = 5–6. C) ELISA analysis of the pro-inflammatory cytokines TNFα, IL-1β, IL-6 and IL12p70
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In this view, the TLR adaptor MyD88 participates in the transmission of signals by all TLRs
except for TLR3. We decided to study MyD88 levels in a time-course infection with Lm by
western blot, demonstrating that the quantity of this molecule was the same between Hdac6+/+
and Hdac6-/- DCs and remaining stable during infection (S6 Fig part C). Remarkably, MyD88-
HDAC6 molecular association was observed by co-immunoprecipitations of endogenous pro-
teins using human dendritic cells after Pam2GSK4, Pam3GSK4 and HKLM stimulation (Fig
9B). Likewise, the MyD88 immunoprecipitation in MyD88- and HDAC6-overexpressed HEK
cell line was also able to co-precipitate HDAC6 (S6 Fig part D). These results were corrobo-
rated by mass spectrometry analysis of MyD88 immunoprecipitates; which in addition
detected two acetylated peptides corresponding to MyD88 (S6 Fig parts E and F). The same
approach was used to determine MyD88-HDAC6 molecular association after TLR-2 activation
with HKLM using a constitutively expressed human TLR-2 HEK cell line, rendering the same
result (Fig 9C). This association is also maintained using a double-deacetylase domain mutant
of HDAC6 (H216A:H611A), called HDAC6-DD, indicating that HDAC6-MyD88 interaction
is independent of its catalytic activity (Fig 9C and S6 Fig part D). The knock-down of HDAC6
expression using a small harping plasmid (sh-HDAC6) blocked this interaction (Fig 9C and S6
Fig part D). However, no acetylated peptides could be detected in the mass spectrometry anal-
ysis of the MyD88 immunoprecipitation from HKLM-stimulated TLR-2 HEK cell line (Fig
9D). Moreover, assessment of NF-κB induction in TLR-2-expressing HEK cell line after
HKLM, Pam2GSK4 and Pam3GSK4 stimulation shows lower activation only in shHDAC6
transfected cells, without affecting the activity of HDAC6-DD-transfected ones (Fig 9E).
Taking into account all these data, HDAC6 associates with the TLR-adaptor molecule
MyD88, and the absence of HDAC6 in DCs seems to diminish the TLR-response after a vari-
ety of stimuli, underlining the scaffold role of HDAC6 in determining the ability of MyD88 to
mediate TLR signalling.
To ascertain the defective TLR-dependent inflammatory response in vivo due to the molec-
ular association of MyD88-HDAC6, Hdac6+/+ and Hdac6-/- mice were intravenously injected
with a lethal dose of Lm (Fig 9F) [44]. A protective effect against Lm-induced septic shock was
observed from 3 to 10 days post-infection (dpi) (Fig 9F). Accordingly, lower levels of the pro-
inflammatory cytokine IL-6 were detected in the serum of Hdac6-/- mice at 72 hpi, highlighting
a reduced systemic cytokine-driven inflammatory response after Lm infection in these mice
(Fig 9G).
Discussion
Recent studies have revealed the involvement of HDAC6 in the innate immune response
against Influenza Virus A (IVA), Sendai virus (SeV), and vesicular stomatitis virus (VSV) [21–
24]. Given the similarities between the innate responses to viruses and intracellular bacteria,
this prompted us to investigate the role of HDAC6 in a model of Lm infection. In this work,
we demonstrated a dual role of HDAC6 in the innate response against Lm, not only due to its
enzymatic activity but also dependent of its function as a scaffold (Fig 10). Our data clearly
demonstrate that Hdac6-/- BMDCs have an impaired immune response against Lm and S.
Typhimurium infection in vitro. Moreover, higher Lm titres observed in Hdac6-/- dendritic
cells, M-CSF-derived macrophages and peritoneal macrophages were corroborated during in
(pg/ml) in supernatants of Hdac6+/+ and Hdac6-/- BMDCs after treatment for 6, 12 and 24 h with Imiquimod.
p0.001,  p0.05, ns>0.05 non-significant; n = 5–6. D) ELISA analysis of the pro-inflammatory cytokines TNFα, IL-
1β, IL-6 and IL12p70 (pg/ml) in supernatants of Hdac6+/+ and Hdac6-/- BMDCs after treatment for 6, 12 and 24 h with
HKST. p0.001,  p0.01, ns>0.05 non-significant; n = 5–6.
https://doi.org/10.1371/journal.ppat.1006799.g008
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Fig 9. Association of HDAC6 with TLR-adaptor MyD88 and its contribution to the inflammatory response to Lm. A)
ELISA analysis of the pro-inflammatory cytokines TNFα, IL-1β, IL-6 and IL12p70 (pg/ml) in supernatants of Hdac6+/+ and
Hdac6-/- FLT3L-DCs activated with LPS, Imiquimod, Pam3GSK4, HKLM, HKST, Lm, Poly(I:C) and flagellin for 24 h.
p0.001,  p0.01,  p0.05; n = 6. B) Immunoprecipitation of endogenous HDAC6 and MyD88 followed by western-
blot for both proteins. Immunoprecipitations were carried out using human moDCs after 30 min of stimulation with
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vivo Lm infection at 6 hpi in various myeloid subsets of the spleen. The absence of this effect
during BMDC in vitro infection by the non-intracellular bacteria S. aureus and E. coli DH5α
indicates that Hdac6-/- BMDCs are specifically unable to efficiently clear intracellular patho-
gens. HDAC6 is involved in two of the most important cellular clearance systems, autophagy
and ubiquitin-proteasome system (UPS) [9, 13]. In the case of Lm and S. Typhimurium, the
main molecular mechanism for degradation of vesicle-contained bacteria is fusion with lyso-
somes in a process called autophagy [45–47]. In agreement with this, our data show that
impaired phagosome-lysosome fusion underlies the phenotype observed in Hdac6-/- BMDCs.
Unsuccessful fusion depends on acetylated-cortactin in Hdac6-deficient cells [9]. A similar
mechanism has been described in Hdac6-deficient MEFs during quality-control autophagy
[9]. We demonstrated that in Hdac6-/- BMDCs co-localized higher levels of acetylated-cortac-
tin with intracellular Lm. The delay in vesicle fusion caused by the acetylation of cortactin,
impairs the phagosome-lysosome fusion and provides more opportunities for phagosome-
containing bacteria to escape to the cytosol, resulting in the higher bacterial load detected in
Hdac6-/- BMDCs. Based on this experimental evidence, it is conceivable to postulate that the
enzymatic activity of HDAC6 on its substrate cortactin controls autophagy of intracellular bac-
teria for their efficient clearance (Fig 10).
Pharmacological autophagy inhibitors erased the observed differences between Hdac6+/+
and Hdac6-/- BMDCs. Conversely, rapamycin did not overcome the Hdac6-/- autophagy defect,
indicating a defect in phagosome-lysosome fusion. However, other authors have reported
opposite observations using pan-HDAC inhibitors or specific inhibitors of HDAC6 during
infection of human macrophages with the Gram-negative intracellular pathogens S. Typhi-
murium and E. coli [48]. These inhibitors, when added at the time of infection, increase mito-
chondrial ROS production [48]. However, overnight pre-treatment before infection hampered
bacterial clearance and reduced phagocytosis [48]. These data indicate that specific HDAC6
chemical inhibitors can have side-effects, including effects on other HDAC members, poten-
tially interfering with the acetylation of other substrates upstream of cortactin that also have a
role during bacterial infection. Our genetic approach unequivocally assigns a specific role to
HDAC6 in innate cells during bacterial infection.
Although we observed an impairment in phagosome-lysosome fusion, we cannot rule out
an involvement of HDAC6 in the anti-microbial response through its BUZ domain, with
a contribution from ubiquitin. The characterized interaction between p62 and HDAC6
through their ubiquitin-binding domains provides a clue about the possible role of ubiquitin
in the activation of innate immunity through the recognition of ubiquitinated-molecules [15].
For example, the ubiquitin-binding regions of HDAC6 and p62 are both essential for MyD88
Pam2GSK4, Pam3GSK4 and HKLM. Endogenous HDAC6 (130 KDa) and MyD88 (33 KDa) are indicated at right of
western-blot. Similar results were obtained in two independent experiments. C) Immunoprecipitation of HA (MyD88)
followed by western-blot for HDAC6 and MyD88. Immunoprecipitations were carried out using different HDAC6-eGFP
plasmids co-transfected with MyD88-HA in HEK-Blue hTLR2 cell line after 30 min of stimulation with HKLM. Over-
expressed (HDAC6-eGFP, 160 KDa) and endogenous HDAC6 (130 KDa) are indicated at right of western-blot. Similar
results were obtained in four independent experiments. D) Immunoprecipitation of HA (MyD88) followed by mass
spectrometry analysis. Immunoprecipitations were carried out using different HDAC6-eGFP plasmids co-transfected with
MyD88-HA in HEK-Blue hTLR2 cell line after 30 min of stimulation with HKLM. The number of unique MyD88 and
HDAC6 peptides is indicated. No acetylated peptides from MyD88 were detected in any sample. Similar results were
obtained in four independent experiments. E) Graph of NF-κB induction in transfected HDAC6-WT, HDAC6-DD and
shHDAC6 HEK-Blue hTLR2 cell line after activation with HKLM, Pam2GSK4 and Pam3GSK4 during 8 h. NF-κB induction
was calculated by the ratio of the signal of stimulated cells with its corresponding transfected cells in basal condition (without
stimuli), p0.001,  p0.01,  p0.05, ns>0.05 non-significant; n = 6. F) Survival curve to intravenous injection with a
lethal dose of Lm in Hdac6+/+ and Hdac6-/- is showed. This curve corresponds to two different experiment of survival to Lm
with a n = 24–21. p0.001. G) Pro-inflammatory cytokine IL-6 was measured in sera of Hdac6+/+ and Hdac6-/- mice
intravenously injected with a lethal dose of Lm at 12, 48 and 72 hpi. p0.05, n = 5.
https://doi.org/10.1371/journal.ppat.1006799.g009
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aggregation and the downstream activation of MyD88-dependent signal transduction [49].
Furthermore, ubiquitin-binding platforms formed by HDAC6 and p62 are able to interact
with interferon stimulated gene 15 (ISG15) to eliminate ISGylated proteins tagged after
interferon stimulation by autophagy [50]. HDAC6 is able to bind to either mono- and poly-
Fig 10. Dual role of HDAC6 during Lm infection in dendritic cells. The scheme shows the involvement of HDAC6
in two different functions of dendritic cell during Lm infection, the autophagy and the TLR signalling. (1) The fusion of
phagosome with lysosome is dependent on cortactin and F-actin. The deacetylation of cortactin by HDAC6 allows the
correct fusion, followed by an autophagic clearance of Lm. The absence of this enzyme delays the fusion of phagosome
and lysosome, facilitating Lm to escape from phagosome leading to an increased bacterial load. (2) Di- and tri-acyl
lipopeptides and peptidoglycan (PGN) of Lm are recognized by TLR1/2 or TLR2/6, activating the TLR pathway.
HDAC6 is able to interact with the TLR-adaptor protein MyD88 which caused an enhanced down-stream signalling of
TLR pathway, increasing NF-κB and MAPK activation. This stronger activation (independent on HDAC6 enzymatic
activity) results in higher pro-inflammatory cytokine production and iNOS induction, reinforcing the ability of the DC
to combat against this intracellular pathogen. Although the absence of HDAC6 does not fully abolish the activation of
the DC, a lower induction of NF-κB and MAPK pathways promotes a lower activation of the anti-bacterial
transcriptional program of the DCs. Note that both processes occur during Lm infection and the pro-inflammatory
cytokines and iNOS induction can impact on the autophagic process. The images in the figure are not scaled.
https://doi.org/10.1371/journal.ppat.1006799.g010
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ubiquitinated proteins, but shows a preference for proteins modified with k63-linked ubiquitin
chains, which share structural similarities with ISG15 [51]. S. Typhimurium is decorated with
this kind of ubiquitin chain for recognition by host cells, and can be recovered with phago-
some proteins to initiate autophagy [52, 53]. Nevertheless, our data demonstrate that autop-
hagy induction does not differ between Hdac6+/+ and Hdac6-/- BMDCs, indicating that this
phenotype is due to p62 accumulation in Hdac6-/- BMDCs as a consequence of impaired pha-
gosome-lysosome fusion. Intact autophagy activation in Hdac6-/- BMDCs could be explained
by compensatory p62 binding to ubiquitinated bacteria in the absence of HDAC6.
Our data also underscore other different function of HDAC6, independent of its enzymatic
activity, in innate immune response to intracellular bacteria and various TLR stimuli (Fig 10).
Hence, we provide evidence for a dampened inflammatory response in the absence of
HDAC6, as shown by lower RNA levels of pro-inflammatory cytokines, chemokines, type-I
interferons, and interferon-related proteins in Hdac6-/- BMDCs than in Hdac6+/+ cells at 6 hpi,
as well as the lower pro-inflammatory cytokine production and IFN-β secretion by infected
Hdac6-/- BMDCs from 6 to 24 hpi. Moreover, Hdac6-/- BMDCs showed diminished iNOS
induction at 6 hpi associated with low nitrite production and iNOS expression at longer times
of Lm infection (24 hpi). These results agree with a lower phosphorylation of the MAPK path-
way after Lm infection in Hdac6-/- dendritic cells, controlling the activation of AP-1 family
transcription factors, which is necessary to switch inflammatory responses on [54]. In addi-
tion, the lower phosphorylation of mTORC1 pathway components in Hdac6-/- DCs is consis-
tent with a lower pro-inflammatory response, as reported in trained macrophages and
dendritic cells, in which a metabolic switch to glycolysis has been described [55]. These data
may indicate that HDAC6 also appears to play a role in the activation of mTOR pathway after
Lm infection to initiate the antibacterial transcriptional response to combat this pathogen. In
summary, our results reveal a defect in DC activation after Lm entry.
Remarkably, this impaired anti-inflammatory response in Hdac6-/- BMDCs was also
observed with other TLR-agonists such as LPS, Imiquimod, poly(I:C) and Pam3GSK4,
highlighting HDAC6 as an important player in TLR signalling activation. Broad-spectrum
HDAC inhibitors such as TSA exert immunosuppressive effects [56]. Genome-wide expres-
sion profiling arrays have revealed that 60% of genes transcriptionally increased by TLR2 or
TLR4 stimulation are inhibited in TSA-treated cells, whereas 16% of genes are potentiated
[56]. However, these observations do not provide any demonstrative evidence for a specific
role of HDAC6, since other HDACs may also be involved.
Because GM-CSF-derived DCs express low levels of TLR3 and 5 in the membrane, we stim-
ulated FLT3-L-derived DCs with poly(I:C) and flagellin to measure pro-inflammatory cyto-
kines [57, 58], noting maintained failure in the inflammatory response in Hdac6-/- cells.
Moreover, we detected impaired responses to PAMPs activation in GM-CSF-derived and
FLT3L-derived Hdac6-/- DCs. In addition, all TLRs except for TLR3 signal through the adaptor
MyD88, and the result obtained with the TLR3 ligand poly(I:C) was similar to that showed for
the rest of TLR stimuli, thereby indicating that the TLR3-response is also affected by absence
of HDAC6. In this regard, these data are in agreement with a recent study showing that acety-
lated retinoic-acid-inducible gene-1 (RIG-1) makes Hdac6-/- cells less sensitive to the presence
of RNA viruses, resulting in a higher viral titre [59]. While this mechanism could explain the
difference between the response of Hdac6+/+ and Hdac6-/- FLT3L-DCs to TLR3 stimulation,
the deficient activation by other TLRs in Hdac6-/- DCs also requires an explanation. In this
respect, we demonstrate the molecular association of HDAC6 with MyD88 with endogenous
proteins and in an overexpression system. Conceivably, the depletion of HDAC6 and therefore
prevention of HDAC6-MyD88 binding, could inhibit TLR-2-signalling pathway activation,
which is in accordance with a lower NF-κB induction measured in Hdac6-/- cells after various
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TLR-2 agonist stimulation. A diminished NF-κB induction in Hdac6-/- cells could explain a
reduced initiation of the pro-inflammatory response observed in Hdac6-/- dendritic cells,
needed to alert the innate and adaptive immune response to Lm. However, NF-κB activity of
HDAC6-DD-transfected HEK cell line after TLR-2 stimuli did not display any significant
change compared to HDAC6-WT-transfected ones, supporting that enzymatic activity of
HDAC6 is not involved in this signalling pathway. Two acetylated peptides corresponding
to MyD88 have been found in basal condition in HEK transfected with HDAC6-DD and
shHDAC6 constructions, which are different from the residue previously described in MyD88
[60]. However, no changes in the acetylation marks on MyD88 were detected after HKLM
incubation, highlighting the scaffold role of HDAC6 in the proper activation of TLR-signalling
pathway (Fig 10). Unexpectedly, a protective effect against systemic infection to a lethal dose
of Lm were observed in Hdac6-/- mice. The reduced level of the inflammatory cytokine IL-6
detected in Hdac6-/- mice are in accordance with its higher resistance to Lm infection. The
defective systemic inflammatory response after Lm infection of Hdac6-/- mice may indicate an
impaired TLR-response in the absence of HDAC6 and might therefore be attributed to the
absence of the molecular association of MyD88 and HDAC6. In this regard, mice resistance to
Lm infection can be mediated by sequential MyD88-independent and -dependent responses
[61–64]. However, the role of TLR-2 during Lm infection does not appear to be clear enough
[62, 63]. On one hand, Tlr-2-/- mice display a deficit in circulating TNF-α and IL-12p40 pro-
duction during intravenously injected Lm infection combined with a lower mice survival and
increased bacterial burden in the liver [61, 63]. Other authors have obtained similar resistance
to intraperitoneal-injected Lm infection between Tlr-2-/- and Tlr-2+/+ mice, indicating that dif-
ferent inoculation routes of bacteria may render different immune outcomes [62]. Although
handling and direct killing of Lm by activated macrophages can be mediated by TLR-2- and
MyD88-independent mechanisms, the role of TLR-signalling has been observed necessary for
nitric oxide and cytokine production [61, 63]. In fact, MyD88 not only works as TLR-adaptor
protein, but also as adaptor of IL-1 and IL-18 receptors, both cytokine responses affected in
Lm-MyD88-/- mice [62, 63, 65].
Overall, our data support a dual role for HDAC6 in the regulation of innate immunity
against intracellular bacteria. An increased bacterial load in different Hdac6-/- myeloid cells
can be explained by the autophagy mechanism, where a permanently acetylated cortactin may
impair the phagosome-lysosome fusion, necessary for the clearance of this pathogen. Our
experiments also show the importance of HDAC6 in DC activation, uncovering a novel mech-
anism of HDAC6 action mediated by the appropriate signalling via the TLR pathway, due to
the association of HDAC6 with the TLR-adaptor protein MyD88. This molecular association
seems to be required for a response to TLR stimuli to initiate the inflammatory response of an
activated dendritic cell. Taken together, both HDAC6 functions described in this manuscript,
reinforce the importance of this molecule to combat intracellular bacteria as Lm by autophagy
and to completely activate the inflammatory response after TLR activation.
Materials and methods
Ethical statement
Mice were housed under specific pathogen-free conditions at the Centro Nacional de Investi-
gaciones Cardiovasculares Carlos III (CNIC), and experiments were approved by the CNIC
Ethical Committee for Animal Welfare and by the Spanish Ministry of Agriculture, Food, and
the Environment. Animal care and animal procedures license were reviewed and approved by
the local Ethics Committee for Basic research at the CNIC Ethical Committee for Animal Wel-
fare and the O´rgano Encargado del Bienestar Animal (OEBA) del Gabinete Veterinario de la
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Universidad Auto´noma de Madrid (UAM). This committee approved the document with an
associated identification number PROEX 158/15 (CNIC 04/15).
Buffy coats of healthy donors were received from the Blood Transfusion Center of Comuni-
dad de Madrid, and all donors signed their consent for the use of samples for research pur-
poses. All the procedures using primary human cells were approved by the Ethics Committee
of the Hospital Universitario de la Princesa.
Mice
HDAC6-/- mice were generated through targeting of exons from 10 to 13 by inserting a neomy-
cin (Neo) and zeocin (Zeo) cassette, resulting in the disruption of the first catalytic domain of
HDAC6 [66]. These mice were intercrossed on a C57BL/6 background to generate sex and age
matched wild-type (wt) and knockout.
Bacteria strains
We used the Listeria monocytogenes EGD (BUG 600) strain, provided by Dr. Esteban Veiga
(Centro Nacional de Biotecnologı´a, CNB, Madrid). Staphylococcus aureus 132 and Escherichia
coli K12, strain DH5α, were purchased from Invitrogen. BUG600 and S. aureus bacteria were
grown in BHI broth. RFP-expressing Listeria monocytogenes (RFP-Lm) was provided by Dr
Carlos Ardavı´n´s laboratory (Centro Nacional de Biotecnologı´a, CNB, Madrid). Salmonella
enterica serovar Thyphimurium strain SL1344 was provided by Dr. J. Garaude (Centro Nacio-
nal de Investigaciones Cardiovasculares, CNIC, Madrid). SL1344 and DH5α bacteria were
grown in LB broth supplemented with 50 μg/ml streptomycin (Sigma). For phagocytosis
experiments, Lm and S. aureus were grown overnight in Brain Herat Infusion (BHI) broth and
E. coli and S. Thyphimurium in Luria-Bertani (LB) broth with shaking, diluted 1/50, and
grown until log-phase (optical density 0.8–1.2 at 600 nm) without shaking. Bacteria were
washed with phosphate-buffered saline (PBS) to remove LB salts before addition to cells.
Cell culture
The HEK293T cell line (ATCC) was cultured in DMEM medium (Sigma) containing 10% FBS
(Invitrogen), 2 mM L-glutamine, 100 mg/ml penicillin and 100 mg/ml streptomycin. HEK
Blue hTLR2 cell line (Invivogen), the HEK293 cell line expressing human TLR2, CD14 and
NF-κB-SEAP (secreted embryonic alkaline phosphatase) reporter gene was cultured in
DMEM medium (Sigma) containing 10% FBS (Invitrogen), 2 mM L-glutamine, 100 μg/ml
Normocin (Invivogen) and 1X HEK-Blue Selection (Invitrogen).
Generation of bone marrow-derived dendritic cells (GM-CSF) and
macrophages (M-CSF)
Mouse primary dendritic cells (BMDCs) and macrophages (BMDMs) were obtained from
bone marrow cell suspensions after culture on non-treated 150-mm Petri dishes in complete
RPMI 1640 supplemented with 10% FBS, 2 mM L-glutamine, 100 mg/ml penicillin, 100 mg/
ml streptomycin, 50 mM 2-ME, and 20 ng/ml granulocyte-macrophage colony-stimulating
factor (GM-CSF, PeproTech, London, U.K.) for BMDCs and macrophage colony-stimulating
factor (30% mycoplasma-free L929 cell supernatant, NCBI Biosample accession number
SAMN00155972) for BMDMs. BMDCs were collected at day 9 and BMDCs were characterized
as CD11c+MHC-II+Gr-1- cells by flow cytometry. BMDMs were collected at day 6 and
BMDMs were characterized as CD11b+F4/80+ or CD11b+CD64+ cells.
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Generation of bone marrow-derived dendritic cells (FLT3L)
Bone marrow cell suspensions were culture on treated 6 well plates in complete RPMI 1640 sup-
plemented with 10% FBS, 2 mM L-glutamine, 100 mg/ml penicillin, 100 mg/ml streptomycin,
50 mM 2-ME, and 150 ng/ml (FLT3L, PeproTech, London, U.K.). After 9–11 days of differenti-
ation cells were collected to be characterized by flow cytometry as CD11c+B220-CD11b+CD24-
(60% of the culture) and CD11c+B220-CD11b+CD24+(40%).
Obtainment of thioglycollate-elicited macrophages (TEMs)
Mice received peritoneal injections with 1ml 4% TG. The peritoneal exudate was collected
after 4 days and cultured in complete RPMI 1640 supplemented with 10% FBS, 2 mM L-gluta-
mine, 100 mg/ml penicillin, 100 mg/ml streptomycin, and 50 mM 2-ME. To enrich the culture
for macrophages, non-adherent cells were eliminated after a few hours by washing five times
with warm PBS and gentle swirling.
Obtainment of human monocyte-derived dendritic cells (moDCs)
Peripheral blood mononuclear cells (PBMCs) from Buffy coats of healthy donors were isolated
using Biocoll separating solution (Millipore) by centrifugation at 700 g 30 min at RT. Mono-
cytes were purified from peripheral blood mononuclear cells (PBMCs) by an adherence step at
37˚C in incomplete RPMI 1640 medium during 1 h. Non-adherent cells were removed and
adherent monocytes were washed three times with warm 1xPBS to remove residual PBMCs.
Monocytes were cultured in complete RPMI 1640 supplemented with 10% FBS, 2 mM L-gluta-
mine, 100 mg/ml penicillin, 100 mg/ml streptomycin, 500 U/ml IL-4 (R&D) and 500 U/ml
GM-CSF (Immunotools) for 6 days. Fresh medium and cytokines were added every 48 hours
to differentiate monocytes to immature human dendritic cells. Cells were characterized by
flow cytometry as HLA-DR+CD3-DC-SIGN+CD14-CD11c+. Activation of dendritic cells was
induced with Pam2GSK4, Pam3GSK4 and HKLM for 30 min (Invivogen).
In vitro Lm-infection of BMDCs, BMDMs and TEMs
Cells were incubated with Lm and assessed for survival to gentamicin exposure [67]. Cells
were infected with Lm at a multiplicity of infection (MOI) of 10 for 30 min at 37˚C. To deter-
mine the number of bacteria entering the cells, extracellular bacteria were killed by treatment
with 100 μg/ml gentamicin (Sigma-Aldrich, St. Louis, MO) for an additional 30 min at 37˚C.
Then, infected cells were washed with PBS three times and lysed with 0.05% Triton X-100
(Sigma-Aldrich, St. Louis, MO) in distilled water. Serial dilutions were seeded on brain-heart
infusion (BHI) agar plates and CFUs were counted after 36 hours.
In vivo Lm systemic infections
Hdac6+/+ and Hdac6-/- were intravenously injected with Listeria monocytogenes EGD (125.000
CFUs/mouse) using a 29-gauge needle. For survival experiments mice were monitored twice a
day in order to detect casualties during 15 days of infection.
Determination of CFUs in target organs
After 12, 24, 48 and 72 hpi, mice were perfused with 1X PBS to clean blood form organs and
spleens and livers were weight. To determine bacterial load, spleens and livers were digested
with 0.1 mg/ml type IV collagenase and 0.5 mg/ml DNAse I (Roche, Mannheim, Germany)
for 30 min at 37˚C. After digestion, organs were homogenized in 70 μm filters and red blood
cells were lysed with ammonium chloride potassium lysis buffer (ACK, Sigma). Splenic cell
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suspensions were resuspended in PBS and cells were counted. Serial dilutions were grown on
BHI agar plates. CFUs were counted after 36 hours of incubation at 37˚C. CFUs were calcu-
lated by cell number and by gram per organ.
Antibodies and reagents
Antibodies were used in western blotting, flow cytometry and immunofluorescence; detailed
information is available in S1 Table. Poly-L-lysine (PLL) was purchased from Sigma. Phalloi-
din-Alexa488 and 647 were from BD Biosciences. Zenon Alexa Fluor 488 rabbit IgG labelling
kit, DAPI and Prolong Gold anti-fade mounting medium were from Thermofisher Scientific.
Anti-human CD3 antibody (T3b hybridoma) was generated in Dr. F. Sa´nchez-Madrid labora-
tory (Hospital Universitario de la Princesa, HUP, Madrid) [68]. Rapamycin, bafilomycin A1,
3-MA, cloroquine, NH4Cl, 1400W and DPI were from Sigma-Aldrich.
Gene overexpression and silencing
HEK293 cells were co-transfected with plasmids encoding human MyD88 fused to the HA-tag
(Addgene plasmid #12287) together with plasmids encoding HDAC6-WT or double deacety-
lase domain mutant DD (mutated human HDAC6-H216A/H611A) fused to the eGFP tag
(HDAC6-WT and HDAC6-DD have been previously described [26]. When indicated, cells
were co-transfected with the appropriate small harping RNA plasmid pLVX-IRES-ZsGreen1,
where shHDAC6-2049 (TRCN0000004842) was cloned between BamH1 and EcoR1 sites. Cells
were transfected using Lipofectamine 2000 (Invitrogen). Experiments were performed after 24
h after transfection.
RNA extraction and real-time quantitative PCR
RNA from mouse BMDCs was isolated with the QIAGEN RNeasy Kit (Qiagen). Residual
DNA contamination was removed with the Turbo DNA-free Kit (Ambion). Total RNA (1–
2 μg) was reverse transcribed to cDNA with a Reverse Trancription Kit (Applied Biosystems).
Quantitative PCR was then performed in an AB7900-384 thermocycler (Applied Biosystem)
using SYBR Green master mix (Applied Biosystems, Warrington, UK) as the reporter. Expres-
sion levels of target genes were normalized to the expression of housekeeping genes β-actin,
GAPDH, β2-microglobulin and Yhwaz (tyrosine 3-monooxygenase/tryptophan 5-monooxy-
genase activation protein, z) for presentation of relative mRNA levels. Data were analysed
with Biogazelle qBasePlus version 2.3 (Biogazelle) and graphs are represented as a normalized
expression scaled to average of all samples. Gene-specific primers used are listed in S2 Table.
Soluble embryonic alkaline phosphatase (SEAP)-NF-κB detection
50.000 transfected HEK-Blue hTLR2 cells with different HDAC6 constructions were place in
bottom p96 well plates resuspended in HEK-Blue Detection medium (Invivogen) without
stimulus (negative control) and with TLR-2 agonists (HKLM stimulus, MOI = 10). After 8–12
h of incubation, SEAP activity was measured by optical density at 620 nm with a microplate
reader. To calculate the NF-κB induction, the signal obtained from each mutant condition
without stimuli (background) was depleted of the signal of each condition of activation with
Pam2GSK4, Pam3GSK4 or HKLM.
ELISAs and nitrite measurement
Cytokine and NO production was analysed in the supernatants of BMDC cultures at 6, 12
and 24 h after stimulation with Lm, heat-killed Listeria monocytogenes (HKLM), heat-killed
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Salmonella Typhimurium (HKST), Pam3CSK4, Flagellin, Imiquimod, polyinosinic-polycy-
tidylic acid (Poly(I:C)) (InvivoGen, San Diego, CA), or LPS from Escherichia coli (Sigma-
Aldrich). TNF-α and IL12p70 were analysed with OptEIA ELISA kits (BD Biosciences, San
Diego, CA), IL-1β and IL-6 with the mouse ELISA Ready-SET-Go! kit from eBioscience (Affy-
metrix, San Diego, CA) and Interferon-β was measured with Legend max mouse IFN-β ELISA
kit (Biolegend). The detection was based on colorimetric quantification of absorbance at 450
nm, corrected with subtraction at 570 nm measured in a microplate reader (Bio-Rad Model
550). NO was estimated from the nitrite concentration measured with a Griess reagent kit
at 548 nm (Molecular Probes/Life Technologies, Thermo Fisher Scientific). Results were
expressed as the means of duplicate wells.
Immunoblotting
Total cell extracts from BMDCs stimulated with Lm, HKLM or the indicated TLR ligands for
the indicated times were prepared in lysis buffer (0.5% Triton X100, 25 mM Tris-HCl pH 7.5,
0.5 mM EGTA, 0.5 mM EDTA, 25 mM NaF, 0.5 sodium glycerol-phosphate, 2.5 mM pyro-
phosphate, 0.135 M sacarose) with a cocktail of protease and phosphatase inhibitors (Roche).
Cell lysates were cleared of nuclei by centrifugation at 15,000 g for 15 min. Protein extracts
were separated by 8–15% SDS-PAGE and transferred to a PVDF membrane (Biorad). Proteins
were visualized with LAS-3000 after membrane incubation with specific antibodies (see S1
Table) and peroxidase-conjugated secondary antibodies (5 μg ml−1). Band intensities were
quantified using Image Gauge software (Fuji Photo Film, Co., Ltd) and results are expressed
relative to loading controls. For quantification of western-blots, phosphorylated/total ratios
were divided by loading control signal. Non-infection (NI) time was considered as 100%, and
following times were relativized to it.
Immunoprecipitation of MyD88 and HDAC6 proteins
Human moDCs (1 × 107 per condition) were lysed (10 mM Tris pH 7.4, 150 mM NaCl, 5% glyc-
erol, 1mM EDTA, 1mM MgCl2, 1mM CaCl2, 1% CHAPS (Sigma) and protease and phosphatase
inhibitors (Roche)) for 1 h at 4˚C. Lysates were incubated for pre-clearing with pre-washed Pro-
tein G Dynabeads (Invitrogen; 50 μl per condition; 2 h, 4˚C). Pre-cleared lysates were incubated
with 6 μg rabbit anti-MyD88 antibody (Cell Signaling) or 6 μg rabbit anti-HDAC6 antibody
(Assay bioTech) per condition O/N at 4˚C. Similar μg of control isotype antibody for rabbit
were used. Fifty microlitres of Dynabeads per condition were washed three times in wash buffer
(10 mM Tris pH 7.4, 150 mM NaCl, 5% glycerol, 1mM EDTA, 1mM MgCl2, 1mM CaCl2, 0.1%
CHAPS) and added to antibody-conjugated lysates for 2 h 4C. Antibody-conjugated Dynabeads
were washed six times with wash buffer and transferred to clean tubes.
HEK293T cells or HEK-Blue hTLR2 (1 × 107 per condition) were lysed (25 mM Tris pH 8,
150 mM NaCl, 0.5% NP-40 and protease and phosphatase inhibitors) and incubated for pre-
clearing with pre-washed Protein G Dynabeads (Invitrogen; 50 μl per condition; 3 h, 4˚C).
Fifty microlitres of Dynabeads per condition were washed three times in wash buffer (25 mM
Tris pH 8, 150 mM NaCl, 0.05% NP-40) and re-suspended in 600 μl of wash buffer containing
1–2 μg mouse anti-HA antibody (Roche) per condition and incubated 3 h at 4˚C. Similar μg of
control isotype antibody for mouse were used. Pre-cleared lysates were incubated with anti-
body-conjugated Dynabeads (O/N, 4˚C). Antibody-conjugated Dynabeads were washed six
times with lysis buffer and transferred to clean tubes. Then, were washed twice with wash
buffer. Protein loading buffer was added, samples were boiled at 95˚C for 5 min and processed
for immunoblotting.
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Flow cytometry
Cells were stained in ice-cold PBS containing FBS (0.5%) and EDTA (5 mM) using appropriate
antibody-fluorophore conjugates. Multiparameter analysis was performed on a FACSCANTO
II flow cytometer (BD Biosciences) and analysed with FlowJo software (Tree Star). Prior to fix-
ing, cells were resuspended in PBS/0.5% BSA/5 mM EDTA solution containing yellow fluores-
cent reactive dye to exclude dead cells (Life Technologies). For intracellular staining, cells were
fixed and permeabilized using the CytoFix/Cytoperm kit (BD).
Fluorescence confocal microscopy
For immunofluorescence assays, cells were plated onto slides coated with poly-L-lysine (50 μg
ml−1) and incubated for 1 h at 37˚C. Infection experiment were carried out at the indicated
times. Cells were then fixed, blocked and stained with the indicated primary antibodies (5 μg
ml−1) followed by alexa488- or Rhodamine Red X-labelled secondary antibodies (5 μg ml−1).
Samples were examined under a Leica SP5 confocal microscope (Leica) fitted with a 63X
objective. Images were acquired with sequential xyz acquisition mode scans with laser ranges
of 418–473 nm for DAPI, 502–548 nm for Alexa-488, 584–644 nm for Rhodamine X and 737–
779 nm for Alexa-647. Z-stacks of 2–5 μm were obtained using a maximum z-step size of
0.3 μm.
Imaris quantification
Images were processed and assembled using Image J 1.51p (Fiji). Confocal 3D images assem-
bled with Imaris 7.7.2 (Bitplane) using the ImarisCell module. Every cell and its corresponding
intracellular bacteria were calculated in each image. Surfaces corresponding to bacteria were
used to calculate the maximal fluorescence intensity of the channels to co-localize with bacte-
ria. Two-channel co-localization was quantified in at least 10 images per genotype, corre-
sponding to 10 biological samples.
In-gel protein digestion
Proteins were in-gel digested using a previously described protocol [69]. Briefly, the coimmu-
noprecipitate was heated at 95˚C for 5 min, after which the magnetic beads were removed
using a magnet. The resulting solution was added sample buffer and loaded in 0.5-cm-wide
wells of an SDS-PAGE gel. The run was stopped as soon as the front entered into the resolving
gel. The protein band was visualized by Coomassie Blue staining, excised, and digested over-
night at 37˚C with 60 ng/μl sequencing-grade modified trypsin (Promega) at 10:1 protein:
enzyme (w/w) ratio in 50 mM ammonium bicarbonate, pH 8.8, containing 10% acetonitrile.
The resulting tryptic peptides were desalted onto C18 OMIX tips (Agilent), dried down and
kept at -80˚C until further use.
Mass spectrometry
The resulting peptides were analyzed by liquid chromatography coupled to tandem mass spec-
trometry (LC-MS/MS) on an Easy nLC-1000 nano-HPLC apparatus (Thermo Scientific, San
Jose, CA, USA) coupled to a hybrid quadrupole-orbitrap mass spectrometer (Q Exactive HF,
Thermo Scientific). The dried peptides were taken up in 0.1% (v/v) formic acid and then
loaded onto a PepMap100 C18 LC pre-column (75 μm I.D., 2 cm, Thermo Scientific) and
eluted on line onto an analytical NanoViper PepMap 100 C18 LC column (75 μm I.D., 50 cm,
Thermo Scientific) with a continuous gradient consisting of 8–31% B in 240 min (B = 80%
ACN, 0.1% formic acid) at 200 nL/min. Peptides were ionized using a Picotip emitter
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nanospray needle (New Objective). Each MS run consisted of enhanced FT-resolution spectra
(120,000 resolution) in the 400–1,200 m/z range followed by data-dependent MS/MS spectra
of the 20 most intense parent ions acquired along the chromatographic run. The AGC target
value in the Orbitrap for the survey scan was set to 1,000,000. Fragmentation in the linear
ion trap was performed at 30% normalized collision energy with a target value of 10,000 ions.
The full target was set to 30,000, with 1 microscan and 50 ms injection time, and the dynamic
exclusion was set to 0.5 min.
Peptide identification
For peptide identification the MS/MS spectra were searched with the Sequest algorithm imple-
mented in Proteome Discoverer 1.4 (Thermo Scientific). Database searching against human
protein sequences from the UniProt database (March 2017, 158,382 entries) was performed
with the following parameters: trypsin digestion with 4 maximum missed cleavage sites; pre-
cursor and fragment mass tolerances of 800 ppm and 0.02 Da, respectively; Cys carbamido-
methylation as static modifications; and Met oxidation and Lys acetylation as dynamic
modifications. The results were analyzed using the probability ratio method [70] and a false
discovery rate (FDR) for peptide identification was calculated based on the search results
against a decoy database using the refined method [71].
Statistical analysis
Data were analysed with GraphPad prism software (La Jolla, CA) for normality (Kolmogorov-
Smirnov test for small samples). Normal data were analysed by Student t-test, non-normal
data by Mann-Whitney test, and grouped data by 2-tailed One-way ANOVA with a Bonferroni
post-test. For western blot quantification, the sample with the maximum signal was assigned a
value of 100%, and signals in other samples were expressed as a percentage of this; significance
was determined by a one-sample test. Long-rank (Mantel-Cox) test and Cehan-Breslow-Wil-
coxon test were used for the analysis of the Kaplan-Meier curve (survival curve).
Supporting information
S1 Fig. Differentiation of GM-CSF-derived DCs, their viability at 6 hpi, comparison of
CFUs of GM-CSF- and M-CSF-derived cells and fluorescent confocal microscopy of Lm.
A) Left: Dot-plots showing CD11c and MHC-II markers, with gating for CD11c+MHC-II+
and CD11c+MHC-II- populations (percentages indicated). Right: Dot-plots on differentia-
tion day 11 showing FSC-H versus Gr-1, gating the Gr-1+ population corresponding to neu-
trophil contamination in GM-CSF-derived DC cultures. Charts show the percentages of
CD11c+MHC-II+, CD11c+MHC-II- and Gr-1+ populations. ns>0.05 non-significant; n = 6.
B) Percentage viability of BMDCs before infections and at 6 hpi with Lm, ns>0.05 non-
significant; n = 6. C) Comparison of CFUs in GM-CSF-derived DCs and M-CSF-derived
macrophages over the time-course of Lm infection. p0.001,  p0.01, ns>0.05 non-sig-
nificant; n = 6. D) ImarisCell Module analysis of the number of cells and the number of bac-
teria per cell in all pictures (10 pictures per genotype). The graph shows the distribution
of cells with a specific number of bacteria per cell. The number of cells with 6 and 7 bacteria
differed significantly between the Hdac6+/+ and Hdac6-/- genotypes.  p0.05, n = 10. E)
Confocal microscopy determination of bacterial load of the Fig 1F. Maximum intensity z-
projections of confocal microscopy images of Lm-infected Hdac6+/+ and Hdac6-/- BMDCs at
6 hpi. ImarisCell Module view of the number of nucleus and bacteria per cell. Actin transpar-
ency is used to visualize bacteria (number indicated on the right). Images show DAPI (blue),
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Lm (red), β-actin (green). Scale bars 20 μm.
(TIF)
S2 Fig. Gating strategy of myeloid populations of the spleen. A) Dot-plots showing the gat-
ing of myeloid populations of spleen. Dot-plots showing SSC-A versus FSC-A indicates p1,
FSC-H versus FSC-W and SSC-H versus SSC-W were used to avoid doublets and FSC-H
versus viability shows live and dead cells. Singlets and live cells were used to choose
CD3-CD19-DX5-Ly6G+ cell population. From this population, neutrophils were gated as Ly6G
+Ly6C+ cells, monocytes as CD11b+CD11clo, Tips DCs as intermedium levels of CD11b and
CD11c, conventional dendritic cells (cDCs) as CD11chi; inside this population cDCs CD8-
were distinguish as CD11chiCD11b+ and cDCs CD8- as CD11chiCD11blo. B) Representative
histograms of different splenic populations (monocytes, neutrophils, Tips DCs, total cDCs,
cDCs CD8- and cDCs CD8+) show Lm signal of Hdac6+/+ and Hdac6-/- mice injected with a
lethal dose of Lm at 6 hpi. A pool of Hdac6+/+ and Hdac6-/- spleens non-infected was used as a
control sample without infection (NI). p0.01,  p0.05; n = 6.
(TIF)
S3 Fig. Control vehicles and autophagy markers. A) Total CFUs at 0 and 6 hpi in Lm-
infected BMDCs (MOI of 10) treated with different control vehicles (H2O, DMSO and etha-
nol). H2O were the control vehicle used for NH4Cl and cloroquine, DMSO for 3-MA, bafilo-
mycin A1, DPI and 1400W and ethanol for rapamycin. Time 0 is included as a bacterial entry
control. p0.001, ns>0.05 non-significant; n = 6. B) PCR analysis of autophagy markers
(ATG-2, 5, 7 and 12, LC3A and B, p62 and Beclin-1) and lysosome markers (LAMP-1 and 2)
(arbitrary units) after 6 hpi with Lm, ns>0.05 non-significant; n = 5.
(TIF)
S4 Fig. Pro-inflammatory cytokine secretion. ELISA detection of the pro-inflammatory
cytokines IL-1β and IL12p70 (pg/ml) in supernatants (S) and in supernatants plus the corre-
sponding cell pellets (S+P) of Lm-infected Hdac6+/+ and Hdac6-/- BMDCs at 6, 12 and 24 hpi.
p0.001,  p0.01,  p0.05, ns>0.05 non-significant; n = 5.
(TIF)
S5 Fig. TLR expression and TLR-signalling pathway activation by LPS and HKLM. A)
Western-blot analysis in Hdac6+/+ and Hdac6-/- BMDCs over the time-course of LPS or
HKLM treatment. Total and phosphorylated AKT were detected for both treatments. Accom-
panying charts on the right show quantification, indicating the percentage of phAKT/total
AKT ratio.  p0.01,  p0.05; n = 4. B) PCR analysis of TLR-1, 2 and 6 (arbitrary units) in
Hdac6+/+ and Hdac6-/- BMDCs non-infected (NI) and after Lm-infection at 6 hpi. ns>0.05
non-significant; n = 6.
(TIF)
S6 Fig. Differentiation of FLT3-L DCs, their pro-inflammatory cytokine secretion at 6
hpi and association of HDAC6 with TLR-adaptor MyD88. A) Left: Dot-plots of FLT3-L
DC cultures at day 11 of differentiation, showing gating for the CD11c+ population (percent-
ages indicated). Centre: Dot-plots showing CD11b versus B220 to select two populations:
CD11c+CD11b+B220+ (plasmacytoid DCs, pDCs) and CD11c+CD11b+B220- (conventional
DCs, cDCs) (percentages indicated). Right: Dot-plots showing CD11b versus CD24 to select
the CD11b+CD24+ and CD11b+CD24- populations (gated from cDCs) (percentages indi-
cated). The charts on the right show the percentages of CD11c+, CD11c+CD11b+B220-CD24-
and CD11c+CD11b+B220-CD24+ populations, ns>0.05 non-significant; n = 6. B) ELISA
detection of the pro-inflammatory cytokines IL-1β and IL-6 (pg/ml) in supernatants of
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Hdac6+/+ and Hdac6-/- FLT3L-DCs activated with LPS, Imiquimod, Pam3GSK4, HKLM,
HKST, Lm, Poly(I:C) or flagellin for 6 h. p0.001,  p0.01,  p0.05; n = 6. C) MyD88
adaptor protein in Hdac6+/+ and Hdac6-/- BMDCs. Western-blot analysis of MyD88 over the
time-course of Lm infection in Hdac6+/+ and Hdac6-/- BMDCs (left). Accompanying charts on
the right show quantification of the percentage of MyD88; ns non-significant; n = 5. D) Immu-
noprecipitation of HA (MyD88) followed by western-blot for HDAC6 and MyD88. Immuno-
precipitations were carried out using different HDAC6-eGFP plasmids co-transfected with
MyD88-HA in HEK cell line. Over-expressed (HDAC6-eGFP, 160 kDa) is indicated at right of
western-blot. E) Immunoprecipitation of HA (MyD88) followed by mass spectrometry analy-
sis. Immunoprecipitations were carried out using different HDAC6-eGFP plasmids co-trans-
fected with MyD88-HA in HEK cell line. The number of unique MyD88 and HDAC6 peptides
identified is indicated. () indicates the presence of acetylated MyD88 peptides. Similar results
were obtained in three independent experiments. F) MS2 fragmentation spectra from the pep-
tides showing at 1217.0699 (Top), and 599.3803 (Bottom). Ion adscription to carboxy- (y ions,
blue) and amino-terminal (b ions, red) fragmentation series is indicated. Kac denotes acety-
lated lysine and Ccm indicates carbamidomethylated cysteine. Fragment ion sequence coverage
is schematically indicated. Similar results were obtained in three independent experiments.
(TIF)
S1 Table. Antibody table. Table of antibodies used in experimental procedures disclosed by
reference, brand, host, application and dilution.
(PDF)
S2 Table. qPCR primers. Table of qPCR primers used in experimental procedures disclosed
by gene name and sequence 5´-3´.
(PDF)
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Abstract
Non-alcoholic fatty liver disease (NAFLD) is a major health problem
and the main cause of liver disease in Western countries. Although
NAFLD is strongly associated with obesity and insulin resistance, its
pathogenesis remains poorly understood. The disease begins with an
excessive accumulation of triglycerides in the liver, which stimulates
an inflammatory response. Alternative p38mitogen-activated kinases
(p38c and p38d) have been shown to contribute to inflammation
in different diseases. Here we demonstrate that p38d is elevated in
livers of obese patients with NAFLD and that mice lacking p38c/d
in myeloid cells are resistant to diet-induced fatty liver, hepatic
triglyceride accumulation and glucose intolerance. This protective
effect is due to defective migration of p38c/d-deficient neutrophils to
the damaged liver. We further show that neutrophil infiltration in
wild-type mice contributes to steatosis development by means of
inflammation and liver metabolic changes. Therefore, p38c and p38d
in myeloid cells provide a potential target for NAFLD therapy.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of
chronic liver disease in Western countries and estimates of its
worldwide prevalence range from 6 to 35% (Vernon et al, 2011).
NAFLD refers to a wide spectrum of liver damage, ranging from
simple steatosis caused by intracellular triglyceride accumulation to
inflammation (non-alcoholic steatohepatitis [NASH]), fibrosis, and
cirrhosis (Marchesini et al, 2003). NAFLD is a main cause of crypto-
genic cirrhosis and may also predispose to hepatocarcinoma (Farrell
& Larter, 2006).
The pathogenesis of NAFLD is strongly associated with insulin
resistance, obesity and type 2 diabetes (Fabbrini et al, 2010).
However, the mechanisms involved in the accumulation of triglyc-
erides in the liver and subsequent hepatocellular damage are multi-
factorial and not completely understood. Metabolic deregulation
and hepatic steatosis have been linked to stress signaling (Sabio &
Davis, 2010; Sabio et al, 2010), and the activation of stress kinases
in steatosis and obesity suggests a role for these proteins in this
disease (Sabio & Davis, 2010). The stress-activated protein kinase
group consists of two subfamilies: p38 mitogen-activated kinases
(p38 MAPKs) and c-Jun N-terminal kinases (JNKs). While the role
of JNKs in the development of steatosis has been widely studied
(Sabio et al, 2008, 2009), less is known about the role of the p38
MAPK signaling pathway. In mammals, four p38 MAPK isoforms
have been identified: p38a, -b, -c, and -d. Despite biochemical
evidence of specific roles for the individual isoforms, redundancy
and embryonic lethality have impeded attempts to establish their
distinct functions in vivo (Sabio & Davis, 2014). Embryos lacking
p38a die due to defects in placental development (Adams et al,
2000; Allen et al, 2000; Tamura et al, 2000), but mice lacking p38b,
-c, and -d are viable without any obvious defects under basal
conditions (Beardmore et al, 2005; Sabio et al, 2005). Kinases p38c
and -d were recently shown to control inflammation by regulating
1 Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
2 Department of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, Madrid, Spain
3 Bariatric Surgery Unit, Department of General Surgery, University Hospital of Salamanca, Salamanca, Spain
4 Department of Surgery, University of Salamanca, Salamanca, Spain
5 Department of Internal Medicine, University Hospital of Salamanca-IBSAL, Salamanca, Spain
6 Department of Medicine, University of Salamanca, Salamanca, Spain
7 Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
8 CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, Spain
*Corresponding author. Tel: +34 91453 12 00; E-mail: guadalupe.sabio@cnic.es
†These authors contributed equally to this work
The EMBO Journal Vol 35 | No 5 | 2016 ª 2016 The Authors536
Published online: February 3, 2016 
macrophage production of tumor necrosis factor (TNF)-a (Risco
et al, 2012; Gonzalez-Teran et al, 2013) and T-cell activation
(Criado et al, 2014); moreover, p38d also influences neutrophil
inflammatory responses in the lung (Ittner et al, 2012).
Since chronic inflammation is central to the progression of
NAFLD, we aimed to define the role of p38c and p38d in the devel-
opment of this disorder. We detected elevated liver expression of
p38d in a cohort of obese patients with NAFLD and found that p38c
and p38d are responsible for the development of steatosis and NASH
in three animal models of NAFLD: mice fed a high-fat diet (HFD),
mice fed a high-fat fructose diet (HFF), and mice fed a methionine–
choline-deficient (MCD) diet. Lack of p38c and p38d in myeloid cells
impaired neutrophil migration to the liver and thus protected
against steatosis and further hepatic damage. These results highlight
the importance of p38 kinases and neutrophils in NAFLD and open
a new avenue for the treatment of this disease.
Results
p38c and p38d are overexpressed in NAFLD
Analysis of liver biopsies from obese NAFLD patients (body mass
index [BMI] > 35 kg/m2) revealed elevated mRNA expression of
MAPK13 (p38delta) compared with non-obese individuals without
NAFLD, and a similar tendency was detected for MAPK12
(p38gamma) (Fig 1A). Further, among individuals with a BMI
< 35 kg/m2, hepatic MAPK12 and MAPK13 mRNA was elevated in
individuals with liver steatosis compared with control individuals
without liver disease (Fig 1B). Western blot analysis confirmed
higher liver expression of p38d protein in obese individuals with
steatosis (Fig 1C). To corroborate these results in a mouse model of
steatosis, we studied the expression and activation of p38c and p38d
in livers from mice fed a methionine–choline-deficient (MCD) diet,
which induces macrovesicular steatosis and is widely used in NASH
research (Anstee & Goldin, 2006). MCD diet increased the mRNA
expression of p38d (Fig 1D) and induced the activation of p38c and
p38d after 1 week (Fig 1E). This activation remained high during
the 3 weeks of the diet (Fig 1E and F). These results indicate a
possible role of p38c and p38d in the development of steatosis.
Mice lacking p38c and p38d are protected against MCD-
induced steatosis
To study how these kinases affect the development of fatty liver, we
fed a MCD diet to WT mice and mice lacking p38c (p38c/), p38d
(p38d/), and both p38c and p38d (p38c/d/). Compared with
MCD-diet WT mice, MCD-diet p38c/ and p38d/ mice showed
only a slightly milder liver steatosis as evaluated by H&E and Oil
Red staining (Appendix Fig S1A); in contrast, the development of
steatosis and inflammation was strongly attenuated in p38c/d/
mice (Fig 2A and Appendix Fig S2A). These findings were con-
firmed by biochemical analysis of hepatic triglyceride content
(Fig 2B and Appendix Fig S1B). Moreover, whereas MCD diet
increased serum levels of alanine transaminase (ALT) in WT,
p38c/, and p38d/ mice, the level in p38c/d/ mice was signifi-
cantly lower, indicating milder liver necrosis (Fig 2C and
Appendix Fig S1C). The appearance of steatosis protection only in
mice doubly deficient for p38c and p38d probably reflects the previ-
ously described partial functional redundancy between the two
isoforms (Risco et al, 2012; Gonzalez-Teran et al, 2013).
An early event in MCD-induced choline deficiency is the appear-
ance in liver of oxidized lipids, DNA, and proteins. Assay of thiobar-
bituric acid reactive substances in the livers of MCD-fed animals
detected lower oxidized lipid content in p38c/d/ mice than in WT
animals, correlating with lower levels of hydrogen peroxide in the
double-knockout mice (Fig 2D). Liver fibrosis is a hallmark of
NASH. Livers of MCD-diet WT mice expressed higher levels of
Col1a1 and Acta2 than MCD-diet p38c/d/ mice (Fig 2E), correlat-
ing with higher Masson’s trichrome staining (Fig 2F). These results
demonstrate that p38c/d/ mice are protected against MCD-diet-
induced steatosis and NASH.
Inflammation plays a key role in the pathogenesis of NAFLD,
and the development of hepatic steatosis is associated with
increased liver infiltration by myeloid cells (Tiniakos et al, 2010).
p38c/d kinases regulate inflammation through the control of TNF-a
production in macrophages and Kupffer cells (Risco et al, 2012;
Gonzalez-Teran et al, 2013), and p38d modulates neutrophil
motility in lung disease (Ittner et al, 2012), prompting us to exam-
ine the mRNA expression levels of myeloid cell markers and pro-
inflammatory cytokines in mice fed the MCD diet. Liver expression
▸Figure 1. p38c and p38d are up-regulated in NAFDL.A Left: qRT–PCR analysis of mRNA expression of MAPK12 (p38gamma) and MAPK13 (p38delta) in liver extracts prepared from obese patients with alcoholic fatty liver
disease (NAFLD) and control individuals without NAFLD. mRNA expression was normalized to the amount of Gapdh mRNA (n = 11–74). Right: representative H&E-
stained liver sections. Scale bar: 50 lm.
B Left: qRT–PCR analysis of mRNA expression of MAPK12 (p38gamma) and MAPK13 (p38delta) in liver extracts prepared from control patients with NAFLD/non-alcoholic
steatohepatitis (NASH) and control individuals without NAFLD/NASH. mRNA expression was normalized to the amount of Gapdh mRNA (n = 9–11). Right:
representative H&E-stained liver sections. Scale bar: 50 lm.
C Quantification of immunoblot analysis of p38d expression in liver extracts prepared from obese patients with NAFLD and individuals without NAFLD. Representative
blots are shown (n = 7–40).
D qRT–PCR analysis of Mapk12 (p38gamma) and Mapk13 (p38delta) mRNA expression in liver extracts prepared from wild-type mice (WT) fed a diet deficient in
methionine and choline (MCD) or control diet (ND) for 3 weeks; mRNA expression was normalized to the amount of Gapdh mRNA (n = 5–10).
E Immunoprecipitation analysis of activation and protein levels of p38c and p38d isoforms in liver extracts prepared from WT fed a MCD or ND diet for the times
indicated.
F Immunoprecipitation analysis of activation and protein levels of p38c and p38d isoforms in liver extracts prepared from WT fed a MCD or ND for 3 weeks (n = 5).
Western blot against vinculin was used to assay the protein amount in the total lysate (TL) used for each IP. Protein expression was normalized to vinculin.
Data information: Data are means  SEM. *P < 0.05; **P < 0.01. Statistical significance by two-tailed Student’s t-test. Characteristics of patients and controls were
compared by means of v2 or Mann–Whitney U-tests.
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Figure 2. p38c/d/ mice are protected against steatohepatitis and fibrosis.
A Representative H&E- and Oil Red-stained liver sections prepared from WT and p38c/d/ mice fed a ND or the MCD diet for 3 weeks. Scale bar: 50 lm.
B, C Liver triglycerides (B) and plasma transaminase activity (ALT) (C) measured in WT and p38c/d/ mice after 3 weeks of MCD diet.
D TBARS and hydrogen peroxide detected in liver samples from mice fasted overnight after the 3-week MCD diet.
E qRT–PCR analysis of Col1a1, Acta2, and Timp1 mRNA expression. mRNA expression was normalized to the amount of Gapdh mRNA.
F Representative Masson’s trichrome-stained liver sections prepared from WT and p38c/d/ mice fed a ND or the MCD diet for 3 weeks. Scale bar: 50 lm.
Data information: Data are means  SEM (n = 5–10). *P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA coupled to Bonferroni’s post-tests).
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levels of the myeloid cell marker F4/80 and the cytokines Tnfa and
Il6 were significantly lower in p38c/d/ mice than in WT mice
(Appendix Fig S2B). However, analysis of M1 and M2 macrophage-
differentiation markers revealed no differences in M1 (Ifng, Il23)
and M2 markers (Il10, Il13 or Arg) between WT and p38c/d/ mice
(Appendix Fig S2C).
Effect of myeloid cell expression of p38c and p38d on MCD-
induced steatosis
To elucidate the role of myeloid-expressed p38c/d in the develop-
ment of steatosis, we analyzed mice lacking p38c/d in myeloid cells.
These mice have complete deletion of p38c and p38d in macro-
phages, and neutrophils infiltrated in liver and spleen while only
partial deletion of p38d was observed in dendritic cells
(Appendix Fig S3A). Control mice expressing Cre recombinase
(Lyzs-Cre mice) developed the typical hepatic steatosis in response
to the MCD diet, with associated liver accumulation of triglycerides
and hepatocyte necrosis indexed by serum ALT (Fig 3A–C). In
contrast, the response of p38c/dLyzs-KO mice to the MCD diet was
milder for all three parameters (Fig 3A–C), demonstrating a
protection similar to that seen in global p38c/d/ mice. The p38c/
dLyzs-KO mice also had lower circulating levels of TNF-a and IL-6
than Lyzs-Cre mice after the MCD diet (Fig 3D), and gene expression
analysis revealed significantly lower levels of the pro-inflammatory
and myeloid cell markers Il6, Gr1, Lyzs, and F4/80 (Fig 3E). In
contrast, there were no between-genotype differences in the M1/M2
polarization of liver-infiltrated macrophages (Fig 3F).
Myeloid-specific p38c and p38d deficiencies do not affect diet-
induced obesity, but protect against steatosis and diabetes
To confirm that the protection against liver steatosis in MCD-diet
p38c/dLyzs-KO mice was independent of the model used to induce the
disease, we fed Lyzs-Cre and p38c/dLyzs-KO mice with a high-fat diet
(HFD). Weight gain was the same in p38c/dLyzs-KO and Lyzs-Cre
mice (Fig 4A), consistent with their similar lean and fat mass
(Fig 4B). Liver mass was slightly lower in p38c/dLyzs-KO mice
(Fig 4C), while white adipose tissue mass was similar in both
genotypes (Fig 4D). Histological analysis revealed less severe liver
HFD-induced steatosis in the p38c/dLyzs-KO mice (Fig 5A and B),
correlating with lower circulating ALT levels (Fig 5C). We found
higher energy expenditure in p38c/dLyzs-KO animals with no dif-
ferences in the respiratory exchange quotient [VCO2]/[VO2]
between p38c/dLyzs-KO and Lyzs-Cre mice (Fig 4E).
To study whether the protection against steatosis ameliorates
HFD-induced diabetes, we performed a glucose tolerance test
(GTT). HFD-fed p38c/dLyzs-KO mice showed significantly higher
glucose tolerance (Fig 5D) and lower fasting glucose (Fig 5E) than
age-matched Lyzs-Cre controls on the same diet. These results indi-
cate that the protection against steatosis in mice lacking p38c/d in
myeloid cells also protects against HFD-induced diabetes.
A diet high in cholesterol, saturated fat, and fructose (HFF) has
been found to recapitulate features of metabolic syndrome and
NASH better than the traditional HFD (Charlton et al, 2011). Histo-
logical analysis of p38c/dLyzs-KO and Lyzs-Cre mice fed a HFF diet
revealed less severe liver steatosis in the p38c/dLyzs-KO mice
(Appendix Fig S3B and F), inflammation and fibrosis (Appendix
Fig S3F), correlating with lower triglyceride accumulation and
circulating ALT levels (Appendix Fig S3C and D). This protection
against liver steatosis was associated with an improvement in
fasting glucose (Appendix Fig S3E).
p38c-floxed mice have below-normal expression of p38c in
muscle and fat (data not shown), raising the possibility that this
defective expression might contribute to the protection against
steatosis. To exclude this, we generated radiation chimeras by trans-
planting p38c/dLyzs-KO or Lyzs-Cre bone marrow cells into lethally
irradiated WT mice and fed a HFD or MCD diet. Efficient reconstitu-
tion of B6.SJL (CD45.1) mice with p38c/dLyzs-KO or Lyzs-Cre bone
marrow from C57BL/6J (CD45.2) mice was confirmed by staining
peripheral blood leukocytes and liver-infiltrated leukocytes with
antibodies to CD45.1/CD45.2 and analysis by flow cytometry
(Fig 6A). Histological analysis showed milder steatosis (Fig 6B and
C and Appendix Fig S4A), correlating with lower circulating ALT
levels (Fig 6D and Appendix Fig S4B) after MCD or HFD in CX BM
p38c/dLyzs-KO than in the control CX BM Lyzs-Cre mice. Protection
against HFD-induced steatosis associated with lower fasting glucose
in CX BM p38c/dLyzs-KO (Fig 6E). These results confirmed that this
protection is a specific consequence of the loss of p38c/d in bone
marrow-derived cells.
p38c and p38d control neutrophil infiltration during steatosis by
regulating neutrophil adhesion
The protection of p38c/d myeloid KO mice against steatosis and
liver inflammation, together with the low levels of myeloid cell
markers in the livers of these animals suggested a possible effect on
liver infiltration in animals fed a MCD diet or HFD. Characterization
of liver-infiltrating leukocyte subsets in mice fed either diet revealed
that the diet-induced increase in liver-infiltrating neutrophil counts
(CD11b+Gr-1high) was significantly bigger in Lyzs-Cre mice than in
p38c/dLyzs-KO mice (Fig 7A), and similar results were observed in
radiation chimeras restored by bone marrow from Lyzs-Cre mice
versus p38c/dLyzs-KO mice (Appendix Figs S4C and S5). This result
correlated with lower levels of circulating neutrophils in p38c/dLyzs-KO
mice after both diets (Fig 7B and C).
Figure 3. p38c/dLyzs-KO mice are protected against steatohepatitis induced by MCD diet.
Lyzs-Cre and p38c/dLyzs-KO mice were fed a ND or a MCD diet for 3 weeks.
A Representative H&E- and Oil Red-stained liver sections. Scale bar: 50 lm.
B, C Liver triglycerides (B) and plasma ALT (C) at the end of the diet period.
D Measurement of plasma TNF-a and IL-6.
E qRT–PCR analysis of myeloid cell markers and cytokine mRNA expression from liver tissue; mRNA expression was normalized to the amount of Gapdh mRNA.
F qRT–PCR analysis of M1 and M2 polarization cell markers from liver-infiltrated macrophages. mRNA expression was normalized to the amount of Gapdh mRNA.
Data information: Data are means  SEM (n = 5–10). *P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA coupled to Bonferroni’s post-tests).
▸
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Figure 4. p38c and p38d deficiency in myeloid cells improves glucose metabolism in an obesity model.
Lyzs-Cre and p38c/dLyzs-KO mice were fed a ND or a high-fat diet (HFD) for 10 weeks.
A Body weight measured at the indicated times during HFD treatment.
B Fat mass and lean mass determined by MRI at the end of the diet period.
C, D Liver mass and white fat (WF) mass.
E Respiratory exchange quotient, energy expenditure, and locomotor activity, detected in metabolic cages.
Data information: Data are means  SEM (n = 5–10). *P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA coupled to Bonferroni’s post-tests).
The EMBO Journal Vol 35 | No 5 | 2016 ª 2016 The Authors
The EMBO Journal p38c and p38d control neutrophil migration and steatosis Bárbara González-Terán et al
542
Published online: February 3, 2016 
Neutrophils are the first immune cell type to respond to inflamma-
tion and can induce a chronic inflammatory state by promoting
macrophage recruitment and interacting with antigen-presenting cells
(Mantovani et al, 2011; Talukdar et al, 2012). Neutrophil levels by
defensin 1–3 and neutrophils activation by nitrotyrosine staining, a
measure of NO production, were elevated in the livers of obese
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Figure 5. p38c/dLyzs-KO mice are protected against steatohepatitis induced by HFD.
Lyzs-Cre and p38c/dLyzs-KO mice were fed a ND or a HFD for 10 weeks.
A, B Representative H&E- and Oil Red-stained liver sections (scale bar: 50 lm) (A) and liver triglycerides (B).
C Plasma ALT at the end of the diet period.
D Glucose tolerance measured at the end of the diet period. Blood glucose concentration was measured in mice given an intraperitoneal glucose injection (1 g/kg)
after overnight fasting.
E Basal blood glucose in overnight-fasted ND and HFD-fed Lyzs-Cre and p38c/dLyzs-KO mice.
Data information: Data are means  SEM (n = 5–10). *P < 0.05; **P < 0.01; ***P < 0.001 refers to p38c/dLyzs-KO versus Lyzs-Cre; ##P < 0.01; ###P < 0.001 refers to ND
versus HFD (one-way ANOVA coupled to Bonferroni’s post-tests or Newman–Keuls post-test for liver triglycerides).
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patients with NAFLD (Appendix Fig S6A and B). To test the possible
role of neutrophil p38c/d expression in the etiology of inflammation-
induced liver steatosis, we first compared the capacity of WT and
p38c/d-neutrophils to migrate to steatotic liver. For this, we
performed a competitive cell migration assay that allows direct and
simultaneous comparison of the migration of multiple cell subsets in
the same mouse. MCD-diet WT mice were i.v. injected with a 1:1 mix
of DiO-labeled WT and DiD-labeled p38c/d/ neutrophils (6 × 106
cells in total). WT neutrophils arrived at the steatotic liver 1 h after
injection, but recruitment of p38c/d/ neutrophils was markedly
curtailed (Fig 7D and E). The more extensive recruitment of WT
neutrophils appear to be not due to better survival since neutrophils
from both genotypes showed the same survival ratio; however, we
cannot rule out some role of p38c/d in neutrophil survival
(Appendix Fig S7A).
Using intravital microscopy (IVM), we further quantified TNF-a-
stimulated neutrophil migration in the microcirculation of the
cremaster muscle of mice reconstituted with bone marrow (BM)
from Lyzs-Cre or p38c/dLyzs-KO mice (Movies EV1 and EV2).
Numbers of rolling neutrophils were slightly higher in mice receiv-
ing p38c/dLyzs-KO BM, accompanied by higher rolling velocity and
contrasting with lower numbers of adherent neutrophils (Fig 7F).
This higher rolling velocity is consistent with increased expression
of L-selectin observed in neutrophils lacking p38c/d. Moreover, the
defective adhesion might be explained by the lower expression in
p38c/dLyzs-KO neutrophils of CD11b, an integrin that regulates
neutrophil adhesion and migration (Appendix Fig S7B). These
results show that neutrophil adhesion and recruitment are compro-
mised in the absence of p38c/d. Neutrophil rolling under flow
conditions is mediated by L-selectin (Abbassi et al, 1993). To test
the involvement L-selectin in the impaired rolling of p38c/dLyzs-KO
neutrophils, we assayed neutrophil migration under flow conditions
on plates coated with the CD11b ligand ICAM-1 and the L-selectin
ligand E-selectin. Our results indicated that p38c/dLyzs-KO neutro-
phils presented a higher rolling velocity than Lyzs-Cre neutrophils
(Appendix Fig S7C).
To investigate whether the altered migration capacity of p38c/
dLyzs-KO neutrophils is due to an autonomous effect or a defective
production of chemokines, we performed a parabiosis experiment.
Efficiency of parabiosis was evaluated by using congenic markers to
distinguish blood cells in parabiotic pairs, in which one partner was
CD45.1+. Parabiotic exposure of p38c/dLyzs-KO mice to the circula-
tion of WT (CD45.1) mice, both fed the MCD diet, was enough to
worsen the steatosis phenotype of p38c/dLyzs-KO (Appendix Fig
S8A). The exacerbated steatosis correlated with a higher proportion
of CD45.1 (WT) neutrophils in p38c/dLyzs-KO livers compared to the
proportion observed in livers from Lyzs-Cre mice (Appendix Fig
S8B). There were no differences in macrophage infiltration
(Appendix Fig S8B), indicating that the wild-type circulation specifi-
cally increases liver neutrophil infiltration in p38c/dLyzs-KO mice.
Neutrophils thus appear to be crucial to the steatosis protection in
p38c/dLyzs-KO mice.
Neutrophil-specific p38d deficiency protects against steatosis
The most abundant p38 isoform in neutrophils is p38d (Ittner et al,
2012). To test the implication of neutrophil p38d in liver steatosis,
we crossed p38d-floxed mice with Mrp8-Cre mice (Passegue et al,
2004) to generate mice lacking p38d specifically in neutrophils
(p38dMrp8-KO mice; Appendix Fig S9A). H&E and Oil Red staining of
liver sections revealed that these mice were partially protected
against MCD-induced steatosis (Appendix Fig S9B). Moreover,
p38dMrp8-KO mice had below-normal levels of MCD-induced ALT
(Appendix Fig S9C). This protection was associated with low
Figure 6. p38c/dLyzs-KO hematopoietic cells protect mice against HFD-induced steatosis.
Lethally irradiated WT mice were reconstituted with BM from Lyzs-Cre (Cx BM Lyzs-Cre) or p38c/dLyzs-KO mice (Cx BM p38c/dLyzs-KO). Two months after the transplant, mice
were fed the HFD for 10 weeks.
A Freshly prepared CD45.2 whole BM mononuclear cells (2 × 107) were transplanted into lethally irradiated B6.SJL (CD45.1) mice, and engraftment by CD45.2 cells (%)
was analyzed by antibody staining and FACS of peripheral blood and liver CD45+ cells. Charts show CD45.1 and CD45.2 expression in blood cells (left) and liver cells
(right) isolated from transplanted mice (n = 3). Representative FACS dot plots of CD45.1 and CD45.2 expression are shown beneath the charts.
B Representative H&E- and Oil Red-stained liver sections. Scale bar: 50 lm.
C Liver triglyceride content.
D Plasma transaminase ALT activity.
E Fasted glucose, detected at the end of the diet period in overnight-fasted mice.
Data information: Data are means  SEM (n = 5–10). *P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA coupled to Bonferroni’s post-tests).
◀
▸Figure 7. p38c/dLyzs-KO neutrophils have deficient migration to the liver.A Flow cytometry analysis of liver myeloid subsets (CD11b+ Gr-1high, CD11b+ Gr-1intermediate, CD11b+ Gr-1) isolated from Lyzs-Cre and p38c/dLyzs-KO mice fed a MCD
for 3 weeks or HFD for 10 weeks. Representative dot plots are shown, and bar charts show the diet-induced increase in each population as a percentage of the
total intrahepatic CD11b+ leukocyte population. Myeloid infiltrating cells isolated from livers were sorted by FACS and stained with H&E. Representative cells are
shown next to the appropriate myeloid subsets.
B, C Neutrophils and monocytes as a percentage of total circulating leukocytes, measured in total blood in animals fed the MCD diet for 3 weeks (B) or the HFD for
10 weeks (C).
D, E WT mice fed the MCD diet were i.v. injected with a 1:1 mix of DiO-labeled Lyzs-Cre neutrophils and DiD-labeled p38c/dLyzs-KO neutrophils (6 × 106 cells in total;
n = 10). One hour after injection, liver-infiltrating neutrophils were assessed by flow cytometry (D) and fluorescence micrography on liver sections (E).
F Intravital microscopy quantification of the rolling and adhesion frequencies and rolling velocities of neutrophils recruited to venules irrigating inflamed (TNF-a-
injected) cremaster muscle.
Data information: Data are means  SEM (n = 5–10). *P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA coupled to Bonferroni’s post-tests).
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Figure 8. Neutrophil depletion protects against steatosis.
Osmotic minipumps containing saline or Ly6G antibody were implanted subcutaneously in Lyzs-Cre and p38c/dLyzs-KO mice. These animals were fed a ND or MCD for 3 weeks.
A Neutrophils and monocytes as a percentage of circulating leukocytes, measured in total blood.
B Representative H&E- and Oil Red-stained liver sections after 3 weeks of treatment. Scale bar: 50 lm.
C, D Liver triglyceride (C) and plasma transaminase activity (ALT) (D) at the end of the diet period.
E Total RNA was extracted from livers, and chemokine and cytokine mRNA levels were determined by qRT–PCR. mRNA expression was normalized to the amount of
Gapdh mRNA.
Data information: Data are means  SEM (n = 5–10). *P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA coupled to Bonferroni’s post-tests).
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neutrophil infiltration of the liver compared with MCD-diet-fed
Mrp8-Cre mice (Appendix Fig S9D). These results indicate that the
protection against steatosis is at least partially due to the expression
of p38d in neutrophils.
Neutrophil depletion protects against steatosis development
Early neutrophil accumulation triggers monocyte migration and
inflammation (Savill et al, 1989), and diminished neutrophil accu-
mulation can ameliorate NAFLD (Nathan, 2006). To clarify whether
defective neutrophil migration contributes to the milder hepatic
steatosis in MCD-diet p38c/dLyzs-KO mice, we depleted neutrophils in
MCD-diet Lyzs-Cre mice by administering anti-Ly6G antibody.
Administration of this antibody (0.4 mg/kg per day i.v. for 7 days)
reduced the levels of circulating neutrophils without affecting mono-
cytes (Fig 8A), and treatment for 21 days significantly improved
liver steatosis and reduced triglyceride accumulation to an extent
similar to that observed in the MCD-diet p38c/dLyzs-KO mice; in
contrast, anti-Ly6G treatment of MCD-diet p38c/dLyzs-KO mice did
not appear to provide further benefit (Fig 8B and C). Anti-Ly6G anti-
body treatment of MCD-diet Lyzs-Cre animals also reduced liver
necrosis assessed by serum ALT levels (Fig 8D). Moreover, while
liver expression of Il6 was not affected neutrophil depletion in
Lyzs-Cre mice also significantly reduced liver expression of the pro-
inflammatory markers Tnfa and Lyzs (Fig 8E).
Neutrophil depletion protects against steatosis by modulating
lipid metabolism
We next measured the fatty-acid oxidation metabolite b-hydroxybu-
tyrate, to investigate whether the improvement in hepatic steatosis
in MCD-diet p38c/d/, p38c/dLyzs-KO, and Ly6G-treated mice was
linked to an increase in lipid oxidation. p38c/d/, p38c/dLyzs-KO,
and Ly6G-treated mice all had higher levels of serum b-hydroxy-
butyrate than similarly fed WT or Lyzs-Cre mice (Fig 9A–C), and
this higher lipid oxidation correlated with the higher energy expen-
diture observed in p38c/dLyzs-KO mice (Fig 4E).
To confirm an effect of impaired neutrophil infiltration on liver
lipid metabolism, we examined the effect of MCD-diet on hepatic
gene expression in Lyzs-Cre, p38c/dLyzs-KO, and anti-Ly6G-treated
Lyzs-Cre mice by RNA-seq (Fig 9D–G). Differentially regulated
genes that potentially contribute to the hepatic phenotype of the
neutrophil-deficient mice were identified by comparing gene expres-
sion patterns with MCD-diet-fed Lyzs-Cre mice (Fig 9D–G). Most
gene alterations observed in p38c/dLyzs-KO mice were also detected
in anti-Ly6G-treated Lyzs-Cre mice (Fig 9D). Gene ontology analysis
of genes that changed in the same manner in both mice identified
significant (adjusted P < 0.001) association of neutrophil deficiency
with elevated oxidative lipid metabolism and decreased inflamma-
tion (Fig 9E), including genes regulated by PPAR-a (peroxisome
proliferator-activated receptor-alpha) and by IL-2b and TNF-a
(Fig 9E). Neutrophil deficiency thus causes increased lipid oxidation
and decreased inflammation (Fig 9E–G).
Discussion
The alternative p38 MAPKs p38c and p38d regulate inflammatory
processes through several mechanisms. Here, we demonstrate that
expression of both kinases in myeloid cells is necessary for the
development of liver steatosis and inflammation in animal models
of NAFLD. Further, these kinases control neutrophil migration to
the liver, and hepatic neutrophils contribute to liver steatosis by
promoting liver inflammation and lipogenic metabolism. Deletion of
p38c/d expression in the myeloid compartment curtails neutrophil
recruitment to the liver, protecting animals against diet-induced
steatosis and associated liver damage, and effect that is also
partially mediated by the lack of p38d in neutrophils. These findings
indicate a major role of p38c/d in controlling neutrophil recruitment
during inflammation and suggest that inhibition of neutrophil
trafficking is a potential treatment route for steatosis.
The analysis of NAFLD mouse models clearly demonstrates that
the protection in p38c/d/ mice is attributable to the loss of p38c/d
expression in hematopoietic cells. The bone marrow transfer
experiments and conditional KO animal results confirm that p38c
and d expressions by hematopoietic cells drive steatosis in both diet-
induced steatosis models. Neutrophils were recently shown to be
important mediators of alcoholic fatty liver disease (Bertola et al,
2013), and p38d is known to control neutrophil inflammatory
response in lung by regulating PKD1 activity (Ittner et al, 2012).
Our analysis shows that loss of p38c and p38d in neutrophils might
be responsible for the protection observed in the KO animals. Livers
from mice lacking p38c and p38d had lower neutrophil infiltration,
and neutrophils lacking these kinases could not be recruited to the
liver in a competition assay, indicating a cell autonomous effect.
The low adhesion and higher rolling velocity detected in neutrophils
lacking p38c and p38d are broadly consistent with previous reports
using p38d/ animals (Ittner et al, 2012). We also observed lower
▸Figure 9. Neutrophils control liver metabolic changes in steatosis development.A–C Plasma levels of 3-hydroxybutyrate in WT and p38c/d/ (A), Lyzs-Cre and p38c/dLyzs-KO mice (B) and Lyzs-Cre Ly6G Ab treated after MCD diet (C) (n = 5–10).
D Overlap of gene expression changes between Lyzs-Cre mice treated with anti-Ly6G and p38c/dLyzs-KO at the end of the MCD diet period n = 4 (each n is a mix of
two different animals).
E Hierarchical clustering of the expression profiles of genes differentially expressed both between p38c/dLyzs-KO and MCD-diet-fed Lyzs-Cre and between Lyzs-Cre
treated with anti-Ly6G and MCD-diet-fed Lyzs-Cre mice. Genes up-regulated in both comparisons (red cluster) were mainly regulated by PPAR-a, SREBF1, and
SREBF2, while the enriched upstream regulators of genes down-regulated in both conditions versus the control group (blue cluster) were IL-1b, TNF-a, and PDGFB-b.
F IPA (http://ingenuity.com) functional categories enriched in the set of genes differentially expressed between p38c/dLyzs-KO and MCD-diet-fed Lyzs-Cre and between
Lyzs-Cre treated with anti-Ly6G and MCD-diet-fed Lyzs-Cre mice (n = 4).
G Genes differentially expressed between p38c/dLyzs-KO and MCD-diet-fed Lyzs-Cre and between Lyzs-Cre treated with anti-Ly6G and MCD-diet-fed Lyzs-Cre mice and
involved in liver steatosis according to IPA.
Data information: Data are means  SEM. *P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA coupled to Bonferroni’s post-tests).
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CD11b and higher L-selectin membrane expression, which could
account for these defects in adhesion and rolling observed in the
neutrophils lacking p38c and p38d. Moreover, lack of p38d alone is
insufficient to reduce neutrophil infiltration after the MCD diet and
protect against liver steatosis. The ability of p38c to compensate for
the loss of p38d is somewhat surprising given the low expression
level of p38c in neutrophils (Gonzalez-Teran et al, 2013; Han et al,
2013). A possible explanation is that p38d/ neutrophils might
increase the activation or expression of p38c as a compensatory
mechanism. It is also possible that p38c in another myeloid cell type
(e.g. resident macrophages) contributes to neutrophil migration by
controlling cytokine and chemokine production. However, the
results of competition migration assays in which resident macro-
phages are WT, and of the parabiosis experiment, argue against this
possibility. Further experiments will be needed to determine the
specific roles of p38c and p38d in different myeloid subsets and how
these two isoforms can compensate each other. However, a role of
neutrophils is clear because lack of p38d only in neutrophils is
enough to protect against steatosis.
On the other hand, the fact that neutrophil-specific deletion of
p38d has a more marked effect on phenotype than the whole-body
p38d KO might indicate that p38d has an opposing role in another
tissue and thereby modulates biological actions in a tissue-specific
fashion. Opposing effects in different tissues have been shown for
the stress kinase JNK: deletion of this kinase in the liver induces
steatosis whereas deletion in fat is protective (Sabio et al, 2008,
2009).
Our data point out an important role of p38c/d in neutrophils.
The same level of protection against diet-induced steatosis observed
in p38c/dLyzs-KO mice was also achieved in mice depleted of neutro-
phils with anti-Ly6G antibody. Moreover, deletion of p38d in neutro-
phils reduces hepatic neutrophils infiltration and partially protected
against steatosis. These observations strongly suggest that neutro-
phil recruitment to the liver is essential for the initiation and
progression of NAFLD and that neutrophil p38c/d expression contri-
butes to the progression of this disease. The central role for neutro-
phils in NAFLD is consistent with their roles in ethanol-induced
liver damage (Bertola et al, 2013) and macrophage recruitment to
damaged tissue in obesity (Mansuy-Aubert et al, 2013) and with the
description of neutrophil elastase as an important mediator of
obesity-induced diabetes (Talukdar et al, 2012; Mansuy-Aubert
et al, 2013). The importance of infiltrating neutrophils in liver
inflammatory responses is also indicated by the underexpression of
inflammatory genes in MCD-diet-fed p38c/dLyzs-KO and neutrophil-
depleted mice and by the increased lipid oxidation and reduced lipo-
genesis in the neutrophil-depleted mice.
The data from mouse models correlate well with the overexpres-
sion p38d and p38c in livers of individuals with NAFLD, regardless
of BMI, which could indicate the involvement of these kinases in
the development of steatosis. This elevated p38d expression could
be due to increased neutrophil influx to these livers, as neutrophils
are known to express high levels of p38d (Ittner et al, 2012;
Gonzalez-Teran et al, 2013). Accordingly, we also observed
elevated neutrophil activity in the livers of obese patients with
NAFLD. It would be interesting to characterize the cell-type
contribution to p38d and p38c expression in human liver. However,
we cannot rule out important roles for p38d and p38c expressed
in other cell types involved in steatosis development.
In summary, our findings indicate that neutrophil infiltration trig-
gers the development of NAFLD and that p38c/d regulate this
process by controlling neutrophil infiltration. Therefore, inhibition
of p38c/d might represent a novel therapeutic target for NAFLD in
humans, with the potential to limit injury and possibly prevent
progression to NASH and cirrhosis.
Materials and Methods
Study population and sample collection
The study population included a group of obese adult patients with
body mass index (BMI) ≥ 35 kg/m2 and a liver biopsy compatible
with NAFLD. Participants were recruited from patients undergoing
elective bariatric surgery at the University Hospital of Salamanca.
As controls, we included individuals with BMI < 35 kg/m2 who
underwent laparoscopic cholecystectomy for gallstones. These indi-
viduals were divided into two groups according to the presence of
NAFLD: (i) controls without NALFD (n = 11) if they had no labora-
tory or histopathological evidence of NAFLD or other liver diseases;
(ii) controls with NAFLD (n = 9) if they had a liver biopsy compati-
ble with NAFLD. Therefore, three groups of subjects were included
in the study: obese patients (BMI ≥ 35 kg/m2) with NAFLD, controls
with BMI < 35 without liver disease, and controls with BMI
< 35 kg/m2 and with NAFLD. Baseline characteristics of these
groups are listed in Appendix Table S1.
Participants were excluded if they had a history of alcohol use
disorders or excessive alcohol consumption (> 30 g/day in men and
> 20 g/day in women), chronic hepatitis C or B, or if laboratory
and/or histopathological data showed causes of liver disease other
than NAFLD. The study was approved by the Ethics Committee of
the University Hospital of Salamanca and all subjects provided writ-
ten informed consent to undergo liver biopsy under direct vision
during surgery.
Data were collected on demographic information (age, sex, and
ethnicity), anthropomorphic measurements (BMI), smoking and
alcohol history, coexisting medical conditions, and medication use.
Before surgery, fasting venous blood samples were collected for
determination of complete cell blood count, total bilirubin, aspartate
aminotransferase (AST), alanine aminotransferase (ALT), total
cholesterol, high-density lipoprotein, low-density lipoprotein,
triglycerides, creatinine, glucose, and albumin.
A portion of each liver biopsy was fixed in 10% formalin and
stained with hematoxylin–eosin and Masson’s trichrome for stan-
dard histopathological analysis. The remaining portion was stored
at 80°C for later protein was extraction. The presence of NAFLD
was diagnosed using standard criteria, and severity of the disease
was established using the NAFLD activity score (NAS) described by
Kleiner (Kleiner et al, 2005).
Mice
Mice deficient for p38c (B6.129-Mapk12tm1) and p38d (B6.129-
Mapk13tm1) were crossed with B6.129P2-Lyz2tm1(cre)Ifo/J mice or
with B6.Cg-Tg(S100A8-cre,-EGFP)1Ilw/J mice backcrossed for 10
generations to the C57BL/6J background (Jackson Laboratory).
Genotype was confirmed by PCR analysis of genomic DNA.
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Radiation chimeras were generated by exposing recipient mice to 2
doses of ionizing radiation (625 Gy) and reconstituting them with
2 × 107 donor BM cells by injection into the tail vein. Proper
reconstitution was checked in B6.SJL (CD45.1) control mice
transplanted with CD45.2 BM mononuclear cells by immunostaining
and FACS analysis of peripheral blood and liver CD45+ cells. Mice
were fed a standard chow diet or a methionine–choline-deficient
(MCD) diet for 3 weeks (Research Diets Inc). Alternatively, mice
were fed a high-fat diet (HFD) or a high-fat and high-fructose (HFF)
diet (Research Diets Inc) for 10 weeks. For neutrophil depletion,
mice were treated with anti-Ly6G antibody (0.4 mg/kg per day,
21 days) via subcutaneously implanted mini-osmotic pumps
(Alzet); saline was administered as a control. All animal procedures
conformed to EU Directive 86/609/EEC and Recommendation 2007/
526/EC regarding the protection of animals used for experimental
and other scientific purposes, enacted under Spanish law 1201/
2005.
Hepatic peroxidation
Liver extracts were prepared by sonication (15 cycles) in cytoplas-
mic lysis buffer [25 mM Tris–HCl (pH 7.5), 10 mM NaCl, 1 mM
EDTA, 100 mM MgCl2, 1% NP-40, 0.1 mM phenylmethylsulfonyl
fluoride, and 10 lg/ml aprotinin and leupeptin]. Malondialdehyde
and hydrogen peroxide were assayed with the TBARS Assay kit
(Cayman) and the Amplex Red Hydrogen Peroxide/Peroxidase
Assay Kit (Invitrogen).
Glucose tolerance test
Glucose tolerance test was performed as described (Mora et al,
2005).
Isolation of liver-infiltrating mononuclear leukocytes
Mouse livers were collected, and a single-cell suspension was
obtained and passed through a 70-lm strainer. Leukocytes were
collected from the interphase of centrifuged Ficoll gradients.
Flow cytometry
Isolated liver-infiltrating leukocytes were counted with a CASY Cell
Counter (57) and then labeled by surface staining (Streptavidin-
PERCP/biotin-conjugated anti-CD11b and APC-conjugated anti-Gr-1;
Invitrogen). Flow cytometry was performed with a FACScan cytoflu-
orometer (FACS Canto BD), and data were collected and analyzed
with FlowJo software.
Intravital microscopy
Intravital microscopy of the cremaster muscle after TNF-a injection
(0.5 lg, intrascrotal injection) was performed as reported
(Sreeramkumar et al, 2013) using an Axio Examiner Z.1 work-
station (Zeiss, Germany). Fluorescently conjugated anti-Ly6G
(1 mg/mouse) was injected immediately before acquisition to
specifically identify neutrophils. Recorded videos were analyzed
using Slidebook software (Intelligent Imaging Innovations). At least
30 venules were analyzed from 3 mice per group.
Competitive cell migration assay
Lyzs-Cre and p38c/dLyzs-KO neutrophils were isolated from bone
marrow by labeling with biotin-conjugated anti-Ly6C/G antibody
(BD Pharmigen) and magnetic streptavidin microbeads (Miltenyi
Biotec) and then separating them on MACS MS columns (Miltenyi
Biotec). Isolated Lyzs-Cre neutrophils were stained with DiO and
p38c/dLyzs-KO neutrophils were stained with DiD (Vybrant Cell-
Labeling Solution, Molecular Probes). Cell viability was checked by
DAPI staining followed by FACS. The labeled cells were then mixed
at a 1:1 ratio and injected (6 × 106 cells) into MCD-diet WT mice.
After 1 h, liver-infiltrating mononuclear leukocytes were isolated and
directly detected by FACS. Fluorescent neutrophils were also detected
by confocal microscopy in OCT-cryopreserved liver sections.
Statistical analysis
Differences between experimental groups were examined for statisti-
cal significance by two-tailed Student’s t-test or one-way ANOVA
coupled to Bonferroni’s and Newman–Keuls post-test. Characteris-
tics of patients and controls were compared by means of Mann–
Whitney U-test for quantitative variables and v2 or Fisher’s tests for
qualitative variables.
For more Materials and Methods, see the Appendix.
Expanded View for this article is available online.
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